

Sunday, 14. April 2024*Non-Profit Symposium*

08:30 - 10:00

LOMOND

IS02 - Optimization of transplantation in AML and MDS patients: Standpoint of the SFGM-TC | SFGM-TC With the institutional support of MEDAC*Chair:* Dr. Marie Robin (France)*Chair:* Prof. Edouard Forcade (France)

IS02-1	Optimization of GVHD prophylaxis <i>Speaker:</i> Marie Thérèse Rubio (France)	08:30 - 08:55
IS02-2	Q&A	08:55 - 09:05
IS02-3	Comparison of haplo-identical vs. unrelated donors <i>Speaker:</i> Raynier Devillier (France)	09:05 - 09:25
IS02-4	Q&A	09:25 - 09:35
IS02-5	Prevention of post-transplant relapses <i>Speaker:</i> Prof. Patrice Chevallier (France)	09:35 - 09:55
IS02-6	Q&A	09:55 - 10:00

Non-Profit Symposium

08:30 - 10:00

Hall 3 North

IS03 - How to optimize the outcome of haplo-identical stem cell transplantation? | Sorbonne University*Chair:* Prof. Dr. Florent Malard (France)*Chair:* Dr. Annalisa Ruggeri (Italy)

IS03-1	Optimizing post-Cy dosage after haplo-transplant <i>Speaker:</i> Remy Dulery (France)	08:30 - 08:45
IS03-2	Optimal choice of the stem cell donor <i>Speaker:</i> Prof. Arnon Nagler (Israel)	08:45 - 09:00
IS03-3	Haplo-identical transplant in lymphoma <i>Speaker:</i> Prof. Ali Bazarbachi (Lebanon)	09:00 - 09:15
IS03-4	Management of severe acute GVHD <i>Speaker:</i> Prof. Dr. Florent Malard (France)	09:15 - 09:30
IS03-5	Late effects after haplo-identical transplant <i>Speaker:</i> Bipin Savani (United States)	09:30 - 09:45
IS03-6	Round table discussion - Speakers and chairs	09:45 - 10:00

Non-Profit Symposium

08:30 - 10:00

Hall 2

IS04 - GMMG symposium*Chair:* Dr. Hans Salwender (Germany)

IS04-1	Role of cellular therapy in multiple myeloma <i>Speaker:</i> Prof. Dr. Christoph Scheid (Germany)	08:30 - 08:43
IS04-2	Antibody treatment in multiple myeloma <i>Speaker:</i> Dr. Marc-Andrea Bärtsch (Germany)	08:43 - 08:56
IS04-3	Update in Amyloidosis <i>Speaker:</i> Prof. Dr. Stefan Schönland (Germany)	08:56 - 09:09
IS04-4	Treatment of high-risk multiple myeloma	09:09 - 09:22

	<i>Speaker:</i> Katja Weisel (Germany)	
IS04-5	Therapy of newly-diagnosed, non-transplant eligible multiple myeloma patients <i>Speaker:</i> Dr. Maximilian Merz (Germany)	09:22 - 09:35
IS04-6	Therapeutic developments for refractory multiple myeloma patients <i>Speaker:</i> Dr. Hans Salwender (Germany)	09:35 - 09:48
IS04-7	Q&A	09:48 - 10:00
 <i>Non-Profit Symposium</i>		
08:30 - 10:00		Hall 5
IS05 - Immunotherapy joining forces with autologous transplantation in multiple myeloma: the IFM perspective - With the institutional support of H.A.C. Pharma ATERHIT / IFM		
<i>Chair:</i> Jean-Luc Harousseau (France)		
<i>Chair:</i> Prof. Mohamad Mohty (France)		
IS05-1	Optimizing induction prior to ASCT: from the past to the future <i>Speaker:</i> Jean-Luc Harousseau (France)	08:30 - 08:50
IS05-2	Immunotherapy for elderly myeloma <i>Speaker:</i> Thierry Facon (France)	08:50 - 09:10
IS05-3	CAR-T cells for early relapse in myeloma <i>Speaker:</i> Aurore Perrot (France)	09:10 - 09:30
IS05-4	Bispecific antibodies in relapsed myeloma <i>Speaker:</i> Prof. Mohamad Mohty (France)	09:30 - 09:50
IS05-5	Round table discussion - Speakers and Chairs	09:50 - 10:00
 <i>Nurses Group</i>		
08:30 - 10:00		Hall 1
NG01 - Nurses Education Day 1 50 years of EBMT community - a transplant journey The 1970's		
<i>Chair:</i> Ms. Marijke Quaghebeur (Belgium)		
<i>Chair:</i> Ms. Lorna Welsh (United Kingdom)		
NG01-1	Welcome and Introduction	08:30 - 08:35
NG01-2	First steps in transplantation <i>Speaker:</i> Dr. Anne Parker (United Kingdom)	08:35 - 09:00
NG01-3	A history of HLA typing developments <i>Speaker:</i> Dr. Neema Mayor (United Kingdom)	09:00 - 09:25
NG01-4	Allogeneic transplant story <i>Speaker:</i> Dr. Isabel Salcedo-Diego (Spain)	09:25 - 09:50
NG01-5	Q&A	09:50 - 10:00
 <i>ePoster</i>		
08:30 - 18:00		ePoster area
Acute Leukaemia		
B178	AUTOLOGOUS VERSUS HAPLOIDENTICAL DONOR STEM CELL TRANSPLANTATION FOR FAVORABLE-AND INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST REMISSION AND UNDETECTABLE MINIMAL RESIDUAL DISEASE: A MULTI-CENTER, PROSPECTIVE STUDY <i>Poster Presenter:</i> Jia Chen (China)	08:30 - 08:30
B179	OUTCOME OF ALLOGRAFTED ACUTE LYMPHOBLASTIC	08:30 - 08:30

	LEUKEMIA PATIENTS TREATED WITH THE PEDIATRIC-INSPIRED, MRD-ORIENTED GIMEMA LAL 1913 PROTOCOL IN THE REAL-LIFE: A CAMPUS ALL STUDY	
	<i>Poster Presenter:</i> Gianluca Cavallaro (Italy)	
B180	INTENSIVE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL CAN OVERCOME THE POOR PROGNOSIS OF T(6;9)/DEK-NUP214 AML	08:30 - 08:30
	<i>Poster Presenter:</i> Hai He (China)	
B181	FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Ali Bazarbachi (Lebanon)	
B182	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: A STUDY FROM THE SOCIÉTÉ FRANCOPHONE DE GREFFE DE MOELLE ET THÉRAPIE CELLULAIRE (SFGM-TC)	08:30 - 08:30
	<i>Poster Presenter:</i> Yves Chalandon (Switzerland)	
B183	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A SURVEY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Sebastian Giebel (Poland)	
B184	OUTCOME OF PATIENTS WITH IDH-MUTATED AML FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Thomas Schroeder (Germany)	
B185	UMBILICAL CORD BLOOD TRANSPLANT COMBINING CAR-T CELL THERAPY IS HIGHLY EFFECTIVE AND RELATIVELY SAFE FOR CHILDHOOD RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	08:30 - 08:30
	<i>Poster Presenter:</i> Liu Fang (China)	
B186	CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> He Huang (China)	
B187	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RESCUES THE DISMAL OUTCOMES OF INTERMEDIATE-RISK AML PATIENTS WITH <i>DNMT3A</i>^{MUT}<i>NPM1</i>^{MUT}<i>FLT3-ITD</i>^{MUT}: A MULTICENTER STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Wenxuan Huo (China)	
B188	COMPARISON OF THE PROGNOSTIC IMPACT BETWEEN ELN2022 AND ELN2017 RISK CLASSIFICATION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH AML	08:30 - 08:30
	<i>Poster Presenter:</i> Yanmin Zhao (China)	
B189	EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA WITH RELAPSED DISEASE OR PERSISTENT MRD BRIDGING TO ALLO-HSCT	08:30 - 08:30
	<i>Poster Presenter:</i> XiaoYu Zhang (China)	
B190	INTRACELLULAR CYTOKINE ASSAYS IN COMBINATION WITH DEGRANULATION ASSAY CONTRIBUTE SIGNIFICANTLY TO DETECT AND QUANTIFY LEUKEMIA SPECIFIC IMMUNE CELLS IN AML PATIENTS' BLOOD OR CULTURE SETTINGS	08:30 - 08:30

	<i>Poster Presenter:</i> Helga Schmetzer (Germany)	
B191	TOTAL MARROW AND LYMPHOID IRRADIATION IN COMBINATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS CONFERS FAVORABLE GVHD-FREE/RELAPSE-FREE SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Anthony Stein (United States)	08:30 - 08:30
B192	INCREASED MESENCHYMAL STROMAL CELLS SENEESCENCE AND HIGH CXCL14 LEVELS IN BONE MARROW ARE LINKED WITH THE OCCURRENCE OF GVHD AFTER HEMATOPOIETIC STEM CELLS TRANSPLANTATION <i>Poster Presenter:</i> Alexandra Guelton (France)	08:30 - 08:30
B193	CORRELATION OF THE OVERALL SURVIVAL IN MIXED-PHENOTYPE ACUTE LEUKAEMIA AND ACUTE LYMPHOBLASTIC LYMPHOMA WITH THE REFINED DISEASE RISK INDEX APPLIED IN AN UPPER-MIDDLE INCOME COUNTRY <i>Poster Presenter:</i> Naty López-Córdova (Peru)	08:30 - 08:30
B194	ASSOCIATION BETWEEN GUT MICROBIOTA AND LEUKEMIA: A BIDIRECTIONAL MULTIVARIABLE MENDELIAN RANDOMIZATION STUDY <i>Poster Presenter:</i> DaHua Lan (China)	08:30 - 08:30
B195	SIGNIFICANT IMPROVEMENT OF SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA OVER TWO DECADES - A SINGLE CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Paula Kessler (Germany)	08:30 - 08:30
B196	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING BLINATUMOMAB IN CHILDREN AND YOUNG ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Dr. Mattia Algeri (Italy)	08:30 - 08:30
B197	THE ROLE OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CONSOLIDATION OF MINIMAL RESIDUAL DISEASE-NEGATIVE REMISSION IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS AFTER PHARMACOLOGIC IMMUNOTHERAPY <i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	08:30 - 08:30
B198	AZACITIDINE AND VENETOCLAX WITH OR WITHOUT DLI IN RELAPSED MYELOID MALIGNANCIES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE MULTICENTER STUDY OF THE SFGM-TC <i>Poster Presenter:</i> Turot Mélanie (France)	08:30 - 08:30
B199	FLAG-IDA/VENETOCLAX IS ASSOCIATED WITH HIGHER REMISSION RATES AND IMPROVED POST-TRANSPLANT SURVIVAL COMPARED TO VENETOCLAX/AZACITIDINE IN RELAPSED/REFRACTORY AML PATIENTS <i>Poster Presenter:</i> Radwan Massoud (Germany)	08:30 - 08:30
B200	COMPARISON OF OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND EX-VIVO TCRAB+CD19 DOUBLE-NEGATIVE SELECTED GRAFT IN ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> László Gopcsa (Hungary)	08:30 - 08:30
B201	EFFICACY AND SAFETY ANALYSIS OF PROPHYLACTIC BRENTUXIMAB VEDOTIN ADMINISTRATION AFTER PEDIATRIC ACUTE LEUKEMIA HAPLOIDENTICAL HEMATOPOIETIC STEM	08:30 - 08:30

CELL TRANSPLANTATION*Poster Presenter:* Zhu Huili (China)

- | | | |
|------|--|---------------|
| B202 | <p>OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA IN YOUNG ADULTS COMPARED WITH CHILDREN, ADOLESCENTS AND ELDERLY PATIENTS IN GERMANY</p> <p><i>Poster Presenter:</i> Jochen J. Frietsch (Germany)</p> | 08:30 - 08:30 |
| B203 | <p>PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND BENDAMUSTINE AS POST-TRANSPLANTATION GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN REFRACTORY MYELOID NEOPLASMS</p> <p><i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)</p> | 08:30 - 08:30 |
| B204 | <p>REAL-WORLD OUTCOME OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT STANDARD INDUCTION CHEMOTHERAPY</p> <p><i>Poster Presenter:</i> Francesca Biavasco (Germany)</p> | 08:30 - 08:30 |
| B205 | <p>DURING CB TRANSPLANT IN MRD-POSITIVE AML, RELAPSE IS USUALLY EARLY, IS REDUCED BY ACUTE GVHD AND IS INFLUENCED BY CICLOSPORIN EXPOSURE: A MULTICENTER NATIONAL EXPERIENCE</p> <p><i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)</p> | 08:30 - 08:30 |
| B206 | <p>IMPACT OF RESPONSE TO THE FIRST INDUCTION COURSE IN AML PATIENTS ON ALLOHSCT OUTCOMES WITH PTCY</p> <p><i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)</p> | 08:30 - 08:30 |
| B207 | <p>POST-TRANSPLANT TYROSINE KINASE INHIBITOR MAINTENANCE IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA DELIVERS BENEFIT TOWARD IMPROVED OVERALL, RELAPSE-FREE, GVHD/RELAPSE-FREE SURVIVAL AND DECREASED NON-RELAPSE MORTALITY WITHOUT REDUCED RELAPSE</p> <p><i>Poster Presenter:</i> Eshrak Al-Shaibani (Canada)</p> | 08:30 - 08:30 |
| B208 | <p>IMPACT OF DONOR AND STEM-CELL SOURCE IN ADULTS WITH HIGH-RISK PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA TRANSPLANTED IN FIRST COMPLETE REMISSION: A STUDY FROM GRAALL AND SFGM-TC</p> <p><i>Poster Presenter:</i> Nathalie Dhédin (France)</p> | 08:30 - 08:30 |
| B209 | <p>HOW DISEASE STATUS IMPACTS ON LONG-TERM SURVIVAL AFTER ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: ANALYSIS ON 456 PATIENTS</p> <p><i>Poster Presenter:</i> Dr. Maria Teresa Lupo Stanghellini (Italy)</p> | 08:30 - 08:30 |
| B210 | <p>TLS::ERG FUSION GENE PREDICTS A POOR PROGNOSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTER STUDY</p> <p><i>Poster Presenter:</i> Gele Tong (China)</p> | 08:30 - 08:30 |
| B211 | <p>HIGH TOLERABILITY OF PROLONGED AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML LACKING A TARGETABLE MUTATION</p> <p><i>Poster Presenter:</i> Cuong An Do (Switzerland)</p> | 08:30 - 08:30 |
| B212 | <p>OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA FLT3 IN THE ERA OF FLT3 INHIBITORS - STUDY OF THE POLISH ADULT LEUKAEMIA GROUP (PALG)</p> <p><i>Poster Presenter:</i> Barbara Nasilowska-Adamska (Poland)</p> | 08:30 - 08:30 |

B213	CLINICAL CHARACTERISTICS AND PROGNOSIS OF ADULT T CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ACTIVATING RAS MUTATIONS <i>Poster Presenter:</i> Mimi Xu (China)	08:30 - 08:30
B214	VENETOCLAX-BASED SALVAGE: A LESS TOXIC AND EFFECTIVE THERAPY TO BRIDGE TO TRANSPLANT IN RELAPSE/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA(ALL) IN LOW AND MIDDLE-INCOME COUNTRIES(LMIC) <i>Poster Presenter:</i> Sujay Rainchwar (India)	08:30 - 08:30
B215	PREVENTION AND TREATMENT OF ACUTE MYELOID LEUKEMIA RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT: A NATIONAL SURVEY BY GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) <i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	08:30 - 08:30
B216	TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Prof. Sebastian Giebel (Poland)	08:30 - 08:30
B217	ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA - A SINGLE CENTER 25-YEARS EXPERIENCE <i>Poster Presenter:</i> Veronika Válková (Czech Republic)	08:30 - 08:30
B218	STRUCTURAL ANALYSIS OF LEUKEMIA-ASSOCIATED PROTEIN PTPN21 REVEALS A DOMINANT-NEGATIVE EFFECT OF THE FERM DOMAIN ON ITS PHOSPHATASE ACTIVITY <i>Poster Presenter:</i> Zijun Qian (China)	08:30 - 08:30
B219	EARLY DETECTION OF RELAPSE AND PROMPT TREATMENT WITH DLI FACILITATED BY PROPHYLACTIC LYMPHOCYTE STORAGE PERI-TRANSPLANT RESULTS IN EFFECTIVE DISEASE CONTROL IN ACUTE LEUKAEMIA AND MDS <i>Poster Presenter:</i> Daire Quinn (United Kingdom)	08:30 - 08:30
B220	THIOTEPA, BUSULFAN, AND FLUDARABINE CONDITIONING REGIMEN IN T-CELL REplete HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSION <i>Poster Presenter:</i> Ahmad Ibrahim (Lebanon)	08:30 - 08:30
B221	REDUCED INTENSITY CHEMOTHERAPY WITH TYROSINE KINASE INHIBITOR FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION WAS EFFECTIVE IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Dong Won Baek (Korea, Republic of)	08:30 - 08:30
B222	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS EVALUATED BY FLOW CYTOMETRY ASSOCIATES WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES <i>Poster Presenter:</i> Liangyi Liu (China)	08:30 - 08:30
B223	IMPACT OF CO-MUTATIONS ON THE TRANSPLANT OUTCOMES IN AML PATIENTS WITH DNMT3A MUTATION <i>Poster Presenter:</i> Xavier Cheng-Hong Tsai (Taiwan)	08:30 - 08:30
B224	ADAT1-MEDIATED TRNA 37 A-TO-I EDITING PROMOTES LEUKAEMOGENESIS VIA CONTROLLING TRANSLATIONAL EFFICIENCY OF HOXA13 DURING MYELOID DIFFERENTIATION <i>Poster Presenter:</i> Lin Xia (China)	08:30 - 08:30

B225	SALVAGE TREATMENTS HAVE EXTREMELY POOR OUTCOMES FOR PATIENTS WITH RELAPSED T-ACUTE LYMPHOBLASTIC LEUKAEMIA POST TRANSPLANT <i>Poster Presenter:</i> Dr. Alexandros Rampotas (United Kingdom)	08:30 - 08:30
B226	FEASIBILITY OF ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PREVIOUSLY TREATED WITH CPX-351: REPORT FROM A SINGLE CENTER <i>Poster Presenter:</i> Sabrina Giammarco (Italy)	08:30 - 08:30
B227	VENETOCLAX PLUS LOW-DOSE AZACITIDINE IS EFFECTIVE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH INTERMEDIATE/HIGH-RISK ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Caixia Wang (China)	08:30 - 08:30
B228	COMPARISON OF VENETOCLAX-BASED NON-ANTHRACYCLINE INDUCTION THERAPY VERSUS 3 + 7 FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS <i>Poster Presenter:</i> Tran-Der Tan (Taiwan)	08:30 - 08:30
B229	MYELOFIBROSIS GRADE II-III IS AN INDEPENDENT RISK FACTOR FOR RELAPSE OF ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
B230	INCIDENCE AND MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LIMITED RESOURCE COUNTRIES <i>Poster Presenter:</i> Nour Ben Abdeljelil (Tunisia)	08:30 - 08:30
B231	IMPACT OF BODY MASS INDEX ON OUTCOME IN ADULT PATIENTS WITH ACUTE MYELOID AND ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Silvia Cingelova (Slovakia)	08:30 - 08:30
B233	VENETOCLAX COMBINED WITH HMAS-BASED THERAPY AS PRE-EMPTIVE TREATMENT FOR ACUTE MYELOID LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Mimi Xu (China)	08:30 - 08:30
B234	VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Qingxiao Song (China)	08:30 - 08:30
P230	TARGET THERAPY IN ACUTE LEUKAEMIA RELAPSES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Riccardo Boncompagni (Italy)	08:30 - 08:30
P231	BRAIN-TARGETING PHAGE-GUIDED NANOMEDICINE CROSSING OF THE BBB FOR LOW-DOSE CHEMOTHERAPY AGAINST CNSI <i>Poster Presenter:</i> Xue Dong (China)	08:30 - 08:30
P232	ALLOGENEIC STEM CELL TRANSPLANTATION IN THE MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA: A TEN YEAR EXPERIENCE IN IRELAND'S NATIONAL ADULT ALLOGENEIC TRANSPLANT CENTRE <i>Poster Presenter:</i> Conor Browne (Ireland)	08:30 - 08:30

P233	EFFICACY AND SAFETY OF RECOMBINANT <i>ERWINIA</i> ASPARAGINASE (JZP458) IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)/LYMPHOBLASTIC LYMPHOMA (LBL): COMPLETE FOLLOW-UP OF THE CHILDREN'S ONCOLOGY GROUP AALL1931 STUDY <i>Poster Presenter:</i> Luke Maese (United States)	08:30 - 08:30
P234	FLT3-MUTATED AML: MANAGEMENT AND LONG-TERM OUTCOME OVER 24 YEARS AT A SINGLE CENTER <i>Poster Presenter:</i> Saveria Capria (Italy)	08:30 - 08:30
P235	THE ROLE OF TOLEROGENIC DENDRITIC CELLS IN SUPPRESSING AND DCLEU IN INCREASING ANTILEUKEMIC CYTOTOXICITY <i>Poster Presenter:</i> Helga Schmetzer (Germany)	08:30 - 08:30
P236	CHIDAMIDE MAINTENANCE THERAPY IN HIGH-RISK AML WITH RUNX1-RUNX1T1 AFTER ALLO-HSCT <i>Poster Presenter:</i> Wewen Guo (China)	08:30 - 08:30
P237	TREATMENT EFFICACY OF BLINATUMOMAB FOR MAINTENANCE THERAPY OF PATIENTS WITH B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Xiaoxia Hu (China)	08:30 - 08:30
P238	EFFICACY, SAFETY AND TOLERABILITY OF MITOXANTRONE HYDROCHLORIDE LIPOSOME CONTAINING REGIMEN IN TREATING RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Li Liu (China)	08:30 - 08:30
P239	STUDY ON THE EFFICACY AND SAFETY OF BLINATUMOMAB MAINTENANCE THERAPY OF HIGH RISK PH NEGATIVE ALL AFTER ALLO-HSCT <i>Poster Presenter:</i> Zhang Jianping (China)	08:30 - 08:30
P240	THE IMPACT OF PRE-TRANSPLANT MDS-ASSOCIATED SOMATIC MUTATIONS AND CO-MUTATIONS IN PATIENTS WITH AML ON POST-TRANSPLANT OUTCOMES <i>Poster Presenter:</i> Khalid Halahleh (Jordan)	08:30 - 08:30
P241	PRACTICE PATTERNS OF TRANSPLANT CENTERS REGARDING MAINTENANCE TREATMENT POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN AML: ON BEHALF OF THE EBMT ACUTE LEUKEMIA WORKING PARTY <i>Poster Presenter:</i> Iman Abou Dalle (Lebanon)	08:30 - 08:30
P242	PREVALENCE OF ELIGIBILITY FOR GERMLINE MUTATION TESTING IN PATIENTS WITH MDS/AML UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN A US ACADEMIC MEDICAL CENTER <i>Poster Presenter:</i> Tyler Fugere (United States)	08:30 - 08:30
P243	TRIALS IN PROGRESS: A PHASE 1B SINGLE-ARM, OPEN-LABEL STUDY OF EMAVUSERTIB IN COMBINATION WITH AZACITIDINE AND VENETOCLAX IN AML PATIENTS IN COMPLETE RESPONSE WITH MRd <i>Poster Presenter:</i> Adolfo de la Fuente (Spain)	08:30 - 08:30
P244	REFINED DISEASE RISK INDEX APPLIED IN AN UPPER-MIDDLE INCOME COUNTRY AS A TOOL TO ESTIMATE OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN HAEMATOLOGICAL MALIGNANCIES <i>Poster Presenter:</i> Naty López-Córdova (Peru)	08:30 - 08:30

P245	IN CHILDREN WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA GIVEN ALLOGENEIC-HSCT EMPLOYING REDUCED-INTENSITY CONDITIONING, GVHD IS LESS FREQUENT IF THE PROCEDURE IS CONDUCTED ON AN OUTPATIENT BASIS <i>Poster Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	08:30 - 08:30
P246	PREEMPTIVE DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA - SINGLE CENTRE ANALYSIS OF EFFECTIVENESS AND SAFETY <i>Poster Presenter:</i> Anna Łojko Dankowska (Poland)	08:30 - 08:30
P247	IMPLEMENTATION OF NON-TBI CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN RESOURCE-LIMITED SETTINGS <i>Poster Presenter:</i> Lusine Krmoyan (Armenia)	08:30 - 08:30
P248	RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Nour Ben Abdeljelil (Tunisia)	08:30 - 08:30
P249	IAMP21 ACUTE LYMPHOBLASTIC LEUKEMIA WITH DELETION AROUND SUBTELOMERIC REGION OF CHROMOSOME 21 : REPORT OF ONE CASE AND REVIEW OF LITERATURE <i>Poster Presenter:</i> Jiantuo Liu (China)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00	Stem Cell Donor	ePoster area
B002	DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSAS) IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MISMATCHED DONORS, ON BEHALF OF GITMO AND AIBT <i>Poster Presenter:</i> Anna Paola Iori (Italy)	08:30 - 08:30
B003	DETERMINING THE PREDICTIVE IMPACT OF DONOR PARITY ON THE OUTCOMES OF HUMAN LEUKOCYTE ANTIGEN MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTS: A RETROSPECTIVE, SINGLE-CENTER STUDY <i>Poster Presenter:</i> Maryam Barkhordar (Iran)	08:30 - 08:30
B004	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES GRAFT-VERSUS-HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL IN HLA-DPB1 MISMATCHED UNRELATED DONOR ALLOGENEIC TRANSPLANT <i>Poster Presenter:</i> Yung-Tsi Bolon (United States)	08:30 - 08:30
B005	THE RESCUE TRANSPLANTATION STRATEGY FOR GRAFT FAILURE: DONOR SELECTION AND GVHD PROPHYLAXIS IN THE CURRENT ERA <i>Poster Presenter:</i> Mizuki Watanabe (Japan)	08:30 - 08:30
B006	UNRELATED DONOR SELECTION FOR STEM CELL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Dr. Jaime Sanz (Spain)	08:30 - 08:30
B007	PATIENT HLA GENOTYPE AND REGISTRY DIVERSITY STRONGLY INFLUENCE DONOR SEARCH DURATION AND SUCCESS <i>Poster Presenter:</i> Stefanie V. Dorner (Germany)	08:30 - 08:30

B008	FEASIBILITY AND SAFETY OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PERIPHERAL BLOOD STEM CELL MOBILIZATION AND COLLECTION BY APHERESIS IN RELATED DONORS AGED 65 AND OVER <i>Poster Presenter:</i> Kahina Amokrane (France)	08:30 - 08:30
B009	HAPLOIDENTICAL VERSUS MISMATCHED UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES: AN ANALYSIS ON 1413 PATIENTS FROM THE GERMAN REGISTRY <i>Poster Presenter:</i> Andrea Gantner (Germany)	08:30 - 08:30
B010	THE POST-PANDEMIC HAEMATOPOIETIC STEM CELL (HSC) GRAFT CRYOPRESERVATION TRENDS AND THEIR EFFECTS ON UNRELATED DONOR REGISTRIES: THE UK EXPERIENCE <i>Poster Presenter:</i> Dr. Robert Danby (United Kingdom)	08:30 - 08:30
B011	ALLOGENIC STEM CELL TRANSPLANTATION AND PERI TRANSPLANT STRATEGIES IN PATIENTS WITH MISMATCH DONORS - A SINGLE CENTER EXPERIENCE IN 151 PATIENTS <i>Poster Presenter:</i> Benno Biermann (Germany)	08:30 - 08:30
B012	SURVIVAL PROGNOSTIC FACTORS AFTER A SECOND ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION <i>Poster Presenter:</i> Ms. Tatiana Fernández-Barge (Spain)	08:30 - 08:30
B013	QUALITY OF ENGRAFTMENT AND INCIDENCE OF ACUTE GVHD GRADE II - IV POST PERIPHERAL HAEMOPOIETIC CELLS CRYOPRESERVATION IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM HLA IDENTICAL DONORS <i>Poster Presenter:</i> Anna Maria Raiola (Italy)	08:30 - 08:30
B014	WHAT WORKS AND WHAT DOES NOT? - THE IMPACT OF DONOR CHARACTERISTICS IN T REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST -TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	08:30 - 08:30
B015	OUTCOMES OF OLDER ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED PROPHYLAXIS <i>Poster Presenter:</i> Victoria Murillo Cortés (Spain)	08:30 - 08:30
B016	RECIPIENT-DONOR HLA-B LEADER MISMATCHING IMPACT ON THE HAPLOIDENTICAL TRANSPLANTATION OUTCOMES FOR PEDIATRIC ACUTE LEUKEMIA PATIENTS <i>Poster Presenter:</i> Tahereh Rostami (Iran)	08:30 - 08:30
B017	COMPARING THE CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED-SIBLING DONORS AND ALTERNATIVE DONORS IN PATIENTS WITH SEVERE THALASSEMIA : SYSTEMATIC REVIEW AND META-ANALYSIS <i>Poster Presenter:</i> Sirichai Srichairatanakool (Thailand)	08:30 - 08:30
B018	IMPACT OF DONOR BLOOD GROUP AND CMV MATCH ON ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER LONG TERM FOLLOW UP STUDY <i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	08:30 - 08:30
P082	DIFFERENCES IN OVERALL SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT WITH IDENTICAL AND HAPLOIDENTICAL DONORS IN MEXICO <i>Poster Presenter:</i> Marco Alejandro Jiménez-Ochoa (Mexico)	08:30 - 08:30
P083	ALLOGENEIC STEM CELL TRANSPLANTATION IN AN ISOIMMUNIZED PATIENT WITH HEREDITARY CD36 DEFICIENCY	08:30 - 08:30

TYPE I*Poster Presenter:* Philipp Nakov (Germany)

P084 **ANTI-T LYMPHOCYTE GLOBULIN (ATLG) TO PREVENT GRAFT FAILURE AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH DONOR SPECIFIC ANTIBODIES (DSA)** 08:30 - 08:30

Poster Presenter: Christian Niederwieser (Germany)

P085 **HAPLOIDENTICAL TRANSPLANT WITH POST- CY WITHOUT T DEPLETION. PEDIATRIC EXPERIENCE IN HIGH-RISK LEUKEMIAS FROM GATMO [ARGENTINIAN GROUP OF BONE MARROW TRANSPLANT]** 08:30 - 08:30

Poster Presenter: Maria Laura Rizzi (Argentina)

P086 **DONOR SELECTION CRITERIA IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA: RETROSPECTIVE SINGLE-CENTER EVALUATION** 08:30 - 08:30

Poster Presenter: Saveria Capria (Italy)

P087 **IRANIAN DONORS SAVE LIVES: COLLABORATING WITH COMMUNITY ADVOCATES TO ADDRESS RACIAL DISPARITY IN ACCESS TO UNRELATED DONORS FOR ALLOGENEIC TRANSPLANTATION** 08:30 - 08:30

Poster Presenter: Farnaz Farahbakhsh (Canada)

P088 **INVESTIGATE THE POTENTIAL ASSOCIATION OF HLA ALLELES WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES** 08:30 - 08:30

Poster Presenter: Fatma Al Lawati (Oman)

P089 **ANALYSIS OF BONE MARROW TRANSPLANTATION OUTCOMES BETWEEN JAPANESE AND NON-JAPANESE DONORS AND RECIPIENTS** 08:30 - 08:30

Poster Presenter: Ryu Yanagisawa (Japan)

P090 **SUCCESSFUL OUT-PATIENT SELF-ADMINISTRATION OF MOBILISATION AGENTS FOR HAEMATOPOIETIC STEM CELL TRANSPLANT** 08:30 - 08:30

Poster Presenter: Yona Skosana (South Africa)

P091 **PSYCHOLOGICAL ASSESSMENT OF HEMATOPOIETIC STEM CELL DONORS UNDERGOING PERIPHERAL BLOOD STEM CELL MOBILISATION** 08:30 - 08:30

Poster Presenter: Alka Khadwal (India)

P092 **IMPACT AND EFFICACY OF DONOR TYPE IN ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LEUKEMIA, SINGLE CENTER EXPERIENCE** 08:30 - 08:30

Poster Presenter: Lazar Chadievski (North Macedonia)*ePoster*

08:30 - 18:00

ePoster area

Conditioning Regimens

B087 **ATG-TARGETED DOSING STRATEGY REDUCED CMV/EBV REACTIVATION AND IMPROVED SURVIVAL WITHOUT INCREASING GVHD AFTER URD-PBSCT : A SINGLE-CENTER, PROSPECTIVE ,SINGLE-ARM, CLINICAL TRIAL** 08:30 - 08:30

Poster Presenter: Sheng Chen (China)

B088 **COMPARISON OF TWO REDUCED-INTENSITY CONDITIONING REGIMENS: BALTIMORE WITH CLOFARABINE VERSUS THIOTEPA-BUSULFAN-FLUDARABINE IN ADULTS RECEIVING HAPLOIDENTICAL TRANSPLANTATION FOR MYELOID MALIGNANCIES: A RETROSPECTIVE STUDY OF THE SFGM-TC** 08:30 - 08:30

	<i>Poster Presenter:</i> Prof. Patrice Chevallier (France)	
B089	IMPACT OF FLUDARABINE DOSE ON OUTCOME AFTER ALLO-HCT WITH REDUCED INTENSITY CONDITIONING FOR OLDER PATIENTS WITH AML: A STUDY FROM THE ALWP OF THE EBMT <i>Poster Presenter:</i> Guillaume Dachy (Belgium)	08:30 - 08:30
B090	TOXICITY COMPARISON OF TWO REDUCED INTENSITY CONDITIONING (RIC) TRANSPLANT REGIMENS FOR ADULT ALL IN CR1/2: RESULTS FROM THE RANDOMISED PHASE 2 MULTICENTRE ALL-RIC TRIAL <i>Poster Presenter:</i> Dr. Anna Castleton (United Kingdom)	08:30 - 08:30
B091	CXCR4 DIRECTED ENDORADIO THERAPY WITH [¹⁷⁷Lu] PENTIXATHER ADDED TO TBI IS FEASIBLE AND SPARES THE HEMATOPOIETIC NICHE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Krischan Braitsch (Germany)	08:30 - 08:30
B092	EVALUATION OF THE TRANSPLANT CONDITIONING INTENSITY (TCI) SCORE FOR SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT2) - A STUDY OF THE ALWP OF THE EBMT <i>Poster Presenter:</i> Giuliano Filippini Velázquez (Germany)	08:30 - 08:30
B093	VENETOCLAX COMBINED WITH FLUDARABINE AND MELPHALAN CONDITIONING REGIMEN IN PATIENTS > 50 YEARS WITH MYELOID MALIGNANCIES: INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, PHASE II TRIAL <i>Poster Presenter:</i> Panpan Zhu (China)	08:30 - 08:30
B094	FLUDARABINE/TREOSULFAN VS. FLUDARABINE/TBI CONDITIONING FOR ALLOSCT FOR AML AND MDS: COMPARABLE SURVIVAL RATES BUT DIVERGENT IMMUNE RECONSTITUTION <i>Poster Presenter:</i> Matthias Stelljes (Germany)	08:30 - 08:30
B095	CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): INTERMEDIATE-DOSE TBI DOES THE JOB <i>Poster Presenter:</i> Prof. Dr. Thomas Luft (Germany)	08:30 - 08:30
B096	5-YEAR TRANSPLANT SUCCESS AFTER TREOSULFAN CONDITIONING <i>Poster Presenter:</i> Rohtesh S. Mehta (United States)	08:30 - 08:30
B097	EFFICACY ANALYSIS OF HAPLOIDENTICAL TRANSPLANTATION USING BUSULFAN/CYCLOPHOSPHAMIDE AND MELPHALAN AS CONDITIONING REGIMEN FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Zhijie Wei (China)	08:30 - 08:30
B098	POST-TRANSPLANT CYCLOPHOSPHAMIDE RESULTS IN LOW INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN UNRELATED OR MATCHED-SIBLING DONOR STEM CELL TRANSPLANTATION WITHOUT COMPROMISING IMMUNE RECONSTITUTION AND GRAFT-VERSUS-LEUKEMIA EFFECT <i>Poster Presenter:</i> Ioannis Tsonis (Greece)	08:30 - 08:30
B099	CONDITIONING INTENSITY IN STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Dr. Jaime Sanz (Spain)	08:30 - 08:30
B100	EVALUATION OF A BALTIMORE MODIFIED NON-TBI CONDITIONING BEFORE ALLOGENEIC TRANSPLANT FROM HAPLOIDENTICAL OR MISMATCHED UNRELATED DONORS,	08:30 - 08:30

	RESULTS FROM A MONOCENTRIC RETROSPECTIVE STUDY <i>Poster Presenter:</i> Victoria Volpari (France)	
B101	EXPLORING THE IMPACT OF CONDITIONING REGIMEN INTENSITY ON ALLOGENEIC STEM CELL TRANSPLANT OUTCOMES: INSIGHTS FROM A SINGLE-CENTER STUDY <i>Poster Presenter:</i> Vera Radici (Italy)	08:30 - 08:30
B102	IMPACT OF PRETRANSPLANT MRD IN PATIENTS ALLOGRAFTED FOR AML AFTER TREOSULFAN-BASED CONDITIONING <i>Poster Presenter:</i> Jacob Pyka (Germany)	08:30 - 08:30
B103	FLUDARABINE TREOSULFAN REDUCED-INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN FRAIL/OLDER AML PATIENTS: PRELIMINARY RESULTS OF A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Raynier Devillier (France)	08:30 - 08:30
B104	PHARMACOKINETIC ANALYSIS OF TARGETED DOSING OF ANTITHYMOCYTE GLOBULIN IN ADULTS: A PROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Jishan Du (China)	08:30 - 08:30
B105	THE COMBINATION OF FLUDARABINE, BUSULFAN AND ANTI-T LYMPHOCYTE GLOBULIN IS WELL TOLERATED AND OFFERS EFFECTIVE REDUCED INTENSITY CONDITIONING THERAPY FOR PATIENTS WITH MYELOID DISEASE <i>Poster Presenter:</i> Chris Armstrong (Ireland)	08:30 - 08:30
B106	COMPARING PTCY AND GIAC IN HAPLOIDENTICAL SETTINGS: UPDATED ANALYSIS FROM A NATIONWIDE TRANSPLANTATION REGISTRY <i>Poster Presenter:</i> Yi-Wei Lee (Taiwan)	08:30 - 08:30
B107	THE RESULTS OF ALLOGENEIC HSCT AFTER TREOSULFAN-BASED CONDITIONING REGIMEN IN CHILDREN WITH AML: MULTICENTER RETROSPECTIVE STUDY OF THE POLISH PEDIATRIC STUDY GROUP FOR HSCT <i>Poster Presenter:</i> Agnieszka Sobkowiak-Sobierajska (Poland)	08:30 - 08:30
B108	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS AFTER CONDITIONING WITH FLUDARABINE/TOTAL BODY IRRADIATION(2GY) WITH OR WITHOUT ANTI-THYMOCYTE GLOBULINE OR POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Thomas Heinicke (Germany)	08:30 - 08:30
B109	CONFIRMING BETTER OUTCOMES WITH TBI-BASED MYELOABLATIVE CONDITIONING FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION EVEN IN SECOND COMPLETE REMISSION <i>Poster Presenter:</i> Mario Delia (Italy)	08:30 - 08:30
B110	POST TRANSPLANT CYCLOPHOSPHAMIDE PLUS ABATACEPT LEADS TO DECREASED DAY +30 CHIMERISM LEVELS <i>Poster Presenter:</i> Peter Abdelmessieh (United States)	08:30 - 08:30
B111	HEMATOPOIETIC STEM CELL TRANSPLANT WITH REGULATORY AND CONVENTIONAL T CELL ADOPTIVE IMMUNOTHERAPY IN TP53-MUTATED/DELETED AML <i>Poster Presenter:</i> Antonio Pierini (Italy)	08:30 - 08:30
B112	LOMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN (LEAM)	08:30 - 08:30

	PROTOCOL AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH LYMPHOMAS: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Željko Prka (Croatia)	
B113	SAFETY AND EFFICACY OF BUSULFAN 9.6 BASED RIC (AUGMENTED RIC) IN OLDER PATIENTS WITH AML WHO ARE NOT SUITABLE FOR MAC <i>Poster Presenter:</i> Kalina Abrol (Canada)	08:30 - 08:30
B114	TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA <i>Poster Presenter:</i> Anthony Stein (United States)	08:30 - 08:30
B115	TREOSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Aura Arola (Finland)	08:30 - 08:30
B116	CONDITIONING WITH I.V. BUSULFAN, ONCE VERSUS FOUR TIMES DAILY IN ADULTS: IMPACT ON PHARMACOKINETICS, ORGAN TOXICITIES AND SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Prof. Jakob Passweg (Switzerland)	08:30 - 08:30
B117	NON MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING IN ELDERLY PATIENTS WITH PTCY. A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS FROM GATMO-TC <i>Poster Presenter:</i> Mariano Berro (Argentina)	08:30 - 08:30
B118	IMPACT OF TRANSPLANT CONDITIONING INTENSITY ON BOTH ACUTE AND CHRONIC GVHD IN HAPLO-PTCY TRANSPLANT: TWO GITMO CENTRES' EXPERIENCE <i>Poster Presenter:</i> Dr. Maria Teresa Lupo Stanghellini (Italy)	08:30 - 08:30
B119	CHANGES IN PROGNOSTIC VARIABLES FOR ALLOGENEIC TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING IN ELDERLY PATIENTS OVER TIME <i>Poster Presenter:</i> Prof. Seong Kyu Park (Korea, Republic of)	08:30 - 08:30
B120	COMPARISON OF FLUDARABINE-MELPHALAN AND FLUDARABINE-TREOSULFAN AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maria Liga (Greece)	08:30 - 08:30
B121	PHARMACOKINETIC-TARGETING AND DOSE-ADJUSTMENT OF I.V. BUSULFAN FOR MYELOABLATIVE CONDITIONING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Rutvij Khanolkar (Canada)	08:30 - 08:30
B122	OUTCOMES OF PATIENTS WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1 UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH A FIXED TRANSPLANTATION POLICY INCLUDING A CHEMOTHERAPY-BASED CONDITIONING <i>Poster Presenter:</i> Raffaella Ceretti (Italy)	08:30 - 08:30
B123	DESENSITISATION TREATMENT FOR HLA-DONOR SPECIFIC ANTIBODIES IN EX-VIVO T CELL DEPLETED HAPLOIDENTICAL ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT - A MULTI-CENTRE RETROSPECTIVE STUDY IN SINGAPORE <i>Poster Presenter:</i> Prof. William Hwang (Singapore)	08:30 - 08:30

B124	PROMISING OUTCOMES IN HAPLOIDENTICAL TRANSPLANTATION USING ABATACEPT IN COMBINATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE IN TREOSULFAN BASED CONDITIONING REGIMEN <i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	08:30 - 08:30
B125	A NOVEL REDUCED TOXICITY CONDITIONING REGIMEN FOR OLDER MYELODYSPLASTIC NEOPLASMS PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A PROSPECTIVE COHORT STUDY <i>Poster Presenter:</i> Wen-Jing Yu (China)	08:30 - 08:30
P181	FOLLOW-UP OF TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA RECEIVED BUSULFAN-BASED CONDITIONING VERSUS HIGH-DOSE MELPHALAN <i>Poster Presenter:</i> Seonyang Park (Korea, Republic of)	08:30 - 08:30
P182	PRE-GRAFT IMMUNE STATUS PREDICTS SURVIVALS AND RELAPSE IN ADULTS RECEIVING MATCHED PERIPHERAL BLOOD ALLOTRANSPLANT FOR MYELOID MALIGNANCIES <i>Poster Presenter:</i> Prof. Patrice Chevallier (France)	08:30 - 08:30
P183	RETROSPECTIVE EVALUATION OF NUTRITIONAL STATUS PRE AND POST HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Yuva Vishalini Ravindran (United Kingdom)	08:30 - 08:30
P184	BEAM/LEAM VERSUS LACE CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMAS - A RETROSPECTIVE, SINGLE-CENTRE ANALYSIS OF CLINICAL OUTCOMES AND TOXICITY PROFILE <i>Poster Presenter:</i> Hegta Tainá Rodrigues Figueiroa (Brazil)	08:30 - 08:30
P185	CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING BUSULFAN/CYCLOPHOSPHAMIDE AND MELPHALAN OR THIOTEPA AS CONDITIONING REGIMEN IN 37 PATIENTS WITH ACUTE MEGAKARYOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Fei Pan (China)	08:30 - 08:30
P186	REAL-WORLD, SINGLE-CENTRE OUTCOME DATA OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION UTILISING TREOSULFAN-BASED CONDITIONING REGIMENS <i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	08:30 - 08:30
P187	SEQUENTIAL CONDITIONING REGIMEN WITH THIOTEPA, CLOFARABINE AND BUSULFAN (TEC/CLOB2A2) AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ADULTS WITH REFRACTORY AML: A RETROSPECTIVE MONOCENTRIC STUDY <i>Poster Presenter:</i> Prof. Patrice Chevallier (France)	08:30 - 08:30
P188	IMPACT OF CO-ADMINISTERED ACETAMINOPHEN ON BUSULFAN PHARMACOKINETICS <i>Poster Presenter:</i> Rutvij Khanolkar (Canada)	08:30 - 08:30
P189	T CELL REplete MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANT USING THIOTEPA BASED CONDITIONING- SINGLE CENTRE STUDY FROM INDIA <i>Poster Presenter:</i> Divya Doval (India)	08:30 - 08:30
P190	TREOSULFAN-BASED CONDITIONING REGIMEN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE SERIES OF SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Ilgen Sasmaz (Turkey)	08:30 - 08:30
P191	A MODIFIED BUSULFAN/CYCLOPHOSPHAMIDE	08:30 - 08:30

	PRECONDITIONING REGIMEN INCORPORATING SELINEXOR FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AML/MDS	
	<i>Poster Presenter:</i> Xiaofei Ni (China)	
P192	MITOCHONDRIAL COPY NUMBER VARIATION AS A SURROGATE MARKER OF ACQUIRED RESISTANCE TO THE BIFUNCTIONAL ELECTROPHILIC CHEMOTHERAPEUTIC DRUG BUSULFAN	08:30 - 08:30
	<i>Poster Presenter:</i> Isabelle Dupanloup (Switzerland)	
P193	CLOFARABINE, MELPHALAN AND THIOTEPA REDUCED-INTENSITY CONDITIONING CHEMOTHERAPY ALONG WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANT	08:30 - 08:30
	<i>Poster Presenter:</i> Rajneesh Nath (United States)	
P194	IMPLEMENTATION OF MACHINE LEARNING TO MEASURE THE IMPACT OF OVER- AND UNDER-EXPOSURE, AND PREDICT BUSULFAN'S PHARMACOKINETICS, IN PATIENTS RECEIVING CONDITIONING PRIOR TO HSCT	08:30 - 08:30
	<i>Poster Presenter:</i> Benjamin Bouchacourt (France)	
P195	THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ASCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Weihua Zhai (China)	
P196	SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING AND DONOR CHANGES IN HEMATOLOGICAL NON-MALIGNANCIES AFTER THE FIRST TAB+ CELL DEPLETED HAPLO-HSCT	08:30 - 08:30
	<i>Poster Presenter:</i> Jianyun Liao (China)	
P197	FIRST ALLOGENIC STEM CELL TRANSPLANTATION IN A PATIENT WITH ROIFMAN SYNDROME AND EBV-ASSOCIATED PLASMABLASTIC LYMPHOMA RELAPSE USING AUC CONTROLLED BUSULFAN BASED MYELOABLATIVE CONDITIONING	08:30 - 08:30
	<i>Poster Presenter:</i> Uwe Thiel (Germany)	
P198	A NOVEL AND SAFE PROTOCOL FOR PATIENTS WITH HCT-CI ≥ 3 WHO UNDERGO HAPLO-HSCT: A SINGLE-CENTER PROSPECTIVE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Wei Sun (China)	
P199	HIGH GRAFT FAILURE WITH FLUDARABINE, TREOSULPHAN CONDITIONING REGIMEN IN MYELOID MALIGNANCIES	08:30 - 08:30
	<i>Poster Presenter:</i> Sinem Civriz Bozdağ (Turkey)	
P200	ALLOGENEIC TRANSPLANTATION USING MYELOABLATIVE CONDITIONING REGIMENS IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS OVER 60 YEARS WITH AML AND MDS	08:30 - 08:30
	<i>Poster Presenter:</i> Yan-Li Zhao (China)	
P201	MODIFIED GIAC CONDITIONING REGIMEN IN HAPLOIDENTICAL TRANSPLANT: SINGLE CENTRE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Sabitha Paramasivam (India)	
P202	AUTOLOGOUS HEMATOPIETIC STEM CELL TRANSPLANT IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH BUSULPHAN THIOTEPA CONDITIONING	08:30 - 08:30
	<i>Poster Presenter:</i> Vibhor Sharma (India)	
P203	COMPARISON BETWEEN DIFFERENT REDUCED INTENSITY CONDITIONING REGIMENS IN AML OR MDS	08:30 - 08:30

Poster Presenter: José Emilio Salinas (Chile)

ePoster

08:30 - 18:00

ePoster area

Experimental Transplantation and Gene Therapy

- | | | |
|------|---|---------------|
| A121 | <p>PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS</p> <p><i>Poster Presenter:</i> Alejandro Villar-Prados (United States)</p> | 08:30 - 08:30 |
| A122 | <p>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING DONOR CAR-T CELLS FOR R/R B-CELL LYMPHOMA AND R/R MULTIPLE MYELOMA FAILING CAR T-CELL THERAPY</p> <p><i>Poster Presenter:</i> Rui Liu (China)</p> | 08:30 - 08:30 |
| A123 | <p>SMADCAM-1 IS DECREASED AFTER ALLOHCT, ALONG WITH GUT MICROBIOTA DYSBIOSIS, AND IS ASSOCIATED WITH HEMATOPOIETIC RECOVERY</p> <p><i>Poster Presenter:</i> Karen Fadel (France)</p> | 08:30 - 08:30 |
| A124 | <p>PENTOSTATIN AND CYCLOPHOSPHAMIDE DECREASE GRAFT REJECTION BUT INCREASE TRANSPLANT-RELATED COMPLICATIONS IN HAPLOIDENTICAL HCT FOR SICKLE CELL DISEASES</p> <p><i>Poster Presenter:</i> Dr. Matthew Hsieh (United States)</p> | 08:30 - 08:30 |
| A125 | <p>GRANULOCYTES TO INDUCE DONOR-DERIVED T CELL EXPANSION AFTER T REPLETE, MISMATCHED CB IN POST-TRANSPLANT RELAPSED AND REFRACTORY PAEDIATRIC ACUTE LEUKAEMIA: RESULTS OF GRANS TRIAL</p> <p><i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)</p> | 08:30 - 08:30 |
| A126 | <p>GENOME EDITING OF LONG-TERM REPOPULATING HEMATOPOIETIC STEM CELLS USING CCR5-UCO-HETTALLEN</p> <p><i>Poster Presenter:</i> Alexander Kulagin (Russian Federation)</p> | 08:30 - 08:30 |
| P069 | <p>AZACITIDINE COMBINED WITH INTERFERON A FOR PREEMPTIVE TREATMENT OF AML/MDS AFTER ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: A PROSPECTIVE PHASE II STUDY</p> <p><i>Poster Presenter:</i> Chongmei Huang (China)</p> | 08:30 - 08:30 |
| P070 | <p>ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES PROGNOSIS IN AML PATIENTS WITH CSF3R MUTATION AND CEBPA DOUBLE MUTATION</p> <p><i>Poster Presenter:</i> Yawei Zheng (China)</p> | 08:30 - 08:30 |

ePoster

08:30 - 18:00

ePoster area

Patient Advocacy: Patients' Reported Outcome and Expectations

- | | | |
|------|--|---------------|
| P377 | <p>THERAPEUTIC UTILISATION ACROSS THE SPECTRUM OF LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA - AN ANALYSIS OF THE LYMPHOMA COALITION'S 2022 GLOBAL PATIENT SURVEY</p> <p><i>Poster Presenter:</i> Ms. Natacha Bolaños (Spain)</p> | 08:30 - 08:30 |
| P378 | <p>A DIETETIC PREHABILITATION SERVICE WITHIN A MULTI-PROFESSIONAL PREHABILITATION SERVICE FOR PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): EVALUATED WITH PATIENT REPORTED EXPERIENCE AND OUTCOME MEASURES</p> | 08:30 - 08:30 |

	<i>Poster Presenter:</i> Juliet Morgan (United Kingdom)	
P379	PREQOL - PILOT FEASIBILITY STUDY OF PROSPECTIVE SOCIOECONOMIC AND QUALITY OF LIFE DATA COLLECTION AMONG HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Dr. Gemma Pugh (United Kingdom)	08:30 - 08:30
P380	THE HLA-A, -B, -DRB1 ALLELES FREQUENCY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY IN MOROCCO <i>Poster Presenter:</i> Laaziri Khalid (Morocco)	08:30 - 08:30
P381	WHO ARE WE NOT HEARING FROM? IMPROVING DIVERSITY IN PATIENT INVOLVEMENT IN PUBLIC POLICY WORK <i>Poster Presenter:</i> Caitlin Farrow (United Kingdom)	08:30 - 08:30
P382	NEW LIFE OR DEATH: A RETROSPECTIVE REVIEW ON MORTALITY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN A PRIVATE TERTIARY HOSPITAL IN THE PHILIPPINES <i>Poster Presenter:</i> Joseph Angelo Madlambayan (Philippines)	08:30 - 08:30
P383	A QUALITATIVE STUDY TO EXPLORE THE IMPACT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ON PATIENT AND CARER HEALTH-RELATED QUALITY OF LIFE <i>Poster Presenter:</i> Katharina Ecsy (United Kingdom)	08:30 - 08:30
P384	INVESTIGATING THE IMPACT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ON PATIENT AND CARER HEALTH-RELATED QUALITY OF LIFE: A QUANTITATIVE STUDY <i>Poster Presenter:</i> Katharina Ecsy (United Kingdom)	08:30 - 08:30
P385	MICROWAVE AND RADIOFREQUENCY ABLATION TREATMENT FOR HEPATOCELLULAR CARCINOMA PATIENTS BRIDGED TO LIVER TRANSPLANTATION: META-ANALYTIC SYNTHESIS <i>Poster Presenter:</i> Rao Nargis Jahan (India)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
	Multiple Myeloma	
A273	REAL-WORLD OUTCOMES OF UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DEL (17P) <i>Poster Presenter:</i> Curtis Marcoux (Canada)	08:30 - 08:30
A274	IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE REAL-LIFE PRIMULA STUDY <i>Poster Presenter:</i> Immacolata Attolico (Italy)	08:30 - 08:30
A275	SAFETY AND EARLY EFFICACY OF TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER DARATUMUMAB VTD INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA <i>Poster Presenter:</i> Annalisa Natale (Italy)	08:30 - 08:30
A276	RESPONSE AND SURVIVAL IMPROVEMENT WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: DIFFERENT INDUCTION THERAPY IMPACT OVER THE LAST 30 YEARS <i>Poster Presenter:</i> José Miguel Mateos Pérez (Spain)	08:30 - 08:30
A277	OUTCOMES OF FRAIL PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY/AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA	08:30 - 08:30

	<i>Poster Presenter:</i> Stephanie Yohay (United States)	
P309	BASILINE INVESTIGATIONS AND AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES: A RETROSPECTIVE REVIEW OF ECHOCARDIOGRAPHY AND PULMONARY FUNCTION TESTS <i>Poster Presenter:</i> Yousif Badri (United Kingdom)	08:30 - 08:30
P310	IMPROVED SURVIVAL OF MULTIPLE MYELOMA PATIENTS IN RELAPSE AFTER AUTOLOGOUS STEM CELL FOR THOSE WHO PREVIOUSLY ACHIEVED COMPLETE REMISSION AFTER TRANSPLANT <i>Poster Presenter:</i> Nour Moukalled (Lebanon)	08:30 - 08:30
P311	NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELL AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA AS A SAFE ALTERNATIVE IN COUNTRIES WITH LOW RESOURCES: A NINE-YEARS OF BICENTRIC EXPERIENCE <i>Poster Presenter:</i> Siham Ahchouch (Morocco)	08:30 - 08:30
P312	UP-FRONT HIGH DOSE MELPHALAN AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA - SINGLE CENTER REAL-WORLD ANALYSIS OF 165 CASES <i>Poster Presenter:</i> Nobuhiro Tsukada (Japan)	08:30 - 08:30
P313	SELINEXOR ADDED TO MELPHALAN CONDITIONING FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA <i>Poster Presenter:</i> Jiali Li (China)	08:30 - 08:30
P314	SALVAGE SECOND AUTOLOGOUS STEM CELL TRANSPLANTS FOR PATIENTS WITH MYELOMA: A 24-YEAR RETROSPECTIVE AUDIT IN A NATIONAL TERTIARY REFERRAL CENTRE (1999-2022) <i>Poster Presenter:</i> Micheal Brennan (Ireland)	08:30 - 08:30
P315	SETTING UP A HEMATOPOIETIC STEM CELL TRANSPLANT PROGRAM IN BAHRAIN -EXPERIENCE FROM BAHRAIN ONCOLOGY CENTER <i>Poster Presenter:</i> Hazem Afify (Bahrain)	08:30 - 08:30
P316	NOVEL DRUGS INCLUDING MONOCLONAL ANTIBODIES AND/OR DONOR LYMPHOCYTE INFUSIONS CONFERRED LONG TERM SURVIVAL TO MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Chiara Nozzoli (Italy)	08:30 - 08:30
P317	HAPLOIDENTICAL ALLOGENEIC CELL TRANSPLANTATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA <i>Poster Presenter:</i> Julia Frimmel (Germany)	08:30 - 08:30
P318	ANTI-HLA ANTIBODIES AND INCIDENCE OF PLATELET TRANSFUSION IN PATIENTS WITH MULTIPLE MYELOMA AFTER AUTO-HSCT <i>Poster Presenter:</i> Sergey Gritsaev (Russian Federation)	08:30 - 08:30
P319	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL HARVESTING AND UTILIZATION IN MULTIPLE MYELOMA PATIENTS IN LUHS KAUNAS CLINICS, LITHUANIA 2015-2022 <i>Poster Presenter:</i> Titas Tiskevicius (Lithuania)	08:30 - 08:30
P320	SAFETY AND EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS <i>Poster Presenter:</i> Arda Bayar (Turkey)	08:30 - 08:30
P321	EFFICACY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG AND HIGH-RISK MULTIPLE MYELOMA PATIENTS	08:30 - 08:30

	<i>Poster Presenter:</i> Pan Pan (China)	
P322	AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AT DHARMAIS HOSPITAL - INDONESIAN NATIONAL CANCER CENTER <i>Poster Presenter:</i> Resti Mulya Sari (Indonesia)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
CAR-based Cellular Therapy - Preclinical		
A063	CAR T CELLS TARGETING CD28 SHOW PRECLINICAL ACTIVITY AGAINST T-ALL <i>Poster Presenter:</i> Tobias Feuchtinger (Germany)	08:30 - 08:30
A064	A REVERSIBLE SWITCH FOR CAR-T CELL BY GENETIC CODE EXPANSION SYSTEM <i>Poster Presenter:</i> Yue Liu (China)	08:30 - 08:30
A065	SIRT3 REGULATES CAR-T CELL DIFFERENTIATION AND EXHAUSTION STATE <i>Poster Presenter:</i> Yue Huang (China)	08:30 - 08:30
A066	HAMBURG REAL-WORLD EXPERIENCE WITH AXICABTAGENE CILOLEUCEL IN AGGRESSIVE B-CELL LYMPHOMA: IN-VIVO EXPANSION CORRELATES WITH TREATMENT OUTCOME <i>Poster Presenter:</i> Francis Ayuk (Germany)	08:30 - 08:30
A067	CD45-DIRECTED CAR-T CELLS WITH CD45 KNOCKOUT EFFICIENTLY KILL MYELOID LEUKEMIA AND LYMPHOMA CELLS IN-VITRO EVEN AFTER EXTENDED CULTURE <i>Poster Presenter:</i> Maraike Harfmann (Germany)	08:30 - 08:30
A068	COMPARISON OF CD123- AND CD33-CAR-NK CELL PREPARATIONS IN A XENOGRAFT MOUSE MODEL FOR TREATMENT OF ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Fenja Gierschek (Germany)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Lymphoma and Chronic Lymphocytic Leukaemia		
B264	THE IMPACT OF ORAL AND GUT MICROBIOTA WITH CONSIDERATION OF CLINICAL AND IMMUNOLOGICAL FACTORS ON MUCOSITIS OUTCOMES: AN ASIAN HAEMATOPOIETIC STEM CELL TRANSPLANT POPULATION <i>Poster Presenter:</i> Shu Ping Wong (Malaysia)	08:30 - 08:30
B265	FACTORS AFFECTING OUTCOME OF SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA RELAPSING OR PROGRESSING AFTER A FRONT-LINE PET-ADAPTED THERAPY <i>Poster Presenter:</i> Prof. Alessandro Rambaldi (Italy)	08:30 - 08:30
B266	REDUCED RELAPSE INCIDENCE AFTER CHECK-POINT INHIBITORS RELATIVE TO BRENTUXIMAB VEDOTIN AS SALVAGE THERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Jacopo Mariotti (Italy)	08:30 - 08:30
B267	LOW NON-RELAPSE MORTALITY ASSOCIATED WITH ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION AFTER CAR-T FAILURE IN PATIENTS AFFECTED BY LARGE B CELL LYMPHOMA	08:30 - 08:30

	<i>Poster Presenter:</i> Jacopo Mariotti (Italy)	
B268	TREOSULFAN-BASED CONDITIONING AND SIROLIMUS-PTCY GVHD PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AGGRESSIVE B-CELL NHL <i>Poster Presenter:</i> Lorenzo Lazzari (Italy)	08:30 - 08:30
B269	OUTCOME OF HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AT A SINGLE INSTITUTION OVER 20 YEARS <i>Poster Presenter:</i> Joanna Romejko-Jarosińska (Poland)	08:30 - 08:30
B270	IMPROVING RESULTS OF ALLO-HCT FOR PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA. A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Andrzej Frankiewicz (Poland)	08:30 - 08:30
B271	THE SINGLE-CELL LANDSCAPE EXPLORING ABNORMAL T CELL STATES AND DEVELOPMENTAL TRAJECTORIES IN HETEROGENEOUS NON-HODGKIN LYMPHOMA <i>Poster Presenter:</i> Yuqing Wang (China)	08:30 - 08:30
B272	BEYOND TRANSPLANTATION: BRENTUXIMAB'S IMPACT ON LONG-TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN ROMANIAN TRANSPLANT CENTERS <i>Poster Presenter:</i> Alina Daniela Tanase (Romania)	08:30 - 08:30
B273	A NOVEL PROGNOSTIC NOMOGRAM BASED ON IMAGING AND MOLECULAR PARAMETERS FOR NEWLY DIAGNOSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS <i>Poster Presenter:</i> Dezhi Huang (China)	08:30 - 08:30
B274	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG) <i>Poster Presenter:</i> Małgorzata Sobczyk-Kruszelnicka (Poland)	08:30 - 08:30
P288	OPTIMIZING OUTCOMES: THE VITAL SIGNIFICANCE OF TRANSPLANTATION IN RESCUING PATIENTS DISCONTENTED WITH INITIAL PERIPHERAL T-CELL LYMPHOMA TREATMENT <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
P289	LOW DOSE NIVOLUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY BEFORE AUTO-HSCT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA - A PILOT STUDY <i>Poster Presenter:</i> Rakesh Reddy Boya (India)	08:30 - 08:30
P291	PREDICTORS OF DELAYED PLATELET ENGRAFTMENT AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN LYMPHOMA <i>Poster Presenter:</i> Rita Costa e Sousa (Portugal)	08:30 - 08:30
P292	NON-MYELOABLATIVE ALLOGENEIC TRANSPLANTATION AFTER TOTAL SKIN ELECTRON BEAM THERAPY (TSEBT) IN CUTANEOUS T-CELL LYMPHOMA. A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Carlos De Miguel (Spain)	08:30 - 08:30
P293	ROLE OF AUTOLOGOUS STEM CELL TRANSPLANT IN PRIMARY AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA - A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Meredith Tan (Singapore)	08:30 - 08:30
P294	HIGH DOSE THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN 236 PATIENTS WITH HODGKIN LYMPHOMA ON 25 YEARS PERIOD (1998-2022)	08:30 - 08:30

	<i>Poster Presenter:</i> Sabrina Akhrouf (Algeria)	
P295	NON-CRYOPRESERVED AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA. ELEVEN-YEAR SINGLE CENTRE EXPERIENCE FROM ORAN. ALGERIA <i>Poster Presenter:</i> Nabil Yafour (Algeria)	08:30 - 08:30
P296	AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN MATURE NK/T-CELL LYMPHOMA: A TWO-CENTER RETROSPECTIVE REAL-LIFE ANALYSIS <i>Poster Presenter:</i> Michele Wieczorek (Italy)	08:30 - 08:30
P297	PRETREATMENT WITH RITUXIMAB IS SUSPECTED TO INCREASE RISK FOR OCCURRENCE OF VENO-OCCLUSIVE DISEASE IN PATIENTS WITH AGGRESSIVE LYMPHOMA AFTER ALLOGENEIC TRANSPLANT <i>Poster Presenter:</i> Ahmet Elmaagacli (Germany)	08:30 - 08:30
P298	A REAL WORLD EXPERIENCE WITH PD1 INHIBITORS IN RELAPSED/REFRACTORY HODGKINS LYMPHOMA <i>Poster Presenter:</i> Disha Kakkar (India)	08:30 - 08:30
P299	GENETIC PREDICTORS OF PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM NEXT-GENERATION SEQUENCING <i>Poster Presenter:</i> Jarosław Dybko (Poland)	08:30 - 08:30
P300	PEGFILGRASTIM AFTER CONDITIONING WITH BEAM AND AUTOLOGOUS HEMATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA PATIENTS <i>Poster Presenter:</i> Barbara Loteta (Italy)	08:30 - 08:30
P301	BEGEV AS SECOND-LINE SALVAGE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A REAL-LIFE EXPERIENCE <i>Poster Presenter:</i> Ant Uzay (Turkey)	08:30 - 08:30
P302	EVALUATION IN SARDINIAN GENETIC UNIQUENESS POPULATION: STEREOTYPED SUBSETS# AND MOLECULAR PROGNOSTIC MARKERS, CATEGORIZATION IN U-MUTATED POOR PROGNOSTIC GROUP OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) <i>Poster Presenter:</i> Fabio Culurgioni (Qatar)	08:30 - 08:30
P303	A NATIONWIDE STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA INCIDENCE AND MORTALITY IN THE REPUBLIC OF KOREA <i>Poster Presenter:</i> Ka-Won Kang (Korea, Republic of)	08:30 - 08:30
P304	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED AND REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA <i>Poster Presenter:</i> Lyudmila Zubarovskaya (Russian Federation)	08:30 - 08:30
P305	THE LONG-TERM IMPACT OF RITUXIMAB-BASED CHEMOIMMUNOTHERAPY IN PATIENTS WITH DLBCL, REAL WORLD OUTCOMES USING NATIONAL HEALTH INSURANCE DATABASE OF SOUTH KOREA <i>Poster Presenter:</i> Hyun Jung Lee (Korea, Republic of)	08:30 - 08:30
P306	HAPLOIDENTICAL TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FOR PATIENT WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE <i>Poster Presenter:</i> Vera Vasilyeva (Russian Federation)	08:30 - 08:30
P307	ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN LYMPHOMA: A SINGLE-CENTRE EXPERIENCE; A CASE SERIES	08:30 - 08:30

	<i>Poster Presenter:</i> Jan Miko Aaron Baybay (Philippines)	
P308	THE FIRST CASE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION AT DHARMAIS HOSPITAL - INDONESIAN NATIONAL CANCER CENTER <i>Poster Presenter:</i> Dwi Wahyunianto Hadisantoso (Indonesia)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
ePoster Viewing		
<i>ePoster</i> 08:30 - 18:00		ePoster area
Haematopoietic Stem Cells		
A001	THE IMPORTANCE OF CYTOGENETIC BONE MARROW TESTS IN POST-TRANSPLANT CARE OF PATIENTS AFTER ALLO-HSCT DUE TO ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME- A SINGLE-CENTER ANALYSIS <i>Poster Presenter:</i> Ewa Karakulska-Prystupiuik (Poland)	08:30 - 08:30
A002	INFECTION BY HUMAN HERPES VIRUS 6 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA <i>Poster Presenter:</i> María Suárez-Lledó (Spain)	08:30 - 08:30
A003	SECOND HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AS RESCUE STRATEGY FOR HIGH RISK CHILDREN WITH LEUKEMIA <i>Poster Presenter:</i> Prof. Adriana Balduzzi (Italy)	08:30 - 08:30
A004	DISTINCT CLINICO-BIOLOGICAL FEATURES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Xiaolin Yuan (China)	08:30 - 08:30
A005	DIFFERENT SOURCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR: RELATIONSHIP BETWEEN IMMUNE RECONSTITUTION, GRAFT-VERSUS-HOST DISEASE, AND VIRAL INFECTIONS <i>Poster Presenter:</i> Jianyun Liao (China)	08:30 - 08:30
A006	COMBINATION OF POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH ANTITHYMOCYTE GLOBULIN AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A SINGLE CENTER ANALYSIS <i>Poster Presenter:</i> Chiara Bernardi (Switzerland)	08:30 - 08:30
A007	TRIPLE STEM CELL INFUSION ALLEVIATE GRAFT VERSUS HOST DISEASE AND IMPROVE OUTCOME IN UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Guang-Cui He (China)	08:30 - 08:30
A008	HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION IN MULTI-REFRACTORY TESTICULAR GERM CELL CANCER: A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS <i>Poster Presenter:</i> Jose Sanchez Pina (Spain)	08:30 - 08:30
A009	KIR-MISMATCH IMPACTS THE OUTCOMES AFTER HLA-HAPLOIDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	08:30 - 08:30

	<i>Poster Presenter:</i> Lucía López Corral (Spain)	
A010	NOVEL AUTOMATIC APPLICATION FOR ENRICHMENT OF CD34+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY <i>Poster Presenter:</i> Julia Dzionek (Germany)	08:30 - 08:30
A011	UP-FRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST-LINE TREATMENT: A MULTICENTER REAL-WORLD ANALYSIS <i>Poster Presenter:</i> Shuang Fan (China)	08:30 - 08:30
A012	OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WISKOTT-ALDRICH SYNDROME <i>Poster Presenter:</i> Prof. Mary Slatter (United Kingdom)	08:30 - 08:30
A013	GENE MUTATION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RECURRENCE OF HEMATOPOIETIC NEOPLASM PATIENTS AFTER TRANSPLANTATION <i>Poster Presenter:</i> Jia Liu (China)	08:30 - 08:30
A014	STEM CELL TRANSPLANT ACTIVITY IN KYIV NATIONAL CANCER INSTITUTE IN THE CONDITIONS OF FULL-SCALE RUSSIAN AGGRESSION IN UKRAINE <i>Poster Presenter:</i> Nazar Shokun (Ukraine)	08:30 - 08:30
A015	SAFETY AND EFFICACY OF POMALIDOMIDE AND AZACITIDINE COMBINATION IN MRD-GUIDED PREEMPTIVE TREATMENT OF ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lu Wang (China)	08:30 - 08:30
A016	HOME-BASED HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE AND SAFER IN TERMS OF NUTRITIONAL PARAMETERS, TOXICITY AND LENGTH OF HOSPITALIZATION STAY <i>Poster Presenter:</i> Laura Pardo Gambarte (Spain)	08:30 - 08:30
A017	A RISK-ADAPTED STRATEGY TO SELECT AUTOLOGOUS OR ALLOGENEIC TRANSPLANT CONSOLIDATION IS EFFECTIVE IN MATURE T-CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Fabio Giglio (Italy)	08:30 - 08:30
A018	EFFECTS OF THE PERIPHERAL EXPANSION OF CYTOTOXIC T LYMPHOCYTES ON OUTCOMES FOLLOWING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Oriana Jimena López Godino (Spain)	08:30 - 08:30
A019	OUTCOME OF ALLO-HSCT IN THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER PREVIOUSLY TREATED WITH CHEMOTERAPY AND PARP INHIBITORS <i>Poster Presenter:</i> Fabio Giglio (Italy)	08:30 - 08:30
A020	EFFECTS OF LOW-DOSE HYPOMETHYLATING AGENTS ON THE PREVENTION OF RELAPSE AFTER TRANSPLANTATION IN PEDIATRIC HIGH-RISK AML <i>Poster Presenter:</i> Shaoyan Hu (China)	08:30 - 08:30
A021	OUTCOMES OF PEDIATRIC CHRONIC MYELOID LEUKEMIA IN ADVANCED PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING REGIMEN	08:30 - 08:30

	<i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	
A022	UPDATE ON DONOR DERIVED NK CELLS INFUSION FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT IN PEDIATRIC HIGH-RISK AND RELAPSED/REFRACTORY LEUKEMIA <i>Poster Presenter:</i> Francesco Paolo Tambaro (Italy)	08:30 - 08:30
A023	EFFECT OF CYTOMEGALOVIRUS REACTIVATION ON RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Nour Ben Abdeljelil (Tunisia)	08:30 - 08:30
A024	COMPARISONS OF SAFETY AND EFFICACY OF ALLO-HSCT AFTER CAR T-CELL OR CHEMOTHERAPY-BASED COMPLETE REMISSION IN PEDIATRIC T-ALL <i>Poster Presenter:</i> Ruijuan Sun (China)	08:30 - 08:30
A025	OUTCOMES AFTER BONE MARROW VERSUS PERIPHERAL BLOOD MATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED PROPHYLAXIS <i>Poster Presenter:</i> Joe S. Al-Ramahi (United States)	08:30 - 08:30
A026	LOWER INCIDENCE OF CHRONIC GVHD WITH ATLG AS GVHD PROPHYLAXIS IN ALL PATIENTS IN FIRST COMPLETE REMISSION UNDERGOING ALLOGENEIC SCT COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Normann Steiner (Germany)	08:30 - 08:30
A027	LONGITUDINAL FOLLOW-UP ON HUMORAL AND T CELL IMMUNE RESPONSES AFTER COVID-19 VACCINATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTED PATIENTS <i>Poster Presenter:</i> Alma Wegener (Denmark)	08:30 - 08:30
A028	HAPLOIDENTICAL DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION USING THIRD-PARTY CORD BLOOD COMPARED WITH MATCHED UNRELATED DONOR TRANSPLANTATION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Yajing Xu (China)	08:30 - 08:30
A029	EFFECTIVENESS OF 2ND LINE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE ERA OF CAR-T THERAPY <i>Poster Presenter:</i> Youngwoo Jeon (Korea, Republic of)	08:30 - 08:30
A030	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS: A RETROSPECTIVE MULTICENTER STUDY IN CHINA <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
A031	SAFETY AND EFFICACY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MUD, MMUD AND HAPLOIDENTICAL STEM CELL TRANSPLANTS IN PAEDIATRIC POPULATION <i>Poster Presenter:</i> Gloria Miguel (Spain)	08:30 - 08:30
A032	EFFICACY AND SAFETY OF THROMBOPOIETIN RECEPTOR AGONIST COMBINED WITH MSCS FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lidan Zhu (China)	08:30 - 08:30
A033	A SINGLE CENTER REAL-WORLD RETROSPECTIVE COHORT STUDY ON THE PREVENTION OF CYTOMEGALOVIRUS INFECTION WITH LETERMOVIR AFTER HLA HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Huanfeng Liu (China)	
A034	BEYOND BORDERS: HSCT'S GLOBAL SITUATIONS AND INDONESIA'S PURSUIT OF HEALTH EQUITY <i>Poster Presenter:</i> Daniel Rizky (Indonesia)	08:30 - 08:30
A035	EFFECTIVENESS OF THE SIMPLIFIED COMORBIDITY INDEX COMPARED TO THE HCT-CI AS A PREDICTOR OF TRANSPLANT RELATED MORTALITY AND OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maria Alejandra Nunez Atahualpa (Mexico)	08:30 - 08:30
A036	8 VS 12 GRAY TBI IN ALLOGENEIC SCT FOR ALL PATIENTS RESULTS IN SIMILAR SURVIVAL, BUT IMPROVED SURVIVAL FOR MRD+ PATIENTS AFTER 12 GRAY <i>Poster Presenter:</i> Normann Steiner (Germany)	08:30 - 08:30
A037	PROPHYLACTIC USE OF DEFIBROTIDE IN HIGH-RISK RECIPIENTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE OVER 8 YEARS <i>Poster Presenter:</i> Giulia Baresi (Italy)	08:30 - 08:30
A038	POST-TRANSPLANT MAINTENANCE THERAPY WITH AZACITIDINE FOR HIGH-RISK MYELOID MALIGNANCIES: WHO BENEFITS THE MOST? <i>Poster Presenter:</i> Xin Li (China)	08:30 - 08:30
A039	PHYSICIAN PERSPECTIVES ON THE BURDEN AND CLINICAL MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN TRANSPLANT RECIPIENTS IN CENTRAL AND EASTERN EUROPE <i>Poster Presenter:</i> Radovan Vrhovac (Croatia)	08:30 - 08:30
A040	THE DOSES OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL STEM CELL ALLOGRAFTS CAN BE REDUCED <i>Poster Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	08:30 - 08:30
A041	OUTCOMES WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY RELATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Poster Presenter:</i> Moazzam Shahzad (United States)	08:30 - 08:30
A042	OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THERAPY RELATED ACUTE MYELOID LEUKEMIA: MULTICENTER REAL-LIFE EXPERIENCE <i>Poster Presenter:</i> Costanza Fraenza (Italy)	08:30 - 08:30
A043	OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC DISEASES: A SINGLE-CENTER REAL-WORLD EXPERIENCE <i>Poster Presenter:</i> Marta Castelli (Italy)	08:30 - 08:30
A044	PERSPECTIVES OF GENERAL HEMATOLOGISTS ON A PROPOSED SHARED CARE MODEL FOR HSCT IN SAUDI ARABIA FOR SICKLE CELL DISEASE <i>Poster Presenter:</i> Abdulrahman Alsultan (Saudi Arabia)	08:30 - 08:30
P001	DOES AGE MATTER? IMPACT OF DONOR AGE IN ENGRAFTMENT AND GRAFT FUNCTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Alina Daniela Tanase (Romania)	08:30 - 08:30
P002	COMPARABLE RESULTS OF HAPLOIDENTICAL AND MATCHED RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH BLAST PHASES CHRONIC MYELOID LEUKEMIA <i>Poster Presenter:</i> Renat Badaev (Russian Federation)	08:30 - 08:30

P003	THE CLINICAL ANALYSIS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS <i>Poster Presenter:</i> Fang Xu (China)	08:30 - 08:30
P004	THE IMPACT OF THE TRAVELED DISTANCE TO THE TRANSPLANT CENTER ON THE CLINICAL OUTCOME OF ALLOGENEIC BONE MARROW TRANSPLANT PATIENTS <i>Poster Presenter:</i> Prof. Dr. Jean El-Cheikh (Lebanon)	08:30 - 08:30
P005	ANALYSIS OF THE EFFICACY OF LUSPATERCEPT IN THE TREATMENT OF ANEMIA AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lei Dong (China)	08:30 - 08:30
P006	RESOLUTION OF VOD/SOS WITH DEFIBROTIDE AFTER HSCT AND PERSISTENT HEPATIC DAMAGE: MONOCENTRIC PEDIATRIC EXPERIENCE <i>Poster Presenter:</i> Francesco Paolo Tambaro (Italy)	08:30 - 08:30
P007	NK-CELL INFUSIONS TO PREVENT RELAPSE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Nina Minakovskaya (Belarus)	08:30 - 08:30
P008	HAPLOIDENTICAL TRANSPLANTATION FOR PATIENTS WITH FANCONI ANEMIA HAPLOIDENTICAL TRANSPLANTATION FOR PATIENTS WITH FANCONI ANEMIA <i>Poster Presenter:</i> Eman Khattab (Jordan)	08:30 - 08:30
P009	SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA WITH ASCT IN ONCOSALUD - AUNA BETWEEN 2015 AND 2021 <i>Poster Presenter:</i> Shirley Quintana (Peru)	08:30 - 08:30
P010	ACCURATE DIETARY EVALUATION AND ADEQUATE NUTRITIONAL THERAPY ARE INDISPENSABLE FOR BETTER OUTCOMES OF ALLO-HSCT <i>Poster Presenter:</i> Yuki Mori (Japan)	08:30 - 08:30
P011	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY OVERCOME THE ADVERSE IMPACT OF IKZF1 ON THE PROGNOSIS OF B-ALL IN CR1 WITH NO DETECTABLE MINIMAL RESIDUAL DISEASE <i>Poster Presenter:</i> Jiali Wang (China)	08:30 - 08:30
P012	TOTAL MARROW IRRADIATION/ETOPOSIDE/ CYCLOPHOSPHAMIDE AND BUSULFAN/ETOPOSIDE/CYCLOPHOSPHAMIDE OVERCOME THE IMPACT OF PRE-TRANSPLANT MINIMAL RESIDUAL DISEASE ON OUTCOMES IN HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IN COMPLETE REMISSION <i>Poster Presenter:</i> Xiaoyan Zhao (China)	08:30 - 08:30
P013	ALLOGENOUS BONE MARROW TRANSPLANT IN HIGH-RISK CHRONIC MYELOID LEUKEMIA IN THE ERA TKI INHIBITOR: A SYSTEMATIC REVIEW <i>Poster Presenter:</i> Nia Novianti Siregar (Indonesia)	08:30 - 08:30
P014	LONELINESS AND RUMINATIONS IN CANCER PATIENT-CAREGIVER DYADS - ANALYSIS OF DAILY FLUCTUATIONS <i>Poster Presenter:</i> Małgorzata Sobczyk-Kruszelnicka (Poland)	08:30 - 08:30
P015	PATIENTS WITH FOLLICULAR LYMPHOMA AND CANDIDATES FOR AUTOLOGOUS TRANSPLANTATION: IS THE COLLECTION OF HEMATOPOIETIC PROGENITORS EFFICIENT AFTER THE FIRST LINE OF TREATMENT? <i>Poster Presenter:</i> Paula Zoco Gallardo (Spain)	08:30 - 08:30

P016	HAPLOIDENTICAL BONE MARROW TRANSPLANTATION IN A COLOMBIAN BMT UNIT: CLINICAL DESCRIPTION AND OUTCOMES <i>Poster Presenter:</i> Jorge Cuervo sierra (Colombia)	08:30 - 08:30
P017	TOXIC EFFECTS OF IMMUNOTHERAPY FOR CHILDREN WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Kirill Kirgizov (Russian Federation)	08:30 - 08:30
P018	CONTROVERSIAL INDICATION TO TRASPLANT: NOW OR NEVER? <i>Poster Presenter:</i> Giulia Baresi (Italy)	08:30 - 08:30
P019	HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Guzmán López de Hontanar (Spain)	08:30 - 08:30
P020	EARLY AUTOLOGOUS AND/OR ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH ADVANCED STAGE T- LYMPHOBLASTIC LEUKEMIA/LYMPHOMA OR BURKITT LYMPHOMA. A RETROSPECTIVE SINGLE-CENTRE ANALYSIS <i>Poster Presenter:</i> Normann Steiner (Germany)	08:30 - 08:30
P021	FIRST REPORT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION USED TO TREAT NOVEL <i>POLE</i> VARIANT-ASSOCIATED BONE MARROW FAILURE <i>Poster Presenter:</i> Kentaro Fujimori (Japan)	08:30 - 08:30
P022	SETTING UP THE FIRST PEDIATRIC BONE MARROW TRANSPLANTATION UNIT IN THE UAE AND THE EXPERIENCE OF COMPLETING THE FIRST 30 PEDIATRIC BMTS WITHOUT ANY MORTALITY <i>Poster Presenter:</i> Zainul Aabideen (United Arab Emirates)	08:30 - 08:30
P023	MONOCYTES IN ALLO-HSCT WITH AGED DONORS SECRET IL-1/IL-6/TNF TO INCREASE THE RISK OF GVHD AND DAMAGE THE AGED HSCS <i>Poster Presenter:</i> Xia Li (China)	08:30 - 08:30
P024	POST-TRANSPLANT CYCLOPHOSPHAMIDE ± ANTI-THYMOCYTE GLOBULIN IN PATIENTS WITH AML/MDN UNDERGOING ALLOGENEIC HCT WITH PBSC FROM HAPLOIDENTICAL DONOR: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Francesca Cavallaro (Italy)	08:30 - 08:30
P025	ROMIPLOSTIM TREATMENT FOR SEVERE THROMBOCYTOPENIA AFTER MIBG THERAPY AND AUTOLOGOUS HSCT IN HIGH-RISK NEUROBLASTOMA <i>Poster Presenter:</i> Ali Naderi (Iran)	08:30 - 08:30
P026	DESCRIPTION OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WHO UNDERWENT TO ALLOGENEIC STEM CELL TRANSPLANTATION IN A REFERENCE CENTER IN BOGOTA, COLOMBIA <i>Poster Presenter:</i> Carlos Fernando Gómez Calcetero (Colombia)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
CAR-based Cellular Therapy - Clinical		
A069	BRIDGING THERAPY PRIOR TO TREATMENT WITH ANTI-CD19 CAR T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS - A MULTINATIONAL RETROSPECTIVE ANALYSIS	08:30 - 08:30

	<i>Poster Presenter:</i> Tobias Feuchtinger (Germany)	
A070	SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS <i>Poster Presenter:</i> Kexin Wang (China)	08:30 - 08:30
A071	PREDICTIVE VALUE OF PRE-TREATMENT CIRCULATING TUMOR DNA GENOMIC LANDSCAPE IN PATIENTS WITH R/RMM UNDERGOING ANTI-BCMA CAR-T THERAPY: INSIGHTS FROM TUMOR CELLS AND T CELLS <i>Poster Presenter:</i> Rongrong Chen (China)	08:30 - 08:30
A072	FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA <i>Poster Presenter:</i> Olalekan Oluwole (United States)	08:30 - 08:30
A073	EUPLAGIA-1: SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE MANUFACTURED GLPG5201 ANTI-CD19 CAR-T CELLS DISPLAY EARLY PHENOTYPES IN RELAPSED/REFRACTORY CLL INCLUDING RT <i>Poster Presenter:</i> Esmée P. Hoefsmit (Netherlands)	08:30 - 08:30
A074	TAILORED VERSUS WIDESPREAD ANTIFUNGAL PROPHYLAXIS IN LYMPHOMA PATIENTS TREATED WITH CD19 CAR T- CELL THERAPY: RESULTS FROM A LARGE RETROSPECTIVE COHORT <i>Poster Presenter:</i> Alejandro Luna de Abia (United States)	08:30 - 08:30
A075	EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1-3 PRIOR LINES WHO RECEIVED CILTACABTAGENE AUTOLEUCEL AS STUDY TREATMENT CARTITUDE-4 TRIAL (PHASE 3) <i>Poster Presenter:</i> Jordan M. Schechter (United States)	08:30 - 08:30
A076	INCIDENCES AND FACTORS ASSOCIATED WITH EARLY HEMATOTOXICITY AFTER CAR T-CELL THERAPY ASSESSED BY EHA/EBMT ICAHT CRITERIA <i>Poster Presenter:</i> Dr. Emily Liang (United States)	08:30 - 08:30
A077	COMPARISON OF IMMUNOPHENOTYPIC AND FUNCTIONAL PROPERTIES OF ANTI-CD19 CAR-T CELL PRODUCTS MANUFACTURED USING CLINIMACS PRODIGY AND G-REX PLATFORMS <i>Poster Presenter:</i> Dmitriy Pershin (Russian Federation)	08:30 - 08:30
A078	ALLOGENEIC HSCT AFTER CAR T-CELL THERAPY HAD DELAYED PLATELET ENGRAFTMENT, HIGHER RISK OF CYTOMEGALOVIRUS VIRUS VIREMIA AND THROMBOTIC MICROANGIOPATHY COMPARED TO CHEMOTHERAPY <i>Poster Presenter:</i> Luxin Yang (China)	08:30 - 08:30
A079	AUTOMATED GRADING OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY <i>Poster Presenter:</i> Dr. Emily Liang (United States)	08:30 - 08:30
A080	RELEVANT STUDIES ON CYTOKINES LEVEL AND CAR-T EXPANSION ASSOCIATED TO CD7 CAR-T THERAPY <i>Poster Presenter:</i> Man Chen (China)	08:30 - 08:30
A081	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN RELAPSED REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA <i>Poster Presenter:</i> Rui Liu (China)	08:30 - 08:30
A082	SAFETY AND EFFICACY OF BENDAMUSTINE VERSUS	08:30 - 08:30

	FLUDARABINE-CYCLOPHOSPHAMIDE LYMPHODEPLETION PRIOR TO CAR-T CELL THERAPY WITH AXICABTAGENE CILOLEUCEL FOR NON-HODGKIN LYMPHOMA: A SINGLE-INSTITUTION STUDY <i>Poster Presenter:</i> Anthony Stack (United States)	
A083	PSEUDOPROGRESSION: A FREQUENT AND CLINICALLY RELEVANT ADVERSE EVENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY <i>Poster Presenter:</i> Torsten Schroeder (Germany)	08:30 - 08:30
A084	CAR-T CELL TREATMENT OF LARGE B-CELL LYMPHOMA (LBCL): DO PROGRAM DURATION AND TREATMENT LINE MATTER? <i>Poster Presenter:</i> Maria-Luisa Schubert (Germany)	08:30 - 08:30
A085	GENE-EDITED UNIVERSAL CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA <i>Poster Presenter:</i> Liu Fang (China)	08:30 - 08:30
A086	REAL-WORLD EXPERIENCE OF CAR T-CELL THERAPY: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Susana Pereira (Portugal)	08:30 - 08:30
A087	IMPACT OF ACUTE KIDNEY INJURY IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL <i>Poster Presenter:</i> Rafael Hernani (Spain)	08:30 - 08:30
A088	CHARACTERISTICS OF CENTRAL NERVOUS SYSTEM RELAPSE AFTER CD19 CAR-T CELL THERAPY IN R/R NHL <i>Poster Presenter:</i> Mengyu Zhao (China)	08:30 - 08:30
A089	DAY7-CART COUNT ENHANCES PREDICTIVE POWER OF PET30 AND POSSIBLY ANTICIPATES CD19 LOSS IN RELAPSE AFTER CART <i>Poster Presenter:</i> Fabian Müller (Germany)	08:30 - 08:30
A090	EXCELLENT OUTCOME OF CAR-T CELL THERAPY IN CHILDREN WITH PB-ALL RELAPSING POST HSCT, WHO HAD VERY LOW MRD AT LYMPHODEPLETING CHEMOTHERAPY - POLISH CENTRES' EXPERIENCE <i>Poster Presenter:</i> Karolina Liszka (Poland)	08:30 - 08:30
A091	THE DARK SIDE OF CORTICOSTEROIDS IN CD19.CAR-T CELL THERAPY <i>Poster Presenter:</i> Marcello Roberto (Italy)	08:30 - 08:30
A092	MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFECTIVE CHARACTERISTICS AMONG DIFFERENT BCMA TARGETING CAR-T IN TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMAS <i>Poster Presenter:</i> Chunrui Li (China)	08:30 - 08:30
A093	IMPACT OF EARLY CAR⁻ CD4⁺ T-LYMPHOCYTES RECOVERY FOLLOWING CAR-T CELL INFUSION FOR RELAPSED OR REFRACTORY B CELL LYMPHOMAS <i>Poster Presenter:</i> Massimiliano Gambella (Italy)	08:30 - 08:30
A094	ACUTE INFECTION AND BASELINE C-REACTIVE PROTEIN - KEY MARKERS OF PROGRESSION IN RELAPSED REFRACTORY DLBCL PATIENTS RECEIVING CAR-T CELL THERAPY <i>Poster Presenter:</i> Jayachandran Perumal Kalaiyarasi (United Kingdom)	08:30 - 08:30
A095	THIRD-LINE CAR-T IN PATIENTS WITH EARLY RELAPSE FOLLOWING FIRST-LINE TREATMENT FOR AGGRESSIVE B-CELL LYMPHOMA: STILL A VALUABLE OPTION <i>Poster Presenter:</i> Massimiliano Gambella (Italy)	08:30 - 08:30

A096	DEVELOPMENT OF DISEASE-SPECIFIC COMPOSITE END-POINTS OF TOXICITY-FREE, PROGRESSION-FREE SURVIVAL (TPFS) AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR PATIENTS WITH LARGE B-CELL LYMPHOMA AND MULTIPLE MYELOMA <i>Poster Presenter:</i> Aleksandr Lazaryan (United States)	08:30 - 08:30
A097	EASIX SCORE AS A PROGNOSTIC FACTOR OF CYTOKINE RELEASE SYNDROME IN CAR-T PATIENTS - A RETROSPECTIVE ANALYSIS OF MM AND LBCL COHORTS <i>Poster Presenter:</i> Jaromir Tomasik (Poland)	08:30 - 08:30
A098	HEMATOTOXICITY POST CAR-T CELL THERAPY: REAL-WORLD DATA ON RISK FACTORS AND OUTCOMES <i>Poster Presenter:</i> Zoi Bousiou (Greece)	08:30 - 08:30
A099	DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT UPDATE <i>Poster Presenter:</i> Guang-Cui He (China)	08:30 - 08:30
A100	A RETROSPECTIVE REVIEW TO IDENTIFY OPTIMAL LYMPHODEPLETION PRIOR TO TISAGENLECLEUCIL IN PATIENTS WITH REFRACTORY OR RELAPSED LARGE B-CELL LYMPHOMA IN SCOTLAND'S NATIONAL CAR-T CENTRE <i>Poster Presenter:</i> Daire Quinn (United Kingdom)	08:30 - 08:30
A101	LOCOMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - FINAL ANALYSIS AT 2-YEAR FOLLOW-UP <i>Poster Presenter:</i> Dr. Reuben Benjamin (United Kingdom)	08:30 - 08:30
A102	METAGENOMIC NEXT-GENERATION SEQUENCING VISUALLY DISPLAYS A FALSE-POSITIVE DETECTION OF HIV NUCLEIC ACID RELATED TO CART TREATMENT: A CASE STUDY IN A CHILD <i>Poster Presenter:</i> M. I. Zhou (China)	08:30 - 08:30
A103	IMPACT OF SERUM INTERLEUKIN 1-BETA LEVELS DURING CAR-T CELLS THERAPY ON CLINICAL OUTCOME: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Ilaria Cutini (Italy)	08:30 - 08:30
A104	THE SCOTTISH EXPERIENCE WITH CAR-T CELL THERAPY: A FOCUS ON DLBCL <i>Poster Presenter:</i> David Hopkins (United Kingdom)	08:30 - 08:30
A105	DONOR-DERIVED LYMPHOID ANTIGEN-DIRECTED CAR-T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 17 CASES <i>Poster Presenter:</i> Dmitriy Pershin (Russian Federation)	08:30 - 08:30
P045	CARDIOVASCULAR COMPLICATIONS OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY <i>Poster Presenter:</i> Giorgia Mancini (Italy)	08:30 - 08:30
P046	EFFICACY OF ANTI-CD19 CAR-T CELL TREATMENT IN MANTLE-CELL LYMPHOMA HARBORING P53 ALTERATION: A MONOCENTRIC RETROSPECTIVE STUDY <i>Poster Presenter:</i> Jacopo Mariotti (Italy)	08:30 - 08:30
P047	CORRELATION OF IL-6 LEVELS WITH THE EXPANSION OF LYMPHOCYTIC POPULATIONS, SEVERITY OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY FOLLOWING CAR-T CELL	08:30 - 08:30

THERAPY*Poster Presenter:* Maria Liga (Greece)

P048	OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE	08:30 - 08:30
	<i>Poster Presenter:</i> Cindy Krisnadi (Singapore)	
P049	PAPILIO-1: PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE FEASIBILITY, SAFETY AND EFFICACY OF POINT-OF-CARE-MANUFACTURED ANTI-BCMA CAR T-CELL THERAPY (GLPG5301) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	08:30 - 08:30
	<i>Poster Presenter:</i> Anna D.D. van Muyden (Belgium)	
P050	ASSESSMENT OF MALNUTRITION DURING PREHABILITATION FOR PATIENTS UNDERGOING CAR-BASED CELLULAR THERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> Juliet Morgan (United Kingdom)	
P051	EARLIER INTRATHECAL DEXAMETHASONE EFFECTIVELY ALLEVIATE IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME	08:30 - 08:30
	<i>Poster Presenter:</i> Qi Ji (China)	
P052	CHOICE OF COMMERCIALY AVAILABLE CAR T-CELLS PRODUCT FOR AGGRESSIVE LYMPHOMA: A SURVEY OF BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP) OF THE EBMT	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Dr. Florent Malard (France)	
P053	SEVERE HHV-6 RELATED ENCEPHALITIS FOLLOWING ANTI-CD19 CAR-T TREATMENT: A CASE STORY FROM A POINT OF CARE PRODUCTION FACILITY	08:30 - 08:30
	<i>Poster Presenter:</i> Katrine Kielsen (Denmark)	
P054	UNLOCKING POSSIBILITIES: THE IMPACT OF CYTOGENETIC ANALYSIS ON PATIENTS UNDERGOING CAR-T CELL THERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> Christos Varelas (Greece)	
P055	LEUKAPHERESIS FOR AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN CHILDREN: REPORT FROM A SINGLE PEDIATRIC CENTER	08:30 - 08:30
	<i>Poster Presenter:</i> June Iriondo (Spain)	
P056	T-CELL LARGE GRANULAR LYMPHOCYTE POPULATION INVOLVING CHIMERIC ANTIGEN RECEPTOR-MODIFIED T (CAR T) CELLS IN PATIENTS WITH CYTOPENIA AFTER CD19-TARGETED CAR T-CELL THERAPY: CASE SERIES	08:30 - 08:30
	<i>Poster Presenter:</i> Aya Albittar (United States)	
P060	TREATMENT WITH TISAGENLECLEUCEL OF RELAPSE REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA - SINGLE CENTER EXPERIENCE UHC ZAGREB	08:30 - 08:30
	<i>Poster Presenter:</i> Barbara Dreta (Croatia)	
P061	SERUM AMYLOID-A IN CAR-T CELL THERAPY: A NEW ACUTE PHASE REACTANT	08:30 - 08:30
	<i>Poster Presenter:</i> Eugenio Galli (Italy)	
P062	CHALLENGES IN CHIMERIC ANTIGEN RECEPTOR-T CELL PRODUCT ADMINISTRATION IN A HIGH TUMOR-BURDEN ELDERLY PATIENT WITH MANTLE-CELL LYMPHOMA	08:30 - 08:30
	<i>Poster Presenter:</i> Marta Lisa Battista (Italy)	
P063	REGIONAL REPRESENTATION OF THE OUTCOMES OF A COHORT OF PATIENTS WITH B-CELL ALL TREATED WITH TISAGENLECLEUCEL FROM A CENTRE IN THE MIDDLE EAST	08:30 - 08:30

	<i>Poster Presenter:</i> Fahad Bahkali MD (Saudi Arabia)	
P064	DELAYED ICANS IN POST BCMA CAR-T CELL THERAPY CHALLENGES <i>Poster Presenter:</i> Mohamed Abuhaleeqa (United Arab Emirates)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Stem Cell Mobilization, Collection and Engineering		
A045	THE EFFECT OF GRAFT MANIPULATION AND CRYOPRESERVATION ON DIFFERENT GRAFT COMPONENT AND ITS POTENTIAL CLINICAL APPLICATIONS <i>Poster Presenter:</i> Mohammed Kawari (Canada)	08:30 - 08:30
A046	A SIMPLE PREDICTIVE ALGORITHM FOR ESTIMATION OF THE BLOOD VOLUME TO BE PROCESSED TO YIELD TARGET CELL NUMBERS FOR MANUFACTURING OF TISA-CEL® AND AXI-CEL® <i>Poster Presenter:</i> Stephanie Winter (Austria)	08:30 - 08:30
A047	REAL-WORLD MOBILIZATION AND HARVEST OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING D-VTD: UK EXPERIENCE <i>Poster Presenter:</i> Jose Aspa Cilleruelo (United Kingdom)	08:30 - 08:30
A048	FACTORS AFFECTING CD34+ CRUDE COLLECTION EFFICIENCY IN MOBILIZED DONORS UNDERGOING LEUKOCYTAPHERESIS <i>Poster Presenter:</i> Jesús Fernandez (Spain)	08:30 - 08:30
A049	EFFICACY OF PROPHYLACTIC ANTIBIOTICS FOR THE PREVENTION OF NEUTROPENIC FEVER IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE FOR STEM CELL MOBILIZATION <i>Poster Presenter:</i> Juan Li (China)	08:30 - 08:30
A050	EFFICACY OF PLERIXAFOR IN CD34⁺ STEM CELL MOBILIZATION IN HEALTHY PEDIATRIC STEM CELL DONORS <i>Poster Presenter:</i> Vimal Kumar Gunasekaran (India)	08:30 - 08:30
A051	PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA <i>Poster Presenter:</i> Hegta Tainá Rodrigues Figueiroa (Brazil)	08:30 - 08:30
A052	IMPROVING AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN PERIPHERAL T CELL LYMPHOMA : A STUDY ON CD34+ CELL EX VIVO PURGING <i>Poster Presenter:</i> Youngwoo Jeon (Korea, Republic of)	08:30 - 08:30
A053	A MID-APHERESIS CD34 COUNT UTILITY IN EARLY STOPPAGE OF APHERESIS IN PATIENTS/DONORS IN A PBSCT PROCEDURE - ANALYSIS OF EXPERIENCE IN TWO SOUTH INDIAN CANCER CENTRES <i>Poster Presenter:</i> Veni Prasanna Gedala (India)	08:30 - 08:30
A054	PLERIXAFOR AS A MOBILIZING AGENT FOR SALVAGE HIGH-DOSE CHEMOTHERAPY IN RELAPSED/REFRACTORY TESTICULAR CANCER: AN EXPERIENCE OF 22 CASES <i>Poster Presenter:</i> Ugo De Giorgi (Italy)	08:30 - 08:30
A055	ASSESSING AND REFINING PREDICTIVE MODELS OF POTENTIAL POOR MOBILIZERS <i>Poster Presenter:</i> Kai Wan (United Kingdom)	08:30 - 08:30
A056	LEFT OUT IN THE COLD: STEM CELL GRAFTS ARE STILL FUNCTIONAL AFTER MORE THAN 20 YEARS IN CRYOSTORAGE	08:30 - 08:30

	<i>Poster Presenter:</i> Rebecca Axelsson Robertson (Sweden)	
A057	SAFETY AND EFFICACY OF PLERIXAFOR IN POOR MOBILIZERS: AN INTERIM ANALYSIS AND MULTICENTER PROSPECTIVE STUDY <i>Poster Presenter:</i> Jie Ji (China)	08:30 - 08:30
A058	BONE MARROW HARVESTING IN ALLOGENEIC DONORS: HOW TO PREDICT SUCCESSFUL AND SATISFYING BM PRODUCT <i>Poster Presenter:</i> Tigran Torosian (Poland)	08:30 - 08:30
A059	COMPARISON OF MOBILIZATION REGIMENS USED IN LYMPHOMA AND FACTORS THAT INFLUENCE PERIPHERAL BLOOD STEM CELL MOBILIZATION <i>Poster Presenter:</i> Laxma Reddy (India)	08:30 - 08:30
A060	THIRTEEN-YEAR EXPERIENCE WITH PLERIXAFOR IN CHILDREN FROM A SINGLE CENTRE: TOLERABILITY, GRAFT QUALITY AND ENGRAFTMENT <i>Poster Presenter:</i> Kamélia Alexandrova (France)	08:30 - 08:30
A061	AN ALTERNATIVE USE OF A COLLOIDAL SUBSTITUTE (SUCCINYLATED GELATINE) FOR QUALITY CONTROLS IN PERIPHERAL BLOOD STEM TRANSPLANTATION <i>Poster Presenter:</i> Claudia Del Fante (Italy)	08:30 - 08:30
P027	ANTI-CD38 TREATMENT AS A PREDICTIVE FACTOR FOR STEM CELL MOBILIZATION FAILURE AND DELAYED GRAFT RECOVERY IN MULTIPLE MYELOMA: A TERTIARY HOSPITAL EXPERIENCE <i>Poster Presenter:</i> Paula Zoco Gallardo (Spain)	08:30 - 08:30
P028	INCREASED DOSE OF G-CSF OVERCOMES AGE AS A RISK FACTOR FOR POOR MOBILIZATION <i>Poster Presenter:</i> Yuliya Shestovska (United States)	08:30 - 08:30
P029	THE IMPACT OF TRANSPORTATION TIME ON STEM HEMATOPOIETIC CELL VIABILITY AFTER CRYOPRESERVATION <i>Poster Presenter:</i> Iwona Mitrus (Poland)	08:30 - 08:30
P030	LENOGRASTIM AND FILGRASTIM: REAL-LIFE COMPARISON IN MOBILIZATION OF ALLOGENEIC HEMATOPOIETIC STEM CELL DONORS <i>Poster Presenter:</i> Rosamaria Nitti (Italy)	08:30 - 08:30
P031	NIVOLUMAB-IFOSFAMIDE-CARBOPLATIN-ETOPOSIDE (NICE) AS MOBILIZING REGIMEN FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA (R/R HL) <i>Poster Presenter:</i> Athanasios Liaskas (Greece)	08:30 - 08:30
P032	IMPACT OF DARATUMUMAB, BORTEZOMIB, THALIDOMIDE DEXAMETHASONE INDUCTION THERAPY ON STEM CELL MOBILIZATION: A REAL WORLD EXPERIENCE <i>Poster Presenter:</i> Giuseppe Sapienza (Italy)	08:30 - 08:30
P033	INSTITUTIONAL THRESHOLD OF PREAPHERESIS PERIPHERAL BLOOD CD34⁺ CELL COUNT: A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Yandy Marx Castillo Aleman (United Arab Emirates)	08:30 - 08:30
P034	APPLICATION OF GRANULOCYTE COLONY STIMULATING FACTOR DURING CYTAPHERESIS LEADS TO BETTER STEM CELL YIELDS <i>Poster Presenter:</i> Ivan Tonev (Bulgaria)	08:30 - 08:30
P035	COMPARISON OF CE CHEMOTHERAPY PLUS G-CSF VS. G-CSF ALONE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS	08:30 - 08:30

	<i>Poster Presenter:</i> Veronika Dill (Germany)	
P036	ENHANCING PRECISION IN PERIPHERAL BLOOD HAEMATOPOIETIC PROGENITOR CELL APHERESIS: A NOVEL APPROACH TO INTEGRATE COLLECTION EFFICIENCY VARIANCE FOR PRECISE CD34+ YIELD PREDICTION <i>Poster Presenter:</i> Kai Wan (United Kingdom)	08:30 - 08:30
P037	BLOOD TRANSFUSION NEEDS DURING PERIPHERAL BLOOD STEM CELL COLLECTION - A SINGLE-CENTER RETROSPECTIVE STUDY <i>Poster Presenter:</i> Ana Salselas (Portugal)	08:30 - 08:30
P038	ADAPTATION OF THE VOLUMETRIC METHOD ON THE FACSLYRIC CYTOMETER FOR THE ENUMERATION OF CD34+ STEM CELLS <i>Poster Presenter:</i> Mohamed Brahimi (Algeria)	08:30 - 08:30
P039	STEM CELL MOBILIZATION IN MULTIPLE MYELOMA: DESCRIPTIVE ANALYSIS AND PREDICTIVE FACTORS FOR STEM CELL MOBILIZATION FAILURE <i>Poster Presenter:</i> Laura Pardo Gambarte (Spain)	08:30 - 08:30
P040	MOBILIZATION AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA WITH DARATUMUMAB-BASED INDUCTION TREATMENTS <i>Poster Presenter:</i> Isabel Izquierdo (Spain)	08:30 - 08:30
P041	STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER STUDY IN TUNISIA <i>Poster Presenter:</i> Karima Kacem (Tunisia)	08:30 - 08:30
P042	MOBILIZATION AND HARVEST OF HEMATOPOIETIC STEM CELLS IN LYMPHOMA: MONOCENTRIC STUDY <i>Poster Presenter:</i> Raoudha Mansouri (Tunisia)	08:30 - 08:30
P043	CHALLENGES OF HEMATOPOIETIC STEM CELL COLLECTION IN BIG PEDIATRIC TRANSPLANT CENTER: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Nara Stepanyan (Russian Federation)	08:30 - 08:30
P044	IMMUNOPHENOTYPING OF PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED BY APHERESIS <i>Poster Presenter:</i> Carlos Agustin Villegas-Valverde (United Arab Emirates)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Nurses Posters - Adult		
NP001	GVHD PATIENT SUPPORT GROUP <i>Poster Presenter:</i> Ms. Deborah Anderson (United Kingdom)	08:30 - 08:30
NP002	NURSING ROLE IN IMPLEMENTING EHEALTH FOR ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: INITIAL FINDINGS FROM THE MYMEDULA STUDY'S RANDOMIZED CLINICAL TRIAL <i>Poster Presenter:</i> Irene García-Cadenas (Spain)	08:30 - 08:30
NP003	NURSE LED PERSONALISED CARE AND SUPPORT PLANNING FOR PATIENTS PREPARING FOR ALLOGENEIC BLOOD AND MARROW TRANSPLANT AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY - PATIENT CO-DESIGN <i>Poster Presenter:</i> Polly Pattenden (United Kingdom)	08:30 - 08:30
NP004	TEACH-BACK METHOD IN ONCO-HEMATOLOGICAL PATIENTS' EDUCATION: A SCOPING REVIEW <i>Poster Presenter:</i> Silvia Gneccchi (Italy)	08:30 - 08:30

NP005	ESTABLISHING A WBMT NURSING GROUP <i>Poster Presenter:</i> Reggie Belkhedim (France)	08:30 - 08:30
NP006	NUTRITIONAL IMPLICATIONS OF CAR-T THERAPY IN SCOTLAND <i>Poster Presenter:</i> Abigail Dean (United Kingdom)	08:30 - 08:30
NP007	SETTING UP A PATIENT INITIATED FOLLOW-UP (PIFU) PROGRAMME FOR THE LONG TERM FOLLOW UP OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS- THE WESSEX BMTCT EXPERIENCE <i>Poster Presenter:</i> Jenna Sloan (United Kingdom)	08:30 - 08:30
NP008	EVALUATING COGNITIVE IMPAIRMENT AND NEUROTOXICITY POST CAR T CELL THERAPY <i>Poster Presenter:</i> Eleni Gavriilaki (Greece)	08:30 - 08:30
NP009	THE SAFE DELIVERY OF A 'BLOODLESS' AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA - PUTTING THE PATIENT'S WISHES AT THE FOREFRONT OF TRANSPLANT DELIVERY <i>Poster Presenter:</i> Emma Storey (United Kingdom)	08:30 - 08:30
NP010	MALAY-TRANSLATED PATIENT-REPORTED OUTCOME MEASURES FOR BOTH ORAL AND GASTROINTESTINAL MUCOSITIS IN A MULTI-ETHNIC ASIAN AUTOLOGOUS STEM CELL TRANSPLANT POPULATION <i>Poster Presenter:</i> Shu Ping Wong (Malaysia)	08:30 - 08:30
NP011	WILL STEM CELL TRANSPLANT AFFECT MY FERTILITY? ADDRESSING PATIENT CONCERNS WITH COMPREHENSIVE INFORMATION AT ANTHONY NOLAN <i>Poster Presenter:</i> Louise Jones (United Kingdom)	08:30 - 08:30
NP012	THE NEW GITMO ACADEMY: OUR EXPERIENCE FOR OUR FUTURE <i>Poster Presenter:</i> Matteo Steduto (Italy)	08:30 - 08:30
NP013	ENHANCING WARD-BASED NURSING TEACHING IN A BONE MARROW TRANSPLANT UNIT: EVALUATING THE IMPACT OF AN INDUCTION PACK FOR NEW NURSING STAFF. PILOT STUDY <i>Poster Presenter:</i> Krzysztof Dariusz Ciesielski (United Kingdom)	08:30 - 08:30
NP014	A RETROSPECTIVE AUDIT OF LENGTH OF STAY AND PATIENT EXPERIENCE WITHIN A UK AMBULATORY CARE DEPARTMENT, TO DEMONSTRATE THE EFFECTIVENESS OF THIS MODEL WITHIN HSCT <i>Poster Presenter:</i> Preya Assi (United Kingdom)	08:30 - 08:30
NP015	HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN OUTPATIENT SETTING: A SINGLE CENTER EXPERIENCE IN SAUDI ARABIA <i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	08:30 - 08:30
NP016	"MASTERS OF SEX": INCREASING AWARENESS OF AND KNOWLEDGE ABOUT SEXUAL HEALTH OF HSCT PATIENTS <i>Poster Presenter:</i> Limor Mintz-Manor (Israel)	08:30 - 08:30
NP017	PATIENTS' PSYCHOLOGICAL DISTRESS PRE HSCT AND CAR-T: FINDINGS FROM TWO YEARS' ROUTINE PRE-TREATMENT PSYCHOLOGICAL ASSESSMENTS <i>Poster Presenter:</i> Ms. Surabhi Chaturvedi (United Kingdom)	08:30 - 08:30
NP018	DEVELOPING AN INDUCTION PROGRAMME FOR NEWLY QUALIFIED NURSES ON A SPECIALIST HAEMATOLOGY AND TRANSPLANT UNIT <i>Poster Presenter:</i> Annie Hamilton (United Kingdom)	08:30 - 08:30
NP020	IMPLEMENTATION OF A HOSPITAL- AT- HOME PROGRAM FOR	08:30 - 08:30

	AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION: SAFETY AND PATIENT-PERCEIVED SATISFACTION	
	<i>Poster Presenter:</i> Estefanía Pérez-Lopez (Spain)	
NP021	AUTONOMOUS NURSE PRACTITIONER FOLLOW-UP OF HSCT OUTPATIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Lasse Johan Thue (Norway)	
NP022	CURRENT EXPERIENCES AND SPECIFIC PSYCHOSOCIAL SUPPORT NEEDS OF RELATED STEM CELL DONORS: A QUALITATIVE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Fran Willemsens (Belgium)	
NP023	THE AMBULATORY AUTOLOGOUS STEM CELL TRANSPLANT PROGRAMME FOR MULTIPLE MYELOMA; A SERVICE EVALUATION	08:30 - 08:30
	<i>Poster Presenter:</i> Ethan Brough (United Kingdom)	
NP024	NURSE NAVIGATOR ROLE FOR THE HAEMATOLOGY PATIENT UNDERGOING CAR T THERAPY: A SCOPING REVIEW	08:30 - 08:30
	<i>Poster Presenter:</i> Alfonso Parisi (Italy)	
NP025	CAR-T PATIENT PERSPECTIVES ON AHP INPATIENT SERVICES	08:30 - 08:30
	<i>Poster Presenter:</i> Jennie Simcock (United Kingdom)	
NP026	GREATIX - QUALITY IMPROVEMENT BY SHARING SUCCESS / BEST PRACTICE	08:30 - 08:30
	<i>Poster Presenter:</i> Aidan MacDonald (United Kingdom)	
NP027	PALLIATIVE CARE IN CAR T THERAPY - A CASE STUDY DEMONSTRATING THE IMPORTANCE OF HOPING FOR THE BEST BUT PREPARING FOR THE WORST	08:30 - 08:30
	<i>Poster Presenter:</i> Ms. Bethany Colton (United Kingdom)	
NP028	REDUCED HSCT PATIENTS' ER VISITS BY ASSIGNED 2 BEDS IN HSCT UNIT AS QUICK ER ACCESS , SINGLE CENTER IN SAUDI ARABIA	08:30 - 08:30
	<i>Poster Presenter:</i> Suha Alkhraisat (Saudi Arabia)	
NP029	COMBATTING CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTIONS IN BONE MARROW TRANSPLANT RECIPIENTS: A MULTIFACETED INTERVENTION APPROACH FOR ENHANCED PATIENT OUTCOMES	08:30 - 08:30
	<i>Poster Presenter:</i> Hassan Mkashar (Lebanon)	
NP030	BUILDING CAPABILITY AND CAPACITY: UPSKILLING APHERESIS NURSES TO BE COMPETENT IN ULTRASOUND GUIDED PERIPHERAL CANNULATION (USGPC)	08:30 - 08:30
	<i>Poster Presenter:</i> Sinju Thomas (United Kingdom)	
NP031	HSCT CAREGIVER ANXIETY AND DEPRESSION ASSOCIATIONS WITH QUALITY OF LIFE AND REACTION TO CARE. A LONGITUDINAL STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Arianna Rosich-Soteras (Spain)	
NP032	NURSE LED CAR T CELL THERAPY LONG TERM EFFECTS CLINIC	08:30 - 08:30
	<i>Poster Presenter:</i> Katie Brice (United Kingdom)	
NP033	COMMENCING LOPERAMIDE FOR DIARRHOEA PRIOR TO NEGATIVE CULTURE RESULT AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IS SAFE AND EFFECTIVE	08:30 - 08:30
	<i>Poster Presenter:</i> Amy Colada (United Kingdom)	
NP034	"ANALYSIS OF NUTRITIONAL STATUS AND HOSPITALIZATION DURATION IN ALLOGENEIC TRANSPLANTED PATIENTS IN	08:30 - 08:30

	CROATIA: NURSING INSIGHTS OVER THE PAST 2 YEARS <i>Poster Presenter:</i> Valentina Milinković (Croatia)	
NP035	ADHERENCE TO ORAL IMMUNOSUPPRESSORS USING THE THERAPEUTIC DRUG MONITORING: A RETROSPECTIVE STUDY <i>Poster Presenter:</i> Chiara Visintini (Italy)	08:30 - 08:30
NP036	THE IMPORTANCE OF MAINTAINING GOOD STANDARDS OF DOCUMENTATION TO SUPPORT THE SAFE DELIVERY OF CHEMOTHERAPY <i>Poster Presenter:</i> Ivy Adu (United Kingdom)	08:30 - 08:30
NP037	FILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION SHORTENED TIME TO NEUTROPHIL RECOVERY AND HOSPITAL STAY <i>Poster Presenter:</i> K.A. Oosterink (Netherlands)	08:30 - 08:30
NP038	RESEARCH ON THE RELATIONSHIP BETWEEN NURSES' COMPLIANCE WITH STANDARD PRECAUTIONS, SERVANT LEADERSHIP AND EMOTIONAL EXHAUSTION:A CROSS-SECTIONAL SURVEY IN CHINA <i>Poster Presenter:</i> Xin Du (China)	08:30 - 08:30
NP039	NURSES ROLE IN CAR-T ADVERSE EFFECTS MANAGEMENT - SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Ms. Iwona Przewozna (Poland)	08:30 - 08:30
NP040	DOES THE VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) COLONIZATION PREDICT WORSE OUTCOMES IN AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-HSCT) RECIPIENTS? A PROSPECTIVE SINGLE CENTRE STUDY <i>Poster Presenter:</i> Benedetta Scaioli (Italy)	08:30 - 08:30
NP041	THE FIRST CAR-T NURSING PRECEPTORSHIP PROGRAM IN THE KINGDOM OF SAUDI ARABIA <i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	08:30 - 08:30
NP042	IMPACT OF LVA TECHNIQUES ON COLLECTION OUTCOMES/APHERESIS CAPACITY <i>Poster Presenter:</i> Marisa Pereira (United Kingdom)	08:30 - 08:30
NP043	IDENTIFYING CORE SYMPTOM AND SYMPTOM CLUSTERS IN PATIENTS DURING MYELOSUPPRESSION PERIOD OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CROSS-SECTIONAL STUDY <i>Poster Presenter:</i> Fangfang Wu (China)	08:30 - 08:30
NP044	IDENTIFYING THE INEQUALITIES BETWEEN REGISTRY AND RELATED DONORS <i>Poster Presenter:</i> Helen Morgan (United Kingdom)	08:30 - 08:30
NP045	HAEMATOLOGY AMBULATORY CARE SERVICE FOR STEM CELL TRANSPLANT PATIENTS IN A DISTRICT GENERAL HOSPITAL SETTING - RESULTS OF PILOT STUDY <i>Poster Presenter:</i> Debora Almeida (United Kingdom)	08:30 - 08:30
NP046	HAEMATOLOGY 'CRIB CARDS' <i>Poster Presenter:</i> Carmel Ann Galligan (Ireland)	08:30 - 08:30
NP047	COULD PATIENT WITH PERSISTENT COVID-19 INFECTION PROCEED TO ALLOGENEIC TRANSPLANTATION? LIFE-SAVING ALLO-SCT FOR A REFRACTORY LYMPHOMA PATIENT <i>Poster Presenter:</i> Yu-Chen Fan (Taiwan)	08:30 - 08:30
NP048	BARRIERS IN THE MANAGEMENT OF HEMATO-ONCOLOGICAL PALESTINIAN PATIENTS BY ISRAELI PROFESSIONAL	08:30 - 08:30

	CAREGIVERS: IMPLEMENTATION OF THE CULTURAL HUMILITY APPROACH	
	<i>Poster Presenter:</i> Lubna Khatib (Israel)	
NP049	HAS AN INCREASE IN CAR-T ACTIVITY MEANT A DELAY IN AUTOLOGOUS TRANSPLANT ADMISSIONS DUE TO CAPACITY AND ACUITY CONCERN?	08:30 - 08:30
	<i>Poster Presenter:</i> Ally Braden (United Kingdom)	
NP050	HOSPICE CARE FOR PATIENTS WITH REFRACTORY ACUTE GVHD BUT IN DISEASE-REMISSION STATUS -TOUGH BUT NECESSARY DECISION	08:30 - 08:30
	<i>Poster Presenter:</i> Ching-Ho Chou (Taiwan)	
NP051	COLONIZATION ANALYSIS AND MANAGEMENT COUNTERMEASURES OF MULTIDRUG-RESISTANT BACTERIA IN 183 PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Qiuhui Zhang (China)	
NP052	THE MEDIATING EFFECT OF INTIMATE RELATIONSHIP ON DYADIC COPING AND FEAR OF CANCER RECURRENCE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Qiuhui Zhang (China)	
NP053	CREATION OF A VACCINE RECORD FOR ALLOGRAFTED PATIENTS: A MONOCENTRIC EXPERIENCE IN FRANCE	08:30 - 08:30
	<i>Poster Presenter:</i> Dominique Issarni (France)	
NP054	NURSING CARE PLAN IN EARLY HOME CARE AFTER CAR-T THERAPY: CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Núria Ballestar (Spain)	
NP055	COMPARISON OF PICC AND CVC IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Pavla Šlehofer (Czech Republic)	
NP056	A DEDICATED PSYCHOLOGICAL SECTION IN THE NURSING FOLDER IMPROVES PATIENTS CARE QUALITY AND REDUCES HEALTHCARE PROFESSIONALS DISTRESS	08:30 - 08:30
	<i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	
NP057	PHYSICAL AND PSYCHOLOGICAL NEEDS AFTER CAR-T THERAPY: TWO NURSES' PERSPECTIVES	08:30 - 08:30
	<i>Poster Presenter:</i> Joy Meli (Switzerland)	
NP058	IRON DEFICIENCY IN PATIENTS UNDERGOING EXTRACORPOREAL PHOTOPHERESIS (ECP)	08:30 - 08:30
	<i>Poster Presenter:</i> Carmel Ann Galligan (Ireland)	
NP059	TRIPLE CHALLENGES FOR POSTTRANPLANT NURSING CARE - LOW SOCIOECONOMY, RADIATION BRAIN NECROSIS, AND GRADE IV SKIN ACUTE GVHD AFTER MISMATCHED UNRELATED DONOR TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Yu-Chieh Chen (Taiwan)	
NP060	PROFILE OF PATIENTS UNDERGOING CAR-T CELL THERAPY AT A PRIVATE HOSPITAL IN RIO DE JANEIRO IN 2023	08:30 - 08:30
	<i>Poster Presenter:</i> Maria Carolina Xavier (Brazil)	
NP061	STRATEGIC ADJUSTMENTS IN THE DAY HOSPITAL CIRCUIT: IMPROVING CARE FOR HSCT AND CT PATIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Marta Pamias (Spain)	

ePoster

08:30 - 18:00

ePoster area

Non-infectious Late Effects, Quality of Life and Fertility

A238	ECULIZUMAB TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	08:30 - 08:30
A239	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS OLDER THAN 70 YEARS WITH HEMATOLOGIC DISEASES: A 10-YEAR RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Poster Presenter:</i> Simona Sestili (France)	08:30 - 08:30
A240	IMMUNE THROMBOCYTOPENIA FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT : RESULTS FROM A FRENCH MULTICENTRIC RETROSPECTIVE STUDY OF 35 CASES <i>Poster Presenter:</i> Antoine Gondé (France)	08:30 - 08:30
A241	AT-HOME AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT FOR ADULTS WITH HEMATOLOGICAL MALIGNANCIES. HOW FRAILTY SYNDROME IMPACTS AND EVOLVES DURING HCT PROCEDURE <i>Poster Presenter:</i> Juan Ortiz (Spain)	08:30 - 08:30
A242	POST ALLOGENIC BONE MARROW TRANSPLANT PURE RED CELL APLASIA: A NON-FATAL COMPLICATION WHERE NO INTERVENTION IS THE BEST INTERVENTION <i>Poster Presenter:</i> Isha Gambhir (India)	08:30 - 08:30
A243	FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC) <i>Poster Presenter:</i> Maria Queralt Salas (Spain)	08:30 - 08:30
A244	LATE EFFECTS AFTER PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Mónica López Duarte (Spain)	08:30 - 08:30
A245	OUTCOMES AND RISK FACTORS FOR SURVIVAL OF LUNG TRANSPLANTATION AFTER PRIOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Dr. Juan Montoro Gómez (Spain)	08:30 - 08:30
A246	DEPRESSION IN SURVIVORS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED WITH A MATCHED GENERAL POPULATION COMPARISON SAMPLE: THE MOSA STUDY <i>Poster Presenter:</i> Bianca Wauben (Netherlands)	08:30 - 08:30
A247	PREGNANCY OUTCOMES IN WOMEN FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT FOR HAEMATOLOGICAL CONDITIONS <i>Poster Presenter:</i> Panagiotis Kottaridis (United Kingdom)	08:30 - 08:30
A248	SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR SOLID ORGAN MALIGNANCIES AFTER ALLOGENEIC HSCT: A RETROSPECTIVE, MULTICENTRIC STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Dr. Jan Brijs (Belgium)	08:30 - 08:30
A249	POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH REDUCED RATE OF SECONDARY MALIGNANCIES POST ALLOGENEIC STEM CELL TRANSPLANT	08:30 - 08:30

	<i>Poster Presenter:</i> Dr. Nihar Desai (Canada)	
A250	MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL <i>Poster Presenter:</i> Sara Redondo (Spain)	08:30 - 08:30
A251	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS FROM AREAS OF CONFLICT: THE KING HUSSEIN CANCER CENTER TRANSPLANTATION PROGRAM EXPERIENCE <i>Poster Presenter:</i> Dr. Salwa Saadeh (Jordan)	08:30 - 08:30
A252	RITUXIMAB RESPONSIVE CYTOPENIA FOLLOWING HAEMATOPOETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Joanita Kintu (United Kingdom)	08:30 - 08:30
P176	AUTOIMMUNE NEUTROPENIA AFTER ALLOGENIC BONE MARROW TRANSPLANTATION DUE TO ANTIBODIES SPECIFICALLY TARGETING THE HNA-1A ANTIGEN IN PEDIATRIC PATIENTS <i>Poster Presenter:</i> Maria Luz Uria Oficialdegui (Spain)	08:30 - 08:30
P177	IONA - INTERDISCIPLINARY ONCOLOGICAL FOLLOW-UP CLINIC IN VIENNA <i>Poster Presenter:</i> Alexandra Böhm (Austria)	08:30 - 08:30
P178	RAISING FOLLOW-UP AFTER CELL THERAPY TO THE NEXT LEVEL: A TRANS-REGIONAL, TRANS-SECTORAL, INTERDISCIPLINARY RESEARCH PROJECT <i>Poster Presenter:</i> Dr. Katharina Egger-Heidrich (Germany)	08:30 - 08:30
P179	SEVERE POLYAUTOIMMUNITY AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: POTENTIAL ROLE OF THE GENETIC BACKGROUND AND CHIMERISM LOSS <i>Poster Presenter:</i> Eva Parolo (Italy)	08:30 - 08:30
P180	A CASE REPORT OF A REFRACTORY EVANS SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Viktoria Yankova (Bulgaria)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
	Myelodysplastic Syndromes	
B275	WT1 GENE MUTATIONS IMPACT POST-TRANSPLANT RELAPSE IN MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS 2 PATIENTS <i>Poster Presenter:</i> Wewen Guo (China)	08:30 - 08:30
B276	OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - A SINGLE-CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Marketa Stastna Markova (Czech Republic)	08:30 - 08:30
B277	CHALLENGES AND REALITIES OF HEMATOPOIETIC CELL TRANSPLANTATION OF MYELODYSPLASTIC SYNDROMES PATIENTS IN LATIN AMERICA: A SURVEY <i>Poster Presenter:</i> Fernando Barroso Duarte (Brazil)	08:30 - 08:30
P323	OUTCOMES OF RELAPSE POST HEMATOPOIETIC CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROMES FROM THE LATIN AMERICAN REGISTER <i>Poster Presenter:</i> Fernando Barroso Duarte (Brazil)	08:30 - 08:30

P324	OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION OF IN CHILDREN WITH A <i>NPM1</i> MUTATION AND MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS <i>Poster Presenter:</i> Ayami Yoshimi (Germany)	08:30 - 08:30
P325	SYSTEMATIC LITERATURE REVIEW ON THE SAFETY, EFFICACY, AND EFFECTIVENESS OF EATG VERSUS COMPARATORS FOR MDS <i>Poster Presenter:</i> Raj Gokani (United States)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Nurses Posters - Paediatric		
NP062	A NO-NONSENSE EDUCATIONAL RESOURCE FOR NO-NONSENSE PAEDIATRIC HSCT NURSES <i>Poster Presenter:</i> Andrew Gooding (United Kingdom)	08:30 - 08:30
NP063	ASSESSMENT OF PEDIATRIC EARLY WARNING SCORES IN STEM CELL TRANSPLANT PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW AND FOR PREDICTING CLINICAL DETERIORATION <i>Poster Presenter:</i> Matilde Gabrieli (Italy)	08:30 - 08:30
NP064	PAEDIATRIC SIBLING STEM CELL DONORS - ESTABLISHING A NURSE LED CLINIC <i>Poster Presenter:</i> Annette Hill (United Kingdom)	08:30 - 08:30
NP065	IMPACT OF THE NURSE-DESIGNED PROTOCOL ON CENTRAL VENOUS CATHETER-RELATED COMPLICATIONS IN PEDIATRIC HEMATO-ONCOLOGICAL PATIENTS: ONE PEDIATRIC FACILITY'S TEN-YEAR EXPERIENCE <i>Poster Presenter:</i> Stefania Braidotti (Italy)	08:30 - 08:30
NP066	REDUCING THE LENGTH OF STAY FOR PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BY PERFORMING PRE-HSCT WORKUP IN AN OUTPATIENT SETTING <i>Poster Presenter:</i> Noha Alneedy (Saudi Arabia)	08:30 - 08:30
NP067	OPTIMIZING COLLABORATION BETWEEN PATIENTS, CAREGIVERS, AND NURSES THROUGH NURSING MENTORSHIP IN PEDIATRIC HSCT <i>Poster Presenter:</i> Anouk Plug (Netherlands)	08:30 - 08:30
NP068	ASSESSING COPING STRATEGIES OF PARENTS WHOSE CHILDREN UNDERWENT HSCT <i>Poster Presenter:</i> Rosaria Pinto (India)	08:30 - 08:30
NP069	EVALUATING THE USE OF PARENTERAL NUTRITION IN PAEDIATRIC PATIENTS UNDERGOING A HAEMOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Chloe Elliott (United Kingdom)	08:30 - 08:30
NP070	AT FIRST SIGHT - WHAT ADOLESCENTS AND YOUNG ADULTS ARE TELLING US AT FIRST VISIT TO ADULT LONG TERM FOLLOW UP <i>Poster Presenter:</i> Yvonne Panek-Hudson (Australia)	08:30 - 08:30
NP071	DEVELOPMENT OF INDEPENDENT NURSE LED CLINIC <i>Poster Presenter:</i> Petra Brevdo (Finland)	08:30 - 08:30
NP072	WHAT ARE THE CHARACTERISTIC OF PAEDIATRIC PATIENTS WHO REQUIRE NUTRITIONAL SUPPORT DURING ALLOGENIC HSCT? <i>Poster Presenter:</i> Laura McIntyre (United Kingdom)	08:30 - 08:30
NP073	THE GOOD, THE BAD AND THE UGLY - NURSING STRATEGIES	08:30 - 08:30

	BASED ON DONOR SOURCE FOR CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSAEMIA MAJOR	
	<i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	
NP074	PATIENT AND PUBLIC INVOLVEMENT (PPD) IN A PAEDIATRIC AND YOUNG PERSONS TRANSPLANT SERVICE	08:30 - 08:30
	<i>Poster Presenter:</i> Julie Guest (United Kingdom)	
NP075	PPIE - HOW CAN WE INVOLVE CHILDREN IN RESEARCH?	08:30 - 08:30
	<i>Poster Presenter:</i> Annette Hill (United Kingdom)	
NP076	BUILDING A DEEPER UNDERSTANDING OF THE LIFEWORLD AND BURDEN OF ILLNESS THROUGH RELAPSE HSCT TRANSPLANTATION THEN NOVEL CAR-T TREATMENTS' A PATIENT AND FAMILY JOURNEY	08:30 - 08:30
	<i>Poster Presenter:</i> Julie Guest (United Kingdom)	
NP077	THE VALUE OF THE HSCT QUALITY EXPERT ON A HAEMATOLOGICAL STEM CELL TRANSPLANT WARD	08:30 - 08:30
	<i>Poster Presenter:</i> Jochem Van Vliet (Netherlands)	
NP078	WILL MY CHILD SURVIVE? VOICES OF PARENTS TO A SEVERELY ILL CHILD AND A HEALTHY SIBLING AS STEM CELL DONOR	08:30 - 08:30
	<i>Poster Presenter:</i> Ms. Carina Rinaldo (Sweden)	
NP079	ASSESSMENT BY CAREGIVERS OF THE PRE-HSCT INTERVIEW	08:30 - 08:30
	<i>Poster Presenter:</i> Juana Membrado (Spain)	
NP080	GROUNDBREAKING AND PASSIONATE INTERNATIONAL NURSING CARE	08:30 - 08:30
	<i>Poster Presenter:</i> Manon Van Slooten (Netherlands)	
NP081	THE POSITIVE EFFECT OF VIDEO GAMES FOR ADOLESCENT PATIENTS DURING HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Ying Wang (China)	
NP082	PATIENT EXPERIENCE IN THE TRANSITION FROM SICKLE CELL UNIT TO HEMATOPOIETIC PROGENITOR TRANSPLANTATION UNIT IN PEDIATRIC AGE	08:30 - 08:30
	<i>Poster Presenter:</i> Georgina Pedrals Portabella (Spain)	
NP083	THE MONITORING OF PATIENTS UNDERGOING CAR-T THERAPY: ESSENTIAL ASPECTS FOR A PROMPT RECOGNITION OF COMPLICATIONS. FORMS OF THE PEDIATRIC BMT CENTER OF THE A.S.S.T. SPEDALI CIVILI BRESCIA	08:30 - 08:30
	<i>Poster Presenter:</i> Alessandra Buccino (Italy)	
NP084	KNOWLEDGE SHARING AND COLLABORATION IN HEALTHCARE BETWEEN INDONESIA AND THAILAND FOR HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Jiraporn Chanapai (Thailand)	
NP085	NUTRITIONAL TRACKING IN PEDIATRIC BONE MARROW TRANSPLANT RECOVERY	08:30 - 08:30
	<i>Poster Presenter:</i> Lucija Kralj (Croatia)	
NP086	SUBSTITUTIVE THERAPY WITH S.C. IMMUNOGLOBULINS IN PEDIATRIC HSCT RECEIPIENTS: A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Rosanna Ceresoli (Italy)	

ePoster

08:30 - 18:00

Autoimmune Diseases

ePoster area

B235	THYMIC SIZE LONGITUDINAL CHANGES ON CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS <i>Poster Presenter:</i> Gregory Pugnet (France)	08:30 - 08:30
B236	LONG TERM PERSISTENCE OF T MEMORY STEM CELLS FOLLOWING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS <i>Poster Presenter:</i> Prof. John Moore (Australia)	08:30 - 08:30
B237	EFFECTS OF HIGH DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS FROM PATIENT'S PERSPECTIVE: LONG-TERM QUALITY OF LIFE OUTCOMES <i>Poster Presenter:</i> Denis Fedorenko (Russian Federation)	08:30 - 08:30
B238	THE MATHEC-SFGM-TC REGISTRY FOR CELL THERAPY IN AUTOIMMUNE DISEASES: A DEDICATED TOOL FOR REAL-WORLD DATA COLLECTION <i>Poster Presenter:</i> Prof. Dominique Farge (France)	08:30 - 08:30
B239	ATG AND OTHER SEROTHERAPY IN CONDITIONING REGIMENS FOR ASCT IN AUTOIMMUNE DISEASES: A SURVEY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP) <i>Poster Presenter:</i> Rosamaria Nitti (Italy)	08:30 - 08:30
B240	ADOPTING A STANDARD OF CARE: AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SCLERODERMA <i>Poster Presenter:</i> Ernesto Ayala (United States)	08:30 - 08:30
B241	FLUDARABINE AND CYCLOPHOSPHAMIDE AS A SAFE AND EFFECTIVE LYMPHOABLATIVE CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS (MS) <i>Poster Presenter:</i> Denis Fedorenko (Russian Federation)	08:30 - 08:30
B242	IMMUNE RESET AND GRAFT COMPOSITION IN AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS: EARLY RECOVERY OF NATURAL KILLER CELLS MAY BE IMPORTANT IN EFFECTING DURABLE RESPONSES <i>Poster Presenter:</i> Latoya Reid (Jamaica)	08:30 - 08:30
B243	REDUCED PRO-INFLAMMATORY INTERLEUKINS IL-6 AND IL-8 SECRETED BY SKIN FIBROBLASTS IN SYSTEMIC SCLEROSIS PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Gunter Assmann (Germany)	08:30 - 08:30
B244	THE QUALITY OF LIFE OF PERSONS WITH MULTIPLE SCLEROSIS IMPROVES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	08:30 - 08:30
P261	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF MULTI-REFRACTORY STIFF PERSON SYNDROME: A CASE STUDY <i>Poster Presenter:</i> Tamim Alsuliman (France)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Haemoglobinopathy		
A265	OUTCOME OF HSCT IN BETA THALASSEMIA MAJOR. EXPERIENCE FROM A LOW- AND MIDDLE-INCOME COUNTRY	08:30 - 08:30

	<i>Poster Presenter:</i> Hashim Khan (Pakistan)	
A266	TREOSULFAN-BASED HAPLOIDENTICAL T CELL DEPLETED HSCT FOR ADOLESCENTS AND YOUNG ADULTS (AYA) WITH ADVANCED STAGE SICKLE CELL DISEASE AND THALASSEMIA <i>Poster Presenter:</i> Anja Troeger (Germany)	08:30 - 08:30
A267	IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH SEVERE SICKLE CELL DISEASE <i>Poster Presenter:</i> Nanxin Li (United States)	08:30 - 08:30
A268	COMPARISON OF THE UNRELATED TRANSPLANTATION RESULTS OF AN HLA FULLY MATCHED DONOR AND A HOMOZYGOUS MM DONOR AT ONE LOCUS IN PATIENTS WITH BETA THALASSEMIA <i>Poster Presenter:</i> Koray Yalçın (Turkey)	08:30 - 08:30
A269	CLINICAL OUTCOMES AND HEALTHCARE RESOURCE USE IN PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES WHO RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTS IN FRANCE <i>Poster Presenter:</i> Jessica Baldwin (United States)	08:30 - 08:30
A270	SINGLE-CENTER EXPERIENCE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE SICKLE CELL DISEASE <i>Poster Presenter:</i> Miriam P. Klahr (United States)	08:30 - 08:30
A271	HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A LOW RESOURCE COUNTRY NIGERIA. A 10 YEARS REPORT FROM A SINGLE CENTER <i>Poster Presenter:</i> Nosakahare Bazuaye (Nigeria)	08:30 - 08:30
A272	IMPACT OF THE FIRST ONLINE WEBINAR OF THE WBMT NURSING GROUP IN COLLABORATION WITH THE LAGOS UNIVERSITY TEACHING HOSPITAL AND SICKLE CELL FOUNDATION OF NIGERIA <i>Poster Presenter:</i> Adetola Kassim (United States)	08:30 - 08:30
P269	MATCHED-RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INTERMEDIATE AND HIGH RISK THALASSEMIA PATIENTS USING REDUCED INTENSITY CONDITIONING REGIMEN WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS. A SINGLE CENTER EXPERIENCE FROM JORDAN <i>Poster Presenter:</i> Ayad Ahmed Hussein (Jordan)	08:30 - 08:30
P270	ABO INCOMPATIBILITY DID NOT IMPACT TRANSPLANT OUTCOMES FOLLOWING REDUCED INTENSITY HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOR PATIENTS WITH SICKLE CELL DISEASE: MULTICENTER EXPERIENCE <i>Poster Presenter:</i> Danielle Murphy (United States)	08:30 - 08:30
P271	DURABLE ENGRAFTMENT AFTER PHARMACOLOGICAL PRE-TRANSPLANT IMMUNE SUPPRESSION FOLLOWED BY REDUCED-TOXICITY MYELOABLATIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN HIGHLY HLA-IMMUNIZED ADULTS WITH SICKLE CELL DISEASE <i>Poster Presenter:</i> Sabine Fürst (France)	08:30 - 08:30
P272	CLINICAL OUTCOMES AND HEALTHCARE RESOURCE USE IN PATIENTS WITH TRANSFUSION-DEPENDENT B-THALASSEMIA WHO RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTS IN FRANCE <i>Poster Presenter:</i> Chuka Udeze (United States)	08:30 - 08:30
P273	THE IMPACT OF PANEL REACTIVE ANTIBODIES IN PEDIATRIC	08:30 - 08:30

	BETA THALASSEMIA PATIENTS UNDERGOING STEM CELL TRANSPLANTATION	
	<i>Poster Presenter:</i> Gülay Sezgin (Turkey)	
P274	SICKLE CELL DISEASE WITH SEVERE ACUTE CHEST SYNDROME AND HEPATOPATHY: CAN ALLOGENEIC SCT BE PERFORMED IN SUCH DESPERATE CLINICAL SITUATIONS? - A CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Celia Kaffenberger (Germany)	
<i>ePoster</i>		
08:30 - 18:00		ePoster area
New Drugs and Cell-based Immune Therapies		
A127	FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION	08:30 - 08:30
	<i>Poster Presenter:</i> Vassiliki Zacharioudaki (Greece)	
A128	FACTOR B INHIBITION WITH ORAL IPTACOPAN MONOTHERAPY DEMONSTRATES SUSTAINED LONG-TERM EFFICACY AND SAFETY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): FINAL RESULTS FROM APPLY-PNH	08:30 - 08:30
	<i>Poster Presenter:</i> Dr. Austin Kulasekararaj (United Kingdom)	
A129	GILTERITINIB WITH VENETOCLAX, ACTINOMYCIN D, AND LOW-DOSE CYTARABINE AS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY <i>FLT3</i> MUTATED ACUTE MYELOID LEUKEMIA	08:30 - 08:30
	<i>Poster Presenter:</i> Rita Čekauskienė (Lithuania)	
A130	EFFICACY OF SALVAGE THERAPY INCLUDING NOVEL AGENTS IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) PROGRESSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A REAL-WORLD UK STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Dr. Alexandros Rampotas (United Kingdom)	
A131	TREOSULFAN PLUS FLUDARABINE "REDUCED INTENSITY CONDITIONING" WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 65 YEARS	08:30 - 08:30
	<i>Poster Presenter:</i> Vincenzo Federico (Italy)	
A132	REAL-WORLD CLINICAL EFFECTIVENESS OF LONCASTUXIMAB TESIRINE MONOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING CHIMERIC ANTIGEN T CELL THERAPY IN THE US	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Dr. Pier Luigi Zinzani (Italy)	
A133	ORAL IPTACOPAN MONOTHERAPY MAINTAINS EFFICACY AND SAFETY OVER 48 WEEKS IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE PHASE III APPOINT-PNH TRIAL	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Antonio Risitano (Italy)	
A134	NOVEL HDAC1 INHIBITOR EPIRUBICIN EXERTS ANTI-TUMOR EFFECT OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA CELLS BY INDUCING CELL FERROPTOSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Guancui Yang (China)	
A135	TCR-TRANSGENIC T CELLS AND YB-1 BASED ONCOLYTIC VIROTHERAPY IMPROVE SURVIVAL IN A PRECLINICAL EWING SARCOMA XENOGRAFT MOUSE MODEL	08:30 - 08:30
	<i>Poster Presenter:</i> Uwe Thiel (Germany)	
A136	T CELLS DIRECTED AGAINST THE METASTATIC DRIVER CHONDROMODULIN-1 IN EWING SARCOMA: COMPARATIVE	08:30 - 08:30

	ENGINEERING WITH CRISPR/CAS9 VS. RETROVIRAL GENE TRANSFER FOR ADOPTIVE TRANSFER	
	<i>Poster Presenter:</i> Uwe Thiel (Germany)	
A137	UTILITY OF ROMIPLOSTIM IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT ASSOCIATED POOR GRAFT FUNCTION, IMMUNE MEDIATED CYTOPENIA AND IMMUNE MEDIATED GRAFT FAILURE	08:30 - 08:30
	<i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)	
A138	RAG2^{-/-}TC^{-/-} MICE HUMANIZED WITH CD34⁺ HEMATOPOIETIC STEM CELLS ARE A SUITABLE TOOL TO SCREEN FOR FUNCTIONAL EWING SARCOMA-SPECIFIC T CELLS IN VIVO	08:30 - 08:30
	<i>Poster Presenter:</i> Uwe Thiel (Germany)	
A139	CLINICAL BREAKTHROUGH HEMOLYSIS WITH ORAL FACTOR B INHIBITOR IPTACOPAN MONOTHERAPY IS GENERALLY NOT SEVERE AND MANAGED WITHOUT TREATMENT DISCONTINUATION: 48-WEEK DATA FROM APPLY-PNH AND APPOINT-PNH	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Antonio Risitano (Italy)	
A140	REAL-WORLD EFFECTIVENES OF VENETOCLAX COMBINED WITH IPOMETILATING-AGENTS AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION IN ACUTE MIELOID LEUKEMIA: RETROSPECTIVE AND MULTICENTRIC STUDY OF APULIAN HEMATOLOGICAL NETWORK "REP05"	08:30 - 08:30
	<i>Poster Presenter:</i> Vincenzo Federico (Italy)	
A141	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED LONCASTUXIMAB TESIRINE PRIOR TO CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY	08:30 - 08:30
	<i>Poster Presenter:</i> Prof. Dr. Mehdi Hamadani (United States)	
A142	BUSULFAN AND THIOTEPA AS CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA:A STUDY OF THE WEST OF IRANIAN MULTIPLE MYELOMA PATIENT	08:30 - 08:30
	<i>Poster Presenter:</i> Mehrdad Payandeh (Iran)	
P071	T CELL RECEPTOR IDENTIFICATION AGAINST EWING SARCOMA ASSOCIATED DICKKOPF 2 (DKK2) DERIVED ANTIGEN USING SINGLE-CELL RNA SEQUENCING	08:30 - 08:30
	<i>Poster Presenter:</i> Sophia Laube (Germany)	
P072	HDAC6 INHIBITOR ACY-738 INDUCES FERRITINOPHAGY-MEDIATED FERROPTOSIS IN LEUKEMIA	08:30 - 08:30
	<i>Poster Presenter:</i> Jinyi Liu (China)	
P073	TARGETED CD8+ T CELL THERAPY IN ADVANCED EWING SARCOMA: EXPLORING LIPI, GPR64, PAX7, AND CHM1 AS TARGETS FOR ADOPTIVE TRANSFER APPROACHES	08:30 - 08:30
	<i>Poster Presenter:</i> Hannah Hüls (Germany)	
P074	COMPARATIVE EFFECTIVENESS OF IPTACOPAN VERSUS C5 INHIBITORS IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA FROM THE PHASE III APPOINT-PNH TRIAL AND REAL-WORLD APEX COHORT	08:30 - 08:30
	<i>Poster Presenter:</i> Matthew Holt (United Kingdom)	
P075	A MULTICENTRE, RANDOMIZED, DOUBLE-BLINDED, PHASE 2B TRIAL EVALUATING MAAT033, AN ORAL, POOLED MICROBIOME ECOSYSTEM THERAPY IN ALLOHCT PATIENTS TO IMPROVE OVERALL SURVIVAL : PHOEBUS TRIAL	08:30 - 08:30

	<i>Poster Presenter:</i> Prof. Dr. Florent Malard (France)	
P076	IPTACOPAN INHIBITS ACTIVITY OF FACTOR B VARIANTS IDENTIFIED IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) <i>Poster Presenter:</i> Anna Schubart (Switzerland)	08:30 - 08:30
P077	TREATMENT WITH BLAST-MODULATORY RESPONSE MODIFIERS INDUCED SPECIFIC IMMUNE RESPONSES AND LED TO DISEASE STABILIZATION IN A PATIENT WITH REFRACTORY AML AFTER SECOND ALLOGENEIC SCT <i>Poster Presenter:</i> Giuliano Filippini Velázquez (Germany)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Chronic Leukaemia and Other Myeloproliferative Disorders		
A278	IMPROVING OUTCOMES IN MDS/MPN: TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lorenzo Lazzari (Italy)	08:30 - 08:30
P326	PREVIOUS RESPONSE TO TKIS AS A FAVORABLE PROGNOSTIC FACTOR FOR SURVIVAL IN HSCT FOR CML: LONG TERM RESULTS OF A SINGLE CENTER IN BRAZIL <i>Poster Presenter:</i> Vaneuza Funke (Brazil)	08:30 - 08:30
P327	RESULTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER THERAPY WITH TYROSINE KINASE INHIBITORS <i>Poster Presenter:</i> Vera Vasilyeva (Russian Federation)	08:30 - 08:30
P328	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR MYELOFIBROSIS: UPDATED RESULTS FROM BRAZILIAN REGISTRY <i>Poster Presenter:</i> Vaneuza Funke (Brazil)	08:30 - 08:30
P329	ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKEMIA IN ERA OF TYROSINE KINASE INHIBITORS -A 13-YEAR SINGLE CENTRE EXPERIENCE FROM INDIA <i>Poster Presenter:</i> Lingaraj Nayak (India)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Solid Tumours		
B278	HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION IN ADULT PRIMARY MEDIASTINAL GERM CELL TUMORS. A RETROSPECTIVE STUDY OF THE EBMT, CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY <i>Poster Presenter:</i> Simona Secondino (Italy)	08:30 - 08:30
P330	RESULTS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 16 CHILDREN WITH GERM CELL TUMORS: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Kirill Kirgizov (Russian Federation)	08:30 - 08:30
P331	SURVIVAL OUTCOMES IN PANCREATIC CANCER:EVALUATING THE IMPACT OF WIPPLE'S SURGERY AND HAEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Olle Ringden (Sweden)	08:30 - 08:30
P332	SUCCESSFUL HIGH DOSE CHEMOTHERAPY WITH STEM CELL	08:30 - 08:30

	RESCUE IN DISSEMINATED OVARIAN CHORIOCARCINOMA COMPLICATED WITH CHORIOCARCINOMA SYNDROME	
	<i>Poster Presenter:</i> Abdulaziz Bin Mesained (Saudi Arabia)	
P333	CELL THERAPY IN HEAD AND NECK CARCINOMA: A PROMISING FRONTIER	08:30 - 08:30
	<i>Poster Presenter:</i> Shohreh Ghasemi (United States)	
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Data Management		
P334	EBMT REGISTRY: HOW IS IT CARRIED OUT IN THE SPANISH TRANSPLANT CENTRES? A STUDY ON BEHALF OF SPANISH HEMATOPOIETIC STEM CELL TRANSPLANTATION GROUP (GETH-TC)	08:30 - 08:30
	<i>Poster Presenter:</i> Maria Huguet (Spain)	
P335	ENHANCING THE ADHERENCE OF CELLULAR THERAPY CENTERS TO MULTICENTER DATA REGISTRIES: IMPACT OF NATIONAL STRATEGIES	08:30 - 08:30
	<i>Poster Presenter:</i> Fernando Barroso Duarte (Brazil)	
P336	A PRELIMINARY LOOK INTO 10 YEARS OF LEUKAPHERESIS PROCEDURES REPORTING - A SYSTEMATIC REVIEW OF APHERESIS DEVICES PERFORMANCE	08:30 - 08:30
	<i>Poster Presenter:</i> Patricia Jarabo (Belgium)	
P337	CREATING THE BSBMTCT INDUCTION MANUAL: TRAINING AND SUPPORT FOR UK AND ROI HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) DATA MANAGEMENT STAFF	08:30 - 08:30
	<i>Poster Presenter:</i> Julia Lee (United Kingdom)	
P338	ENRICHING LIVES: A DECADE OF IMPACT-THE EVOLUTION OF A GREEK BONE MARROW DONOR CENTER (2014-2024)	08:30 - 08:30
	<i>Poster Presenter:</i> Dr. Pinelopi Samara (Greece)	
P339	DISTRIBUTION OF RARE MAIN HISTOSCOMPATIBILITY COMPLEX ANTIGENS AMONG RECIPIENTS AND DONORS OF HEMATOPOIETIC STEM CELLS IN THE REPUBLIC OF BELARUS	08:30 - 08:30
	<i>Poster Presenter:</i> Volha Mishkova (Belarus)	
P340	RE-ADMISSIONS WITHIN DAY+100 POST-STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS WITH HEMATOLOGY, ONCOLOGY AND IMMUNE DISORDERS DIAGNOSTIC RELATED GROUPS (DRG)	08:30 - 08:30
	<i>Poster Presenter:</i> Syed Jafri (Saudi Arabia)	
P341	COMPARISON OF DATA FOR ALLOGENEIC TRANSPLANTS IN PATIENTS WITH AML IN CR1 BETWEEN 2010-2016 AND 2017-2022- ONE CENTRE EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Alexandra Jungova (Czech Republic)	
P342	A COLLABORATIVE EFFORT IN BIOSPECIMEN COLLECTION & PROCESSING TO REDUCE TIME BURDEN ON INPATIENT HSCT NURSES & IMPROVE PARTNERSHIP BETWEEN RESEARCH AND CLINICAL TEAMS	08:30 - 08:30
	<i>Poster Presenter:</i> Hannah Packard (United States)	
P343	COST ANALYSIS OF PATIENTS UNDERGOING ALLO HSCT OR CAR-T THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA FROM A GERMAN HEALTHCARE PAYER PERSPECTIVE	08:30 - 08:30
	<i>Poster Presenter:</i> Paymon Ahmadi (Germany)	

P344	TRANSPLANTATION IN PATIENTS WITH INBORN ERRORS OF IMMUNITY IN THE REPUBLIC OF BELARUS <i>Poster Presenter:</i> Volha Mishkova (Belarus)	08:30 - 08:30
P346	HCT RESEARCH DATA MANAGEMENT PROJECT ON BEHALF OF ANTHONY NOLAN AND BSBMTCT: DATA OVERVIEW BY ERA <i>Poster Presenter:</i> Shelley Hewerdine (United Kingdom)	08:30 - 08:30
P347	CURRENT SITUATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILD AND ADULT PATIENTS IN THE REPUBLIC OF BELARUS <i>Poster Presenter:</i> Volha Mishkova (Belarus)	08:30 - 08:30
P348	FOLLOW-UP OF PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ONE TRANSPLANT CENTRE AND IN COLLABORATING CENTRE <i>Poster Presenter:</i> Marie Trnkova (Czech Republic)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Immunodeficiency Diseases and Macrophages		
B254	OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MONOGENIC INFLAMMATORY BOWEL DISEASE <i>Poster Presenter:</i> Xiaowen Zhai (China)	08:30 - 08:30
B255	CLINICAL CHARACTERISATION AND OUTCOME OF 125 CASES WITH GRISCELLI SYNDROME <i>Poster Presenter:</i> Maaïke Kusters (United Kingdom)	08:30 - 08:30
B256	OUTCOMES FOR ALLOGENEIC SCT FOR PATIENTS WITH INBORN ERRORS OF IMMUNITY UTILIZING REDUCED INTENSITY CONDITIONING REGIMEN WITH TARGETED BUSULFAN <i>Poster Presenter:</i> Sonali Chaudhury (United States)	08:30 - 08:30
B257	OUTCOME OF THE PATIENTS DIAGNOSED WITH SEVERE COMBINED IMMUNODEFICIENCY THROUGH NEWBORN SCREENING IN CATALONIA (2017-2023) <i>Poster Presenter:</i> Maria Isabel Benitez Carabante (Spain)	08:30 - 08:30
B258	HSCT AS A CURATIVE TREATMENT OPTION IN PATIENTS WITH A PRIMARY IMMUNODEFICIENCY DUE TO IL2RB-DEFECT: DESCRIPTION OF A SMALL COHORT <i>Poster Presenter:</i> Ommo E. Mauss (Germany)	08:30 - 08:30
B259	WHICH ALTERNATIVE TO CHOOSE? - A COMPARATIVE STUDY BETWEEN MATCHED UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN CHILDREN WITH INBORN ERRORS OF IMMUNITY IN LOW-MIDDLE-INCOME COUNTRIES <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	08:30 - 08:30
B260	MUD-HSCT IN A RARE COMBINED IMMUNODEFICIENCY WITH ARPC1B DEFICIENCY-CASE REPORT <i>Poster Presenter:</i> Devyani Surange (India)	08:30 - 08:30
B261	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN TWO PEDIATRIC PATIENTS WITH CENTRAL NERVOUS SYSTEM-RESTRICTED FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS <i>Poster Presenter:</i> Dimana Dimitrova (United States)	08:30 - 08:30
B262	SIL2-RA AND ST2 LEVELS BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH MORTALITY IN HLH PATIENTS	08:30 - 08:30

	<i>Poster Presenter:</i> Anne B. Verbeek (Netherlands)	
B263	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN FOR PRIMARY IMMUNE DEFICIENCIES: THE EXPERIENCE OF SINGLE CENTER <i>Poster Presenter:</i> Ali Antmen (Turkey)	08:30 - 08:30
P281	THE OUTCOMES OF UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR COMBINED IMMUNODEFICIENCY DISEASE IN CHILDREN WITH CD40LG MUTATION <i>Poster Presenter:</i> Xiaowen Qian (China)	08:30 - 08:30
P282	BACILLE CALMETTE-GUÉRIN (BCG) VACCINE-ASSOCIATED COMPLICATIONS FOLLOWING STEM CELL TRANSPLANTATION IN PATIENTS WITH INBORN ERRORS OF IMMUNITY (IEI) - SINGLE TERTIARY CENTRE EXPERIENCE FROM SOUTH INDIA <i>Poster Presenter:</i> Stalin Ramprakash (India)	08:30 - 08:30
P283	UNSUCCESSFUL HSCT IN 2 ADA2 DEFICIENCY PATIENTS ASSOCIATED WITH HIGH LEVELS OF ANTI-HLA ANTIBODIES <i>Poster Presenter:</i> Amit Dotan (Israel)	08:30 - 08:30
P284	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TO CHILDREN WITH PRIMARY IMMUNODEFICIENCY -THE HELLENIC EXPERIENCE <i>Poster Presenter:</i> Eleni Ioannidou (Greece)	08:30 - 08:30
P285	FATAL NEUROLOGICAL COMPLICATION POST HSCT IN A PEDIATRIC PATIENT WITH IMMUNODEFICIENCY DUE TO NFKB2 MUTATION <i>Poster Presenter:</i> Paula Catalán (Chile)	08:30 - 08:30
P286	POSTTRANSPLANT COMPLICATIONS IN A CASE OF LATE-ONSET FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 2 <i>Poster Presenter:</i> Dr. Delfien Bogaert (Belgium)	08:30 - 08:30
P287	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY IMMUNODEFICIENCY DISEASES: SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Nayera HK El-Sherif (Egypt)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Paediatric Issues		
B146	PLASMA REG3A AND CITRULLINE LEVELS PREDICT GASTROINTESTINAL AGVHD BEFORE CLINICAL ONSET IN PEDIATRIC HSCT <i>Poster Presenter:</i> Sarah Weischendorff (Denmark)	08:30 - 08:30
B147	THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Alexey Maschan (Russian Federation)	08:30 - 08:30
B148	OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR HURLER SYNDROME AFTER IMPLEMENTATION NEWBORN SCREENING IN US AND EUROPE <i>Poster Presenter:</i> Jaap Jan Boelens (United States)	08:30 - 08:30
B149	ADDITION OF DINUTUXIMAB-BETA ON DAY -1 TO IMPROVE GRAFT-VERSUS-NEUROBLASTOMA EFFECTS OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN RELAPSED HIGH-RISK NEUROBLASTOMA <i>Poster Presenter:</i> Christina Lämmle (Germany)	08:30 - 08:30

B150	HHV-6 INFECTION MAY IMPAIR IMMUNE RECONSTITUTION FOLLOWING PEDIATRIC HAPLO-HSCT <i>Poster Presenter:</i> Katrine Kielsen (Denmark)	08:30 - 08:30
B151	FINAL HEIGHT AND IMPACT OF GROWTH HORMONE TREATMENT IN CHILDREN RECEIVING TBI-BASED CONDITIONING REGIMEN BEFORE HSCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Jean-Hugues Dalle (France)	08:30 - 08:30
B152	ENGRAFTMENT SYNDROME AND ACUTE GVHD AFTER HAPLOIDENTICAL POST-TRANSPLANT CYCLOPHOSPHAMIDE: A PAEDIATRIC MULTICENTRIC EXPERIENCE <i>Poster Presenter:</i> Maura Faraci (Italy)	08:30 - 08:30
B153	PULMONARY COMPLICATIONS IN CHILDREN FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Hannah Walker (Australia)	08:30 - 08:30
B154	EXCELLENT SURVIVAL USING T-REPLETE UMBILICAL CORD BLOOD TRANSPLANT IN HIGH RISK PAEDIATRIC MYELOID LEUKAEMIA, INCLUDING IN REFRACTORY DISEASE <i>Poster Presenter:</i> Kate Davies (United Kingdom)	08:30 - 08:30
B155	TCRAB+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Larisa Shelikhova (Russian Federation)	08:30 - 08:30
B156	IMPLEMENTATION OF CYP3A5 GENOTYPING TO INDIVIDUALISE TACROLIMUS DOSE IN PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Iván López Torija (Spain)	08:30 - 08:30
B157	EPIDEMIOLOGY OF GUT COLONIZATION AND INFECTION BY CARBAPENEM-RESISTANT GRAM-NEGATIVE BACILLI (CR-GNB) IN PEDIATRIC HEMATO-ONCOLOGICAL AND TRANSPLANTED PATIENTS <i>Poster Presenter:</i> Prof. Adriana Balduzzi (Italy)	08:30 - 08:30
B158	ALPHA/BETA-DEPLETION AND EARLY TIMING OF SEROTHERAPY PROVIDES RELIABLE ENGRAFTMENT AND LOW TRANSPLANT RELATED MORBIDITY IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS <i>Poster Presenter:</i> Annika Ewert (Germany)	08:30 - 08:30
B159	CARDIORESPIRATORY FITNESS, PHYSICAL PERFORMANCE, AND METABOLIC SYNDROME IN ADULT SURVIVORS OF PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Anne Nissen (Denmark)	08:30 - 08:30
B160	HEMATOPOIETIC TRANSPLANTATION WITH CD45RA⁺ DEPLETION AND ADOPTIVE THERAPY WITH CD45RO⁻ T-LYMPHOCYTES AND NK CELLS IN PEDIATRIC PATIENTS DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT DISEASES <i>Poster Presenter:</i> Mercedes Gasior Kabat (Spain)	08:30 - 08:30
B161	PSYCHOLOGICAL IMPACT OF HEMATOPOIETIC STEM CELL DONATION ON PEDIATRIC SIBLING DONORS <i>Poster Presenter:</i> Sara Mostafa Makkeyah (Egypt)	08:30 - 08:30
B162	AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA: A LONG-TERM FOLLOW-UP	08:30 - 08:30

	<i>Poster Presenter:</i> Isabelina Ferreira (Portugal)	
B163	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANEMIA - REPORT OF THE POLISH PEDIATRIC STUDY GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Anna Pieczonka (Poland)	08:30 - 08:30
B164	OUTCOMES OF ALLO-HSCT FROM MISMATCHED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH NON- MALIGNANT DISEASES <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	08:30 - 08:30
B165	CARDIOVASCULAR RISK FACTORS AND SUBCLINICAL ORGAN DAMAGE ARE COMMON AND INCREASING OVER TIME IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Damaris Werner (Germany)	08:30 - 08:30
B166	POSITIVE PRE-TRANSPLANT RESPIRATORY VIRAL PCR IS ASSOCIATED WITH INCREASED DAY 100 TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HSCT RECIPIENTS <i>Poster Presenter:</i> Jane Trainor (United States)	08:30 - 08:30
B167	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	08:30 - 08:30
B168	INCIDENCE AND CHARACTERISTICS OF EPILEPSY AFTER ACUTE CENTRAL NERVOUS SYSTEM COMPLICATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER STUDY <i>Poster Presenter:</i> Davide Leardini (Italy)	08:30 - 08:30
B169	COMPARISONS OF PROGNOSIS OF ALLO-HSCT AFTER CAR-T CELL THERAPY OR CHEMOTHERAPY IN PAEDIATRIC PATIENTS OF REFRACTORY/RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA : A MULTICENTER STUDY CCCG-ALL-2015 <i>Poster Presenter:</i> Bohan Li (China)	08:30 - 08:30
B170	TCR-AB DEPLETED HAPLOIDENTICAL TRANSPLANT WITH CD 45 RA- DEPLETED MEMORY T CELL ADD-BACK IN PAEDIATRIC NON-MALIGNANT DISEASES IN A SINGLE PAEDIATRIC CENTER: 10-YEAR RESULTS <i>Poster Presenter:</i> Tan Ah Moy (Singapore)	08:30 - 08:30
B171	AIEOP EXPERT BOARD RECOMMENDATIONS FOR MANAGEMENT OF POST-HCT HEMORRHAGIC CYSTITIS IN PEDIATRIC SETTING <i>Poster Presenter:</i> Gianluca Dell'Orso (Italy)	08:30 - 08:30
B172	RISK FACTORS IN HIGH RISK NEUROBLASTOMA PATIENTS OVER 5 YEARS: RESULTS FROM THE HR-NBL1/SIOPEN TRIAL <i>Poster Presenter:</i> Ruth Ladenstein (Austria)	08:30 - 08:30
B173	EXCELLENT SURVIVAL AND LONG TERM OUTCOMES IN INFANTS RECEIVING TOTAL BODY IRRADIATION FOR CONDITIONING PRIOR TO ALLOGENEIC TRANSPLANT <i>Poster Presenter:</i> Sonali Chaudhury (United States)	08:30 - 08:30
B174	BCG-VACCINE COMPLICATIONS IN CHILDREN WITH INFANT ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Alexandra Laberko (Russian Federation)	08:30 - 08:30
B175	WORKFORCE CONSENSUS RECOMMENDATIONS FOR PAEDIATRIC HSCT CENTRES ON BEHALF OF THE PAEDIATRIC SUB-COMMITTEE OF THE BRITISH SOCIETY OF BLOOD, BONE	08:30 - 08:30

	MARROW TRANSPLANTATION CELLULAR THERAPY (BSBMTCT)	
	<i>Poster Presenter:</i> Reem Elfeky (United Kingdom)	
B176	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH A CONTROLLED NUMBER OF CD3+ CELLS AND POST-TRANSPLANT CYCLOPHOSPHAMIDE: EXPERIENCE FROM A SINGLE PEDIATRIC CENTER	08:30 - 08:30
	<i>Poster Presenter:</i> Giulia Albrici (Italy)	
B177	PLASMA AMINO ACIDS AND FECAL CALPROTECTIN USAGE FOR THE PREDICTION OF INTESTINAL INJURY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN	08:30 - 08:30
	<i>Poster Presenter:</i> Igne Kairiene (Lithuania)	
P214	COMPARISON OF BUSULFAN-BASED AND TREOSULFAN-BASED HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA	08:30 - 08:30
	<i>Poster Presenter:</i> Kyung-Nam Koh (Korea, Republic of)	
P215	MULTIPLE MINOR PHLEBOTOMIES IN EPP INVOLVING THE LIVER: IS THERE A WAY TO AVOID NEEDING A LIVER AND HAEMATOPOIETIC STEM CELL TRANSPLANT?	08:30 - 08:30
	<i>Poster Presenter:</i> Rita Beier (Germany)	
P216	USE OF BLINATUMOMAB TO ACHIEVE REMISSION AND CONSOLIDATION WITH HAPLOIDENTICAL TRANSPLANT WITH CYCLOPHOSPHAMIDE FOR THE TREATMENT OF CHILDREN WITH REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA	08:30 - 08:30
	<i>Poster Presenter:</i> Alberto Olaya Vargas (Mexico)	
P217	TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) IN CHILDREN TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT): ONE CENTER STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Tomasz Jarmoliński (Poland)	
P218	DISTANCE MAKES THE CELLS GROW FONDER- PAEDIATRIC ALLOGENIC TRANSPLANT AND CELLULAR THERAPY REFERRAL PROGRAM, THE SOUTH AUSTRALIAN EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Matthew O'Connor (Australia)	
P219	INCREASING TIM-3+ T CELLS IN PERIPHERAL BLOOD OF PEDIATRIC PATIENTS WITH RELAPSE B-ALL AFTER HAPLOIDENTICAL ALLO-HSCT	08:30 - 08:30
	<i>Poster Presenter:</i> Liubov Tsvetkova (Russian Federation)	
P220	HEMORRHAGIC CYSTITIS IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE, TREATMENT, OUTCOME, AND RISK FACTORS	08:30 - 08:30
	<i>Poster Presenter:</i> Nur Ayca Celik (Turkey)	
P221	SEQUENTIAL KIDNEY-STEM CELL TRANSPLANTATION IN PATIENT WITH SCHIMKE IMMUNO-OSSEOUS DYSPLASIA: CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Michael Maschan (Russian Federation)	
P222	IMMUNE-MEDIATED CYTOPENIA AFTER PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION - A RETROSPECTIVE ANALYSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Mária Füssiová (Slovakia)	
P223	NUTRITIONAL DYNAMICS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MONOCENTRIC STUDY ASSESSING BMI PERCENTILES AND CLINICAL OUTCOMES	08:30 - 08:30
	<i>Poster Presenter:</i> Michaela Döring (Germany)	

P224	CYCLOSPORINE PLUS METHOTREXATE VERSUS CYCLOSPORINE ALONE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA-IDENTICAL SIBLING <i>Poster Presenter:</i> Vincenzo Apolito (Italy)	08:30 - 08:30
P225	INTEGRATING CAR T-CELL THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA. THE EXPERIENCE OF A SINGLE CENTER <i>Poster Presenter:</i> Blanca Molina (Spain)	08:30 - 08:30
P226	ASSESSMENT OF THE ENDOTHELIAL GLYCOCALYX BY VIDEO MICROSCOPY IN CHILDREN WITH ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	08:30 - 08:30
P227	INTRODUCTION OF BODY IMPEDENCE ANALYSIS TO MEASURE BODY COMPOSITION CHANGES AND FLUID STATUS OF PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Rebecca Fisher (Australia)	08:30 - 08:30
P228	BUILDING A PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT UNIT IN PARAGUAY: LESSON LEARNT <i>Poster Presenter:</i> Marta Verna (Italy)	08:30 - 08:30
P229	TRANSPLANTATION OUTCOME OF HIGH RISK ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME IN CHILDREN: SINGLE CENTER EXPERIENCE IN KOREA <i>Poster Presenter:</i> Young Tak Lim (Korea, Republic of)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Quality Management		
P356	GLOBAL TRENDS IN BLOOD AND CELL TECHNOLOGIES: A COMPREHENSIVE SURVEY ACROSS LEADING COLLECTION AND TRANSPLANT CENTERS IN FRANCE, GERMANY, JAPAN, UK AND USA <i>Poster Presenter:</i> Franziska Wautl (Germany)	08:30 - 08:30
P357	INCREASE IN INFECTION RATE IN MARROW HARVEST PRODUCTS - A SINGLE CENTER STUDY <i>Poster Presenter:</i> Ann-Mari Berthelsen (Denmark)	08:30 - 08:30
P358	CURRENT AND FUTURE STANDARDS DEVELOPMENT IN HEMATOLOGY AND CAR-T. WHAT ARE THE CHALLENGES FOR HOSPITALS AND THE PHARMACEUTICAL INDUSTRY? <i>Poster Presenter:</i> Nick van Sinderen (Germany)	08:30 - 08:30
P359	WE BELIEVE IN NUMBERS: IS IT POSSIBLE TO EVOLVE THE BENCHMARK FOR OUR PROCESSING UNIT? <i>Poster Presenter:</i> Valentino Granero (Italy)	08:30 - 08:30
P360	MICROBIAL CONTAMINATION OF HAEMATOPOIETIC STEM CELL PRODUCTS: ANALYSIS OF >5000 PRODUCTS FROM MULTIPLE COLLECTION SITES <i>Poster Presenter:</i> Sue Davey (United Kingdom)	08:30 - 08:30
P361	POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) INSTEAD OF ANTI-THYMOCYTE GLOBULIN (ATG) PLUS SHORT-COURSE METHOTREXATE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) TO PREVENT CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD): PROCESS VALIDATION	08:30 - 08:30

	<i>Poster Presenter:</i> Maria Huguet (Spain)	
P362	THE MANAGEMENT OF POSITIVE MICROBIALS IN THE SOUTH AFRICAN NATIONAL BLOOD SERVICES APHERESIS COLLECTION AND PROCESSING FACILITY <i>Poster Presenter:</i> Laurel Ellen Anderson (South Africa)	08:30 - 08:30
P363	IMPACT OF ACCREDITATION PROGRAM ON OUR LABORATORY QUALITY SYSTEM MANAGEMENT: ONE YEAR EXPERIENCE OF THE APPROACH TO EFI STANDARDS SCHEME <i>Poster Presenter:</i> Assunta Viola (Italy)	08:30 - 08:30
P364	OPTIMIZING SMALL VOLUME BONE MARROW HARVEST MANIPULATION FOR RBC REDUCTION IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Dunia Jawdat (Saudi Arabia)	08:30 - 08:30
P365	CRYOPRESERVATION IS NOT STRICTLY NECESSARY TO PERFORM ASCT IN LYMPHOMA PATIENTS WITH BEAM REGIMEN. A SINGLE CENTER EXPERIENCE FROM PARAGUAY <i>Poster Presenter:</i> Aline Paats (Paraguay)	08:30 - 08:30
P366	INTEGRATION OF GCP REQUIREMENTS FOR A PHASE 1 CLINICAL TRIAL WITH JACIE REQUIREMENTS OF A HPC TRANSPLANT PROGRAM <i>Poster Presenter:</i> Dr. Emanuele Angelucci (Italy)	08:30 - 08:30
P367	HOW TO MEET THE JACIE AUDIT REQUIREMENTS FOR A CLINICAL PROGRAMME <i>Poster Presenter:</i> Stuart Kennedy (United Kingdom)	08:30 - 08:30
P368	LEAVING A "LEGACY": AN INTERNAL CENTRE-SPECIFIC QUALITY MANAGERS' GUIDEBOOK WITH REFERENCE TO EBMT AND JACIE AT THE ROYAL UNITED HOSPITAL BATH NHS FOUNDATION TRUST <i>Poster Presenter:</i> Antonette Amao (United Kingdom)	08:30 - 08:30
P369	HOW TO IMPLEMENT AND VALIDATE A COMPUTERIZED SYSTEM IN A CELLULAR THERAPY UNIT <i>Poster Presenter:</i> Fátima Amado (Portugal)	08:30 - 08:30
P370	VALIDATING THE WORLD BLOOD AND MARROW TRANSPLANT (WBMT) MINIMUM RECOMMENDATIONS FOR ESTABLISHING A FORMAL HEMATOPOIETIC CELL TRANSPLANTATION (HCT) PROGRAM IN PARAGUAY <i>Poster Presenter:</i> Dr. Cristobal Frutos (Paraguay)	08:30 - 08:30
P371	OPTIMIZE AND PRESERVE THE GRAFT QUALITY IN HEMATOPOIETIC STEM CELLS STORAGE FOR AUTOLOGOUS TRANSPLANTATION <i>Poster Presenter:</i> Gabriella Peluso Cassese (Italy)	08:30 - 08:30
P372	VALIDATION OF THE CRYOSHIPPER CONTAINER FOR TRANSPORT OF CELLULAR THERAPY PRODUCTS AT TEMPERATURES $\leq -150^{\circ}\text{C}$ <i>Poster Presenter:</i> Fátima Amado (Portugal)	08:30 - 08:30
P373	HEMOLYTIC ANEMIA DUE TO ABO INCOMPATIBILITY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT <i>Poster Presenter:</i> Mehrdad Payandeh (Iran)	08:30 - 08:30
P374	UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION WITHOUT CRYOPRESERVATION FOR MULTIPLE MYELOMA. OUTCOMES FROM A LMIC SETTING	08:30 - 08:30

	<i>Poster Presenter:</i> María Enciso (Paraguay)	
P375	ACUTE MYELOID LEUKEMIA WITH CNS INVOLVEMENT FOLLOWING HBC-AB POSITIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT <i>Poster Presenter:</i> Mehrdad Payandeh (Iran)	08:30 - 08:30
P376	HLA TYPING OF A PATIENT WITH SEVERE COMBINED IMMUNODEFICIENCY AND PROVEN MATERNAL MICROCHIMERISM <i>Poster Presenter:</i> Volha Mishkova (Belarus)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Myeloproliferative Neoplasm		
A261	TCRALPHABETA/CD19 DEPLETED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH POST-TRANSPLANT RUXOLITINIB FOR MYELOFIBROSIS <i>Poster Presenter:</i> Moniek de Witte (Netherlands)	08:30 - 08:30
A262	MINIMAL RESIDUAL DISEASE MONITORING OF DRIVER MUTATION BY DIGITAL DROPLET PCR IS PREDICTIVE OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS <i>Poster Presenter:</i> Maria Chiara Finazzi (Italy)	08:30 - 08:30
A263	EVALUATION AND IMPLICATIONS OF PORTAL AND PULMONARY HYPERTENSION IN MYELOFIBROSIS PRIOR TO TRANSPLANT: A PRACTICE-BASED SURVEY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	08:30 - 08:30
A264	IMPACT OF NUMBER OF CD34+ CELLS INFUSED ON OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Filippo Frioni (Italy)	08:30 - 08:30
P262	AVAPRITINIB IN THE POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT SETTING IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS <i>Poster Presenter:</i> Dr. Deborah Christen (Germany)	08:30 - 08:30
P263	ASCIMINIB: A NEW TKI BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKEMIA <i>Poster Presenter:</i> Iuliia Vlasova (Russian Federation)	08:30 - 08:30
P264	OUTCOMES WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TP53-MUTATED MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW AND META-ANALYSIS <i>Poster Presenter:</i> Moazzam Shahzad (United States)	08:30 - 08:30
P265	VENETOCLAX PLUS AZACITIDINE VERSUS AZACITIDINE ALONE AS POST-TRANSPLANT MAINTENANCE TREATMENT IN HIGH-RISK AML AND MDS <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
P266	EXCELLENT LONG TERM SURVIVAL DESPITE LOW RATES OF GVHD IN PATIENTS WITH MYELOFIBROSIS FOLLOWING ALLOGENIC HSCT: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Mariam Amer (United Kingdom)	08:30 - 08:30
P267	LONG-TERM OUTCOME OF ALLOGENEIC TRANSPLANTATION IN PRIMARY AND SECONDARY MYELOFIBROSIS	08:30 - 08:30

	<i>Poster Presenter:</i> Alzbeta Zavrelova (Czech Republic)	
P268	CURRENT PRACTICE WHEN TRANSPLANTING PATIENTS WITH MYELOFIBROSIS: A SURVEY ON BEHALF OF THE BRITISH SOCIETY OF BLOOD AND MARROW TRANSPLANTATION AND CELLULAR THERAPY (BSBMTCT) <i>Poster Presenter:</i> Emma Kempshall (United Kingdom)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Stem Cell Source		
A143	MACHINE LEARNING PREDICTION MODEL FOR NEUTROPHIL RECOVERY AFTER UNRELATED CORD BLOOD TRANSPLANTATION <i>Poster Presenter:</i> Yachiyo Kuwatsuka (Japan)	08:30 - 08:30
A144	REAPPRAISING CORD BLOOD AS A PRIORITY CELL SOURCE IN ALTERNATE DONOR TRANSPLANT AND IN DIFFICULT-TO-CURE PAEDIATRIC HEMATOLOGIC MALIGNANCY <i>Poster Presenter:</i> Abdul Wajid Moothedath (United Kingdom)	08:30 - 08:30
A145	CORTICOSTEROIDS IMPAIR HEMATOPOIETIC MICROENVIRONMENT VIA INDUCING SENESCENCE OF THE MESENCHYMAL STROMAL NICHE <i>Poster Presenter:</i> Yuqing Wang (China)	08:30 - 08:30
A146	THE CORD BLOOD POST THAW CLINIC - HELPING YOU WORK OUT "WHAT GOOD LOOKS LIKE" <i>Poster Presenter:</i> Roger Horton (United Kingdom)	08:30 - 08:30
P080	USE ON NON-CRYOPRESERVED HEMATOPOIETIC STEM CELLS FOR AUTOLOGOUS HSCT IN ADULTS - MULTICENTER STUDY, FROM THE IDWP AND TCWP EBMT - PRELIMINARY RESULTS <i>Poster Presenter:</i> Emilian Snarski (Poland)	08:30 - 08:30
P081	T-CELL DOSE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL GRAFTS - THE SOUTH AFRICAN EXPERIENCE <i>Poster Presenter:</i> Tanya Nadia Glatt (South Africa)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Non-infectious Early Complications		
A211	PROTECTING HLA-A AND HLA-B ANTIGENS THROUGH EPLETS ANALYSIS IN THE SETTING OF PLATELET TRANSFUSIONS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL ALLOGRAFT CANDIDATES <i>Poster Presenter:</i> Nicolas Guillaume (France)	08:30 - 08:30
A212	CLINICAL SIGNIFICANCE OF CYTOKINE RELEASE SYNDROME FOLLOWING HLA-MISMATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MONOCENTRIC STUDY ON 250 TRANSPLANTS <i>Poster Presenter:</i> Filippo Frioni (Italy)	08:30 - 08:30
A213	INVESTIGATING VASCULAR ENDOTHELIAL DYSFUNCTION BY SYNDECAN-1 FOLLOWING PEDIATRIC HSCT <i>Poster Presenter:</i> Sarah Weischendorff (Denmark)	08:30 - 08:30
A214	ASSESSING THE IMPACT OF FLUID OVERLOAD ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	08:30 - 08:30

A215	BEYOND PAIN MANAGEMENT: ASSESSING THE NEGATIVE IMPACT OF INTENSE OPIOID USE ON ALLOHCT SURVIVAL <i>Poster Presenter:</i> Tommy Alfaro Moya (Canada)	08:30 - 08:30
A216	VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)-ASSOCIATED MORBIDITY IN CHILDREN POST HEMATOPOIETIC STEM CELL TRANSPLANTATION - A HINT FOR AN ADEQUATE PROPHYLAXIS? <i>Poster Presenter:</i> Zofia Szmit (Poland)	08:30 - 08:30
A217	OUTCOME AND COMPLEMENT SYSTEM INVOLVEMENT IN PATIENTS WITH THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Jacopo Mariotti (Italy)	08:30 - 08:30
A218	BONE REMODELLING ARE SIGNIFICANTLY IMPAIRED AFTER PEDIATRIC HSCT AND INFLUENCED BY DIAGNOSIS, CONDITIONING REGIMEN AND ACUTE GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Katrine Kielsen (Denmark)	08:30 - 08:30
A219	IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION <i>Poster Presenter:</i> Juan Eiris (Spain)	08:30 - 08:30
A220	PROINFLAMMATORY CYTOKINE RELEASE AND INFUSIONAL SIDE-EFFECTS AFTER ATG SEROTHERAPY FOR GVHD PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Rutvij Khanolkar (Canada)	08:30 - 08:30
A221	ACUTE KIDNEY INJURY AND CRONIC KIDNEY DISEASE AFTER ALLOGENEIC HCT. A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	08:30 - 08:30
A222	SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE: A RETROSPECTIVE STUDY OF THE SPANISH HEMATOLOGY ASSOCIATION-HEMATOPOIETIC STEM CELL TRANSPLANTATION GROUP (GETH) <i>Poster Presenter:</i> Cristina Blázquez Goñi (Spain)	08:30 - 08:30
A223	SAFETY AND BENEFIT OF LIVER BIOPSY AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY <i>Poster Presenter:</i> Marie Maulini (Switzerland)	08:30 - 08:30
A224	INVESTIGATION OF LABORATORY PARAMETERS BEFORE THE ONSET OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Bernd Gruhn (Germany)	08:30 - 08:30
A225	OUTCOME OF ALLOGENEIC HCT RECIPIENTS COMPARED TO OTHER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT. A SINGLE CENTRE STUDY <i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	08:30 - 08:30
A226	ADVERSE PROGNOSTIC IMPACT OF PRETRANSPLANT HEPCIDIN AND FERRITIN ON OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Michelle Pirotte (Belgium)	08:30 - 08:30
A227	IMPACT OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ON CLINICAL OUTCOMES IN ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM A SINGLE-CENTER	08:30 - 08:30

	EXPERIENCE AT PRINCESS MARGARET CANCER CENTRE <i>Poster Presenter:</i> Mohammed Kawari (Canada)	
A228	VALIDATION OF EBMT 2023 VOD CRITERIA: IMPACT ON EARLY DIAGNOSIS AND SENSITIVITY/ESPECIFICITY OF PROBABLE VOD CATEGORY <i>Poster Presenter:</i> Dr. Mónica Cabrero (Spain)	08:30 - 08:30
A229	EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Alessandro Spina (Italy)	08:30 - 08:30
A230	CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND ITS IMPACT ON OVERALL SURVIVAL <i>Poster Presenter:</i> Isabella Silva Pimentel Pittol (Brazil)	08:30 - 08:30
A231	EXPLORING THE SAFETY PROFILE OF NORETHINDRONE IN POST-MENARCHAL STEM CELL TRANSPLANT PATIENTS: ADDRESSING VOD CONCERNS AND CAUTIONARY CONSIDERATIONS <i>Poster Presenter:</i> April Rahrig (United States)	08:30 - 08:30
A232	ANALYSIS OF SAFETY OF TREOSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL IN 117 CHILDREN WITH SOLID TUMORS: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Kirill Kirgizov (Russian Federation)	08:30 - 08:30
A233	POST-TRANSPLANT DE NOVO ANTI-HLA DONOR SPECIFIC ANTIBODIES MAY CONTRIBUTE TO POOR GRAFT FUNCTION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Xinyu Ji (China)	08:30 - 08:30
A234	IMPACT OF EARLY CYCLOSPORINE INITIATION ON CYTOKINE RELEASE SYNDROME AND TRANSPLANT OUTCOMES IN PEDIATRIC T CELL REplete PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Veerendra Patil (India)	08:30 - 08:30
A235	USE OF GRANULOCYTE COLONY-STIMULATING FACTORS IS FEASIBLE IN ALL DONOR SETTING WITHOUT INCREASING THE RISK OF ENGRAFTMENT SYNDROME <i>Poster Presenter:</i> Maria Luisa Giannattasio (Italy)	08:30 - 08:30
A236	MIRNAS AS BIOMARKERS OF EARLY TOXICITY OF HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Anna Czyz (Poland)	08:30 - 08:30
A237	THE UTILITY OF EXTRACORPOREAL ULTRASONOGRAPHY SCORE (HOKUS-10) IN PEDIATRIC SOS/VOD <i>Poster Presenter:</i> Atsushi Narita (Japan)	08:30 - 08:30
P152	FREQUENCY AND IMPACT OF COMPLICATIONS OF ALLOGENEIC STEM CELL TRANSPLANT (ASCT) IN PATIENTS OVER 60 YEARS. EXPERIENCE OF THE UNIVERSITY HOSPITAL OF SALAMANCA <i>Poster Presenter:</i> Mónica Baile (Spain)	08:30 - 08:30
P153	RETROSPECTIVE REVIEW OF TRANSPLANT AND TRANSFUSION OUTCOMES IN PATIENTS WITH PRE-TRANSPLANT RED CELL ALLOANTIBODIES <i>Poster Presenter:</i> Samantha Drummond (United Kingdom)	08:30 - 08:30

P154	TWO GLOBAL PHASE 3 TRIALS OF THE EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT AND PEDIATRIC PATIENTS WITH THROMBOTIC MICROANGIOPATHY AFTER HEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Carolyn Hahn (United States)	08:30 - 08:30
P155	PROBABILISTIC & ROBUST LEARNING OF RELATIONSHIP BETWEEN VOD SEVERITY SCORE AND PRE-TRANSPLANT PARAMETERS, TO PREDICT SCORES OF PATIENTS AT THE PRE-TRANSPLANT STAGE, USING RANDOM GRAPHS <i>Poster Presenter:</i> Joydeep Chakrabartty (India)	08:30 - 08:30
P156	PREDICTIVE FACTORS OF GRAFT FAILURE IN ADULT AND PAEDIATRIC PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISEASE UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) <i>Poster Presenter:</i> Pietro Merli (Italy)	08:30 - 08:30
P157	ALLOGENEIC STEM CELL TRANSPLANT (ASCT) IN PATIENTS OVER 60 YEARS. EXPERIENCE OF THE UNIVERSITARY HOSPITAL OF SALAMANCA OVER TEN YEARS <i>Poster Presenter:</i> Mónica Baile (Spain)	08:30 - 08:30
P158	EARLY LOW DOSE CYCLOSPORINE AND MYCOPHENOLATE REDUCE THE RISK OF CYTOKINE RELEASE SYNDROME AFTER HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH PTCY BASED GVHD PROPHYLAXIS <i>Poster Presenter:</i> Jan Vydra (Czech Republic)	08:30 - 08:30
P159	RITUXIMAB, BORTEZOMIB, PLASMA EXCHANGE COMBINED WITH IVIG FOR DESENSITIZATION DURING HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PATIENTS WITH A POSITIVE DONOR-SPECIFIC ANTI-HLA ANTIBODY <i>Poster Presenter:</i> Fang Liu (China)	08:30 - 08:30
P160	INCIDENCE, RISK FACTORS, AND OUTCOMES OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY IN PEDIATRIC PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Kyung-Nam Koh (Korea, Republic of)	08:30 - 08:30
P161	ABO COMPATIBILITY AND ALLO-HSCT OUTCOMES <i>Poster Presenter:</i> Juan Carlos Caballero Hernández (Spain)	08:30 - 08:30
P162	STEM CELL MOBILIZATION EFFECTS ON HEART SIZES AND FUNCTION <i>Poster Presenter:</i> Domas Vaitiekus (Lithuania)	08:30 - 08:30
P163	EASIX SCORE AS INDEPENDENT PREDICTOR FOR OVERALL SURVIVAL IN PATIENTS WITH ACUTE LEUKEMIA AND MDS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Andriyana Bankova (Bulgaria)	08:30 - 08:30
P164	IMMUNE-MEDIATED CYTOPENIA IN PEDIATRIC PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: ON BEHALF OF THE RBC DISORDER WORKING PARTY OF THE KOREAN SOCIETY OF HEMATOLOGY <i>Poster Presenter:</i> Hyoung Soo Choi (Korea, Republic of)	08:30 - 08:30
P165	EARLY CICLOSPORINE TO EVEROLIMUS CONVERSION POST HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENT WITH CALCINEURIN INHIBITORS INDUCED TOXICITIES <i>Poster Presenter:</i> Benjamin Bouchacourt (France)	08:30 - 08:30
P166	PREDICTIVE VALUE OF LIVER STIFFNESS MEASUREMENT FOR	08:30 - 08:30

	EARLY DIAGNOSIS OF VENO-OCCLUSIVE DISEASE: A SINGLE CENTER EXPERIENCE	
	<i>Poster Presenter:</i> Rebeca Bailén Alomoro (Spain)	
P167	ENGRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A SINGLE-CENTER DATA ANALYSIS OF CLINICAL FEATURES AND RISK FACTORS	08:30 - 08:30
	<i>Poster Presenter:</i> Shanshan Liu (China)	
P168	DONOR SPECIFIC ANTI-HLA ANTIBODIES IN HAPLOIDENTICAL PERIPHERAL STEM CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Alessandro Spina (Italy)	
P169	EARLY ONSET OF EPSTEIN-BARR VIRUS POSITIVE MULTIPLE MYELOMA TYPE OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER - A CASE OF INFREQUENT COMPLICATION AFTER ALLOGENIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Kamila Kruczkowska-Tarantowicz (Poland)	
P170	THE ROLE OF DARATUMUMAB IN POST-TRANSPLANT COMPLICATIONS: A PROSPECTIVE STUDY ON PRCA AND AIHA	08:30 - 08:30
	<i>Poster Presenter:</i> Sabrina Giammarco (Italy)	
P171	TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY IS AN IMPORTANT CAUSE OF HIGH EARLY MORTALITY IN ALLOGENIC BONE MARROW TRANSPLANT	08:30 - 08:30
	<i>Poster Presenter:</i> Pawan Kumar Singh (India)	
P172	IMMUNE DYSREGULATION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BEYOND GVHD - A COMPREHENSIVE PEDIATRIC CASE REPORT - FROM DIAGNOSTICS TO TAILORED BTK INHIBITION BY IBRUTINIB	08:30 - 08:30
	<i>Poster Presenter:</i> Peter Švec (Slovakia)	
P173	A RARE CASE OF MULTIPLY RELAPSED POST-ALLOGENEIC STEM CELL TRANSPLANT IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA IN A YOUNG PATIENT WITH GATA-2 POSITIVE MYELODYSPLASTIC SYNDROME	08:30 - 08:30
	<i>Poster Presenter:</i> Angela Dăscălescu (Romania)	
P174	CENTRAL NERVOUS SYSTEM TOXICITY WITH EXCLUSIVE INVOLVEMENT OF THE BRAIN WHITE MATTER LIKELY RELATED TO TOXIC/IMMUNOLOGIC CAUSES. A PRESENTATION OF 4 SIMILAR CASES	08:30 - 08:30
	<i>Poster Presenter:</i> Elena Agostani (Italy)	
P175	EVALUATING AN UPDATED ANTIEMETIC PROTOCOL IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	
<i>ePoster</i>		
08:30 - 18:00		ePoster area
	Inborn Errors, Granulocyte and Osteoclast Disorders	
B245	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY (IEI): GAP BETWEEN NEED AND REALITY IN A LIMITED RESOURCE SETTING—A FIVE-YEAR SINGLE-CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Stalin Ramprakash (India)	
B246	AN INNOVATIVE PLATFORM APPROACH FOR THE DEVELOPMENT OF EX-VIVO HEMATOPOIETIC STEM AND PROGENITOR CELL-	08:30 - 08:30

	GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH SKELETAL INVOLVEMENT	
	<i>Poster Presenter:</i> Maria Ester Bernardo (Italy)	
B247	HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CURRENT PERSPECTIVE IS SAFE FOR MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> Koray Yalçın (Turkey)	
B248	HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED AND MISMATCHED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES	08:30 - 08:30
	<i>Poster Presenter:</i> Alexandra Laberko (Russian Federation)	
B249	CONDITIONING FOR SECOND HSCTS FROM THE SAME DONOR AFTER MYELOID AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH IEI AND THALASSEMIA: IMMUNOSUPPRESSION IS NOT ALWAYS REQUIRED	08:30 - 08:30
	<i>Poster Presenter:</i> Manfred Hoenig (Germany)	
B250	DESIGN OF A RANDOMIZED PHASE 3 CLINICAL TRIAL (HURCULES) INVESTIGATING THE SAFETY AND EFFICACY OF OTL-203 IN MPS-IH VERSUS ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Maria Ester Bernardo (Italy)	
B251	SINGLE CENTER OBSERVATION ON CLINICAL PRESENTATION, TRANSPLANTATION AND OUTCOME OF SEVEN PATIENTS WITH ZAP-70 DEFICIENCY	08:30 - 08:30
	<i>Poster Presenter:</i> Felix Immanuel Maier (Germany)	
B252	POLYMORPHISM OR RISK ALLELE? PRF1 A91V IN TRANS WITH A "SEVERE" PRF1 MUTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Oliver Wegehaupt (Germany)	
B253	IMMUNE-MEDIATED CYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH INHERITED METABOLIC DISORDERS	08:30 - 08:30
	<i>Poster Presenter:</i> Hirotochi Sakaguchi (Japan)	
P275	PROPHYLACTIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CSF1R-RELATED LEUKOENCEPHALOPATHY- A CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Malu Lian Hestdalen (Norway)	
P276	CLINICAL PROFILE AND TRANSPLANT OUTCOMES OF 41 PATIENTS WITH INBORN ERRORS OF IMMUNITY: A SINGLE CENTER EXPERIENCE FROM SOUTH INDIA	08:30 - 08:30
	<i>Poster Presenter:</i> Stalin Ramprakash (India)	
P277	SUCCESSFUL THIRD ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING TWO GRAFT REJECTIONS IN A PATIENT WITH CHRONIC GRANULOMATOUS DISEASE AND HEPATIC/PARAPHRENIC ABSCESES	08:30 - 08:30
	<i>Poster Presenter:</i> Daniela Sperl (Austria)	
P278	HEMATOPOIETIC CELL TRANSPLANTATION AND SPLIT LIVER TRANSPLANTATION IN A PATIENT WITH ERYTHROPOIETIC PROTOPORPHYRIA - A CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Lasse Jost (Germany)	
P279	CHRONIC GRANULOMATOUS DISEASE DO NOT NEED MOST OF THE TIMES NGS FOR DIAGNOSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Marianna Maffei (Italy)	

P280	BLINATUMOMAB IS AN EFFECTIVE AND LOW TOXICITY BRIDGE TREATMENT TO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA ASSOCIATED WITH SHWACHMAN- DIAMOND SYNDROME <i>Poster Presenter:</i> Francesco Paolo Tambaro (Italy)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Graft-versus-host Disease - Clinical		
B034	EFFECTOR SITE IMMUNE DYNAMICS IN REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A ROCKSTAR TRIAL COMPANION STUDY AFTER BELUMOSUDIL TREATMENT <i>Poster Presenter:</i> Jacqueline Mays (United States)	08:30 - 08:30
B035	CAST REGIMEN FOR GVHD PROPHYLAXIS YIELDS LOWER RELAPSE RATE AND IMPROVED DISEASE-FREE SURVIVAL: A CIBMTR PROPENSITY SCORE MATCHED CASE-CONTROL ANALYSIS <i>Poster Presenter:</i> Stephen Spellman (United States)	08:30 - 08:30
B036	SEQUENTIAL INTRAVENOUS UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (MSCS) FOR SALVAGE TREATMENT OF STEROID-REFRACTORY ACUTE GVHD (RS-AGVHD): A PHASE IB/II STUDY <i>Poster Presenter:</i> Yanmin Zhao (China)	08:30 - 08:30
B037	GRAFT VERSUS HOST DISEASE PROPHYLAXIS WITH TACROLIMUS, SIROLIMUS AND MMF IN PATIENTS UNDERGOING ALLOGENIC TRANSPLANT WITH REDUCED INTENSITY CONDITIONING <i>Poster Presenter:</i> Lucía López Corral (Spain)	08:30 - 08:30
B038	NOVEL GVHD PROPHYLAXIS WITH POST-TRANSPLANT INTERMEDIATE DOSE CYTOXAN AND ABATACEPT - LOW RATES OF ACUTE GVHD AND TRANSPLANT-RELATED TOXICITY <i>Poster Presenter:</i> Yuliya Shestovska (United States)	08:30 - 08:30
B039	REDUCING PTCY DOSE IN PATIENTS RECEIVING CAST FOR GVHD PREVENTION RESULTS IN ACCELERATED ENGRAFTMENT AT THE COST OF HIGHER INCIDENCE OF GVHD <i>Poster Presenter:</i> J. Andres Suarez-Londono (United States)	08:30 - 08:30
B040	RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY <i>Poster Presenter:</i> Virginia Escamilla Gómez (Spain)	08:30 - 08:30
B041	PHASE 1 TRIAL INVESTIGATING THE SAFETY AND TOLERABILITY OF LEFLUNOMIDE IN PATIENTS WITH STEROID-DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT) <i>Poster Presenter:</i> Amandeep Salhotra (United States)	08:30 - 08:30
B042	COMPARISON OF EFFICACY AND TOLERABILITY OF RUXOLITINIB ALONE OR RUXOLITINIB WITH EXTRACORPOREAL PHOTOPHERESIS OR EXTRACORPOREAL PHOTOPHERESIS MONOTHERAPY FOR STEROID REFRACTORY AGVHD: A GITMO RETROSPECTIVE STUDY <i>Poster Presenter:</i> Marta Lisa Battista (Italy)	08:30 - 08:30
B043	MINI-DOSE METHOTREXATE COMBINED WITH METHYLPREDNISOLONE FOR INITIAL TREATMENT OF MILD ACUTE GVHD: A MULTI-CENTER, RANDOMIZED TRIAL <i>Poster Presenter:</i> Yu Wang (China)	08:30 - 08:30

B044	IMPROVED LONG-TERM OUTCOME OF RUXOLITINIB PLUS ECP VS RUXOLITINIB ALONE IN STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (SR-AGVHD) <i>Poster Presenter:</i> Prof. Dr. Nicolaus Kröger (Germany)	08:30 - 08:30
B045	ANTITHYMOCYTE GLOBULIN (ATG) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN MULTICENTER STUDY: EVALUATING OUTCOMES ACCORDING TO CYTOGENETIC RISK <i>Poster Presenter:</i> Mihee Kim (Korea, Republic of)	08:30 - 08:30
B046	COMPARISON BETWEEN POSTTRANSPLANT CYCLOPHOSPHAMIDE AND ATG BASED REGIMENS AS GVHD PROPYLAXIS IN ONE-ANTIGEN MISMATCH UNRELATED DONOR TRANSPLANTATION <i>Poster Presenter:</i> Marta Lisa Battista (Italy)	08:30 - 08:30
B047	PROSPECTIVE EVALUATION OF PLASMA INFLAMMATORY PROTEINS FOR PREDICTION OF SEVER GRAFT-VERSUS-HOST DISEASE AFTER TRANSPLANT	08:30 - 08:30
B048	LYMPHOPENIA BUT NOT ABSOLUTE LYMPHOCYTE COUNT BEFORE ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) ADMINISTRATION IMPACTS TRANSPLANT OUTCOMES IN MATCHED UNRELATED PERIPHERAL BLOOD STEM CELL ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Radwan Massoud (Germany)	08:30 - 08:30
B049	A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL TO EXPLORE THE ROLE OF MESENCHYMAL STEM CELLS IN PREVENTING GRAFT VERSUS HOST DISEASE <i>Poster Presenter:</i> Han Yao (China)	08:30 - 08:30
B050	RUXOLITINIB AS SECOND-LINE TREATMENT FOR BOS AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Feng Chen (China)	08:30 - 08:30
B051	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE WITH OR WITHOUT PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER HLA-MATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MDS/AMI <i>Poster Presenter:</i> Mr. Joost van der Hem (Netherlands)	08:30 - 08:30
B052	IMPROVED GRFS WHEN ATG/ATLG IS USED IN ALLO-PBSCT FROM MATCHED SIBLING DONORS - AN EBMT REGISTRY STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Dr. Agnieszka Piekarska (Poland)	08:30 - 08:30
B053	NAVIGATING GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN MATCHED SIBLING DONOR ALLOGENEIC TRANSPLANTS: A COMPARATIVE ANALYSIS OF POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS DIVERSE REGIMENS - INSIGHTS FROM A SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Dennis Kim (Canada)	08:30 - 08:30
B054	POST TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN PATIENTS RECEIVING HLA MISMATCHED (7/8) UNRELATED DONOR FOR MYELOID MALIGNANCIES: RESULTS OF THE GITMO PROSPECTIVE PHYLOS TRIAL <i>Poster Presenter:</i> Anna Maria Raiola (Italy)	08:30 - 08:30
B055	EXTRACORPOREAL PHOTOPHERESIS AS SALVAGE TREATMENT IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: A MULTICENTER, RETROSPECTIVE STUDY <i>Poster Presenter:</i> Dr. Mattia Algeri (Italy)	08:30 - 08:30
B056	BELUMOSUDIL PHASE 1 DOSE-ESCALATION STUDY IN HEALTHY	08:30 - 08:30

	VOLUNTEERS AND PHASE 2 STUDY IN PATIENTS WITH CGVHD WHO FAILED ≥ 1 LINE OF SYSTEMIC THERAPY IN CHINA <i>Poster Presenter:</i> Ying Wang (China)	
B057	IMPACT OF RESPIRATORY FUNCTION TESTS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Francisco Manuel Martin Dominguez (Spain)	08:30 - 08:30
B058	MANAGEMENT OF CORTICOSTEROIDS IN PATIENTS RECEIVING RUXOLITINIB TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A POST HOC ANALYSIS FROM THE RANDOMIZED PHASE 3 REACH3 STUDY <i>Poster Presenter:</i> Valkal Bhatt (United States)	08:30 - 08:30
B059	A PROGNOSTIC MODEL FOR NON-RELAPSE MORTALITY RISK BASED ON MACHINE LEARNING IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION <i>Poster Presenter:</i> Xiawei Zhang (China)	08:30 - 08:30
B060	A HIGH FREQUENCY OF TYPE 3 DENDRITIC CELLS IN CD1C+DC ON DAY +28 AFTER HSCT COULD BE AN EFFECTIVE INDICATOR OF SEVERE GVHD IN PEDIATRIC PATIENTS <i>Poster Presenter:</i> Xin Liu (China)	08:30 - 08:30
B061	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH UNRELATED CORD BLOOD ENHANCES SURVIVAL AND REDUCES THE INCIDENCE OF AGVHD FOR PEDIATRIC ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Zhijie Wei (China)	08:30 - 08:30
B062	RUXOLITINIB AND ANTI-TNF-ALPHA THERAPY SUBSTANTIALLY IMPROVE SURVIVAL IN PEDIATRIC PATIENTS WITH SEVERE STEROID REFRACTORY GVHD <i>Poster Presenter:</i> Ingo Müller (Germany)	08:30 - 08:30
B063	IMMUNOPHENOTYPE OF EXTRACELLULAR VESICLES AS A BIOMARKER OF CHRONIC GRAFT-VERSUS-HOST-DISEASE: A PILOT STUDY <i>Poster Presenter:</i> Luisa Giaccone (Italy)	08:30 - 08:30
B064	T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION WITH ALEMTUZUMAB IS A VIABLE ALTERNATIVE TO POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME <i>Poster Presenter:</i> Alexandra Rojek (United States)	08:30 - 08:30
B065	EXTENDED ABATACEPT USE WITH SEROTHERAPY TO REDUCE ACUTE GVHD INCIDENCE IN PEDIATRIC PATIENTS TRANSPLANTED FROM HLA-MISMATCHED UNRELATED DONORS <i>Poster Presenter:</i> Pietro Merli (Italy)	08:30 - 08:30
B066	ENDOTHELIAL DYSFUNCTION AND RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A PRELIMINARY ANALYSIS OF A SINGLE CENTRE STUDY <i>Poster Presenter:</i> Giulia Losi (Italy)	08:30 - 08:30
B067	EXTENDED ABATACEPT DOSING MAY REDUCE RATES OF CHRONIC GRAFT VS HOST DISEASE IN PEDIATRIC PATIENTS UNDERGOING BONE MARROW TRANSPLANT FOR UNDERLYING HEMATOLOGICAL DISEASES <i>Poster Presenter:</i> Michael Grimley (United States)	08:30 - 08:30
B068	COMPARISON OF THE EFFICACY OF MYCOPHENOLATE MOFETIL AFTER ORAL OR INTRAVENOUS ADMINISTRATION IN THE	08:30 - 08:30

PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE

B069	NEAR ELIMINATION OF GVHD WITH AN ABBREVIATED CALCINEURON AND M-TOR INHIBITOR-FREE GVHD PREVENTION REGIMEN <i>Poster Presenter:</i> Samer Al-Homsy (United States)	08:30 - 08:30
B070	EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING <i>Poster Presenter:</i> Sara Redondo (Spain)	08:30 - 08:30
B071	A LOW TRAJECTORY OF PLATELETS IN THE EARLY STAGES AFTER TRANSPLANTATION IS LINKED TO THE DEVELOPMENT OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
B072	ADDITION OF TOCILIZUMAB TO STANDARD GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MOTHER DONORS: A NESTED CASE-CONTROL STUDY <i>Poster Presenter:</i> Lizhen Liu (China)	08:30 - 08:30
B073	GVHD PROPHYLAXIS WITH THREE VERSUS FIVE DRUGS COMBINATION IN AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANT FROM HLA MISMATCHED UNRELATED OR HAPLOIDENTICAL RELATED DONOR <i>Poster Presenter:</i> Alessandra Picardi (Italy)	08:30 - 08:30
B074	CYTOKINE SECRETION DURING REDUCED INTENSITY CONDITIONING HAEMATOPOIETIC STEM CELL TRANSPLANT FOR MYELOID DISEASE, AN OPPORTUNITY FOR OUTCOME PREDICTION <i>Poster Presenter:</i> Chris Armstrong (Ireland)	08:30 - 08:30
B075	INTERFERON GAMMA ACTIVITY IN IMPAIRED HAEMATOPOIETIC STEM CELL (HSC) PROLIFERATION AND GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Régis Peffault de Latour (France)	08:30 - 08:30
B076	DELETIONS OF COMPLEMENT FACTOR H-RELATED GENES CFHR-1 AND CFHR-3 AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Dr. Lars Klinge Gjørde (Denmark)	08:30 - 08:30
B077	EXTERNAL VALIDATION OF SAINT LOUIS SCORE TO PREDICT ACUTE GRAFT-VERSUS-HOST DISEASE SEVERITY <i>Poster Presenter:</i> Alessandro Criscimanna (Italy)	08:30 - 08:30
B078	EVALUATION OF RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING REGIMENS <i>Poster Presenter:</i> Kristina Maas-Bauer (Germany)	08:30 - 08:30
B079	THE MACROPHAGE ACTIVATION MARKER SCD163 AND ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HSCT <i>Poster Presenter:</i> Maja Munk Kristoffersen (Denmark)	08:30 - 08:30
B080	ETIOLOGY OF DIARRHEA IN PATIENTS UNDERGOING COLONOSCOPIC BIOPSIES POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR SUSPECTED ACUTE GUT GRAFT VERSUS HOST DISEASE <i>Poster Presenter:</i> Niket Mantri (India)	08:30 - 08:30

B081	ABATACEPT ADDED TO POST TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS IN ALLOGENEIC HEMATOPOYETIC STEM CELL TRANSPLANTATION: ONE SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Paula Fernández- Caldas González (Spain)	08:30 - 08:30
B082	SAFETY AND EFFICACY OF THE ROCK2-INHIBITOR BELUMOSUDIL IN CGVHD TREATMENT - A RETROSPECTIVE, MULTICENTER REAL-WORLD DATA ANALYSIS <i>Poster Presenter:</i> Silke Heidenreich (Germany)	08:30 - 08:30
B083	EFFICACY AND SAFETY OF IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A SYSTEMATIC REVIEW <i>Poster Presenter:</i> Daniel Rizky (Indonesia)	08:30 - 08:30
B084	WHEN SHOULD RUXOLITINIB BE CEASED? A SINGLE CENTRE, RETROSPECTIVE, REAL-WORLD ANALYSIS OF RUXOLITINIB IN GRAFT VS HOST DISEASE POST ALLOGENEIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Harshita Rajasekariah (Australia)	08:30 - 08:30
B085	CLINICAL RESPONSE AND IMMUNOLOGICAL RECOVERY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) TREATED WITH THE ASSOCIATION OF EXTRACORPOREAL PHOTOPHERESIS (ECP) AND RUXOLITINIB <i>Poster Presenter:</i> Eleonora Toffoletti (Italy)	08:30 - 08:30
B086	GVHD PROPHYLAXIS WITH POST-TRANSPLANT HIGH DOSE CYTOXAN OVERCOMING THE BARRIER OF ALLOGENEIC HCT IN FUNCTIONAL HIGH-RISK PATIENTS <i>Poster Presenter:</i> Yuliya Shestovska (United States)	08:30 - 08:30
P094	MESENCHYMAL STROMAL CELLS IN PATIENTS WITH III-IV GRADE STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST-DISEASE: DAY 14 RESPONSE IS PREDICTIVE OF SURVIVAL <i>Poster Presenter:</i> Adomas Bukauskas (Lithuania)	08:30 - 08:30
P095	JAK-2 INHIBITOR RUXOLITINIB FOR THERAPY OF ACUTE STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANT DISEASES <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	08:30 - 08:30
P096	MODULAATE (PART 1): AN OPEN-LABEL, DOSE-FINDING PHASE 2 EVALUATION OF ALPHA-1 ANTITRYPSIN FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN PATIENTS RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Edmund K. Waller (United States)	08:30 - 08:30
P097	RUXOLITINIB TREATMENT OUTCOMES IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN REAL-WORLD SETTING IN FINLAND <i>Poster Presenter:</i> Eeva Martelin (Finland)	08:30 - 08:30
P098	THE IMPACT OF MEASURED RENAL FUNCTION BY IOTHALAMATE CLEARANCE ON ALLOGENEIC STEM CELL TRANSPLANT OUTCOMES IN PATIENTS RECEIVING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR GVHD PROPHYLAXIS <i>Poster Presenter:</i> Jade Kutzke (United States)	08:30 - 08:30
P099	VON WILLEBRAND FACTOR AS A DIAGNOSTIC AND ACTIVITY INDICATOR OF CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Lana Desnica (Croatia)	08:30 - 08:30
P100	A PROSPECTIVE PILOT STUDY OF GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS WITH POSTBIOTICS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Jong-Ho Won (Korea, Republic of)	
P101	POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH ANTI-THYMOCYTE GLOBULIN LOWERED SERUM IL-6 LEVEL COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE ALONE AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Ik-Chan Song (Korea, Democratic People's Republic of)	
P102	ALPHA-1-ANTITRYPSIN TREATMENT OF STEROID-RESISTANT ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE, SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Şebnem İzmir Güner (Turkey)	
P103	USE OF RUXOLITINIB IN STEROID DEPENDENT/REFRACTORY ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Dimitris Galopoulos (United Kingdom)	
P104	EFFICACY AND SAFETY OF INFlixIMAB THERAPY IN THE SETTING OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE	08:30 - 08:30
	<i>Poster Presenter:</i> Khalid Halahleh (Jordan)	
P105	THE EFFICACY AND SAFETY OF EXTRACORPOREAL PHOTOPHERESIS IN STEROID-DEPENDENT-REFRACTORY/ GVHD: COHORT STUDY FROM COMPREHENSIVE ADULT BONE MARROW TRANSPLANTATION PROGRAM IN JORDAN	08:30 - 08:30
	<i>Poster Presenter:</i> Khalid Halahleh (Jordan)	
P106	EFFICACY OF GLUCOCORTICOID THERAPY IN CHINESE PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE	08:30 - 08:30
	<i>Poster Presenter:</i> Xiaoqian Dong (China)	
P107	RITUXIMAB FOR THE TREATMENT OF STEROID-REFRACTORY ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Wei Ma (China)	
P108	EVALUATION AND DIFFERENCE OF QUALITY OF LIFE IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE	08:30 - 08:30
	<i>Poster Presenter:</i> Shiqin Huang (China)	
P109	POST-TRANSPLANT SERUM FERRITIN LEVEL PREDICTS SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN UMBILICAL CORD BLOOD TRANSPLANTATION FOR ACUTE LEUKEMIA	08:30 - 08:30
	<i>Poster Presenter:</i> Zhiqi Zhang (China)	
P110	COMPARING THE OUTCOMES OF MATCHED AND MISMATCHED UNRELATED ALLOHCT WITH DIFFERENT ANTI-THYMOCYTE GLOBULIN FORMULATIONS. A RETROSPECTIVE ANALYSIS ON BEHALF OF POLISH ADULT LEUKEMIA GROUP	08:30 - 08:30
	<i>Poster Presenter:</i> Jarosław Dybko (Poland)	
P111	MUCOSAL ASSOCIATED INVARIANT T CELLS IN THE PERIPHERAL BLOOD IN GRAFT VERSUS HOST DISEASE (GVHD)	08:30 - 08:30
	<i>Poster Presenter:</i> Ayşen Görünmezoğlu (Turkey)	
P112	EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATMENT OF GVHD IN CHILDREN IN THE ERA OF TRANSPLANT FROM PARTIALLY MATCHED DONORS	08:30 - 08:30
	<i>Poster Presenter:</i> Marianna Maffei (Italy)	
P113	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL TRANSPLANT: A REPORT IN LOW AND MIDDLE INCOME COUNTRY	08:30 - 08:30

	<i>Poster Presenter:</i> Rubén Solis Armenta (Mexico)	
P114	EFFICACY AND SAFETY OF RUXOLITINIB FOR PEDIATRIC ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE - A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Shu-Wei Chou (Taiwan)	08:30 - 08:30
P115	SYSTEMATIC LITERATURE REVIEW ON THE SAFETY, EFFICACY, AND EFFECTIVENESS OF EATG VERSUS COMPARATORS FOR GVHD <i>Poster Presenter:</i> Barbara Mozejko-Pastewka (United States)	08:30 - 08:30
P116	A SERIES OF STEROID-REFRACTORY, SEVERE CHRONIC GRAFT-VERSUS- HOST DISEASE CASES, TREATED WITH RUXOLITINIB- A SINGLE-CENTER EXPERIENCES <i>Poster Presenter:</i> Ewa Karakulska-Prystupiak (Poland)	08:30 - 08:30
P117	EFFICACY AND SAFETY IN EARLY APPLICATION OF RUXOLITINIB FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA TO PREVENT GVHD AND RECURRENCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Dan Fang (China)	08:30 - 08:30
P118	BELUMOSUDIL FOR SEVERE, REFRACTORY CHRONIC GVHD IN PEDIATRIC PATIENT: CASE REPORT <i>Poster Presenter:</i> Agnieszka Sobkowiak-Sobierajska (Poland)	08:30 - 08:30
P119	CLINICAL EVOLUTION OF PATIENTS WITH GRAFT-VERSUS-HOST DISEASE - THE EXPERIENCE OF A SINGLE CENTER <i>Poster Presenter:</i> Ana Salselas (Portugal)	08:30 - 08:30
P120	USE OF MYCOPHENOLATE MOFETIL FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM UNRELATED DONORS <i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	08:30 - 08:30
P121	RETROSPECTIVE ANALYSIS OF RUXOLITINIB TREATMENT FOR THE MANAGEMENT OF STEROID REFRACTORY GRAFT VERSUS HOST DISEASE IN ADULTS WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Rubén Solis Armenta (Mexico)	08:30 - 08:30
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Infectious Complications		
A147	BREAKTHROUGH INVASIVE FUNGAL DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A MULTICENTER EPIDEMIOLOGICAL STUDY (CAESAR 2.0) <i>Poster Presenter:</i> Yuqian Sun (China)	08:30 - 08:30
A148	CHANGES IN THE EPIDEMIOLOGY OF INVASIVE FUNGAL DISEASES IN HSCT OVER ALMOST A QUARTER OF A CENTURY <i>Poster Presenter:</i> Marina Popova (Russian Federation)	08:30 - 08:30
A149	OUTCOMES FROM BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Colin Hayes (United States)	08:30 - 08:30
A150	LETTERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IS THE POTENTIAL RISK OF EBV-POSITIVE POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER HAPLOIDENTICAL STEM-CELL TRANSPLANTATION <i>Poster Presenter:</i> Xuying Pei (China)	08:30 - 08:30

A151	<p>DIAGNOSIS OF MUCORMYCOSIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING METAGENOMIC NEXT-GENERATION SEQUENCING: A SINGLE-CENTER CLINICAL STUDY</p> <p><i>Poster Presenter:</i> Fang Xu (China)</p>	08:30 - 08:30
A152	<p>MARIBAVIR USE FOR REFRACTORY CMV INFECTION/DISEASE: THE RESULTS FROM THE FRENCH COMPASSIONATE PROGRAMME</p> <p><i>Poster Presenter:</i> Catherine Cordonnier (France)</p>	08:30 - 08:30
A153	<p>COMPREHENSIVE SCREENING AND SENSITIVITY-GUIDED TREATMENT SIGNIFICANTLY REDUCES THIRTY-DAY MORTALITY OF METALLO-B-LACTAMASES PRODUCING ENTEROBACTERIALES (MBL-E) INFECTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM A PROSPECTIVE STUDY</p> <p><i>Poster Presenter:</i> Yuqian Sun (China)</p>	08:30 - 08:30
A154	<p>PENTAGLOBIN® AS EARLY ADJUVANT TREATMENT FOR FEBRILE NEUTROPENIA IN HEMATOLOGICAL PATIENTS COLONIZED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE OR PSEUDOMONAS AERUGINOSA: INTERIM ANALYSIS OF GITMO STUDY "PENTALLO"</p> <p><i>Poster Presenter:</i> Daniela Clerici (Italy)</p>	08:30 - 08:30
A155	<p>MUCOSITIS-ASSOCIATED BLOODSTREAM INFECTIONS IN HAEMATOLOGY PATIENTS WITH FEVER DURING NEUTROPENIA</p> <p><i>Poster Presenter:</i> Nick de Jonge (Netherlands)</p>	08:30 - 08:30
A156	<p>DESCRIPTIVE ANALYSES OF PULMONARY FUNCTION CHANGES BEFORE AND AFTER COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS. AN INFECTIOUS DISEASE WORKING PARTY STUDY</p> <p><i>Poster Presenter:</i> Dr. José Luis Piñana Sanchez (Spain)</p>	08:30 - 08:30
A157	<p>EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE LETERMOVIR ERA</p> <p><i>Poster Presenter:</i> Xiaoxia Hu (China)</p>	08:30 - 08:30
A158	<p>PATTERN OF SENSITIVITY OF STOOL SURVEILLANCE OVER 13 YEARS AND IMPACT OF STOOL SURVEILLANCE GUIDED SELECTION OF ANTIBIOTIC IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS</p> <p><i>Poster Presenter:</i> Laxma Reddy (India)</p>	08:30 - 08:30
A159	<p>INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-155: PRELIMINARY RESULTS FROM AN ON-GOING PHASE 1B STUDY IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)</p> <p><i>Poster Presenter:</i> Swarna Pandian (United States)</p>	08:30 - 08:30
A160	<p>EBV REACTIVATION AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF LETERMOVIR FOR CMV PROPHYLAXIS: A RETROSPECTIVE COHORT STUDY</p> <p><i>Poster Presenter:</i> Sisi Zhen (China)</p>	08:30 - 08:30
A161	<p>CYTOMEGALOVIRUS (CMV) LOAD PREDICTS CMV DISEASE AND MORTALITY INDEPENDENT OF POSTTRANSPLANT IMMUNOSUPPRESSION AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT)</p> <p><i>Poster Presenter:</i> Alicja Sadowska-Klasa (United States)</p>	08:30 - 08:30
A162	<p>ADENOVIRUS INFECTION IN ADULT ALLOGENEIC TRANSPLANT RECIPIENTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE</p>	08:30 - 08:30

	<i>Poster Presenter:</i> Maria Chiara Quattrocchi (Italy)	
A163	NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A MULTICENTER EUROPEAN CASE-CONTROL STUDY BY THE INFECTIOUS DISEASES WORKING PARTY OF EBMT <i>Poster Presenter:</i> Maria Stamouli (Greece)	08:30 - 08:30
A164	BACTEREMIA IN THE FIRST +100 DAYS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: MICROORGANISMS, RESISTANCE AND PROGNOSTIC IMPACT <i>Poster Presenter:</i> Maria Huguet (Spain)	08:30 - 08:30
A165	ISAVUCONAZOLE THERAPEUTIC DRUG MONITORING-DRIVEN TREATMENT IN A COHORT OF PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE <i>Poster Presenter:</i> Carmen Dolores De Luca (Italy)	08:30 - 08:30
A166	THINK TO CHECK PREVIOUS SEROLOGIES WHEN CMV OR TOXOPLASMA SEROLOGIES ARE NEGATIVE AT TRANSPLANT <i>Poster Presenter:</i> Christine Robin (France)	08:30 - 08:30
A167	IMMUNE POPULATIONS PREDICT CONTROL OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Paula Díaz-Fernández (Spain)	08:30 - 08:30
A168	NEW ANTIMICROBIAL STEWARDSHIP PROGRAM TOOL TO REDUCE THE EMPIRICAL ANTIBACTERIAL THERAPY IN HAPLO-HSCT <i>Poster Presenter:</i> Marina Popova (Russian Federation)	08:30 - 08:30
A169	LETERMOVIR IS SAFE AND EFFECTIVE FOR TREATMENT AND PREVENTION OF CMV REACTIVATION IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Nathanael Lucas (United Kingdom)	08:30 - 08:30
A170	DUAL METAGENOMICS NEXT-GENERATION SEQUENCING FOR FIRST-LINE DIAGNOSIS OF BLOODSTREAM INFECTION IN HEMATOLOGIC PATIENTS WITH FEBRILE NEUTROPENIA: A MULTICENTER PROSPECTIVE STUDY <i>Poster Presenter:</i> Yuqian Sun (China)	08:30 - 08:30
A171	CYTOMEGALOVIRUS-SPECIFIC T CELL IMMUNITY RECONSTITUTION AFTER LETERMOVIR WITHDRAWAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS <i>Poster Presenter:</i> Xiaoxia Hu (China)	08:30 - 08:30
A172	CMV REACTIVATION AND ITS IMPACT ON SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN LETERMOVIR ERA - A SINGLE CENTRE STUDY <i>Poster Presenter:</i> Lana Desnica (Croatia)	08:30 - 08:30
A173	IMPACT OF QUANTIFERON-CMV (QNF-CMV) ON LATE ONSET CLINICALLY SIGNIFICANT CMV INFECTION (CSCMV) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) <i>Poster Presenter:</i> Chiara Maria Dellacasa (Italy)	08:30 - 08:30
A174	THERAPEUTIC DRUG MONITORING (TDM) OF PIPERACILLIN IN PATIENTS WITH NEUTROPENIC FEVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Güzin Surat (Germany)	08:30 - 08:30
A175	ESTABLISHING EBV LOAD THRESHOLDS FOR PREDICTING	08:30 - 08:30

	PERSISTING EBV-DNAEMIA AND ASSOCIATED DISEASE IN HAEMATOPOIETIC CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Svenia Schmid (Switzerland)	
A176	CLINICAL OUTCOMES OF STRONGYLOIDIASIS IN HAEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS <i>Poster Presenter:</i> Avneet Kaur (United States)	08:30 - 08:30
A177	MONITORING OF CMV-SPECIFIC CELL-MEDIATED IMMUNITY - PROGNOSTIC FACTORS AND CLINICAL VALUE <i>Poster Presenter:</i> Jonas Wißkirchen (Germany)	08:30 - 08:30
A178	USE OF LETERMОВIR IN PEDIATRIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP <i>Poster Presenter:</i> Dr. Katharina Kleinschmidt (Germany)	08:30 - 08:30
A179	CONVENTIONAL VERSUS NGS-BASED PATHOGEN DIAGNOSTICS IN FEBRILE ALLOGENEIC STEM CELL TRANSPLANT PATIENTS - A PROSPECTIVE SINGLE-CENTRE STUDY <i>Poster Presenter:</i> Sophie Weil (Germany)	08:30 - 08:30
A180	MUCORMYCOSIS IN TRANSPLANTED OR NON-TRANSPLANTED HEMATOLOGIC PATIENTS <i>Poster Presenter:</i> Jieru Wang (China)	08:30 - 08:30
A181	MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS INFECTION AND INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES <i>Poster Presenter:</i> María Laura Fox (United States)	08:30 - 08:30
A182	EFFICACY OF LETERMОВIR IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER CORD BLOOD TRANSPLANTATION <i>Poster Presenter:</i> Naoki Okada (Japan)	08:30 - 08:30
A183	SARS-COV-2 CYCLE THRESHOLD LEVELS AND COVID-19 OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION. AN INFECTIOUS DISEASE WORKING PARTY STUDY <i>Poster Presenter:</i> Dr. José Luis Piñana Sanchez (Spain)	08:30 - 08:30
A184	SINGLE-DAY TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS FOR PNEUMOCYSTIS PNEUMONIAE AND TOXOPLASMOSIS INFECTION IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION PEDIATRIC PATIENTS <i>Poster Presenter:</i> Maria Speranza Massei (Italy)	08:30 - 08:30
A185	AN INTERIM ANALYSIS OF FOVOICIP: A MULTICENTER RANDOMIZED TRIAL OF FOSFOMYCIN VERSUS CIPROFLOXACIN FOR FEBRILE NEUTROPENIA PREVENTION IN HEMATOLOGIC PATIENTS <i>Poster Presenter:</i> Teresa Bernal (Spain)	08:30 - 08:30
A186	IMPACT OF LETERMОВIR PRIMARY AND SECONDARY PROPHYLAXIS IN A PEDIATRIC COHORT <i>Poster Presenter:</i> Marta Verna (Italy)	08:30 - 08:30
A187	EPSTEIN-BARR VIRUS REACTIVATION AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER IMPLEMENTATION OF ANTITHYMOCYTE GLOBULIN AS GVHD PROPHYLAXIS. A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Camilla Dao Vo (Norway)	08:30 - 08:30
A188	IMPACT OF INVASIVE FUNGAL DISEASE UPDATED DEFINITIONS	08:30 - 08:30

	ON ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION OUTCOME IN ADULT PATIENTS - POST-HOC ANALYSIS OF NATION-WIDE CROSS-SECTIONAL 2012-2014	
	<i>Poster Presenter:</i> Patrycja Mensah-Glanowska (Poland)	
A189	SURVEILLANCE BLOOD CULTURES FROM TUNNELLED CENTRAL VENOUS CATHETERS ON ADMISSION ARE OFTEN POSITIVE, GUIDE MANAGEMENT AND HELP INFORM REPORTING OF HOSPITAL ACQUIRED INFECTIONS	08:30 - 08:30
	<i>Poster Presenter:</i> Dr. Andrew Clark (United Kingdom)	
A190	ROLE OF HUMAN HERPESVIRUS 6 REACTIVATION IN T-DEplete TREG/TCON ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Valerio Viglione (Italy)	
A191	INTERLEUKIN-6 IS SIGNIFICANTLY INCREASED IN SEVERE PNEUMONIA AFTER ALLO-HSCT AND MIGHT INDUCE LUNG INJURY VIA IL-6/SIL-6R/JAK1/STAT3 PATHWAY	08:30 - 08:30
	<i>Poster Presenter:</i> Yuqian Sun (China)	
A192	ECHINOCANDIN PROPHYLAXIS IS ASSOCIATED WITH BREAKTHROUGH <i>TRICHOSPORON</i> AND <i>CANDIDA</i> INFECTIONS AND A LIMITED ROLE OF GALACTOMANNAN MONITORING AMONG ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS	08:30 - 08:30
	<i>Poster Presenter:</i> André Dias Américo (Brazil)	
A193	REAL WORLD EXPERIENCE OF EPSTEIN-BARR VIRUS (EBV) SCREENING FOR PERSISTENT VIRAEMIA POST HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)	08:30 - 08:30
	<i>Poster Presenter:</i> Abigail Downing (United Kingdom)	
A194	EPIDEMIOLOGY OF VIRAEMIA IN CHILDREN UNDERGOING CORD BLOOD STEM CELL TRANSPLANT (CB-SCT) WITH NON-MALIGNANT DISEASES: A RETROSPECTIVE COHORT STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Patel Zeeshan Jameel (United Kingdom)	
A195	PREVALENCE OF VZV REACTIVATION AND EFFECTIVENESS OF VACCINATION WITH RECOMBINANT ADJUVANTED ZOSTER VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL RECIPIENTS- A SINGLE-CENTER ANALYSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Ewa Karakulska-Prystupiuik (Poland)	
A196	LETERMOVIR PROPHYLAXIS REDUCED CYTOMEGALOVIRUS REACTIVATION AND RESISTANCE POST UMBILICAL CORD BLOOD TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Bingbing Yan (China)	
A197	BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS IN POSTTRANSPLANT CYCLOPHOSPHAMIDE-BASED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR IMMUNE DEFICIENCY OR DYSREGULATION	08:30 - 08:30
	<i>Poster Presenter:</i> Dimana Dimitrova (United States)	
A198	INFECTION PREVENTION MEASURES TAKEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS DURING THE COVID-19 PANDEMIC AND THEIR IMPACT ON CLINICAL OUTCOMES	08:30 - 08:30
	<i>Poster Presenter:</i> Sarah Morin (Switzerland)	
A199	EFFECT OF EARLY ADMINISTRATION OF ANTI-MRSA DRUGS ON THE COURSE OF FEBRILE NEUTROPENIA IN ALLO-SCT	08:30 - 08:30
	<i>Poster Presenter:</i> Anna Akaogi (Japan)	
A200	VISCERAL TOXOCARIAS IN THE EARLY POST-TRANSPLANT COURSE	08:30 - 08:30
	<i>Poster Presenter:</i> Iacopo Bellani (Italy)	

A201	DE-ESCALATION ANTIBIOTIC STRATEGY IN MULTIDRUG-RESISTANCE BACTERIAL COLONIZED PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. A 3-YEAR RETROSPECTIVE STUDY <i>Poster Presenter:</i> Giuseppe Sapienza (Italy)	08:30 - 08:30
A202	MARIBAVIR FOR TREATMENT OF REFRACTORY/RECURRENT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HSCT RECIPIENTS <i>Poster Presenter:</i> Marina Popova (Russian Federation)	08:30 - 08:30
A203	REAL LIFE MANAGEMENT OF ANTIBIOTIC THERAPY IN HSCT RECIPIENTS - FOCUS ON DE-ESCALATION IN PRE-ENGRAFTMENT NEUTROPENIA, THE STUDY FROM THE EBMT INFECTIOUS DISEASES WORKING PARTY (IDWP) <i>Poster Presenter:</i> Prof. Dr. Malgorzata Mikulska (Italy)	08:30 - 08:30
A204	INFECTIOUS COMPLICATIONS IN 549 BMTS DONE WITHOUT CENTRAL HEPA FILTRATION OR POSITIVE PRESSURE? <i>Poster Presenter:</i> Dr. Lawrence Faulkner (Italy)	08:30 - 08:30
A205	COVID-19 IN PATIENTS WITH HAEMATOLOGICAL DISEASES: THE ASSOCIATION OF RNAEMIA WITH CLINICAL OUTCOMES IN VACCINATED PATIENTS <i>Poster Presenter:</i> Francisco Manuel Martin Dominguez (Spain)	08:30 - 08:30
A206	COST-EFFECTIVENESS OF MARIBAVIR FOR POST-TRANSPLANT CYTOMEGALOVIRUS INFECTION THAT IS REFRACTORY TO ALTERNATIVE TREATMENTS FROM THREE HEALTHCARE SYSTEM PERSPECTIVES: ITALY, UK AND US <i>Poster Presenter:</i> Tien Bo (United States)	08:30 - 08:30
A207	INVASIVE FUNGAL INFECTIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A 4-YEAR SINGLE INSTITUTION ANALYSIS WITH FOCUS ON PROPHYLAXIS <i>Poster Presenter:</i> Marta Verna (Italy)	08:30 - 08:30
A208	ENHANCING SARS-COV-2 IMMUNITY EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A THREE-DOSE RBD-TT-CONJUGATED VACCINE APPROACH <i>Poster Presenter:</i> Maryam Barkhordar (Iran)	08:30 - 08:30
A209	BLOODSTREAM INFECTIONS IN ALLOGENEIC HEMATOPOIETIC CELL RECIPIENTS: TRENDS OF INCIDENCE, SUSCEPTIBILITY AND RISK FACTORS FOR MULTIDRUG RESISTANCE <i>Poster Presenter:</i> Sara Fernandes (Brazil)	08:30 - 08:30
A210	USE OF LETERMОВIR IN PEDIATRIC POPULATION POST BONE MARROW TRANSPLANT <i>Poster Presenter:</i> Julia Marsal Ricoma (Spain)	08:30 - 08:30
P122	REAL-WORLD OUTCOMES AND TREATMENT PATTERNS OF CMV INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS, REFRACTORY OR INTOLERANT TO TREATMENTS IN EUROPE, CANADA, ISRAEL: INTERIM ANALYSIS <i>Poster Presenter:</i> Prof. Johan Maertens (Belgium)	08:30 - 08:30
P123	THE RESPECT STUDY DESIGN: COMPARISON OF ONCE-WEEKLY REZAFUNGIN AGAINST STANDARD ANTIMICROBIAL PROPHYLAXIS IN ADULTS UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION <i>Poster Presenter:</i> Prof. Johan Maertens (Belgium)	08:30 - 08:30
P124	NO INFERIOR OUTCOME OF OMITTING FLUOROQUINOLONE PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Vanessa Nehrbaß (Germany)	
P125	AEROSOLIZED PENTAMIDINE FOR PNEUMOCYSTIS JIROVECI PNEUMONIA PROPHYLAXIS IN ADULT PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Sung-Hoon Jung (Korea, Republic of)	08:30 - 08:30
P126	LETERMOVIR AS TREATMENT AND SECONDARY PROPHYLAXIS OF CMV REACTIVATION IN LOW-WEIGHT PEDIATRIC PATIENTS <i>Poster Presenter:</i> Chiara Mainardi (Italy)	08:30 - 08:30
P127	COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA IN ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Aleksandr Siniaev (Russian Federation)	08:30 - 08:30
P128	OUTCOMES, CHOICE OF ANTIBIOTICS AND THEIR EFFECTIVENESS IN ALLOGENEIC-HSCT RECIPIENTS COLONIZED WITH MULTIRESTANT GRAM-NEGATIVE BACTERIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Igor Age Kos (Germany)	08:30 - 08:30
P129	COMPARISON OF BLOOD STREAMING INFECTIONS BETWEEN TUNNELED CENTRAL VENOUS CATHETERS AND NON-TUNNELED CENTRAL VENOUS CATHETERS IN ACUTE LEUKEMIA REMISSION INDUCTION - A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Cheongin Yang (Korea, Republic of)	08:30 - 08:30
P130	INCIDENCE OF INFECTIONS AND QUALITY OF IMMUNE RECONSTITUTION FOLLOWING CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS FROM HLA-IDENTICAL DONOR <i>Poster Presenter:</i> Massimiliano Gambella (Italy)	08:30 - 08:30
P131	CMV MONITORING AND LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Yuta Katayama (Japan)	08:30 - 08:30
P132	RISK FACTORS OF CYTOMEGALOVIRUS INFECTION AFTER CORD BLOOD TRANSPLANTATION IN PEDIATRIC ACUTE LEUKEMIA AND ITS IMPACT ON IMMUNE RECONSTITUTION <i>Poster Presenter:</i> Minyuan Liu (China)	08:30 - 08:30
P133	MUTUAL IMPACT AND CHARACTERISTICS OF VIRAL REACTIVATIONS AND IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN. A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Cristian Jinca (Romania)	08:30 - 08:30
P134	DETECTION OF RESPIRATORY VIRUSES AMONG PAEDIATRIC HSCT RECIPIENTS - A TEN YEARS SINGLE-CENTRE EXPERIENCE <i>Poster Presenter:</i> Petr Hubacek (Czech Republic)	08:30 - 08:30
P135	LETERMOVIR COMBINED WITH GANCICLOVIR AS A PREEMPTIVE OR TREATMENT FOR CYTOMEGALOVIRUS INFECTION FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER RETROSPECTIVE REVIEW <i>Poster Presenter:</i> Han Yao (China)	08:30 - 08:30
P136	THE CLINICAL MANIFESTATION, PROGNOSTIC FACTORS, AND OUTCOMES OF ADENOVIRUS PNEUMONIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Yue-Wen Wang (China)	08:30 - 08:30
P137	INVASIVE FUNGAL DISEASES IN PATIENTS WITH CLL TREATED WITH BRUTON TYROSINE KINASE INHIBITORS, A MONO-	08:30 - 08:30

	CENTRIC RETROSPECTIVE STUDY	
	<i>Poster Presenter:</i> Yuri Vanbiervliet (Belgium)	
P138	KLEBSIELLA PNEUMONIAE INFECTION BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF NOVEL ANTIBIOTICS: A COMPARATIVE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Eleni Gavriilaki (Greece)	
P139	OUTCOMES OF HYPERBARIC OXYGEN THERAPY IN LATE-ONSET HEMORRHAGIC CYSTITIS AFTER ALLO-HSCT: A RETROSPECTIVE ANALYSIS	08:30 - 08:30
	<i>Poster Presenter:</i> Mariana Trigo Miranda (Portugal)	
P140	OPTIMIZING CMV PREVENTION IN STEM CELL TRANSPLANTS: HYBRID STRATEGY DELIVERS PROMISING REDUCTION IN REACTIVATION RATES	08:30 - 08:30
	<i>Poster Presenter:</i> Maryam Barkhordar (Iran)	
P141	STRATIFICATION AND IMMUNOLOGIC ANALYSIS OF PATIENTS WITH SARS-COV-2 INFECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Man Chen (China)	
P142	MESENCHYMAL STEM CELL THERAPY BY INTRATHECAL AND INTRAVENOUS INJECTION TO TREAT TOXOPLASMIC ENCEPHALITIS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PEDIATRIC CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Qi Ji (China)	
P143	PREDICTORS OF INVASIVE FUNGAL INFECTION AND IMPACT OF OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: SINGLE CENTER EXPERIENCE FROM THE KINGDOM OF SAUDI ARABIA	08:30 - 08:30
	<i>Poster Presenter:</i> Lama AlHmaly (Saudi Arabia)	
P144	THE ROLE OF COLONIZATION WITH RESISTANT G-BACTERIA IN THE TREATMENT OF FEBRILE NEUTROPENIA AFTER STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Jakub Radocha (Czech Republic)	
P145	COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF LETERMIVIR SINCE ITS USE IN PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTIONS IN ALLOGENEIC TRANSPLANT PATIENTS HEMATOLOGY DEPARTMENT OF CAEN UNIVERSITY HOSPITAL	08:30 - 08:30
	<i>Poster Presenter:</i> Tchuanga Djialeu Yannick Noel (France)	
P146	OUTCOME OF THE USE OF LETERMIVIR AS PROPHYLACTIC TREATMENT FOR HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE	08:30 - 08:30
	<i>Poster Presenter:</i> Marianna Maffeis (Italy)	
P147	IS THERE A PLACE FOR ANTI-HCMV HUMAN IMMUNOGLOBULIN AS PRE-EMPTIVE THERAPY IN T-DEplete TREG/TCON ALLOGENEIC STEM CELL TRANSPLANTATION?	08:30 - 08:30
	<i>Poster Presenter:</i> Valerio Viglione (Italy)	
P148	EXPERIENCE WITH THE USE OF MARIBAVIR IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH REFRACTORY OR RESISTANT CYTOMEGALOVIRUS (CMV)	08:30 - 08:30
	<i>Poster Presenter:</i> Candela Ceballos Bolaños (Spain)	
P149	FREQUENCY AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN RECIPIENTS OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION - AN EXPERIENCE FROM PAKISTAN	08:30 - 08:30
	<i>Poster Presenter:</i> Natasha Ali (Pakistan)	

P150	EVALUATION OF PLATELET AND CLOTTING PARAMETERS IN HEMATOLOGIC MALIGNANCIES AND HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS WITH CANDIDEMIA: A RETROSPECTIVE STUDY <i>Poster Presenter:</i> Hongchen Bi (China)	08:30 - 08:30
P151	CENTRAL VENOUS ACCESS DEVICE IN AUTOLOGOUS STEM CELL TRANSPLANT PATIENTS <i>Poster Presenter:</i> Danah Chakfeh (United Kingdom)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Psychological Issues		
P386	ARE WE DELIVERING EFFECTIVE PSYCHOLOGICAL CARE IN HAEMOPOIETIC CELL TRANSPLANTATION? RESULTS OF A UK MULTI-CENTRE QUALITATIVE STUDY ON PATIENTS' PERSPECTIVES <i>Poster Presenter:</i> Rosalina Naidoo (United Kingdom)	08:30 - 08:30
P387	ONE-YEAR ONLINE GROUP PSYCHOLOGICAL PROGRAM WITH A PEER CONSULTANT FOR YOUNG ADULTS WITH ONCOHEMATOLOGICAL DISEASES RETURNING TO ACTIVE LIFE AFTER TREATMENT <i>Poster Presenter:</i> Natalia Klipinina (Russian Federation)	08:30 - 08:30
P388	CLINICIANS' PERSPECTIVES ON IMPROVING PSYCHOLOGICAL CARE IN HAEMOPOIETIC CELL TRANSPLANTATION - A MULTI-DISCIPLINARY QUALITATIVE STUDY OF CLINICIANS ACROSS THE UK <i>Poster Presenter:</i> Rosalina Naidoo (United Kingdom)	08:30 - 08:30
P390	EVALUATION OF MENTAL HEALTH THROUGH AN EHEALTH PLATFORM IN THE MANAGEMENT OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (MYMEDULA STUDY): DESCRIPTIVE ANALYSIS <i>Poster Presenter:</i> Irene García-Cadenas (Spain)	08:30 - 08:30
P391	SIGNIFICANT IMPROVEMENT OF THE PATIENTS AFTER PSYCHOLOGICAL FOLLOW-UP DURING ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Eliana Kachaamy (Lebanon)	08:30 - 08:30
P392	EVALUATION OF FATIGUE AND SLEEP IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT AS PERCEIVED BY THEIR PARENTAL CAREGIVERS <i>Poster Presenter:</i> Neha Tojan (India)	08:30 - 08:30
P393	A REVIEW OF THE ROLE AND IMPACT OF AN ANTHONY NOLAN CLINICAL PSYCHOLOGIST <i>Poster Presenter:</i> Henrietta Saunders (United Kingdom)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Statistics		
P349	WHOLE GENOME MATCHING ANALYSIS FOR GRAFT-VERSUS-HOST DISEASE AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Julia Nihtilä (Finland)	08:30 - 08:30
P350	THE COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS SECOND-LINE THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN ITALY	08:30 - 08:30

	<i>Poster Presenter:</i> Yael Rodriguez-Guadarrama (United States)	
P351	EPIDEMIOLOGY, CLINICAL OUTCOMES AND TREATMENT PATTERNS OF CYTOMEGALOVIRUS (CMV) INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A SCOPING REVIEW AND META-ANALYSIS <i>Poster Presenter:</i> Lin Ren (China)	08:30 - 08:30
P352	MACHINE LEARNING IDENTIFIES BUSULFAN ADMINISTRATION SCHEDULE AS A SIGNIFICANT RISK FACTOR FOR SOS IN CHILDREN UNDERGOING HSCT <i>Poster Presenter:</i> Isabelle Dupanloup (Switzerland)	08:30 - 08:30
P353	CERTAINTY - A CELLULAR IMMUNOTHERAPY VIRTUAL TWIN FOR PERSONALIZED CANCER TREATMENT <i>Poster Presenter:</i> Dr. Kristin Reiche (Germany)	08:30 - 08:30
P354	IMPACT OF MIC AND NON-CLASSICAL HLA-E, -F AND -G ALLELES AND THEIR MISMATCHING TOGETHER WITH CLINICAL DATA ON ALLO-HSCT COMPLICATIONS <i>Poster Presenter:</i> Julia Nihtilä (Finland)	08:30 - 08:30
P355	A QUADRENNIAL OF PERFORMING ADULT STEM CELL TRANSPLANT IN A DEVELOPING COUNTRY: A SINGLE CENTER EXPERIENCE EXPERIENCE (PART ONE DEMOGRAPHIC DATA) <i>Poster Presenter:</i> Mohamed Elbogdady (Egypt)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
	Pharmacology	
P394	ANTI-POLYOMAVIRUS CELLULAR IMMUNOTHERAPY: AN INNOVATIVE THERAPY IN FOUR PATIENTS WITH POLYOMAVIRUS INFECTIONS <i>Poster Presenter:</i> Alexandre Chevalier (France)	08:30 - 08:30
P395	GANCICLOVIR THERAPEUTIC DRUG MONITORING FOR THE PREVENTION AND TREATMENT OF CYTOMEGALOVIRUS IN IMMUNOCOMPROMISED CHILDREN <i>Poster Presenter:</i> Heather Weerdenburg (Australia)	08:30 - 08:30
P396	NEW <i>IN VITRO</i> MODEL FOR INVESTIGATING THE EFFECT OF GENETIC POLYMORPHISMS ON <i>GSTA1</i> PROMOTER ACTIVITY, ONE OF THE KEY DETERMINANTS OF BUSULFAN INTERINDIVIDUAL VARIABILITY <i>Poster Presenter:</i> Yvonne Gloor (Switzerland)	08:30 - 08:30
P397	DOSE MODIFICATIONS OF FLUDARABINE AS PART OF FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) LYMPHODEPLETION IN PATIENTS WITH RENAL IMPAIRMENT RECEIVING LICENSED CAR-T CELL THERAPIES IN THE UK <i>Poster Presenter:</i> Jackie Chappell (United Kingdom)	08:30 - 08:30
P398	PAEDIVOD INSIGHTS: REVIEWING VENO-OCCLUSIVE DISEASE IN PAEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS - INCIDENCE, RISK FACTORS, AND ANTIFUNGAL IMPACT <i>Poster Presenter:</i> Heather Weerdenburg (Australia)	08:30 - 08:30
P399	AN INVESTIGATION OF ANTIBIOTIC PROPHYLAXIS TO PREVENT PNEUMOCOCCAL INFECTION AFTER STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Mr. Nick Duncan (United Kingdom)	08:30 - 08:30
P400	MOCRAVIMOD DOES NOT HAVE A CLINICALLY RELEVANT DRUG-DRUG INTERACTION WITH STRONG CYP3A4 INHIBITOR	08:30 - 08:30

	ITRACONAZOLE	
	<i>Poster Presenter:</i> Dymphy Huntjens (France)	
P401	DO WEIGHT BASED DOSE MODIFICATIONS IMPACT THE SEVERITY OF MUCOSITIS IN ADULT PATIENTS RECEIVING BUSULFAN AS PART OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT CONDITIONING?	08:30 - 08:30
	<i>Poster Presenter:</i> Katherine Cuthbert (United Kingdom)	
P402	DOES PROCALCITONIN ACCURATELY DIFFERENTIATE BETWEEN CRS AND BACTERIAL SEPSIS IN CAR-T PATIENTS? DOES PROCALCITONIN ACCURATELY DIFFERENTIATE BETWEEN CRS AND BACTERIAL SEPSIS IN CAR-T PATIENTS?	08:30 - 08:30
	<i>Poster Presenter:</i> Douglas Semple (United Kingdom)	
<i>ePoster</i>		
08:30 - 18:00		ePoster area
Nurses Posters - Research		
NP087	HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT	08:30 - 08:30
	<i>Poster Presenter:</i> Ammar Zahreddine (Lebanon)	
NP088	PATIENT'S OWN EXPERIENCES WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION, BEING CARED FOR AT HOME OR NOT. THAT'S THE QUESTION? BUT WHAT IS THE ANSWER?	08:30 - 08:30
	<i>Poster Presenter:</i> Ann Karin Svanberg (Sweden)	
NP089	TURKEY BONE MARROW TRANSPLANT NURSING PROFILE: RESEARCH RELATED FEATURES AND BARRIERS TO RESEARCH UTILIZATION	08:30 - 08:30
	<i>Poster Presenter:</i> Ozgun Gokmen Kaya (Turkey)	
NP090	QUALITY OF LIFE OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A RETROSPECTIVE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Radhika Padawe (India)	
NP091	PHYSICAL AND PSYCHOLOGICAL DISCOMFORT EXPERIENCED BY HEMATOPOIETIC STEM-CELL DONORS	08:30 - 08:30
	<i>Poster Presenter:</i> Vipin PV (India)	
NP092	HOW ARE SEXUALITY, BODY IMAGE, AND SEXUAL HEALTH AFFECTED IN HEMATO-ONCOLOGY PATIENTS AS A RESULT OF THE DISCOVERY OF THE DISEASE AND ITS TREATMENTS?	08:30 - 08:30
	<i>Poster Presenter:</i> Tehila Tanya Litvinov (Israel)	
NP093	QUALITY OF LIFE OF PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING HOSPITALIZATION - A PILOT STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Valentina Pomper Vragovic (Croatia)	
NP094	LIMITED DIAGNOSTIC AND THERAPEUTIC CONSEQUENCES OF CHEST X-RAYS IN HAEMATOLOGICAL PATIENTS WITH FEBRILE NEUTROPENIA	08:30 - 08:30
	<i>Poster Presenter:</i> Dorine Dijkshoorn-Fokker (Netherlands)	
NP095	THE ROLE OF A SPECIALIST SOCIAL WORKER IN TRANSPLANT: A SERVICE AUDIT	08:30 - 08:30
	<i>Poster Presenter:</i> Rachel Davidson (United Kingdom)	
NP096	CONSTRUCTION OF AN EVALUATION INDEX SYSTEM FOR INFECTION CONTROL IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION WARD BASED ON PROCESS MANAGEMENT	08:30 - 08:30
	<i>Poster Presenter:</i> Ying Wang (China)	

NP097	SILTUXIMAB MANAGEMENT IN THE CYTOKINE RELEASE SYNDROME <i>Poster Presenter: Cristina Martin Benito (Spain)</i>	08:30 - 08:30
NP098	NURSING CARE OF A PATIENT WITH REFRACTORY AND RECURRENT ACUTE MYELOID LEUKEMIA WHO SUFFERED FROM EXTENSIVE EXFOLIATIVE SKIN LESIONS THROUGHOUT THE BODY AFTER SECONDARY HSCT <i>Poster Presenter: Xiaoxia Wang (China)</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Aplastic Anaemia		
A253	EFFICACY AND SAFETY IS MAINTAINED IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA RECEIVING PEGCETACOPLAN FOR UP TO 3 YEARS <i>Poster Presenter: Regina Horneff (Sweden)</i>	08:30 - 08:30
A254	MOVING TOWARD INDIVIDUAL TREATMENT GOALS WITH PEGCETACOPLAN IN PATIENTS WITH PNH AND BONE MARROW FAILURE <i>Poster Presenter: Regina Horneff (Sweden)</i>	08:30 - 08:30
A255	RESULTS OF HSCT WITH TCRAB AND CD19-DEPLETION FROM MATCHED RELATED DONORS AND INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES IN PEDIATRIC SEVERE APLASTIC ANEMIA <i>Poster Presenter: Dmitriy Pershin (Russian Federation)</i>	08:30 - 08:30
A256	TREATMENT OUTCOME OF HSCT IN FANCONI ANAEMIA. EXPERIENCE FROM LOW AND MIDDLE INCOME COUNTRY <i>Poster Presenter: Hashim Khan (Pakistan)</i>	08:30 - 08:30
A257	EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA PATIENTS WITH A HISTORY OF APLASTIC ANAEMIA IN PEGASUS AND PRINCE CLINICAL TRIALS <i>Poster Presenter: Regina Horneff (Sweden)</i>	08:30 - 08:30
A258	MITOCHONDRIAL METABOLISM IN FANCONI ANEMIA PATIENTS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Maura Faraci (Italy)</i>	08:30 - 08:30
A259	ATLG HAS BETTER SAFETY THAN RATG IN THE TREATMENT OF ADULT AA WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Zhang Jianping (China)</i>	08:30 - 08:30
A260	TREATMENT WITH DARATUMUMAB IN 4 PATIENTS WITH IMMUNE ANEMIA AFTER HSCT WITH ABO INCOMPATIBILITY OR OTHER IMMUNE-ERYTHROCYTE DISCREPANCIES <i>Poster Presenter: Candela Ceballos Bolaños (Spain)</i>	08:30 - 08:30
P250	UPFRONT T-REPLETE HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE FROM JORDAN <i>Poster Presenter: Ayad Ahmed Hussein (Jordan)</i>	08:30 - 08:30
P251	COMPARISON OF HEMATOPOIETIC STEM CELL TRANSPLANTATION AND REPEATED INTENSIFIED IMMUNOSUPPRESSIVE THERAPY AS SECOND-LINE TREATMENT FOR RELAPSED/REFRACTORY SEVERE APLASTIC ANEMIA <i>Poster Presenter: Lining Zhang (China)</i>	08:30 - 08:30

P253	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH BU(2)/CY/FLU/ATG CAN ACHIEVE GOOD RESULTS IN TREATMENT OF TRANSFUSION DEPENDENT NON-SEVERE APLASTIC ANEMIA <i>Poster Presenter:</i> Li Nannan (China)	08:30 - 08:30
P254	ASSESSMENT OF CHARACTERISTICS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ACQUIRED APLASTIC ANAEMIA IN TURKEY (PLANE-TR STUDY) <i>Poster Presenter:</i> Eren Gündüz (Turkey)	08:30 - 08:30
P255	PERIPHERAL BLOOD AS GRAFT SOURCE FOR APLASTIC ANEMIA TRANSPLANT: OUTCOMES OF YOUNG ADULTS AND ADULTS IN A MEXICAN PUBLIC HOSPITAL <i>Poster Presenter:</i> Guillermo Sotomayor Duque (Mexico)	08:30 - 08:30
P256	UPFRONT HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CLASSICAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) <i>Poster Presenter:</i> Lorie Gandhi (India)	08:30 - 08:30
P257	EXPLORING STRATEGIES TO OPTIMISE OUTCOMES IN HEPATITIS-ASSOCIATED APLASTIC ANAEMIA PATIENTS FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Jia Li (China)	08:30 - 08:30
P258	A REAL-WORLD ANALYSIS OF TREATMENT ADHERENCE AND CLINICAL OUTCOMES FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) RECEIVING PEGCETACOPLAN <i>Poster Presenter:</i> Koo Wilson (Sweden)	08:30 - 08:30
P259	THE EFFICACY OF HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF CHILDREN WITH DIAMOND-BLACKFAN ANEMIA <i>Poster Presenter:</i> Lu Liu (China)	08:30 - 08:30
P260	EXPERIENCE OF SALVAGE HAPLO-HSCT WITH PTCY FOR ACQUIRED SEVERE APLASTIC ANEMIA <i>Poster Presenter:</i> Natalia Kirsanova (Belarus)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
B126	PRE-EMPTIVE DONOR LYMPHOCYTE INFUSION AS OPTIMAL TREATMENT FOR RELAPSED ACUTE MYELOID LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:A FRENCH-ITALIAN EXPERIENCE WITH 103 PATIENTS <i>Poster Presenter:</i> Michele Malagola (Italy)	08:30 - 08:30
B127	HLA-DR+ REGULATORY T CELLS ARE ASSOCIATED WITH THE ONSET AND SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Kinga Hosszu (United States)	08:30 - 08:30
B128	MAINTENANCE THERAPY WITH OLAPARIB AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TP53 MUTATED HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Zhihui Li (China)	08:30 - 08:30
B129	PERSISTENCE OF MINOR HISTOCOMPATIBILITY ANTIGEN- AND VIRUS-SPECIFIC T CELLS IN LEUKEMIC REMISSION AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANTATION	08:30 - 08:30

	<i>Poster Presenter:</i> Lisa Marie Schulz (Germany)	
B130	SERIAL LINEAGE CHIMERISM ANALYSIS IMPROVES EARLY DIAGNOSIS OF GRAFT FAILURE AFTER ALLOGENEIC HAPLOIDENTICAL HSCT <i>Poster Presenter:</i> Rebeca Bailén Alomoro (Spain)	08:30 - 08:30
B131	PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION <i>Poster Presenter:</i> Yue-Wen Wang (China)	08:30 - 08:30
B132	CYTOKINE PROFILES ASSOCIATED WITH GRAFT VERSUS HOST DISEASE AND RECENT THYMIC EMIGRANT T CELL RECONSTITUTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Devin McAvoy (United States)	08:30 - 08:30
B133	FAVOURABLE IMPACT OF POST-TRANSPLANT MINIMAL DISEASE NEGATIVITY ASSESSED BY FLOW CYTOMETRY ON SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES <i>Poster Presenter:</i> Radwan Massoud (Germany)	08:30 - 08:30
B134	FLOW-CYTOMETRIC AND TRANSCRIPTIONAL CHARACTERIZATION OF RECENT THYMIC EMIGRANTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) <i>Poster Presenter:</i> Marco Maria Sindoni (Italy)	08:30 - 08:30
B135	LOW PERCENTAGES OF EARLY B-CELL PRECURSORS IN THE BONE MARROW MAY PREDICT THE DEVELOPMENT OF CGVHD FOLLOWING PEDIATRIC HSCT <i>Poster Presenter:</i> Elisa Christine Peen (Denmark)	08:30 - 08:30
B136	MEASURABLE RESIDUAL DISEASE (MRD) AND T-CELL CHIMERISM ARE PROGNOSTIC BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION (ASCT) <i>Poster Presenter:</i> Elisa Meddi (Italy)	08:30 - 08:30
B137	NK CELLS CHIMERISM STATUS IS A POTENTIAL EARLY PREDICTOR OF RELAPSE AFTER ALLO-HSCT IN ACUTE LEUKEMIA <i>Poster Presenter:</i> Xing Chen (China)	08:30 - 08:30
B138	THE NUMBER OF CENTRAL MEMORY CD8+ T CELLS INFUSED AND THEIR EARLY RECOVERY AFTER ALLOGENEIC HSCT WAS ASSOCIATED WITH A DECREASED RISK OF DISEASE RELAPSE <i>Poster Presenter:</i> Valle Gómez García de Soria (Spain)	08:30 - 08:30
B139	CONTRASTING GENE EXPRESSION PROFILES AND SIGNALING PATHWAYS BETWEEN CIRCULATING DONOR-AND HOST-DERIVED MONOCYTES DURING TOLERANCE IN MIXED CHIMERISM FOLLOWING UNRELATED DONOR CADAVERIC BMT AND LUNG TRANSPLANT <i>Poster Presenter:</i> Paul Szabolcs (United States)	08:30 - 08:30
B140	MEASURABLE RESIDUAL DISEASE AND CHIMERISM ANALYSIS INTERPLAY: IMPACT IN PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Rebeca Bailén Alomoro (Spain)	08:30 - 08:30
B141	THE INFLUENCE OF GRAFT IMMUNE COMPOSITION ON IMMUNE RECOVERY AND TRANSPLANT OUTCOME: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Stefania Leone (Italy)	08:30 - 08:30

B142	RELAPSE MONITORING BY NPM1-PCR AND ITS PROGNOSTIC VALUE BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Oliver Kriege (Germany)	08:30 - 08:30
B143	GUIDING POST-TRANSPLANT RELAPSE TREATMENT IN MYELOID MALIGNANCIES WITH QPCR MONITORING OF CHIMERISM DYNAMIC FROM PERIPHERAL WHOLE BLOOD - SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Polona Novak (Slovenia)	08:30 - 08:30
B144	SNP-BASED NEXT-GENERATION SEQUENCING (NGS) ALLOWS A RELIABLE QUANTIFICATION OF CHIMERISM AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION IN COMPARISON WITH SHORT-TANDEM REPEATS (STR) <i>Poster Presenter:</i> Estefanía Pérez-Lopez (Spain)	08:30 - 08:30
B145	THE COMBINATION OF DISEASE BIOLOGY WITH PRE-HSCT MRD STATUS COULD BETTER STRATIFY RELAPSE RISK AFTER HSCT AMONG ADULT AML PATIENTS IN FIRST COMPLETE REMISSION <i>Poster Presenter:</i> Marcello Roberto (Italy)	08:30 - 08:30
P204	SERUM EXTRACELLULAR VESICLE PROFILING TO DETERMINE EXTRACORPOREAL PHOTOPHERESIS RESPONSE IN GRAFT VERSUS HOST DISEASE <i>Poster Presenter:</i> Rachel E. Crossland (United Kingdom)	08:30 - 08:30
P205	IMPACT OF ABSOLUTE LYMPHOCYTE COUNT RECOVERY AT DIFFERENT TIME-POINTS ON CLINICAL OUTCOMES AFTER THE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Nour Ben Abdeljelil (Tunisia)	08:30 - 08:30
P206	PHENOTYPES OF BONE MARROW MONOCYTES IN HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA: A DESCRIPTIVE PILOT STUDY <i>Poster Presenter:</i> Meltem Kurt Yüksel (Turkey)	08:30 - 08:30
P207	AVAILABLE METHODS FOR MONITORING AML NPM1+ PATIENTS POST ALLOGENEIC TRANSPLANTATION CANNOT PREDICT OUTCOME <i>Poster Presenter:</i> Apostolia Papalexandri (Greece)	08:30 - 08:30
P208	DONOR LYMPHOCYTE INFUSION, A SINGLE-CENTER RETROSPECTIVE SAFETY ANALYSIS <i>Poster Presenter:</i> Birgitte Strand Bergland (Norway)	08:30 - 08:30
P209	WT1 MONITORING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A NEW IDEA OF DYNAMIC ASSESSMENT THROUGH THE PARAMETER "DELTA-WT1 THRESHOLD". A SINGLE-CENTRE RETROSPECTIVE STUDY <i>Poster Presenter:</i> Beatrice Manghisi (Italy)	08:30 - 08:30
P210	CHIMERISM DYNAMICS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A TOUGH NUT TO CRACK <i>Poster Presenter:</i> Nayera HK El-Sherif (Egypt)	08:30 - 08:30
P211	ANALYSIS OF THE EXTENDED T-LYMPHOCYTES PHENOTYPE REVEALS DIFFERENCES IN THE EARLY IMMUNE RECONSTITUTION AMONG PEDIATRIC PATIENTS RECEIVING MATCHED-UNRELATED DONOR OR HAPLOIDENTICAL HSCT <i>Poster Presenter:</i> Alessandro Di Gangi (Italy)	08:30 - 08:30
P212	CLINICAL FACTORS ASSOCIATED WITH IMMUNOGLOBULINS AFTER ALLO-SCT <i>Poster Presenter:</i> Jose Sanchez Pina (Spain)	08:30 - 08:30

P213	RECONSTITUTION OF NK LYMPHOCYTES AND THEIR KINETICS IN CHILDREN WITH GRAFT VERSUS HOST DISEASE. REPORT FROM AN INSTITUTION IN MEXICO <i>Poster Presenter: Yazmin Aidee Gomez Dominguez (Mexico)</i>	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Graft-versus-host Disease - Preclinical and Animal Models		
B019	DR3 AND GITR AGONISTS BOOST ENDOGENOUS TREG POOL TO PREVENT ACUTE GVHD <i>Poster Presenter: Juan Fernando Gamboa Vargas (Germany)</i>	08:30 - 08:30
B020	ROLE OF BCL2 IN GRAFT VERSUS HOST DISEASE <i>Poster Presenter: Jose A. Perez-Simon (Spain)</i>	08:30 - 08:30
B021	DIMETHYL FUMARATE INHIBITS TFH DIFFERENTIATION AND CGVHD VIA NRF2 <i>Poster Presenter: Huanle Gong (China)</i>	08:30 - 08:30
B022	SPECIFIC INHIBITION OF PATHOLOGICAL ANGIOGENESIS TO DECREASE ACUTE GVHD <i>Poster Presenter: Dr. Katarina Riesner (Germany)</i>	08:30 - 08:30
B023	ENDOTHELIAL-TO-MESENCHYMAL TRANSITION IN CHRONIC GVHD <i>Poster Presenter: Dr. Katarina Riesner (Germany)</i>	08:30 - 08:30
B024	RAPID ADAPTATION OF DONOR REGULATORY T CELLS (TREG) TO RECIPIENT TISSUES FOR THE CONTROL OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) <i>Poster Presenter: Franziska Pielmeier (Germany)</i>	08:30 - 08:30
B025	INHIBITION OF MYELOPEROXIDASE AMELIORATES MURINE ACUTE GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter: Michelle Klesse (Germany)</i>	08:30 - 08:30
B026	DEFECTIVE HIF-1A EXPRESSION IN BONE MARROW ENDOTHELIAL PROGENITOR CELLS MAY PROMOTE ACUTE GRAFT-VERSUS-HOST-DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Wen-Kai Zhang (China)</i>	08:30 - 08:30
B027	IFN-GAMMA INDUCES ACUTE GRAFT-VERSUS-HOST DISEASE BY PROMOTING HMGB1-MEDIATED NUCLEAR-TO-CYTOPLASM TRANSLOCATION AND AUTOPHAGIC DEGRADATION OF P53 <i>Poster Presenter: Yajing Xu (China)</i>	08:30 - 08:30
B028	DEFINING THE TRANSCRIPTOMIC LANDSCAPE OF ACUTE SKIN GVHD AT SINGLE CELL RESOLUTION <i>Poster Presenter: Callum Wright (United Kingdom)</i>	08:30 - 08:30
B029	IMPROVING THE THERAPEUTIC EFFECT OF HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS ON ACUTE GRAFT-VERSUS-HOST DISEASE BY CRISPLD2-OVEREXPRESSION <i>Poster Presenter: Qingxiao Song (China)</i>	08:30 - 08:30
B030	TRNA METHYLTRANSFERASE DNMT2 MODULATES GVHD PROCESS VIA TRNA M⁵C MODIFICATION <i>Poster Presenter: Shijie Yang (China)</i>	08:30 - 08:30
B031	RUXOLITINIB USE DURING DONOR STEM CELL MOBILIZATION RESULTS IN RECIPIENTS IMMUNOMODULATION POST BONE MARROW TRANSPLANT IN MURINE MODEL AND MIGHT REDUCE GRAFT VERSUS HOST DISEASE	08:30 - 08:30

	<i>Poster Presenter:</i> Vamsi Kota (United States)	
B032	AMPK COORDINATES GLYCOLYTIC COMPENSATION IN GVHD-CAUSING T CELLS <i>Poster Presenter:</i> Archana Ramgopal (United States)	08:30 - 08:30
B033	ROS DEFICIENCY OF RECEIPT DERIVED MDSCS EXACERBATES ALLO-REACTIVE T CELLS RESPONSES DURING HYPERACUTE GVHD <i>Poster Presenter:</i> Erlic Jiang (China)	08:30 - 08:30
P093	DIAGNOSIS OF CUTANEOUS ACUTE GRAFT-VERSUS-HOST THROUGH CIRCULATING PLASMA MIR-638, MIR-6511B-5P, MIR-3613-5P, MIR-455-3P, MIR-5787, AND MIR-548A-3P AS PROSPECTIVE NONINVASIVE BIOLOGICAL INDICATORS IN ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Marjan Yaghmaie (Iran)	08:30 - 08:30
<i>ePoster</i> 08:30 - 18:00		ePoster area
Cellular Therapies other than CARs		
A106	HELP FOR UKRAINIAN HEMATOLOGY PATIENTS (HUP) - A GLOBAL INITIATIVE SUPPORTING THE ESTABLISHMENT OF HEMATOLOGY CENTERS AND HEMATOPOIETIC CELL TRANSPLANTATION PROGRAMS IN DIFFICULT SITUATIONS <i>Poster Presenter:</i> Irina Korenkova (Ukraine)	08:30 - 08:30
A107	A RETROSPECTIVE ANALYSIS COMPARING ORCA-T TO POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH MATCHED UNRELATED DONORS RECEIVING MYELOABLATIVE CONDITIONING <i>Poster Presenter:</i> Amandeep Salhotra (United States)	08:30 - 08:30
A108	PHASE I/II STUDY ON INFUSION OF ALLOREACTIVE OR EX VIVO IL-15 STIMULATED NK CELLS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA <i>Poster Presenter:</i> Antonio Pérez Martínez (Spain)	08:30 - 08:30
A109	HARNESSING CIK CELL INTERVENTION FOR ACUTE LEUKEMIA OR MDS RELAPSE POST ALLO-HSCT <i>Poster Presenter:</i> Eva Rettinger (Germany)	08:30 - 08:30
A110	RISK FACTORS FOR THE DEVELOPMENT OF GRAFT-VERSUS-HOST-DISEASE FOLLOWING DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Cjm Halkes (Netherlands)	08:30 - 08:30
A111	DONOR-DERIVED CMV-SPECIFIC CYTOTOXIC T-CELLS FOR PREVENTION OF CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION; A RANDOMIZED CLINICAL TRIAL WITH A PARALLEL CONTROL GROUP <i>Poster Presenter:</i> Mohammad Vaezi (Iran)	08:30 - 08:30
A112	RELAPSE AFTER HSCT: MAY DLI/CIK CELLS STILL PLAY A ROLE IN THE CELLULAR THERAPY ERA? DLI/CIK AS A RESCUE STRATEGY FOR CHILDREN WITH POST-TRANSPLANT MRD-POSITIVITY <i>Poster Presenter:</i> Prof. Adriana Balduzzi (Italy)	08:30 - 08:30
A113	PHASE I/II PRELIMINARY RESULTS OF HUMAN PRO-T-CELLS MANUFACTURING IN VITRO TO ACCELERATE IMMUNE RECONSTITUTION AFTER UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULT PATIENT WITH HEMATOLOGIC	08:30 - 08:30

	MALIGNANCIES	
	<i>Poster Presenter:</i> Jean-Sebastien Diana (France)	
A114	INNATE DONOR EFFECTOR ALLOGENEIC LYMPHOCYTES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - THE IDEAL TRIAL	08:30 - 08:30
	<i>Poster Presenter:</i> Lia Minculescu (Denmark)	
A115	HLA EVOLUTIONARY DIVERGENCE : A NEW PREDICTIVE TOOL FOR DLI RESPONSE?	08:30 - 08:30
	<i>Poster Presenter:</i> Sophie Le Grand (France)	
A116	CD45RA DEPLETION PRESERVES PROPORTIONS AND CLONAL BREATH OF VIRUS-SPECIFIC T CELLS	08:30 - 08:30
	<i>Poster Presenter:</i> Amandine Pradier (Switzerland)	
A117	CIRCULAR MRNA-BASED TCR-T OFFERS A SAFE AND EFFECTIVE THERAPEUTIC STRATEGY FOR TREATMENT OF CYTOMEGALOVIRUS INFECTION	08:30 - 08:30
	<i>Poster Presenter:</i> Lianghua Shen (China)	
A118	LAYING THE FOUNDATIONS FOR AN IMMUNOPOTENCY TEST FOR ALLOGENEIC MESENCHYMAL STROMAL CELLS	08:30 - 08:30
	<i>Poster Presenter:</i> María Esther Martínez-Muñoz (Spain)	
A119	CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN COMMERCIALY AVAILABLE BISPECIFIC ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR T-CELLS IN MULTIPLE MYELOMA	08:30 - 08:30
	<i>Poster Presenter:</i> Eden Biltibo (United States)	
A120	TRIAL IN PROGRESS: OBSERVATIONAL, POST-AUTHORISATION SAFETY STUDY TO DESCRIBE SAFETY AND EFFECTIVENESS OF TABELCLEUCEL IN PATIENTS WITH EBV+ PTLD IN A REAL-WORLD SETTING IN EUROPE	08:30 - 08:30
	<i>Poster Presenter:</i> Pavan Randhawa (United Kingdom)	
P065	CD45RO CELLS ADDBACK IN TCR AB/CD45RA DEPLETED HAPLOIDENTICAL HSCT LEADS TO SUPERIOR OUTCOMES IN INFANTS WITH INBORN ERRORS OF IMMUNITY: EXPERIENCE FROM A DEVELOPING COUNTRY!	08:30 - 08:30
	<i>Poster Presenter:</i> Vimal Kumar Gunasekaran (India)	
P066	IMPACT OF MYELOFIBROSIS ON PATIENTS WITH MYELODYSPLASTIC SYNDROMES FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	08:30 - 08:30
	<i>Poster Presenter:</i> Panpan Zhu (China)	
P067	MANAGEMENT AND TOXICITY OF DONOR LYMPHOCYTE INFUSIONS IN PEDIATRIC PATIENTS WITH ONCOLOGICAL DISEASES AFTER ALLOGENIC STEM CELL TRANSPLANTATION IN A SINGLE INSTITUTION	08:30 - 08:30
	<i>Poster Presenter:</i> Luisa Paschke (Germany)	
P068	FIRST SUCCESSFUL ALLOGENEIC MINOR ABO MISMATCHED PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN A PEDIATRIC PATIENT WITH SEVERE APLASTIC ANAEMIA IN SRI LANKA- A CASE REPORT	08:30 - 08:30
	<i>Poster Presenter:</i> Asanka Godamunne (Sri Lanka)	
<i>ePoster</i>		
08:30 - 18:00		ePoster area
	Non-haematopoietic Stem Cells and Regenerative Medicine	
B001	REDUCED PRESENCE OF MESENCHYMAL STEM CELLS IN BONE MARROW ASPIRATES OF FEMALE PATIENTS PERSISTS AFTER	08:30 - 08:30

ALLOGENEIC STEM CELL TRANSPLANTATION*Poster Presenter:* Judith Schaffrath (Germany)

P078	EFFICACY AND SAFETY OF A CORD BLOOD-DERIVED PLATELET CONCENTRATE FOR THE TREATMENT OF OCULAR SURFACE DISEASES: RESULTS FROM A SINGLE-CENTER PROSPECTIVE STUDY	08:30 - 08:30
	<i>Poster Presenter:</i> Francesco Zallio (Italy)	
P079	IMPACT OF DIMENSIONALITY AND EXTRACELLULAR MATRIX ON MESENCHYMAL STEM CELL PHENOTYPE	08:30 - 08:30
	<i>Poster Presenter:</i> Jun Eun Park (Korea, Republic of)	

Patient, Family, and Donor Day

09:00 - 10:15

ARGYLL Suite

PFDD1 - Patient, Family, and Donor Day 1 | Baseline assessments and Long-term follow-up after Hematopoietic Stem Cell Transplantation*Chair:* Mr. Peter Feenstra (France)*Chair:* Ms. Andrea Linke (Germany)

PFDD1-1	Welcome PFDD	09:00 - 09:05
	<i>Speaker:</i> Ms. Natacha Bolaños (Spain)	
PFDD1-2	Introduction	09:05 - 09:10
PFDD1-3	Baseline assessments	09:10 - 09:22
	<i>Speaker:</i> Mr. Peter Feenstra (France)	
PFDD1-4	BMT follow-up in different EU countries: a patient experience from Germany/France	09:22 - 09:34
	<i>Speaker:</i> Ms. Nina Leiner (France)	
PFDD1-5	Long-term follow-up program and clinic setup	09:34 - 09:46
	<i>Speaker:</i> Prof. Dr. Alicia Rovo (Switzerland)	
PFDD1-6	Q&A - discussion and closing remarks	09:46 - 10:11

Statistics

09:00 - 12:30

CASTLE Suite

STATS-C1 - Basic course in Statistics 1 | Data collection and basic statistical methods*Chair:* Dr. Jaques-Emmanuelle Galimard (France)

STATS-C1.1	Data collection and checking	09:00 - 09:00
STATS-C1.2	Descriptive statistics	09:00 - 09:00
STATS-C1.3	Comparison of groups for continuous data	09:00 - 09:00
STATS-C1.4	Correlation and linear regression analyses	09:00 - 09:00
STATS-C1.5	Comparison of proportions	09:00 - 09:00

Breaks

10:00 - 10:30

CLYDE

Coffee Break, ePoster Viewing, Visit Exhibition

Industry Symposium

10:30 - 12:00

CLYDE

IS06 - A focus on chronic GvHD in 2024 | SANOFI*Chair:* Dr. Deborah Richardson (United Kingdom)*Chair:* Prof. Mohamad Mohty (France)

IS06-1	Welcome and introduction <i>Speaker:</i> Dr. Deborah Richardson (United Kingdom) <i>Speaker:</i> Prof. Mohamad Mohty (France)	10:30 - 10:35
IS06-2	Advances in the biology of chronic GvHD <i>Speaker:</i> Prof. Dr. Ernst Holler (Germany)	10:35 - 10:50
IS06-3	Frontline treatment of chronic GvHD <i>Speaker:</i> Dr. Francesca Bonifazi (Italy)	10:50 - 11:05
IS06-4	Treatment of steroid refractory chronic GvHD <i>Speaker:</i> Prof. Mohamad Mohty (France)	11:05 - 11:20
IS06-5	Quality of life and chronic GvHD <i>Speaker:</i> Dr. Francesca Kinsella (United Kingdom)	11:20 - 11:35
IS06-6	Roundtable discussion: Exploring clinical cases - All faculty <i>Moderator:</i> Dr. Deborah Richardson (United Kingdom) <i>Moderator:</i> Prof. Mohamad Mohty (France)	11:35 - 11:55
IS06-7	Meeting close <i>Speaker:</i> Dr. Deborah Richardson (United Kingdom) <i>Speaker:</i> Prof. Mohamad Mohty (France)	11:55 - 12:00

Industry Symposium

10:30 - 12:00

LOMOND

IS07 - Promotional Meeting: Unlocking the Potential of CAR T Cell Therapy in the Clinic: An Interactive Expert Session | Bristol Myers Squibb*Chair:* Dr. Rakesh Popat (United Kingdom)

IS07-1	Welcome <i>Speaker:</i> Dr. Rakesh Popat (United Kingdom)	10:30 - 10:35
IS07-2	Current Treatment Landscape in MM and LBCL: Clinical Data and Real-World Evidence <i>Speaker:</i> Bertrand Arnulf (France) <i>Speaker:</i> Dr. Samuel Yamshon (United States)	10:35 - 11:15
IS07-3	How Can We Optimize CAR T Cell Therapy? Expert Roundtable and Q&A - All faculty	11:15 - 11:55
IS07-4	Summary and Close <i>Speaker:</i> Dr. Rakesh Popat (United Kingdom)	11:55 - 12:00

Industry Symposium

10:30 - 12:00

Hall 3 North

IS08 - Recognition of HSCT-TMA: the what, the why and the how | Alexion*Chair:* Dr. Christopher Dandoy (United States)

IS08-1	Introduction <i>Speaker:</i> Dr. Christopher Dandoy (United States)	10:30 - 10:40
IS08-2	HSCT-TMA: Pathophysiology and diagnostic challenges <i>Speaker:</i> Eleni Gavriilaki (Greece)	10:40 - 11:10
IS08-3	HSCT-TMA: Strategies in screening and risk stratification to improve outcomes <i>Speaker:</i> Dr. Christopher Dandoy (United States)	11:10 - 11:40

NG02-3	Unrelated donor registries <i>Speaker:</i> Ms. Gabi Rall (Germany)	11:20 - 11:45
NG02-4	Q&A	11:45 - 12:00
<i>Trainee Day</i>		
10:30 - 11:45		ALSH
TD1 - Trainee Day 1 Harmonization in education & research: a roundtable		
<i>Chair:</i> Prof. Antonio Almeida (Portugal)		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
TD1-1	EBMT Trainee <i>Speaker:</i> Dr. Claire Horgan (United Kingdom) <i>Speaker:</i> Dr. Nico Gagelmann (Germany)	10:30 - 10:40
TD1-2	YoungEHA committee <i>Speaker:</i> Dr. Mandy Lauw (Netherlands)	10:40 - 10:50
TD1-3	ASH Trainee Council <i>Speaker:</i> Dr. Maya Abdallah (United States)	10:50 - 11:00
TD1-4	Panel Discussion	11:00 - 11:45
<i>Patient, Family, and Donor Day</i>		
10:45 - 12:00		ARGYLL Suite
PFDD2 - Patient, Family, and Donor Day 2 GVHD, The beauty and the beast		
<i>Chair:</i> Ms. Riikka-Leena Manninen (Finland)		
<i>Chair:</i> Mr. Guy Bouguet (France)		
PFDD2-1	Introduction	10:45 - 10:50
PFDD2-2	Early detection of GVHD <i>Speaker:</i> Dr. Katharina Egger-Heidrich (Germany)	10:50 - 11:07
PFDD2-3	The beast behind GVHD <i>Speaker:</i> Dr. Andrew Clark (United Kingdom)	11:07 - 11:24
PFDD2-4	Living with GVHD	11:24 - 11:41
PFDD2-5	Q&A - discussion and closing remarks	11:41 - 12:00
<i>Breaks</i>		
12:00 - 12:30		CLYDE
Break, ePoster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
12:30 - 14:00		CLYDE
IS11 - Overcoming IFI and antifungal treatment challenges: Managing resistance and DDIs Kite-Gilead		
<i>Chair:</i> Prof. Livio Pagano (Italy)		
<i>Chair:</i> Dr. Jennifer Clay (United Kingdom)		
IS11-1	Welcome and meeting overview <i>Speaker:</i> Prof. Livio Pagano (Italy)	12:30 - 12:35
IS11-2	Management of DDIs of targeted therapies for haematological malignancies and antifungal treatments <i>Speaker:</i> Prof. Roger Brüggemann (Netherlands)	12:35 - 12:55
IS11-3	Tackling the emerging threat of antifungal resistance <i>Speaker:</i> Prof. Lewis White (United Kingdom)	12:55 - 13:15

IS11-4	The benefits of early treatment using an antifungal agent with a broad spectrum and low potential of resistance <i>Speaker:</i> Prof. Johan Maertens (Belgium)	13:15 - 13:35
IS11-5	Panel discussion and Q&A <i>Moderator:</i> Dr. Jennifer Clay (United Kingdom) <i>Moderator:</i> Prof. Livio Pagano (Italy)	13:35 - 13:55
IS11-6	Meeting summary and close <i>Speaker:</i> Dr. Jennifer Clay (United Kingdom)	13:55 - 14:00

Industry Symposium

12:30 - 14:00

LOMOND

IS12 - Addressing the unmet needs in GvHD: practical insights to bring home to your clinical practice | Novartis*Chair:* Dr. Donal McLornan (United Kingdom)

IS12-1	Welcome and introduction <i>Speaker:</i> Dr. Donal McLornan (United Kingdom)	12:30 - 12:32
IS12-2	What is the current standard of care and what are the unmet needs? Current clinical landscape of GvHD and the unmet medical needs for steroid-refractory/dependent patients <i>Speaker:</i> Prof. Olaf Penack (Germany)	12:32 - 12:47
IS12-3	Addressing the unmet needs in acute GvHD: insights from the latest data Latest clinical data on steroid-refractory/dependent acute GvHD <i>Speaker:</i> Prof. Dr. Zinaida Peric (Croatia)	12:47 - 12:57
IS12-4	Bringing it home to your clinical practice (I) A case-based discussion focusing on a patient with acute GvHD <i>Speaker:</i> Prof. Dr. Zinaida Peric (Croatia)	12:57 - 13:12
IS12-5	Addressing the unmet needs in chronic GvHD: insights from the latest data Latest clinical data on steroid-refractory/dependent chronic GvHD <i>Speaker:</i> Prof. Robert Zeiser (Germany)	13:12 - 13:22
IS12-6	Bringing it home to your clinical practice (II) A case-based discussion focusing on a patient with chronic GvHD <i>Speaker:</i> Prof. Robert Zeiser (Germany)	13:22 - 13:37
IS12-7	Optimising clinical outcomes- Panel discussion and Q&A Roundtable discussion on the impact of the latest data on the clinical landscape - All <i>Moderator:</i> Dr. Donal McLornan (United Kingdom)	13:37 - 13:57
IS12-8	Summary and close <i>Speaker:</i> Dr. Donal McLornan (United Kingdom)	13:57 - 14:00

Industry Symposium

12:30 - 14:00

Hall 3 North

IS13 - Hepatic VOD management and intervention - Putting the patient first: perspectives from the MDT | Jazz Pharmaceuticals*Chair:* Prof. Mohamad Mohty (France)

IS13-1	MDT briefing: welcome <i>Speaker:</i> Prof. Mohamad Mohty (France)	12:30 - 12:40
--------	--	---------------

IS13-2	Nurses at the bedside: risk assessment and monitoring <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	12:40 - 12:50
IS13-3	MDT collaboration to identify hepatic VOD: utilising the refined EBMT 2023 criteria <i>Speaker:</i> Prof. Dr. Rafael Duarte (Spain)	12:50 - 13:05
IS13-4	MDT debrief: discussion and audience Q&A <i>Moderator:</i> Prof. Mohamad Mohty (France) <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom) <i>Speaker:</i> Prof. Dr. Rafael Duarte (Spain)	13:05 - 13:15
IS13-5	MDT collaboration to identify hepatic VOD: imaging and results from the ElastoVOD study <i>Speaker:</i> Dr. Francesca Bonifazi (Italy)	13:15 - 13:30
IS13-6	Preventing MOD and ICU admission: the importance of prompt intervention <i>Speaker:</i> Prof. Anthony Pagliuca (United Kingdom)	13:30 - 13:45
IS13-7	MDT debrief: discussion and audience Q&A <i>Moderator:</i> Prof. Mohamad Mohty (France) <i>Speaker:</i> Dr. Francesca Bonifazi (Italy) <i>Speaker:</i> Prof. Anthony Pagliuca (United Kingdom)	13:45 - 13:55
IS13-8	MDT handover: summary and close <i>Speaker:</i> Prof. Mohamad Mohty (France)	13:55 - 14:00

Industry Symposium

12:30 - 14:00

Hall 2

IS14 - Advances in cell therapy: preventing GVHD and driving PoC CAR T to new horizons | Miltenyi Biotec*Chair:* Prof. Andrew Gennery (United Kingdom)

IS14-1	Welcome & introduction <i>Speaker:</i> Prof. Andrew Gennery (United Kingdom)	12:30 - 12:40
IS14-2	Promotion of engraftment in TCR$\alpha\beta$+ cell depleted HSCT for patients with thalassemia major <i>Speaker:</i> Prof. Chunfu Li (China)	12:40 - 13:00
IS14-3	Donor regulatory T cells for the treatment of chronic graft-versus-host disease <i>Speaker:</i> Prof. Joao F Lacerda (Portugal)	13:00 - 13:20
IS14-4	Developing an academic point of care CAR T network in Canada: the CLIC experience <i>Speaker:</i> Prof. Kevin Hay (Canada)	13:20 - 13:40
IS14-5	Allogeneic, HSCT donor-derived, CD19-directed CAR T cells in pediatric R/R BCP-ALL and GD2-directed CAR T therapy for R/R high-risk neuroblastoma <i>Speaker:</i> Prof. Franco Locatelli (Italy)	13:40 - 14:00

Nurses Group

12:30 - 14:00

Hall 1

NG03 - Nurses Education Day 3 | 50 years of EBMT community - a transplant journey | The 1990's & 2000's*Chair:* Ms. Marijke Quaghebeur (Belgium)*Chair:* Ms. Lorna Welsh (United Kingdom)

NG03-1	Reduced-intensity transplants <i>Speaker:</i> Ms. Marina Ben Izhak (Israel)	12:30 - 12:55
--------	---	---------------

NG03-2	Magic bullets (TKIs) <i>Speaker:</i> Ms. Lucie Lacheze (France)	12:55 - 13:20
NG03-3	Alternative donor transplants <i>Speaker:</i> Ms. Kader Caliskan (Turkey)	13:20 - 13:45
NG03-4	Q&A	13:45 - 14:00
<i>Trainee Day</i>		
12:30 - 13:45		ALSH
TD2 - Trainee Day 2 Paediatric - How I treat...		
<i>Chair:</i> Dr. Rafaella Muratori (Brazil)		
<i>Chair:</i> Dr. Kath Colman (Australia)		
TD2-1	Survey to assess the global landscape of Paediatric BMT training and access <i>Speaker:</i> Dr. Manuela Spadea (Italy)	12:30 - 12:40
TD2-2	Select conditioning strategy for inherited BMF <i>Speaker:</i> Prof. Dr. Carmem Bonfim (Brazil)	12:40 - 12:55
TD2-3	Challenging cases in paediatric leukemia <i>Speaker:</i> Prof. Dr. Krzysztof Kalwak (Poland)	12:55 - 13:15
TD2-4	Diagnose & manage TMA in paediatrics <i>Speaker:</i> Dr. Christopher Dandoy (United States)	13:15 - 13:30
TD2-5	Q&A	13:30 - 13:45
<i>Patient, Family, and Donor Day</i>		
13:30 - 14:45		ARGYLL Suite
PFDD3 - Patient, Family, and Donor Day 3 Perspectives about BMT success and failure		
<i>Chair:</i> Ms. Noëlle Tassy (France)		
<i>Chair:</i> Ms. Natacha Bolaños (Spain)		
PFDD3-1	Introduction	13:30 - 13:35
PFDD3-2	BMT for MS: uncertain limits between successful and failed autologous HSCT <i>Speaker:</i> Ms. Noëlle Tassy (France)	13:35 - 13:53
PFDD3-3	A wounded spirit in a cured body <i>Speaker:</i> Mr. Peter Feenstra (France)	13:53 - 14:11
PFDD3-4	Nurse perspective <i>Speaker:</i> Ms. Corinna Wright (United Kingdom)	14:11 - 14:29
PFDD3-5	Q&A - discussion and closing remarks	14:29 - 14:44
<i>Statistics</i>		
13:30 - 16:00		CASTLE Suite
STATS-C2 - Basic course in Statistics 2 Survival analysis		
<i>Chair:</i> Dr. Jaques-Emmanuelle Galimard (France)		
STATS-C2.1	The Kaplan Meier method and logrank test <i>Speaker:</i> Dr. Jaques-Emmanuelle Galimard (France)	13:30 - 13:30
STATS-C2.2	Competing events and the cumulative incidence method and Gray test <i>Speaker:</i> Luuk Gras (Netherlands)	13:30 - 13:30
STATS-C2.3	The use of multivariable methods	13:30 - 13:30

	<i>Speaker:</i> Luuk Gras (Netherlands)	
STATS-C2.4	Stat issues in Haematologic Studies <i>Speaker:</i> Dr. Myriam Labopin (France)	13:30 - 13:30
<i>Breaks</i>		
14:00 - 14:30		CLYDE
Break, ePoster Viewing, Visit Exhibition		
<i>Industry Symposium</i>		
14:30 - 16:00		CLYDE
IS16 - CAR T: Improving survival with the SOC in 2L LBCL Kite-Gilead		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
<i>Chair:</i> Wendy Osborne (United Kingdom)		
IS16-1	Introduction <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain) <i>Speaker:</i> Wendy Osborne (United Kingdom)	14:30 - 14:35
IS16-2	Why has CAR T become the SoC in 2L LBCL? <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	14:35 - 15:00
IS16-3	What's the most appropriate treatment choice in 2L DLBCL? A case-based approach <i>Speaker:</i> Wendy Osborne (United Kingdom)	15:00 - 15:20
IS16-4	Diagnosis, treatment and recovery: perspectives from a patient and a psychotherapist <i>Speaker:</i> Ms. Surabhi Chaturvedi (United Kingdom) <i>Moderator:</i> Wendy Osborne (United Kingdom)	15:20 - 15:30
IS16-5	How can we bring CAR T's curative potential to more patients? <i>Speaker:</i> Suzanne van Dorp (Netherlands) <i>Speaker:</i> Ms. Surabhi Chaturvedi (United Kingdom)	15:30 - 15:50
IS16-6	Q&A, summary and close <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain) <i>Speaker:</i> Wendy Osborne (United Kingdom)	15:50 - 16:00
<i>Industry Symposium</i>		
14:30 - 16:00		LOMOND
IS17 - Transform Myeloma: Optimising Patient Outcomes from the Outset - This symposium has been developed, organised and funded by SANOFI		
<i>Chair:</i> Prof. Graham Jackson (United Kingdom)		
IS17-1	Chair's introduction <i>Speaker:</i> Prof. Graham Jackson (United Kingdom)	14:30 - 14:35
IS17-2	Transplant eligible (TE) patients: risk status and response <i>Speaker:</i> Prof. Graham Jackson (United Kingdom)	14:35 - 14:55
IS17-3	The Grey Zone - Assessing patients on the borderline of transplant-eligibility <i>Speaker:</i> Dr. Ceri Bygrave (United Kingdom)	14:55 - 15:15
IS17-4	Transplant non-eligible (TNE) patients: Is frailty dynamic and modifiable? <i>Speaker:</i> Prof. Gordon Cook (United Kingdom)	15:15 - 15:35
IS17-5	Closing remarks and Q&A - All	15:35 - 16:00

Industry Symposium

14:30 - 16:00

Hall 3 North

IS18 - What's New in CMV Management in HSCT? Latest Clinical Advances - MSD products will be discussed | MSD*Chair:* Prof. Dr. Per Ljungman (Sweden)

IS18-1	Welcome, Introductions and Opening Remarks <i>Speaker:</i> Prof. Dr. Per Ljungman (Sweden)	14:30 - 14:35
IS18-2	Exploring the Landscape of CMV Management in HSCT <i>Speaker:</i> Prof. Roy Chemaly (United States)	14:35 - 14:55
IS18-3	Confronting Current Challenges & Controversies <i>Speaker:</i> Dr. Rafael de la Camara (Spain)	14:55 - 15:15
IS18-4	Shaping the Future with Emerging New Data <i>Speaker:</i> Jan Styczynski (Poland)	15:15 - 15:35
IS18-5	Panel Q&A - All	15:35 - 15:55
IS18-6	Closing Remarks <i>Speaker:</i> Prof. Dr. Per Ljungman (Sweden)	15:55 - 16:00

Industry Symposium

14:30 - 16:00

Hall 5

IS20 - Pfizer promotional symposium: suspect, test and treat mould infections and respiratory virus-associated infections in the haematology setting | Pfizer. PP-CRB-GBR-2432. April 2024.

IS20-1	Welcome	14:30 - 14:35
IS20-2	Time to act: suspecting mould, COVID-19 and other respiratory virus-associated infections in haematology patients	14:35 - 14:55
IS20-3	Ongoing learnings: how should we treat COVID-19 in haematology patients?	14:55 - 15:20
IS20-4	Double trouble: managing IMIs in haematology-oncology patients	15:20 - 15:45
IS20-5	Perspectives from the bedside: how to deal with challenging infections - All	15:45 - 15:55
IS20-6	Take-home messages	15:55 - 16:00

Nurses Group

14:30 - 16:00

Hall 1

NG04 - Nurses Education Day 4 | 50 years of EBMT community - a transplant journey | Into the new millennia*Chair:* Ms. Marijke Quaghebeur (Belgium)*Chair:* Ms. Lorna Welsh (United Kingdom)

NG04-1	Haemoglobinopathies transplant & gene therapy <i>Speaker:</i> Ms. Kelly Hennessy (United Kingdom)	14:30 - 14:55
NG04-2	The changing face of cellular therapy - the pediatric perspective <i>Speaker:</i> Dr. Marjola Gjergji (Italy)	14:55 - 15:20
NG04-3	The challenge of nursing in an ever-changing world <i>Speaker:</i> Dr. Sabine Valenta (Switzerland)	15:20 - 15:45
NG04-4	Q&A	15:45 - 16:00

Industry Symposium

14:30 - 15:30

BOISDALE

IS21 - Improving transplant outcomes in rare Leukemias: recent progress in BPDCN | Menarini Stemline*Chair:* Prof. Dr. Hildegard Greinix (Austria)

IS21-1	Welcome and introductions <i>Speaker:</i> Prof. Dr. Hildegard Greinix (Austria)	14:30 - 14:35
IS21-2	From Rarity to Clarity: BPDCN's Unique Challenges and Advances <i>Speaker:</i> Prof. Dr. Hildegard Greinix (Austria)	14:35 - 14:50
IS21-3	Replacing chemotherapy with targeted therapy in young, fit patients <i>Speaker:</i> Prof. Cristina Papayannidis (Italy)	14:50 - 15:05
IS21-4	Addressing the unmet needs in older patients with targeted therapy <i>Speaker:</i> Prof. Dr. Ann de Becker (Belgium)	15:05 - 15:20
IS21-5	Discussion and conclusion - All <i>Moderator:</i> Prof. Dr. Hildegard Greinix (Austria)	15:20 - 15:30

Trainee Day

14:30 - 15:45

ALSH

TD3 - Trainee Day 3 | Treating and living with chronic GVHD*Chair:* Dr. Lars Klingen Gjørde (Denmark)*Chair:* Dr. Carmelo Gurnari (United States)

TD3-1	Overview <i>Speaker:</i> Prof. Dr. Zinaida Peric (Croatia)	14:30 - 14:50
TD3-2	Case 1 <i>Speaker:</i> Dr. Alexandra Martinez (Spain)	14:50 - 14:55
TD3-3	Case 2 <i>Speaker:</i> Chris Lewis (United Kingdom)	14:55 - 15:00
TD3-4	Caregiver perspective <i>Speaker:</i> Dr. Nihar Desai (Canada)	15:00 - 15:05
TD3-5	Nurse perspective <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	15:05 - 15:10
TD3-6	Panel Discussion	15:10 - 15:45

Patient, Family, and Donor Day

15:15 - 16:30

ARGYLL Suite

PFDD4 - Patient, Family, and Donor Day 4 | A new life after BMT?*Chair:* Ms. Andrea Linke (Germany)*Chair:* Ms. Riikka-Leena Manninen (Finland)

PFDD4-1	Introduction	15:15 - 15:20
PFDD4-2	Redefining Identity: Who are you now? <i>Speaker:</i> Dr. Jacqueline del Castillo (United Kingdom)	15:20 - 15:35
PFDD4-3	PTSD in BMT <i>Speaker:</i> Mr. Eugene Beirne (Ireland)	15:35 - 15:55
PFDD4-4	QOL Patients life after HSCT in Slovakia (retrospective survey) <i>Speaker:</i> Dr. Simona Pavukova (Slovakia)	15:55 - 16:10
PFDD4-5	Q&A	16:10 - 16:30

Breaks

16:00 - 16:30

CLYDE

Coffee Break, ePoster Viewing, Visit Exhibition*Industry Symposium*

16:30 - 18:00

LOMOND

IS23 - Understanding the evolving haemoglobinopathy transplant journey | Vertex*Chair:* Prof. Josu de la Fuente (United Kingdom)

IS23-1	Welcome and introduction <i>Speaker:</i> Prof. Josu de la Fuente (United Kingdom)	16:30 - 16:45
IS23-2	Considering transplant options in haemoglobinopathies: The journey for the patient and physician <i>Speaker:</i> Prof. Dr. Peter Bader (Germany)	16:45 - 17:00
IS23-3	The haemoglobinopathy transplant: Key practical considerations with the MDT <i>Speaker:</i> Dr. Mattia Algeri (Italy) <i>Speaker:</i> Dr. Marjola Gjergji (Italy)	17:00 - 17:15
IS23-4	How do we ensure transplant success in an era of innovation? <i>Speaker:</i> Dr. Ben Carpenter (United Kingdom) <i>Speaker:</i> Victoria Potter (United Kingdom)	17:15 - 17:30
IS23-5	Panel discussion and Q&A - All faculty <i>Moderator:</i> Prof. Josu de la Fuente (United Kingdom)	17:30 - 17:55
IS23-6	Summary and close <i>Speaker:</i> Prof. Josu de la Fuente (United Kingdom)	17:55 - 18:00

Industry Symposium

16:30 - 18:00

Hall 3 North

IS24 - Promotional symposium: Changing the face of EBV+ PTLD | Pierre Fabre*Chair:* Prof. Dr. Anna Sureda (Spain)

IS24-1	Welcome and introduction <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	16:30 - 16:35
IS24-2	Facing the facts of EBV+ PTLD: establishing the fundamentals <i>Speaker:</i> Prof. Dr. Nicolaus Kröger (Germany)	16:35 - 16:50
IS24-3	The current face of EBV+ PTLD management <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	16:50 - 17:05
IS24-4	Changing the face of EBV+ PTLD <i>Speaker:</i> Susan Prockop (United States)	17:05 - 17:25
IS24-5	The patient face in EBV+ PTLD <i>Speaker:</i> Alexander Schauwvlieghe (Belgium)	17:25 - 17:40
IS24-6	Facing the change (Panel discussion) - All	17:40 - 17:55
IS24-7	Meeting close <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	17:55 - 18:00

Industry Symposium

16:30 - 18:00

Hall 5

IS26 - The GvHD Hub presents - 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD - Supported through an educational grant by Therakos-Mallinckrodt*Chair:* Prof. Mohamad Mohty (France)

IS26-1	Welcome and Introductions	16:30 - 16:45
--------	----------------------------------	---------------

	<p>- Pre-symposium assessment - Brief overview/timeline of ECP in GvHD <i>Speaker:</i> Prof. Mohamad Mohty (France)</p>	
IS26-2	<p>The long-term burden of cGVHD <i>Speaker:</i> Bipin Savani (United States)</p>	16:45 - 16:55
IS26-3	<p>Early intervention and ECP-based combinations <i>Speaker:</i> Prof. Dr. Florent Malard (France)</p>	16:55 - 17:10
IS26-4	<p>ECP for cGVHD: Patient eligibility, treatment optimization, and follow-up - All - An interactive case-based discussion <i>Speaker:</i> Prof. Dr. Zinaida Peric (Croatia)</p>	17:10 - 17:40
IS26-5	<p>Discussion Q&A session - All</p>	17:40 - 17:50
IS26-6	<p>Closing remarks and evaluation - Post-symposium assessment <i>Speaker:</i> Prof. Mohamad Mohty (France)</p>	17:50 - 18:00
<p><i>Patient, Family, and Donor Day</i> 16:45 - 17:45</p>		ARGYLL Suite
<p>PFDD5 - Patient, Family, and Donor Day 5 What does the future look like for Cell therapy? <i>Chair:</i> Ms. Natacha Bolaños (Spain)</p>		
PFDD5-1	<p>Introduction</p>	16:45 - 16:50
PFDD5-2	<p>CAR-T cell therapy at present: Overview and update <i>Speaker:</i> Prof. Dr. Christian Chabannon (France)</p>	16:50 - 17:05
PFDD5-3	<p>Expectations and reality, the patient experience <i>Speaker:</i> Mr. Kenneth Casler (France)</p>	17:05 - 17:20
PFDD5-4	<p>Q&A - discussion and closing remarks</p>	17:20 - 17:45
<p><i>Breaks</i> 18:00 - 18:15</p>		CLYDE
<p>Break</p>		
<p><i>General</i> 18:15 - 19:50</p>		CLYDE
<p>GS1 - Opening Ceremony <i>Chair:</i> Prof. Dr. Anna Sureda (Spain) <i>Chair:</i> Dr. Grant McQuaker (United Kingdom) <i>Chair:</i> Prof. Charlie Craddock (United Kingdom)</p>		
GS1-1	<p>Welcome and introduction <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)</p>	18:15 - 18:19
GS1-2	<p>Welcome to Glasgow <i>Speaker:</i> Lord Provost (United Kingdom)</p>	18:19 - 18:24
GS1-3	<p>Welcome and introduction to the conference <i>Speaker:</i> Dr. Grant McQuaker (United Kingdom)</p>	18:24 - 18:28
GS1-4	<p>EBMT Patient Advocacy Committee: Welcome note <i>Speaker:</i> Ms. Natacha Bolaños (Spain)</p>	18:28 - 18:32
GS1-5	<p>Welcome from the Nurses Group <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)</p>	18:32 - 18:36

GS1-6	Clinical Achievement Awards - Distinguished Merit Awards - Honorary Members 2024 <i>Speaker:</i> Dr. Anne Parker (United Kingdom) <i>Speaker:</i> Dr. Achilles Anagnostopoulos (Greece) <i>Speaker:</i> Ms. Helen Baldomero (Switzerland) <i>Speaker:</i> Prof. Jakob Passweg (Switzerland) <i>Speaker:</i> Prof. Arnon Nagler (Israel) <i>Speaker:</i> Prof. Jane Apperley (United Kingdom)	18:36 - 18:52
GS1-7	Tribute to Dr Richard Szydlo <i>Speaker:</i> Prof. Jane Apperley (United Kingdom)	18:52 - 18:57
GS1-8	Introduction of the Keynote speaker <i>Speaker:</i> Prof. Charlie Craddock (United Kingdom)	18:57 - 19:00
GS1-9	Keynote lecture: The role of the intestinal microbiome in cancer immunotherapy <i>Speaker:</i> Dr. Marcel Van Den Brink (United States)	19:00 - 19:25
GS1-10	Introduction <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	19:25 - 19:30
GS1-11	Celebrating 50 years of The EBMT community <i>Speaker:</i> Prof. Dr. Eliane Gluckman (France)	19:30 - 19:50

Monday, 15. April 2024*Meetings*

07:00 - 08:45

BOISDALE

BM-CMWP - Business Meeting of the Chronic Malignancies Working Party*Chair:* Dr. Donal McLornan (United Kingdom)*Meetings*

07:00 - 08:45

ALSH

BM-SAAWP - Business Meeting of the Severe Aplastic Anaemia Working Party*Chair:* Prof. Antonio Risitano (Italy)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-1 - Meet-the-Expert: How I decide who to transplant with MDS

MTE-1

How I decide who to transplant with MDS

07:45 - 08:45

Speaker: Prof. Bart Scott (United States)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

QM-MTE-2 - Quality Management Meet-the-Expert: First time for JACIE? Application process, and how and what to prepare

QM-MTE-2

First time for JACIE? How to prepare for your first JACIE

07:45 - 08:45

Accreditation:**Application process, and how and what to prepare***Speaker:* Raquel Espada (Spain)*Speaker:* Ms. Anne Emmet (United Kingdom)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

QM-MTE-1 - Quality Management Meet-the-Expert: First time for JACIE? JACIE Process, roles and responsibilities

QM-MTE-1

First time for JACIE? How to prepare for your first JACIE

07:45 - 08:45

Accreditation:**JACIE Process, roles and responsibilities***Speaker:* Ms. Anne Emmet (United Kingdom)*Speaker:* Raquel Espada (Spain)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-2 - Meet-the-Expert: How to manage relapsed ALL

MTE-2

How to manage relapsed ALL

07:45 - 08:45

Speaker: Prof. Dr. Christina Peters (Austria)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-4 - Meet-the-Expert: Who to transplant with T cell Lymphoma

MTE-4

Who to transplant with T cell Lymphoma

07:45 - 08:45

Speaker: Dr. Kate Cwynarski (United Kingdom)

Meet the Expert

07:45 - 08:45

CASTLE Suite

MTE-3 - Meet-the-Expert: How I manage invasive fungal infections

MTE-3

How I manage invasive fungal infections

07:45 - 08:45

Speaker: Prof. Johan Maertens (Belgium)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE - Breakfast Meet the Expert - Monday*Educational*

09:00 - 10:30

CLYDE

E01 - Genomics relevant to transplant*Chair:* Prof. Dr. Maija Itala-Remes (Finland)*Chair:* Dr. Andrew Clark (United Kingdom)

E01-1

Predisposition to myeloid malignancies: Clonal Haematopoiesis and Familial AML

09:00 - 09:25

Speaker: George Vassiliou (United Kingdom)

E01-2

Implications of inherited genomics on donor selection

09:25 - 09:50

Speaker: Dr. Austin Kulasekararaj (United Kingdom)

E01-3

Optimising a Graft versus Leukaemia effect in AML

09:50 - 10:15

Speaker: Prof. Paresh Vyas (United Kingdom)

E01-4

Q&A - Discussion

10:15 - 10:30

Cell Therapy Day

09:00 - 10:20

LOMOND

CTD1 - Cell Therapy Day 1 | New/other indications for cell therapy products*Chair:* Dr. Annalisa Ruggeri (Italy)*Chair:* Prof. Dr. Florent Malard (France)

CTD1-1

Welcome

09:00 - 09:05

Speaker: Dr. Annalisa Ruggeri (Italy)

CTD1-2

Engineering of tumor-associated macrophages to establish and reinforce anti-cancer immunity

09:05 - 09:30

Speaker: Prof. Dr. Bernhard Gentner (Switzerland)

CTD1-3

CAR T in Neuroblastoma

09:30 - 09:55

Speaker: Prof. Franco Locatelli (Italy)

CTD1-4

CD19 CAR T cells in autoimmune disease

09:55 - 10:20

Speaker: Prof. Dr. Andreas Mackensen (Germany)*Working Party Session*

09:00 - 10:15

Hall 3 North

IDWP - Infectious Diseases Working Party Session*Chair:* Dr. Rafael de la Camara (Spain)

IDWP-1

Clostridioides difficile. What is the impact on HCT patients, and how to manage it

09:00 - 09:18

Speaker: Dr. Agnieszka Piekarska (Poland)

IDWP-2

CMV management based on T cell immunity: time to incorporate in the routine care for allogeneic HCT patients?

09:18 - 09:38

Speaker: Prof. Roy Chemaly (United States)

IDWP-3

How can we decrease antibiotic exposure in patients following

09:38 - 09:56

	HSCT?	
	<i>Speaker:</i> Prof. Dina Averbuch (Israel)	
IDWP-4	Top 10 papers in HSCT infections (2023-2024)	09:56 - 10:14
	<i>Speaker:</i> Prof. Dr. Malgorzata Mikulska (Italy)	
<i>Oral Session</i>		
09:00 - 10:15		Hall 3 South
OS01 - Oral Session 1 Acute leukaemia: session one		
<i>Chair:</i> Dr. Anne-Louise Latif (United Kingdom)		
<i>Chair:</i> Dr. Hannah Choe, MD (United States)		
OS1-01	RELAPSE INCIDENCE POST UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION: FROM THE ALWP OF THE EBMT	09:00 - 09:09
	<i>Oral Presenter:</i> Prof. Arnon Nagler (Israel)	
OS1-02	HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS OF OLDER AGE WITH AML IN FIRST COMPLETE REMISSION: RESULTS OF A RANDOMIZED PHASE III TRIAL OF THE EBMT	09:09 - 09:18
	<i>Oral Presenter:</i> Dietger Niederwieser (Germany)	
OS1-03	IMPACT OF GERMLINE RUNX1 MUTATIONS ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT OUTCOMES IN AML: A CIBMTR ANALYSIS	09:18 - 09:27
	<i>Oral Presenter:</i> Lea Cunningham (United States)	
OS1-04	CELLULAR HIERARCHY FOR UNDERSTANDING HETEROGENEITY OF ACUTE MYELOID LEUKEMIA WITH T (8;21)/RUNX1-RUNX1T1	09:27 - 09:36
	<i>Oral Presenter:</i> Yibo Wu (China)	
OS1-05	A MULTI-CENTER RETROSPECTIVE ANALYSIS OF OUTCOMES POST-ALLO-HCT IN TET2-MUTATED AML PATIENTS: A STUDY ON BEHALF OF THE GLOBAL COMMITTEE AND THE ALWP OF THE EBMT	09:36 - 09:45
	<i>Oral Presenter:</i> Lin Li (China)	
OS1-06	ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH GERMLINE DDX41 MUTATIONS: A COMPARATIVE STUDY FROM THE ALFA-FILO-SFGMTC	09:45 - 09:54
	<i>Oral Presenter:</i> Michael Loschi (France)	
OS1-07	EXCELLENT OUTCOME OF PATIENTS PROCEEDING TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH UNTREATED MOLECULAR RELAPSE OF NPM1-MUTATED AML	09:54 - 10:03
	<i>Oral Presenter:</i> Dr. Gesine Bug (Germany)	
OS1-08	THE PROGNOSTIC IMPACT OF DNMT3A MUTATION ON SURVIVAL OF AML PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST REMISSION: ON BEHALF OF THE EBMT ALWP	10:03 - 10:12
	<i>Oral Presenter:</i> Prof. Ali Bazarbachi (Lebanon)	
<i>Working Party Session</i>		
09:00 - 10:15		Hall 2
CMWP - Chronic Malignancies Working Party Session Relapse: the Great Debate!		
<i>Chair:</i> Dr. Donal McLornan (United Kingdom)		
<i>Chair:</i> Dr. Joanna Drozd-Sokolowska (Poland)		
CMWP-1	Relapsed Myelofibrosis post allo-HCT: role of JAK inhibitors/2nd allo-HCT	09:00 - 09:10
	<i>Speaker:</i> Dr. Donal McLornan (United Kingdom)	

CMWP-2	Relapsed Myelofibrosis post allo-HCT: Role of DLI alone or in combination <i>Speaker:</i> Dr. Alexandros Rampotas (United Kingdom)	09:10 - 09:20
CMWP-3	Relapsed MDS post allo-HCT: role of DLI and 2nd allo-HCT <i>Speaker:</i> Dr. Marie Robin (France)	09:20 - 09:30
CMWP-4	Relapsed MDS post allo-HCT: role of conventional and novel agents <i>Speaker:</i> Dr. Kavita Raj (United Kingdom)	09:30 - 09:40
CMWP-5	Aggressive relapsed/refractory Multiple Myeloma: Role of Bispecifics <i>Speaker:</i> Dr. Joanna Drozd-Sokolowska (Poland)	09:40 - 09:50
CMWP-6	Aggressive relapsed/refractory Multiple Myeloma: Role of CAR T <i>Speaker:</i> Dr. Laurent Garderet (France)	09:50 - 10:00
CMWP-7	Discussion	10:00 - 10:15

Workshop

09:00 - 10:30

Hall 5

W01 - HLA and donor selection*Chair:* Dr. Valerie Dubois (France)*Chair:* Dr. Ann-Margaret Little (United Kingdom)

W01-1	Choosing the optimal unrelated donor <i>Speaker:</i> Prof. Katharina Fleischhauer (Germany)	09:00 - 09:20
W01-2	Immunogenetics of relapse <i>Speaker:</i> Dr. Effie Petersdorf (United States)	09:20 - 09:40
W01-3	The impact of classical and non-classical UHR HLA typing and matching on unrelated donor HCT outcomes <i>Speaker:</i> Dr. Neema Mayor (United Kingdom)	09:40 - 10:00
W01-4	Q&A - Panel discussion (all) <i>Panelist:</i> Prof. Alejandro Madrigal (United Kingdom)	10:00 - 10:30

Nurses Group

09:00 - 10:30

Hall 1

NG05 - Nurses Group Opening Session*Chair:* Dr. Michelle Kenyon (United Kingdom)*Chair:* Ms. Lorna Welsh (United Kingdom)

NG05-1	Welcome and overview <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	09:00 - 09:10
NG05-2	Welcome to Glasgow <i>Speaker:</i> Ms. Lorna Welsh (United Kingdom)	09:10 - 09:15
NG05-3	Presentation of the 16th Distinguished Merit Award & Honorary Member Award <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom) <i>Speaker:</i> Mr. Theo Nering Bögel (Netherlands)	09:15 - 09:30
NG05-4	Keynote lecture: 40 years of EBMT Nurses Group <i>Speaker:</i> Ms. Carole Charley (United Kingdom) <i>Speaker:</i> Mr. Ton van Boxtel (Netherlands)	09:30 - 10:00
NG05-5	Keynote lecture - Research Inclusion: Why it matters and getting it right first time <i>Speaker:</i> Ms. Fay Scott (United Kingdom) <i>Speaker:</i> Ms. Asima Akhtar (United Kingdom)	10:00 - 10:30

Working Party Session

09:00 - 10:15

Hall M1

TCWP - Transplant Complications Working Party Session*Chair:* Prof. Dr. Zinaida Peric (Croatia)

TCWP-1	New definitions in TMA- harmonisation of diagnostic and prognostic criteria <i>Speaker:</i> Dr. Ivan Moiseev (Russian Federation)	09:00 - 09:15
TCWP-2	New perspectives in GVHD - upcoming treatments <i>Speaker:</i> Dr. Katarina Riesner (Germany)	09:15 - 09:30
TCWP-3	Challenges in CAR-T therapy - how to overcome toxicities <i>Speaker:</i> Dr. Charlotte Graham (United States)	09:30 - 09:45
TCWP-4	Novel tools in management of transplant complications: AI and more <i>Speaker:</i> Dr. Alberto Mussetti (Spain)	09:45 - 10:00
TCWP-5	Lost in Silence: Bridging Communication Gaps between Patients and Providers <i>Speaker:</i> Ms. Meredith Cowden (United States)	10:00 - 10:15

Working Party Session

09:00 - 10:15

FORTH

HWP - Haemoglobinopathies Working Party Session*Chair:* Dr. Emanuele Angelucci (Italy)*Chair:* Selim Corbacioglu (Germany)

HWP-1	Haemoglobinopathies Working Party presentation <i>Speaker:</i> Dr. Emanuele Angelucci (Italy)	09:00 - 09:05
HWP-2	Current standard of care and outcome for transfusion dependent Thalassaemia patient worldwide <i>Speaker:</i> Prof. Dr. Ali Taher (Lebanon)	09:05 - 09:25
HWP-3	Advancements and challenges in Hematopoietic Stem Cell Transplantation for thalassemia in Asia: where it matters most <i>Speaker:</i> Dr. Sarita Rani Jaiswal (India)	09:25 - 09:45
HWP-4	A look to the future: future directions of GT in Hemoglobinopathies <i>Speaker:</i> Prof. Stefano Rivella (United States)	09:45 - 10:05
HWP-5	Q&A	10:05 - 10:15

Pharmacists Day

09:00 - 10:25

BOISDALE

Pharm1 - Pharmacists Day 1 | GVHD*Chair:* Dr. Agnes Bonnin (France)*Chair:* Mr. Nick Duncan (United Kingdom)

Pharm1-1	Welcome <i>Speaker:</i> Mr. Nick Duncan (United Kingdom)	09:00 - 09:05
Pharm1-2	Welcome note from BOPA <i>Speaker:</i> Mr. Joe Williams (United Kingdom)	09:05 - 09:10
Pharm1-3	Post-transplant cyclophosphamide - practical aspects <i>Speaker:</i> Ms. Estela Moreno Martinez (Spain)	09:10 - 09:35
Pharm1-4	Management of steroid-refractory acute and chronic GVHD <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	09:35 - 10:00
Pharm1-5	The relationship between the gut microbiome and GVHD	10:00 - 10:25

Speaker: Prof. Dr. Ernst Holler (Germany)

Oral Session

09:00 - 10:15

ALSH

OS02 - Oral Session 2 | The use of data and AI to improve outcomes

Chair: Dr. Thomas Coats (United Kingdom)

Chair: Dr. Emily Liang (United States)

OS2-01	QUALITY IMPROVEMENT BY BENCHMARKING: EXPERIENCES IN BEST PRACTICES OF 4 HOVON ECHELON B HOSPITALS IN THE NETHERLANDS	09:00 - 09:09
	Oral Presenter: Ms. Yvonne Westerman (Netherlands)	
OS2-02	A NEW METHODOLOGY FOR VALIDATING SOFTWARE USED IN STEM CELL TRANSPLANT PROGRAMS	09:09 - 09:18
	Oral Presenter: Vincenzo Iaconianni (Italy)	
OS2-03	MACHINE-LEARNING-BASED CLUSTERING TO REFINE THE EHA/EBMT IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY GRADING CRITERIA	09:18 - 09:27
	Oral Presenter: Dr. Emily Liang (United States)	
OS2-04	DOES SIZE MATTER? CENTER-SPECIFIC CHARACTERISTICS AND SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) FOR ACUTE MYELOBLASTIC LEUKEMIA (AML): A DRST ANALYSIS	09:27 - 09:36
	Oral Presenter: Wolfgang Bethge (Germany)	
OS2-05	INTERPROFESSIONAL SIMULATION-BASED EDUCATION AT A NEW CAR T CENTRE: THE CAR T EDUCATION AND LEARNING THROUGH SIMULATION (CARTELS) APPROACH	09:36 - 09:45
	Oral Presenter: Jack Gallagher (United Kingdom)	
OS2-06	A CASEMIX OUTCOME STRATIFICATION MODEL FOR SCT USING MACHINE LEARNING (COSMOS)	09:45 - 09:54
	Oral Presenter: Dr. Erik von Asmuth (Netherlands)	
OS2-07	USING AN ARTIFICIAL INTELLIGENCE MODEL TO QUANTIFY UNDER-UTILISATION OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA IN UK	09:54 - 10:03
	Oral Presenter: Dr. Thomas Coats (United Kingdom)	
OS2-08	AN AI MODEL TO OPTIMIZE DONOR SELECTION USING A CONTEMPORARY DATASET	10:03 - 10:12
	Oral Presenter: Martin Maiers (United States)	

Psy Day

09:00 - 10:20

CARRON

Psy1 - Psy Day 1 | UK developments in psychological support of people undergoing HSCT

Chair: Dr. Kathleen McHugh (United Kingdom)

Psy1-1	Welcome	09:00 - 09:05
Psy1-2	Pre-transplant work stream: The development of guidelines for the role of psychological specialists in the assessment of adults undergoing Haematopoietic Stem Cell Transplantation	09:05 - 09:25
	Speaker: Dr. Anna Lagerdahl (United Kingdom)	
Psy1-3	HSCT in Sickle Cell Disease: Psychological considerations and outcomes	09:25 - 09:45
	Speaker: Dr. Jenna Love (United Kingdom)	
Psy1-4	Responding to the psychological needs of people with rare bone marrow conditions using a stepped care model	09:45 - 10:05

	<i>Speaker:</i> Dr. Lesley Howells (United Kingdom) <i>Speaker:</i> Ms. Ellie Dawes (United Kingdom)	
Psy1-5	Q&A	10:05 - 10:20
<i>Patient Advocacy Session</i>		
09:00 - 10:15		GALA
PAS1 - Patient Advocacy Committee Session 1 Real World Evidence: patient experience data to inform what is missed in the registries data		
<i>Chair:</i> Ms. Anja van Biezen (Netherlands)		
PAS1-1	Introduction	09:00 - 09:05
PAS1-2	The role of patient organisations as source of RWE <i>Speaker:</i> Ms. Lorna Warwick (Canada)	09:05 - 09:20
PAS1-3	A nationwide, prospective collection of patient reported outcomes in the Cancer Registry of Norway <i>Speaker:</i> Ms. Ylva Maria Gjelsvik (Norway)	09:20 - 09:35
PAS1-4	Discussion <i>Panelist:</i> Ms. Annemiek Markslag (Netherlands)	09:35 - 10:00
<i>Data Management</i>		
09:00 - 10:30		ARGYLL Suite
DMT1 - Hands-On EBMT Registry Training Session 1		
DMT1-1	Data Entry	09:00 - 09:00
DMT1-2	Filtering	09:00 - 09:00
DMT1-3	Common Requests	09:00 - 09:00
<i>Special Session</i>		
09:00 - 10:00		IT
SS1 - How to get Published?		
SS1-1	How to get Published? <i>Speaker:</i> Prof. Mohamad Mohty (France) <i>Speaker:</i> Dr. Edwin Uriel Suarez (Spain)	09:00 - 10:00
<i>ePoster</i>		
09:00 - 18:00		ePoster area
ePoster Viewing		
<i>Breaks</i>		
10:30 - 11:00		CLYDE
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Plenary Session</i>		
11:00 - 12:30		CLYDE
P01 - Gene therapy		
<i>Chair:</i> Dr. Emanuele Angelucci (Italy) <i>Chair:</i> Dr. Shahzaya Chaudhury (United Kingdom)		
P01-1	Gene therapy for rare disorders: current and future potential <i>Speaker:</i> Rob Wynn (United Kingdom)	11:00 - 11:25
P01-2	Engineered T-cells in haemato-oncology	11:25 - 11:50

	<i>Speaker:</i> Prof. Dr. Chiara Bonini (Italy)	
P01-3	Gene therapy for sickle cell disease <i>Speaker:</i> Dr. Julie Kanter (United States)	11:50 - 12:15
P01-4	Q&A - Discussion	12:15 - 12:30
 <i>Cell Therapy Day</i> 11:00 - 12:15		
		LOMOND
CTD2 - Cell Therapy Day 2 Challenges in ATMP development		
<i>Chair:</i> Prof. Dr. Jurgen Kuball (Netherlands)		
<i>Chair:</i> Dr. Simona Pagliuca (France)		
CTD2-1	Predictive parameters of potency assay <i>Speaker:</i> Dr. Valentín Ortiz-Maldonado (Spain)	11:00 - 11:25
CTD2-2	Landscape and challenges in immune monitoring, a survey <i>Speaker:</i> Dr. Simona Pagliuca (France)	11:25 - 11:50
CTD2-3	Consequences of regulatory changes on access to devices and reagents needed for graft processing <i>Speaker:</i> Prof. Dr. Christian Chabannon (France)	11:50 - 12:15
 <i>Educational</i> 11:00 - 12:30		
		Hall 3 North
E02 - Decisions impacting ALL outcome		
<i>Chair:</i> Dr. Anne Parker (United Kingdom)		
<i>Chair:</i> David Marks (United Kingdom)		
E02-1	TYA approach to ALL: at what age should it stop <i>Speaker:</i> Dr. Anna Castleton (United Kingdom)	11:00 - 11:25
E02-2	Ph positive ALL: to transplant or not to transplant <i>Speaker:</i> Prof. Dr. Robin Foa (Italy)	11:25 - 11:50
E02-3	The role of CAR-T therapy in adult ALL <i>Speaker:</i> Dr. Deborah Yallop (United Kingdom)	11:50 - 12:15
E02-4	Q&A - Discussion	12:15 - 12:30
 <i>Oral Session</i> 11:00 - 12:15		
		Hall 3 South
OS03 - Oral Session 3 Infection - diagnosis, management and outcome		
<i>Chair:</i> Dr. Ailsa Holroyd (United Kingdom)		
<i>Chair:</i> Prof. Dr. Malgorzata Mikulska (Italy)		
OS3-01	TRIPLEX VACCINE TO INDUCE PROTECTIVE AND DURABLE CYTOMEGALOVIRUS-SPECIFIC CELLULAR IMMUNITY IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AT RISK FOR CYTOMEGALOVIRUS COMPLICATIONS <i>Oral Presenter:</i> Anna Pawlowska (United States)	11:00 - 11:09
OS3-02	PRELIMINARY RESULTS OF PHASE 2A CLINICAL TRIAL TO EVALUATE SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF INTRAVENOUS BRINCIDOFOVIR IN IMMUNOCOMPROMISED PATIENTS WITH ADENOVIRUS INFECTION <i>Oral Presenter:</i> Michael Grimley (United States)	11:09 - 11:18
OS3-03	INCIDENCE AND OUTCOME OF HHV-6 ENCEPHALITIS IN HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE ANALYSIS OF THE IDWP-EBMT <i>Oral Presenter:</i> Katia Perruccio (Italy)	11:18 - 11:27

OS3-04	TOXOPLASMA QPCR KINETICS TO FOLLOW TREATMENT OF TOXOPLASMOSIS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Alienor Xhaard (France)	11:27 - 11:36
OS3-05	RETROSPECTIVE STUDY ON THE INCIDENCE AND OUTCOME OF ADENOVIRUS INFECTIONS IN PATIENTS AFTER HAPLOIDENTICAL SCT. A STUDY OF INFECTIOUS DISEASE WORKING PARTY OF THE EBMT <i>Oral Presenter:</i> Maura Faraci (Italy)	11:36 - 11:45
OS3-06	CLINICAL EXPERIENCE OF TABELCLEUCEL IN EPSTEIN-BARR VIRUS-POSITIVE POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (EBV⁺ PTLD) INVOLVING THE CENTRAL NERVOUS SYSTEM <i>Oral Presenter:</i> Prof. Dr. Nina Worel (Austria)	11:45 - 11:54
OS3-07	CLINICAL, MICROBIOLOGICAL CHARACTERISTICS AND OUTCOME OF BLOODSTREAM INFECTIONS IN PEDIATRIC HCT RECIPIENTS: RETROSPECTIVE MULTICENTER, ANALYSIS BY INFECTION WORKING GROUP OF ITALIAN PEDIATRIC HEMATOLOGY ONCOLOGY ASSOCIATION <i>Oral Presenter:</i> Francesco Baccelli (Italy)	11:54 - 12:03
OS3-08	THE USE OF GANCICLOVIR OR VALGANCICLOVIR DOES NOT INCREASE RELAPSE RISK FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME <i>Oral Presenter:</i> Dr. Nihar Desai (Canada)	12:03 - 12:12

Workshop

11:00 - 12:30

Hall 2

W02 - EBMT Contest Session | What lessons can transplant and cell therapy health professionals learn from other clinical and scientific disciplines?*Chair:* Victoria Potter (United Kingdom)*Chair:* Dr. Donal McLornan (United Kingdom)*Chair:* Prof. Dr. Fabio Ciceri (Italy)

W02-1	It's the iron in the mind, not in the erythrocytes, that wins medals (adapted from Sir Steven Redgrave) <i>Speaker:</i> Anne PJ de Pagter (Netherlands)	11:00 - 11:15
W02-2	Reaching for the stars <i>Speaker:</i> Dr. Delfien Bogaert (Belgium)	11:15 - 11:30
W02-3	Aligning science with soul: Steering the transplant and cell therapy path with interdisciplinary collaboration and ethical excellence <i>Speaker:</i> Dr. Pinelopi Samara (Greece)	11:30 - 11:45
W02-4	Story of the first Chimeric antigen T-cell therapy program in India-How we aim to achieve scale and improve access <i>Speaker:</i> Prof. Dr. Hasmukh Jain (India)	11:45 - 12:00
W02-5	The heart of scientific disciplines: insights from my journey into BMT and cellular therapy <i>Speaker:</i> Dr. Esra Gülderen (Turkey)	12:00 - 12:15
W02-6	Audience voting & Winner announcement	12:15 - 12:30

Joint Sessions

11:00 - 12:00

Hall 5

JS01 - Joint Session EBMT - EHA | Translating new myelodysplastic syndromes classification into updated indications to allogeneic transplantation*Chair:* Prof. Dr. Anna Sureda (Spain)*Chair:* Prof. Antonio Almeida (Portugal)

JS01-1	MDS classification update <i>Speaker:</i> Prof. Dr. Luca Malcovati (Italy)	11:00 - 11:20
JS01-2	Current practices and outcomes in allogeneic transplantation for MDS <i>Speaker:</i> Dr. Marie Robin (France)	11:20 - 11:40
JS01-3	Q&A	11:40 - 12:00

Nurses Group

11:00 - 12:30

Hall 1

NG06 - Oral Session - Adult Abstract Award Finalists*Chair:* Ms. Sandra Schoenfeld (Switzerland)*Chair:* Ms. Elin Ofverberg (Sweden)

NG06-01	EXPLORING THE RELATIONSHIP BETWEEN DEPENDENCE, CLINICAL-SOCIAL FRAGILITY INDEX, AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AND CAR-T THERAPY: A RETROSPECTIVE STUDY OF GITMO <i>Oral Presenter:</i> Ms. Simona Calza (Italy)	11:00 - 11:15
NG06-02	1-YEAR REVIEW: EVALUATION OF THE PHYSIOTHERAPY PREHABILITATION SERVICE FOR PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) AND CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY <i>Oral Presenter:</i> Evelyn Evans (United Kingdom)	11:15 - 11:30
NG06-03	VACCINATION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A NURSING-LED SINGLE CENTER INITIATIVE TO IMPROVE VACCINATION STATUS <i>Oral Presenter:</i> Ms. Kathy Goris (Belgium)	11:30 - 11:45
NG06-04	'THE LAST BRIDGE'- HOW PATIENTS EXPERIENCE THE CAR T-CELL THERAPY. A QUALITATIVE STUDY <i>Oral Presenter:</i> Verena Leinemann (Austria)	11:45 - 12:00
NG06-05	VULVO-VAGINAL CHRONIC GRAFT-VERSUS-HOST DISEASE ASSESSMENT: A SINGLE-CENTER PROSPECTIVE OBSERVATIONAL STUDY <i>Oral Presenter:</i> Francesca Palmisano (Italy)	12:00 - 12:15

How do I... ?

11:00 - 12:15

Hall M1

HDI1 - How Do I... approach cGVHD patients' supportive care | Supported through an unrestricted educational grant by Sanofi*Chair:* Dr. Emma Nicholson (United Kingdom)*Chair:* Prof. John Moore (Australia)

HDI1-1	Biology of cGVHD: how does it influence my treatment decisions <i>Speaker:</i> Prof. Dr. Thomas Luft (Germany)	11:00 - 11:25
HDI1-2	New treatment strategies: Treating inflammation and fibrosis in cGVHD <i>Speaker:</i> Dr. Corey Cutler (United States)	11:25 - 11:50
HDI1-3	Case discussion	11:50 - 12:15

Working Party Session

11:00 - 12:15

FORTH

SAAWP - Severe Aplastic Anaemia Working Party Session*Chair:* Prof. Antonio Risitano (Italy)*Chair:* Dr. Austin Kulasekararaj (United Kingdom)

SAAWP-1	Current and future SAAWP studies <i>Speaker:</i> Prof. Antonio Risitano (Italy)	11:00 - 11:10
SAAWP-2	Case-based discussion: haplo-HSCT upfront? EPAG dependency? Somatic mutations? <i>Speaker:</i> Dr. Austin Kulasekararaj (United Kingdom)	11:10 - 11:30
SAAWP-3	Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT <i>Speaker:</i> Dr. Juan Montoro Gómez (Spain)	11:30 - 11:45
SAAWP-4	RACE biological study: somatic mutations in SAA patients <i>Speaker:</i> Dr. Deniz Ece Kaya (United Kingdom)	11:45 - 12:00
SAAWP-5	RACE biological study: immune abnormalities in SAA patients <i>Speaker:</i> Dr. Giorgio Napolitani (United Kingdom)	12:00 - 12:15

Pharmacists Day

11:00 - 12:15

BOISDALE

Pharm2 - Pharmacists Day 2 | Supportive care*Chair:* Ms. Sinead Connolly (United Kingdom)*Chair:* Dr. Rick Admiraal (Netherlands)

Pharm2-1	Management of nausea and vomiting <i>Speaker:</i> Ms. Siobhan Smith (United Kingdom)	11:00 - 11:25
Pharm2-2	Prevention and treatment of CMV infection <i>Speaker:</i> Prof. Dr. Per Ljungman (Sweden)	11:25 - 11:50
Pharm2-3	Vaccination strategies for SCT and CAR-T patients <i>Speaker:</i> Mr. Brendan O'Sullivan (United Kingdom)	11:50 - 12:15

Nurses Group

11:00 - 12:30

ALSH

NG07 - Paediatric abstracts*Chair:* Ms. Ida Bremer-Ophorst (Netherlands)*Chair:* Dr. Marjola Gjergji (Italy)

NG07-01	A QUALITATIVE RESEARCH INTO PERSONAL EXPERIENCE AND RELATIONAL MEANING IN SIBLING HSCT DONORS <i>Oral Presenter:</i> Ms. Sophie Van Lancker (Belgium)	11:00 - 11:15
NG07-02	THE INTRODUCTION OF HOME MONITORING, FOR PEDIATRIC PATIENTS WHO RECEIVED CAR T THERAPY, SAFELY REDUCES THE HOSPITAL ADMISSION <i>Oral Presenter:</i> Marieke van der Vlugt (Netherlands)	11:15 - 11:30
NG07-03	A QUALITY IMPROVEMENT PROJECT TO IMPROVE THE ACCURACY OF ASSESSMENT AND REPORTING OF STOOLS IN CHILDREN UNDERGOING HAEMOPOIETIC STEM CELL TRANSPLANT <i>Oral Presenter:</i> Katie Elwig (United Kingdom)	11:30 - 11:45
NG07-04	NURSING TRAINING ENABLES A HEMATOPOIETIC STEM CELL TRANSPLANTATION STARTUP IN DODOMA, TANZANIA <i>Oral Presenter:</i> Anna Carmagnola (Italy)	11:45 - 12:00
NG07-05	A 4-YR AUDIT OF A NURSE-LED VENESECTION SERVICE IN	12:00 - 12:15

MANAGEMENT OF POST-BMT IRON OVERLOAD IN PAEDIATRIC PATIENTS FROM A SINGLE CENTRE IN THE UNITED KINGDOM

Oral Presenter: Lorna Dagg (United Kingdom)

Psy Day

11:00 - 12:15

CARRON

Psy2 - Psy Day 2 | Psychological Impact of HSCT: supportive intervention - I

Chair: Ms. Surabhi Chaturvedi (United Kingdom)

Psy2-1	'Where Now' Pilots: Results from a course aimed at supporting the needs of patients post-transplant <i>Speaker:</i> Dr. Troy Chase (United Kingdom)	11:00 - 11:20
Psy2-2	Let's talk about sex <i>Speaker:</i> Ms. Caroline Lovett (United Kingdom)	11:20 - 11:40
Psy2-3	Medication adherence in patients undergoing HSCT-qualitative study <i>Speaker:</i> Prof. Dr. Hermioni Amonoo (United States)	11:40 - 12:00
Psy2-4	Q&A	12:00 - 12:15

Patient Advocacy Session

11:00 - 12:15

GALA

PAS2 - Patient Advocacy Committee Session 2 | The role of the EBMT registry in the next generation of evidence-based medicine

Chair: Prof. Mohamad Mohty (France)

PAS2-1	Introduction	11:00 - 11:05
PAS2-2	Update on the EBMT Registry <i>Speaker:</i> Ms. Annemiek Markslag (Netherlands) <i>Speaker:</i> Ms. Annelot van Amerongen (Netherlands)	11:05 - 11:23
PAS2-3	PROs in medicines development, the role of the registries <i>Speaker:</i> Dr. Charalampia Kyriakou (United Kingdom)	11:23 - 11:41
PAS2-4	Next Generation Registries: how Artificial Intelligence is elevating evidence generation <i>Speaker:</i> Dr. Ignacio Medrano (Spain)	11:41 - 11:59
PAS2-5	Q&A - discussion and closing remarks	11:59 - 12:14

Data Management

11:00 - 12:30

ARGYLL Suite

DMT2 - Hands-On EBMT Registry Training Session 2

DMT2-1	Data Entry	11:00 - 11:00
DMT2-2	Filtering	11:00 - 11:00
DMT2-3	Common Requests	11:00 - 11:00

Breaks

12:30 - 13:00

CLYDE

Lunch Break, ePoster Viewing, Visit Exhibition

Meetings

12:45 - 14:00

Hall M1

BM-TCWP - Business Meeting of the Transplant Complications Working Party*Chair:* Prof. Dr. Zinaida Peric (Croatia)*Meetings*

12:45 - 14:00

BOISDALE

BM-IDWP - Business Meeting of the Infectious Diseases Working Party*Chair:* Dr. Rafael de la Camara (Spain)*Industry Symposium*

13:00 - 14:00

CLYDE

IS28 - Optimising chronic GvHD management: Reassessing the therapeutic landscape | SANOFI*Chair:* Dr. Corey Cutler (United States)*Chair:* Daniel Wolff (Germany)

IS28-1	Welcome and Introduction <i>Speaker:</i> Dr. Corey Cutler (United States) <i>Speaker:</i> Daniel Wolff (Germany)	13:00 - 13:05
IS28-2	Expanding the chronic GvHD treatment paradigm with novel therapeutics <i>Speaker:</i> Dr. Corey Cutler (United States)	13:05 - 13:15
IS28-3	Expert exchange: Exploring the clinical practicalities of managing GvHD [roundtable discussion] <i>Speaker:</i> Dr. Andrew Clark (United Kingdom) <i>Speaker:</i> Daniel Wolff (Germany) <i>Speaker:</i> Prof. Dr. Rafael Duarte (Spain) <i>Moderator:</i> Dr. Corey Cutler (United States)	13:15 - 13:50
IS28-4	Q&A and meeting close - All faculty <i>Moderator:</i> Dr. Corey Cutler (United States) <i>Moderator:</i> Daniel Wolff (Germany)	13:50 - 14:00

Meetings

13:00 - 14:00

Hall 1

BM-NG - EBMT Nurses Group overview opportunities and networking

BM-NG-1	Introduction opportunities & networking <i>Speaker:</i> Ms. Daphna Hutt (Israel)	13:00 - 13:05
BM-NG-2	President report <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	13:05 - 13:15
BM-NG-3	Research committee <i>Speaker:</i> Ms. Annika Kisch (Sweden)	13:15 - 13:25
BM-NG-4	Scientific committee <i>Speaker:</i> Ms. Marijke Quaghebeur (Belgium)	13:25 - 13:30
BM-NG-5	Pediatric committee <i>Speaker:</i> Ms. Ida Bremer-Ophorst (Netherlands)	13:30 - 13:35
BM-NG-6	Global education <i>Speaker:</i> Ms. Julia Ruiz Pato (Spain)	13:35 - 13:40
BM-NG-7	Working party nurse update <i>Speaker:</i> Ms. Maaïke de Ruijter (Netherlands)	13:40 - 13:45
BM-NG-8	Discussion & close	13:45 - 14:00

<i>Statistics</i>		
13:00 - 14:00		CARRON
STATS1 - Statistical Symposium		
<i>Chair:</i> Prof. Dr. Hein Putter (Netherlands)		
<i>Chair:</i> Luuk Gras (Netherlands)		
STATS1-1	Reporting and methodological quality of machine learning prediction model studies: an overview of results	13:00 - 13:20
	<i>Speaker:</i> Dr. Paula Dhiman (United Kingdom)	
STATS1-2	Modelling survival outcomes for casemix correction by explainable machine learning techniques	13:20 - 13:40
	<i>Speaker:</i> Dr. Erik von Asmuth (Netherlands)	
STATS1-3	Random forests for composite endpoints	13:40 - 14:00
	<i>Speaker:</i> Prof. Dr. Kwang Woo Ahn (United States)	
<i>Industry Meet the Expert</i>		
13:00 - 14:00		CASTLE Suite
S-MTE-1 - Promotional Meeting: The Evolving Eligibility Criteria for CAR T Cell Therapy in LBCL: What Have We Learned so Far? Bristol Myers Squibb		
<i>Chair:</i> Prof. Dr. Catherine Thieblemont (France)		
<i>Industry Meet the Expert</i>		
13:00 - 14:00		CASTLE Suite
S-MTE - Meet the Expert		
<i>Industry Theatre</i>		
13:00 - 13:35		IT
IT2 - Beyond viremia clearance: 360 perspectives in post-transplant CMV infection Takeda		
<i>Moderator:</i> Karl Peggs (United Kingdom)		
<i>Moderator:</i> Ms. Angela Leather (United Kingdom)		
<i>Moderator:</i> Christopher Salmen (United States)		
<i>Breaks</i>		
14:00 - 14:30		CLYDE
Break, ePoster Viewing, Visit Exhibition		
<i>Data Management</i>		
14:00 - 14:50		ARGYLL Suite
DM1 - Data Management Session 1 - Hemoglobinopathies introduction		
<i>Chair:</i> Arnaud Dalissier (France)		
<i>Chair:</i> Dr. Jaques-Emmanuelle Galimard (France)		
DM1-1	Hemoglobinopathies introduction	14:00 - 14:50
	<i>Speaker:</i> Dr. Emanuele Angelucci (Italy)	
<i>Plenary Session</i>		
14:30 - 16:00		CLYDE
P02 - 50 years of Cellular Therapy		
<i>Chair:</i> Prof. Stella Davies (United States)		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
P02-1	Where have we come from?	14:30 - 14:50
	<i>Speaker:</i> Prof. Dr. Mary Horowitz (United States)	
P02-2	Where are we now? State of the art transplant	14:50 - 15:10
	<i>Speaker:</i> Prof. Dr. Fabio Ciceri (Italy)	
P02-3	Where are we going? Cellular therapy in the future	15:10 - 15:30

	<i>Speaker:</i> Dr. Reuben Benjamin (United Kingdom)	
P02-4	Panel discussion	15:30 - 16:00
<i>Cell Therapy Day</i> 14:30 - 15:40		LOMOND
CTD3 - Cell Therapy Day 3 Developing new technologies in cell and gene therapy		
<i>Chair:</i> Prof. Dr. Chiara Bonini (Italy)		
<i>Chair:</i> Prof. Paolo Pedrazzoli (Italy)		
CTD3-1	Building a new ATMP facility in Slovenia: challenges and opportunities <i>Speaker:</i> Prof. Dr. Mojca Bencina (Slovenia)	14:30 - 14:55
CTD3-2	PET-imaging and prediction CART response <i>Speaker:</i> Dr. Margot Jak (Netherlands)	14:55 - 15:20
CTD3-3	CART: Certainty - A cellular immunotherapy virtual twin for personalised cancer treatment <i>Speaker:</i> Dr. Kristin Reiche (Germany)	15:20 - 15:45
<i>Educational</i> 14:30 - 16:00		Hall 3 North
E03 - Improving AML outcomes		
<i>Chair:</i> Dr. Gesine Bug (Germany)		
<i>Chair:</i> Prof. Dr. Sabine Kayser (Germany)		
E03-1	Optimal conditioning in AML <i>Speaker:</i> Prof. Alessandro Rambaldi (Italy)	14:30 - 14:55
E03-2	Preventing post-transplant relapse in AML <i>Speaker:</i> Dr. Simona Pagliuca (France)	14:55 - 15:20
E03-3	What is the landscape of immune therapies for AML? <i>Speaker:</i> Dr. Sara Ghorashian (United Kingdom)	15:20 - 15:45
E03-4	Q&A - Discussion	15:45 - 16:00
<i>Oral Session</i> 14:30 - 15:45		Hall 3 South
OS04 - Oral Session 4 Haemoglobinopathy		
<i>Chair:</i> Prof. Josu de la Fuente (United Kingdom)		
<i>Chair:</i> Dr. Shahzya Chaudhury (United Kingdom)		
OS4-01	UNRELATED DONOR TRANSPLANTATION OFFERS A REAL CURATIVE OPPORTUNITY FOR PATIENTS WITH TRANSFUSION-DEPENDENT THALASSAEMIA. EXPERIENCE OF THE SPANISH GROUP FOR BONE MARROW TRANSPLANTATION IN CHILDREN (GETH-TC) <i>Oral Presenter:</i> Maria Isabel Benitez Carabante (Spain)	14:30 - 14:39
OS4-02	IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA <i>Oral Presenter:</i> Prof. Josu de la Fuente (United Kingdom)	14:39 - 14:48
OS4-03	EXAGAMGLOGENE AUTOTEMCEL FOR SEVERE SICKLE CELL DISEASE <i>Oral Presenter:</i> Roland Meisel (Germany)	14:48 - 14:57
OS4-04	NON-MYELOABLATIVE HAEMATOPOIETIC STEM CELL TRANSPLANT FROM MATCHED RELATED DONORS IN ADULT PATIENTS WITH SEVERE SICKLE CELL DISEASE: THE UK REAL-	14:57 - 15:06

LIFE EXPERIENCE*Oral Presenter:* Fabio Serpenti (United Kingdom)

OS4-05	EXAGAMGLOGENE AUTOTEMCEL FOR TRANSFUSION-DEPENDENT B-THALASSEMIA <i>Oral Presenter:</i> Prof. Franco Locatelli (Italy)	15:06 - 15:15
OS4-06	IMPACT OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE: COMPARISON OF THE OUTCOME IN TRANSPLANTED VERSUS NON-TRANSPLANTED PATIENTS <i>Oral Presenter:</i> Cécile Pivert (France)	15:15 - 15:24
OS4-07	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SICKLE CELL DISEASE: PRELIMINARY RESULTS OF THE FIRST FOUR PATIENTS TRANSPLANTED IN TANZANIA <i>Oral Presenter:</i> Fabio Giglio (Italy)	15:24 - 15:33
OS4-08	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SICKLE CELL DISEASE IN CHILDREN USING THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING WITHOUT SEROTHERAPY IN 101 MATCHED RELATED DONOR TRANSPLANTS -A SINGLE-CENTER STUDY <i>Oral Presenter:</i> Mohammed Essa (Saudi Arabia)	15:33 - 15:42

Joint Sessions

14:30 - 16:00

Hall 2

JS02 - Joint Session EBMT - WBMT | Chimeric Antigen Receptor (CAR) T-cell and advanced cellular and gene therapies, minimizing disparities, regulatory issues and global collaboration to improve access*Chair:* Dr. Mahmoud Aljurf (Saudi Arabia)*Chair:* Prof. Ibrahim Yakoub-Agha (France)

JS02-1	CAR-T and other gene therapies: Perspectives on worldwide access, affordability and clinical indications <i>Speaker:</i> Prof. Dr. Mickey Koh (United Kingdom)	14:30 - 14:55
JS02-2	Chimeric Antigen Receptor (CAR) T-cell and advanced cellular therapies, challenges and opportunities in emerging economies <i>Speaker:</i> Dr. Syed Osman Ahmed (Saudi Arabia)	14:55 - 15:20
JS02-3	Procurement of the starting material for manufacturing of advanced therapies: a global challenge for hospitals and blood banks <i>Speaker:</i> Prof. Dr. Christian Chabannon (France)	15:20 - 15:45
JS02-4	Q&A	15:45 - 16:00

Workshop

14:30 - 16:00

Hall 5

W03 - Optimising outcomes post transplant*Chair:* Dr. Dorine Bresters (Netherlands)*Chair:* Prof. Dr. Stephanie Humblet Baron (Belgium)

W03-1	International late effects guidelines update <i>Speaker:</i> Dr. Rachel Phelan (United States)	14:30 - 14:55
W03-2	Manipulating the microbiome to improve outcomes <i>Speaker:</i> Prof. Dr. Florent Malard (France)	14:55 - 15:20
W03-3	How to manage fertility & pregnancy post HSCT <i>Speaker:</i> Prof. Jane Apperley (United Kingdom)	15:20 - 15:45

W03-4	Q&A - Discussion	15:45 - 16:00
<i>Nurses Group</i>		
14:30 - 16:00		Hall 1
NG08 - GVHD		
<i>Chair: Dr. Michelle Kenyon (United Kingdom)</i>		
<i>Chair: Ms. Marie Jones (United Kingdom)</i>		
NG08-1	Ocular GVHD <i>Speaker: Dr. Lynn Leppla (Germany)</i>	14:30 - 14:50
NG08-2	Lung GVHD <i>Speaker: Dr. Saskia Bos (United Kingdom)</i>	14:50 - 15:10
NG08-3	New treatments for chronic GVHD <i>Speaker: Daire Quinn (United Kingdom)</i>	15:10 - 15:30
NG08-4	Social and emotional cost of GVHD - patient experience <i>Speaker: Mr. Daniel Yeates (United Kingdom)</i> <i>Speaker: Dr. Jenna Love (United Kingdom)</i>	15:30 - 16:00
<i>How do I... ?</i>		
14:30 - 15:45		Hall M1
HDI2 - How Do I... manage in the future pediatric patients with GVHD? Supported through an unrestricted educational grant by Novartis		
<i>Chair: Prof. Dr. Brenda Gibson (United Kingdom)</i>		
HDI2-1	Assessment and treatment of GVHD in children <i>Speaker: Ms. Anita Lawitschka (Austria)</i>	14:30 - 14:55
HDI2-2	Novel approaches for the treatment of GVHD in children <i>Speaker: Dr. Mattia Algeri (Italy)</i>	14:55 - 15:20
HDI2-3	Case discussion	15:20 - 15:45
<i>Special Session</i>		
14:30 - 15:45		FORTH
SS2 - Controlling rising health care costs?		
<i>Chair: Prof. Dr. Nicolaus Kröger (Germany)</i>		
<i>Chair: Prof. Anthony Pagliuca (United Kingdom)</i>		
SS2-1	The role of NICE <i>Speaker: Dr. Charles Crawley (United Kingdom)</i>	14:30 - 14:50
SS2-2	Costs in USA <i>Speaker: Prof. Bart Scott (United States)</i>	14:50 - 15:10
SS2-3	Costs in India <i>Speaker: Prof. Biju George (India)</i>	15:10 - 15:30
SS2-4	Q&A - Discussion	15:30 - 15:45
<i>Pharmacists Day</i>		
14:30 - 15:45		BOISDALE
Pharm3 - Pharmacists Day 3 Service delivery/research		
<i>Chair: Mr. Nick Duncan (United Kingdom)</i>		
Pharm3-1	How to promote wellness and prevent burnout <i>Speaker: Dr. Kathleen McHugh (United Kingdom)</i>	14:30 - 14:55
Pharm3-2	JACIE Standards for Pharmacists	14:55 - 15:15

	<i>Speaker:</i> Dr. Tiene Bauters (Belgium)	
Pharm3-03	EFFICIENT MODEL-INFORMED PRECISION DOSING FOR BUSULFAN IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Khalil Ben Hassine (Switzerland)	15:15 - 15:25
Pharm3-04	POSACONAZOLE DRT IN CHILDREN. TIME TO BRING OUT THE PILL CRUSHER? <i>Oral Presenter:</i> Heather Weerdenburg (Australia)	15:25 - 15:35
Pharm3-05	DEVELOPMENT AND CLINICAL VALIDATION OF LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY FOR INDIVIDUALIZED RUXOLITINIB ADJUSTMENT IN FUTURE CASES OF STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE <i>Oral Presenter:</i> Sara Redondo (Spain)	15:35 - 15:45
<i>Nurses Group</i> 14:30 - 16:00		ALSH
NG09 - Next generation session: early career challenges		
<i>Chair:</i> Mr. Daniel Kisielewski (Germany) <i>Chair:</i> Ms. Hilda Mekelenkamp (Netherlands)		
NG09-1	Walking The Tightrope - How to create work life balance for your nursing career <i>Speaker:</i> Ms. Amy Sinacola (United Kingdom)	14:30 - 14:50
NG09-2	Young nurses caring for young patients <i>Speaker:</i> Ms. Nilufar Sommerfeld (Germany)	14:50 - 15:10
NG09-3	Crossing boundaries of social media: personal vs. professional <i>Speaker:</i> Ms. Kirsty Crozier (United Kingdom)	15:10 - 15:30
NG09-4	Panel discussion - all faculty	15:30 - 16:00
<i>Psy Day</i> 14:30 - 15:45		CARRON
Psy3 - Psy Day 3 Psychological Impact of HSCT: supportive intervention - II		
<i>Chair:</i> Dr. Alice Polomeni (France)		
Psy3-1	Living not 'Existing': the benefits of eye movement desensitisation and reprocessing (EMDR) treatment for post-traumatic stress disorder (PTSD) symptoms following HSCT <i>Speaker:</i> Dr. Helen Aiston (United Kingdom)	14:30 - 14:50
Psy3-2	Patients' and family caregivers' psychosocial perspectives: person-centred care model in allogeneic HSCT in a multi-center study <i>Speaker:</i> Dr. Jeanette Winterling (Sweden) <i>Speaker:</i> Ms. Annika Kisch (Sweden)	14:50 - 15:10
Psy3-3	RCT of a positive psychology intervention for HSCT survivors <i>Speaker:</i> Prof. Dr. Hermioni Amonoo (United States)	15:10 - 15:30
Psy3-4	Q&A	15:30 - 15:45
<i>Special Session</i> 14:30 - 16:00		GALA
SS3 - Equality, Diversity, and Inclusion Session Delivering high quality transplant and cell therapy services against the odds: equity and access		
<i>Chair:</i> Prof. Nada Hamad (Australia) <i>Chair:</i> Dr. Silvia Montoto (United Kingdom)		
SS3-1	CAR-T therapy in New Zealand: developing trailblazing therapy in	14:30 - 14:50

	the heart of the local community	
	<i>Speaker:</i> Dr. Myra Ruka (New Zealand)	
SS3-2	Yes, we do perform stem cell transplants in the West Bank	14:50 - 15:10
	<i>Speaker:</i> Dr. Salwa Saadeh (Jordan)	
SS3-3	Quality without equity, an oximoron	15:10 - 15:30
	<i>Speaker:</i> Dr. Navneet Majhail (United States)	
SS3-4	Q&A - Discussion	15:30 - 16:00
<i>Data Management</i>		
15:00 - 15:50		ARGYLL Suite
DM2 - Data Management Session 2 - Introduction to immunosuppressive therapies for bone marrow failures		
<i>Chair:</i> Mr. Brian Piepenbroek (Netherlands)		
<i>Chair:</i> Mr. Joe Tuffnell (Netherlands)		
DM2-1	Introduction to immunosuppressive therapies for bone marrow failures	15:00 - 15:50
	<i>Speaker:</i> Prof. Dr. Alicia Rovo (Switzerland)	
<i>Breaks</i>		
16:00 - 16:30		CLYDE
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>General</i>		
16:30 - 18:00		CLYDE
GS2 - Presidential Symposium		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
<i>Chair:</i> Dr. Grant McQuaker (United Kingdom)		
<i>Chair:</i> Prof. Charlie Craddock (United Kingdom)		
GS02-01	Van Bekkum Award - Introduction	16:30 - 16:33
	<i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	
GS02-02	LARGE-SCALE TCR DEEP SEQUENCING REVEALS A T CELL DIVERSITY BOTTLENECK WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH IMPLICATIONS FOR EFFICACY AND TOXICITY: RESULTS OF THE BMT-CTN 1801 STUDY	16:33 - 16:48
	<i>Oral Presenter:</i> Leslie Kean (United States)	
GS02-03	Basic Science Award - Introduction	16:48 - 16:51
	<i>Speaker:</i> Dr. Grant McQuaker (United Kingdom)	
GS02-04	LYMPH NODE BLOOD ENDOTHELIAL CELLS PRIME ALLOREACTIVE CD4⁺ T CELLS IN ACUTE GRAFT-VERSUS-HOST DISEASE INITIATION	16:51 - 17:06
	<i>Oral Presenter:</i> Haroon Shaikh (Germany)	
GS02-05	ATIDARSAGENE AUTOTEMCEL (HAEMATOPOIETIC STEM CELL GENE THERAPY) PRESERVES COGNITIVE AND MOTOR DEVELOPMENT IN METACHROMATIC LEUKODYSTROPHY WITH UP TO 12 YEARS FOLLOW-UP	17:06 - 17:15
	<i>Oral Presenter:</i> Dr. Valeria Calbi (Italy)	
GS02-06	HLA MISMATCHING AND SURVIVAL AFTER HCT IN THE PTCY ERA: A COMPREHENSIVE STUDY BY THE EBMT CELLULAR THERAPY AND IMMUNOBIOLOGY WORKING PARTY	17:15 - 17:24
	<i>Oral Presenter:</i> Dr. Esteban Arrieta Bolaños (Germany)	
GS02-07	ELTROMBOPAG ADDED TO STANDARD IST IS SUPERIOR TO IST ALONE AS FRONT-LINE TREATMENT FOR SEVERE APLASTIC	17:24 - 17:33

	ANEMIA : FINAL 2-YEAR ANALYSIS OF EBMT-SAAWP RACE STUDY	
	<i>Oral Presenter:</i> Prof. Antonio Risitano (Italy)	
GS02-08	EFFECTIVE TREATMENT OF POST-TRANSPLANT RELAPSE IN YOUNG PATIENTS WITH ALL: POST APPROVAL REAL WORLD EXPERIENCE OF TREATMENT WITH TISAGENLECLEUCEL	17:33 - 17:42
	<i>Oral Presenter:</i> Laura M. Moser (Germany)	
GS02-09	ADDITION OF NIVOLUMAB TAILORED BY EXPANSION OF CAR-T CELLS IN PATIENTS WITH PROGRESSIVE DLBCL AT LYMPHODEPLETION - A PHASE 2, PROSPECTIVE INTERVENTIONAL STUDY - FINAL ANALYSIS	17:42 - 17:51
	<i>Oral Presenter:</i> Odelia Amit (Israel)	
GS02-10	THE MRD STATUS ON DAY 7 AND CD4 COUNT AT 1 MONTH AFTER CAR-T THERAPY ARE PROGNOSTIC INDICATORS IN CAR-T TREATMENTS	17:51 - 18:00
	<i>Oral Presenter:</i> Li Gao (China)	
<i>Cell Therapy Day</i>		
16:30 - 17:45		
		LOMOND
CTD4 - Cell Therapy Day 4 Old and new friends in allo SCT		
<i>Chair:</i> Dr. Effie Petersdorf (United States)		
<i>Chair:</i> Prof. Dr. Christian Chabannon (France)		
CTD4-1	HLA matching in the PTCy era: revisiting our knowledge	16:30 - 16:55
	<i>Speaker:</i> Dr. Esteban Arrieta Bolaños (Germany)	
CTD4-2	MSC: where do we stand?	16:55 - 17:20
	<i>Speaker:</i> Dr. Lotte van der Wagen (Netherlands)	
CTD4-3	Immunogenetics of Allogeneic HCT	17:20 - 17:45
	<i>Speaker:</i> Dr. Effie Petersdorf (United States)	
<i>Nurses Group</i>		
16:30 - 18:00		
		Hall 1
NG10 - Joint Session NG with the Patient Advocacy Committee representatives Co-creation in transplant and cell therapy- patients and nurses working together to build better care		
<i>Chair:</i> Ms. Natacha Bolaños (Spain)		
<i>Chair:</i> Ms. Marijke Quaghebeur (Belgium)		
NG10-1	Nursing and co-creation of care	16:30 - 16:50
	<i>Speaker:</i> Barbara Sassen (Netherlands)	
NG10-2	Nurse perspective	16:50 - 17:10
	<i>Speaker:</i> Ms. Annika Kisch (Sweden)	
NG10-3	Harnessing the power of nurse-patient co-creation	17:10 - 17:30
	<i>Speaker:</i> Ms. Natacha Bolaños (Spain)	
NG10-4	Panel discussion - Q&A	17:30 - 18:00
<i>How do I... ?</i>		
16:30 - 17:45		
		Hall M1
HDI4 - How Do I... mitigate adverse events to maximize benefit of patient treated with new advanced therapies for multiple myeloma? Supported through an unrestricted educational grant by Johnson and Johnson		
<i>Chair:</i> Dr. Kate Bailey (United Kingdom)		
HDI4-1	CAR-T	16:30 - 16:55
	<i>Speaker:</i> Dr. Rakesh Popat (United Kingdom)	
HDI4-2	Bispecific Antibodies	16:55 - 17:20

	<i>Speaker:</i> Dr. Adam Bryant (Australia)	
HDI4-3	Case discussion	17:20 - 17:45
<i>Pharmacists Day</i> 16:30 - 17:45		BOISDALE
Pharm4 - Pharmacists Day 4 Novel therapies		
<i>Chair:</i> Dr. Katerina Nezvalova Henriksen (Norway)		
<i>Chair:</i> Dr. Claudia Langebrake (Germany)		
Pharm4-1	Bi-specific antibodies for the treatment of B cell Non Hodgkin Lymphoma - a clinical update <i>Speaker:</i> Prof. Dr. Maria Gomes Da Silva (Portugal)	16:30 - 16:50
Pharm4-2	Bi-specific antibodies - a pharmacist's perspective <i>Speaker:</i> Ms. Garbiñe Lizeaga (Spain)	16:50 - 17:10
Pharm4-3	Management of cytopenia post CAR T-cell therapy: a US and UK perspective (joint presentation with ASTCT pharmacist group) <i>Speaker:</i> Mr. Brijesh Gautama (United Kingdom) <i>Speaker:</i> Dr. Mary McGann (United States)	17:10 - 17:45
<i>How do I... ?</i> 16:30 - 17:45		ALSH
HDI3 - How Do I... ensure excellent Nurse-Doctor collaboration to ensure optimal VOD patient management? This session is sponsored by Jazz Pharmaceuticals		
<i>Chair:</i> Ms. Julia Ruiz Pato (Spain)		
<i>Chair:</i> Ms. Iwona Przewozna (Poland)		
HDI3-1	VOD assessment in 2024 - how does this work for Drs? <i>Speaker:</i> Selim Corbacioglu (Germany)	16:30 - 16:45
HDI3-2	VOD assessment in 2024 - how does this work for nurses? <i>Speaker:</i> Ms. Sophie Van Lancker (Belgium)	16:45 - 17:00
HDI3-3	Nurses and doctors working together - how we communicate well and collaborate brilliantly <i>Speaker:</i> Ms. Amy Sinacola (United Kingdom)	17:00 - 17:15
HDI3-4	VOD assessment in 2024 - how we work together <i>Speaker:</i> Dr. Mónica Cabrero (Spain)	17:15 - 17:30
HDI3-5	Q&A	17:30 - 17:45
<i>Psy Day</i> 16:30 - 17:45		CARRON
Psy4 - Psy Day 4 Pre and post transplant support groups		
<i>Chair:</i> Dr. Clare McGowan (United Kingdom)		
Psy4-1	An imprACTical venture? A post-transplant paediatric ACT group <i>Speaker:</i> Dr. Nicholas Hudson (United Kingdom)	16:30 - 16:50
Psy4-2	Exploring the role of a prehab group and readiness for transplant <i>Speaker:</i> Dr. Sarah Airdrie (United Kingdom)	16:50 - 17:10
Psy4-3	Group psychological prehabilitation for HSCT: Considerations on feasibility and programme theory <i>Speaker:</i> Dr. Michael Baliouis (United Kingdom)	17:10 - 17:30
Psy4-4	Q&A	17:30 - 17:45

Data Management

16:30 - 17:20

ARGYLL Suite

DM3 - Data Management Session 3 - How do I? Report CAR-T patients - Differences between CAR-T and Cell Therapy*Chair:* Ms. Jorinde Hoogenboom (Netherlands)*Chair:* Ms. Eva Michel (France)DM3-1 **How do I? Report CAR-T patients - Differences between CAR-T and Cell Therapy** 16:30 - 17:20*Speaker:* Prof. Dr. Jurgen Kuball (Netherlands)*Data Management*

17:30 - 18:20

ARGYLL Suite

DM4 - Data Management Session 4 - How do I? Report infectious complications after Treatment*Chair:* Ms. Nina Knelange (Netherlands)*Chair:* Ms. Lotus Wendel (Netherlands)DM4-1 **How do I? Report infectious complications after Treatment** 17:30 - 18:20*Speaker:* Prof. Dr. Per Ljungman (Sweden)*Printed Poster*

18:00 - 19:00

Hall 3 North

Stem Cell SourceA143 **MACHINE LEARNING PREDICTION MODEL FOR NEUTROPHIL RECOVERY AFTER UNRELATED CORD BLOOD TRANSPLANTATION** 18:00 - 18:00*Poster Presenter:* Yachiyo Kuwatsuka (Japan)A144 **REAPPRAISING CORD BLOOD AS A PRIORITY CELL SOURCE IN ALTERNATE DONOR TRANSPLANT AND IN DIFFICULT-TO-CURE PAEDIATRIC HEMATOLOGIC MALIGNANCY** 18:00 - 18:00*Poster Presenter:* Abdul Wajid Moothedath (United Kingdom)A145 **CORTICOSTEROIDS IMPAIR HEMATOPOIETIC MICROENVIRONMENT VIA INDUCING SENESCENCE OF THE MESENCHYMAL STROMAL NICHE** 18:00 - 18:00*Poster Presenter:* Yuqing Wang (China)A146 **THE CORD BLOOD POST THAW CLINIC - HELPING YOU WORK OUT "WHAT GOOD LOOKS LIKE"** 18:00 - 18:00*Poster Presenter:* Roger Horton (United Kingdom)*Printed Poster*

18:00 - 19:00

Hall 3 North

New Drugs and Cell-based Immune TherapiesA127 **FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION** 18:00 - 18:00*Poster Presenter:* Vassiliki Zacharioudaki (Greece)A128 **FACTOR B INHIBITION WITH ORAL IPTACOPAN MONOTHERAPY DEMONSTRATES SUSTAINED LONG-TERM EFFICACY AND SAFETY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): FINAL RESULTS FROM APPLY-PNH** 18:00 - 18:00*Poster Presenter:* Dr. Austin Kulasekararaj (United Kingdom)A129 **GILTERITINIB WITH VENETOCLAX, ACTINOMYCIN D, AND LOW-DOSE CYTARABINE AS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA** 18:00 - 18:00*Poster Presenter:* Rita Čekauskienė (Lithuania)

A130	EFFICACY OF SALVAGE THERAPY INCLUDING NOVEL AGENTS IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (B-ALL) PROGRESSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A REAL-WORLD UK STUDY <i>Poster Presenter:</i> Dr. Alexandros Rampotas (United Kingdom)	18:00 - 18:00
A131	TREOSULFAN PLUS FLUDARABINE "REDUCED INTENSITY CONDITIONING" WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 65 YEARS <i>Poster Presenter:</i> Vincenzo Federico (Italy)	18:00 - 18:00
A132	REAL-WORLD CLINICAL EFFECTIVENESS OF LONCASTUXIMAB TESIRINE MONOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING CHIMERIC ANTIGEN T CELL THERAPY IN THE US <i>Poster Presenter:</i> Prof. Dr. Pier Luigi Zinzani (Italy)	18:00 - 18:00
A133	ORAL IPTACOPAN MONOTHERAPY MAINTAINS EFFICACY AND SAFETY OVER 48 WEEKS IN COMPLEMENT INHIBITOR-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN THE PHASE III APPOINT-PNH TRIAL <i>Poster Presenter:</i> Prof. Antonio Risitano (Italy)	18:00 - 18:00
A134	NOVEL HDAC1 INHIBITOR EPIRUBICIN EXERTS ANTI-TUMOR EFFECT OF PHILADELPHIA CHROMOSOME-POSITIVE LEUKEMIA CELLS BY INDUCING CELL FERROPTOSIS <i>Poster Presenter:</i> Guancui Yang (China)	18:00 - 18:00
A135	TCR-TRANSGENIC T CELLS AND YB-1 BASED ONCOLYTIC VIROTHERAPY IMPROVE SURVIVAL IN A PRECLINICAL EWING SARCOMA XENOGRAFT MOUSE MODEL <i>Poster Presenter:</i> Uwe Thiel (Germany)	18:00 - 18:00
A136	T CELLS DIRECTED AGAINST THE METASTATIC DRIVER CHONDROMODULIN-1 IN EWING SARCOMA: COMPARATIVE ENGINEERING WITH CRISPR/CAS9 VS. RETROVIRAL GENE TRANSFER FOR ADOPTIVE TRANSFER <i>Poster Presenter:</i> Uwe Thiel (Germany)	18:00 - 18:00
A137	UTILITY OF ROMIPLOSTIM IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT ASSOCIATED POOR GRAFT FUNCTION, IMMUNE MEDIATED CYTOPENIA AND IMMUNE MEDIATED GRAFT FAILURE <i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)	18:00 - 18:00
A138	RAG2^{-/-}TC^{-/-} MICE HUMANIZED WITH CD34⁺ HEMATOPOIETIC STEM CELLS ARE A SUITABLE TOOL TO SCREEN FOR FUNCTIONAL EWING SARCOMA-SPECIFIC T CELLS IN VIVO <i>Poster Presenter:</i> Uwe Thiel (Germany)	18:00 - 18:00
A139	CLINICAL BREAKTHROUGH HEMOLYSIS WITH ORAL FACTOR B INHIBITOR IPTACOPAN MONOTHERAPY IS GENERALLY NOT SEVERE AND MANAGED WITHOUT TREATMENT DISCONTINUATION: 48-WEEK DATA FROM APPLY-PNH AND APPOINT-PNH <i>Poster Presenter:</i> Prof. Antonio Risitano (Italy)	18:00 - 18:00
A140	REAL-WORLD EFFECTIVENES OF VENETOCLAX COMBINED WITH IPOMETILATING-AGENTS AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION IN ACUTE MIELOID LEUKEMIA: RETROSPECTIVE AND MULTICENTRIC STUDY OF APULIAN HEMATOLOGICAL NETWORK "REP05" <i>Poster Presenter:</i> Vincenzo Federico (Italy)	18:00 - 18:00
A141	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL) WHO	18:00 - 18:00

	RECEIVED LONCASTUXIMAB TESIRINE PRIOR TO CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY	
	<i>Poster Presenter:</i> Prof. Dr. Mehdi Hamadani (United States)	
A142	BUSULFAN AND THIOTEPA AS CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA:A STUDY OF THE WEST OF IRANIAN MULTIPLE MYELOMA PATIENT	18:00 - 18:00
	<i>Poster Presenter:</i> Mehrdad Payandeh (Iran)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Experimental Transplantation and Gene Therapy		
A121	PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS	18:00 - 18:00
	<i>Poster Presenter:</i> Alejandro Villar-Prados (United States)	
A122	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING DONOR CAR-T CELLS FOR R/R B-CELL LYMPHOMA AND R/R MULTIPLE MYELOMA FAILING CAR T-CELL THERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Rui Liu (China)	
A123	SMADCAM-1 IS DECREASED AFTER ALLOHCT, ALONG WITH GUT MICROBIOTA DYSBIOSIS, AND IS ASSOCIATED WITH HEMATOPOIETIC RECOVERY	18:00 - 18:00
	<i>Poster Presenter:</i> Karen Fadel (France)	
A124	PENTOSTATIN AND CYCLOPHOSPHAMIDE DECREASE GRAFT REJECTION BUT INCREASE TRANSPLANT-RELATED COMPLICATIONS IN HAPLOIDENTICAL HCT FOR SICKLE CELL DISEASES	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Matthew Hsieh (United States)	
A125	GRANULOCYTES TO INDUCE DONOR-DERIVED T CELL EXPANSION AFTER T REPLETE, MISMATCHED CB IN POST-TRANSPLANT RELAPSED AND REFRACTORY PAEDIATRIC ACUTE LEUKAEMIA: RESULTS OF GRANS TRIAL	18:00 - 18:00
	<i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)	
A126	GENOME EDITING OF LONG-TERM REPOPULATING HEMATOPOIETIC STEM CELLS USING CCR5-UCO-HETTALLEN	18:00 - 18:00
	<i>Poster Presenter:</i> Alexander Kulagin (Russian Federation)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Cellular Therapies other than CARs		
A106	HELP FOR UKRAINIAN HEMATOLOGY PATIENTS (HUP) - A GLOBAL INITIATIVE SUPPORTING THE ESTABLISHMENT OF HEMATOLOGY CENTERS AND HEMATOPOIETIC CELL TRANSPLANTATION PROGRAMS IN DIFFICULT SITUATIONS	18:00 - 18:00
	<i>Poster Presenter:</i> Irina Korenkova (Ukraine)	
A107	A RETROSPECTIVE ANALYSIS COMPARING ORCA-T TO POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT IN PATIENTS WITH MATCHED UNRELATED DONORS RECEIVING MYELOABLATIVE CONDITIONING	18:00 - 18:00
	<i>Poster Presenter:</i> Amandeep Salhotra (United States)	

A108	PHASE I/II STUDY ON INFUSION OF ALLOREACTIVE OR EX VIVO IL-15 STIMULATED NK CELLS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA <i>Poster Presenter:</i> Antonio Pérez Martínez (Spain)	18:00 - 18:00
A109	HARNESSING CIK CELL INTERVENTION FOR ACUTE LEUKEMIA OR MDS RELAPSE POST ALLO-HSCT <i>Poster Presenter:</i> Eva Rettinger (Germany)	18:00 - 18:00
A110	RISK FACTORS FOR THE DEVELOPMENT OF GRAFT-VERSUS-HOST-DISEASE FOLLOWING DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Cjm Halkes (Netherlands)	18:00 - 18:00
A111	DONOR-DERIVED CMV-SPECIFIC CYTOTOXIC T-CELLS FOR PREVENTION OF CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION; A RANDOMIZED CLINICAL TRIAL WITH A PARALLEL CONTROL GROUP <i>Poster Presenter:</i> Mohammad Vaezi (Iran)	18:00 - 18:00
A112	RELAPSE AFTER HSCT: MAY DLI/CIK CELLS STILL PLAY A ROLE IN THE CELLULAR THERAPY ERA? DLI/CIK AS A RESCUE STRATEGY FOR CHILDREN WITH POST-TRANSPLANT MRD-POSITIVITY <i>Poster Presenter:</i> Prof. Adriana Balduzzi (Italy)	18:00 - 18:00
A113	PHASE I/II PRELIMINARY RESULTS OF HUMAN PRO-T-CELLS MANUFACTURING IN VITRO TO ACCELERATE IMMUNE RECONSTITUTION AFTER UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULT PATIENT WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Jean-Sebastien Diana (France)	18:00 - 18:00
A114	INNATE DONOR EFFECTOR ALLOGENEIC LYMPHOCYTES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION - THE IDEAL TRIAL <i>Poster Presenter:</i> Lia Minculescu (Denmark)	18:00 - 18:00
A115	HLA EVOLUTIONARY DIVERGENCE : A NEW PREDICTIVE TOOL FOR DLI RESPONSE? <i>Poster Presenter:</i> Sophie Le Grand (France)	18:00 - 18:00
A116	CD45RA DEPLETION PRESERVES PROPORTIONS AND CLONAL BREATH OF VIRUS-SPECIFIC T CELLS <i>Poster Presenter:</i> Amandine Pradier (Switzerland)	18:00 - 18:00
A117	CIRCULAR MRNA-BASED TCR-T OFFERS A SAFE AND EFFECTIVE THERAPEUTIC STRATEGY FOR TREATMENT OF CYTOMEGALOVIRUS INFECTION <i>Poster Presenter:</i> Lianghua Shen (China)	18:00 - 18:00
A118	LAYING THE FOUNDATIONS FOR AN IMMUNOPOTENCY TEST FOR ALLOGENEIC MESENCHYMAL STROMAL CELLS <i>Poster Presenter:</i> María Esther Martínez-Muñoz (Spain)	18:00 - 18:00
A119	CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY IN COMMERCIALY AVAILABLE BISPECIFIC ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR T-CELLS IN MULTIPLE MYELOMA <i>Poster Presenter:</i> Eden Biltibo (United States)	18:00 - 18:00
A120	TRIAL IN PROGRESS: OBSERVATIONAL, POST-AUTHORISATION SAFETY STUDY TO DESCRIBE SAFETY AND EFFECTIVENESS OF TABELCLEUCEL IN PATIENTS WITH EBV+ PTLD IN A REAL-WORLD SETTING IN EUROPE <i>Poster Presenter:</i> Pavan Randhawa (United Kingdom)	18:00 - 18:00

Printed Poster

18:00 - 19:00

Hall 3 North

Poster Session in Hall 3*Printed Poster*

18:00 - 19:00

Hall 3 North

Haematopoietic Stem Cells

- A001 **THE IMPORTANCE OF CYTOGENETIC BONE MARROW TESTS IN POST-TRANSPLANT CARE OF PATIENTS AFTER ALLO-HSCT DUE TO ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME- A SINGLE-CENTER ANALYSIS** 18:00 - 18:00
Poster Presenter: Ewa Karakulska-Prystupniuk (Poland)
- A002 **INFECTION BY HUMAN HERPES VIRUS 6 IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE POST-TRANSPLANT CYCLOPHOSPHAMIDE ERA** 18:00 - 18:00
Poster Presenter: María Suárez-Lledó (Spain)
- A003 **SECOND HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AS RESCUE STRATEGY FOR HIGH RISK CHILDREN WITH LEUKEMIA** 18:00 - 18:00
Poster Presenter: Prof. Adriana Balduzzi (Italy)
- A004 **DISTINCT CLINICO-BIOLOGICAL FEATURES IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION** 18:00 - 18:00
Poster Presenter: Xiaolin Yuan (China)
- A005 **DIFFERENT SOURCES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH THALASSEMIA MAJOR: RELATIONSHIP BETWEEN IMMUNE RECONSTITUTION, GRAFT-VERSUS-HOST DISEASE, AND VIRAL INFECTIONS** 18:00 - 18:00
Poster Presenter: Jianyun Liao (China)
- A006 **COMBINATION OF POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH ANTITHYMOCYTE GLOBULIN AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A SINGLE CENTER ANALYSIS** 18:00 - 18:00
Poster Presenter: Chiara Bernardi (Switzerland)
- A007 **TRIPLE STEM CELL INFUSION ALLEVIATE GRAFT VERSUS HOST DISEASE AND IMPROVE OUTCOME IN UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION** 18:00 - 18:00
Poster Presenter: Guang-Cui He (China)
- A008 **HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION IN MULTI-REFRACTORY TESTICULAR GERM CELL CANCER: A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS** 18:00 - 18:00
Poster Presenter: Jose Sanchez Pina (Spain)
- A009 **KIR-MISMATCH IMPACTS THE OUTCOMES AFTER HLA-HAPLOIDENTICAL STEM-CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE** 18:00 - 18:00
Poster Presenter: Lucía López Corral (Spain)
- A010 **NOVEL AUTOMATIC APPLICATION FOR ENRICHMENT OF CD34+ CELLS FROM APHERESIS PRODUCTS USING THE CLINIMACS PRODIGY** 18:00 - 18:00
Poster Presenter: Julia Dzionek (Germany)
- A011 **UP-FRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA** 18:00 - 18:00

	PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST-LINE TREATMENT: A MULTICENTER REAL-WORLD ANALYSIS	
	<i>Poster Presenter:</i> Shuang Fan (China)	
A012	OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH WISKOTT-ALDRICH SYNDROME	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. Mary Slatter (United Kingdom)	
A013	GENE MUTATION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RECURRENCE OF HEMATOPOIETIC NEOPLASM PATIENTS AFTER TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Jia Liu (China)	
A014	STEM CELL TRANSPLANT ACTIVITY IN KYIV NATIONAL CANCER INSTITUTE IN THE CONDITIONS OF FULL-SCALE RUSSIAN AGGRESSION IN UKRAINE	18:00 - 18:00
	<i>Poster Presenter:</i> Nazar Shokun (Ukraine)	
A015	SAFETY AND EFFICACY OF POMALIDOMIDE AND AZACITIDINE COMBINATION IN MRD-GUIDED PREEMPTIVE TREATMENT OF ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Lu Wang (China)	
A016	HOME-BASED HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE AND SAFER IN TERMS OF NUTRITIONAL PARAMETERS, TOXICITY AND LENGTH OF HOSPITALIZATION STAY	18:00 - 18:00
	<i>Poster Presenter:</i> Laura Pardo Gambarte (Spain)	
A017	A RISK-ADAPTED STRATEGY TO SELECT AUTOLOGOUS OR ALLOGENEIC TRANSPLANT CONSOLIDATION IS EFFECTIVE IN MATURE T-CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Fabio Giglio (Italy)	
A018	EFFECTS OF THE PERIPHERAL EXPANSION OF CYTOTOXIC T LYMPHOCYTES ON OUTCOMES FOLLOWING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Oriana Jimena López Godino (Spain)	
A019	OUTCOME OF ALLO-HSCT IN THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER PREVIOUSLY TREATED WITH CHEMOTERAPY AND PARP INHIBITORS	18:00 - 18:00
	<i>Poster Presenter:</i> Fabio Giglio (Italy)	
A020	EFFECTS OF LOW-DOSE HYPOMETHYLATING AGENTS ON THE PREVENTION OF RELAPSE AFTER TRANSPLANTATION IN PEDIATRIC HIGH-RISK AML	18:00 - 18:00
	<i>Poster Presenter:</i> Shaoyan Hu (China)	
A021	OUTCOMES OF PEDIATRIC CHRONIC MYELOID LEUKEMIA IN ADVANCED PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH REDUCED-INTENSITY CONDITIONING REGIMEN	18:00 - 18:00
	<i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	
A022	UPDATE ON DONOR DERIVED NK CELLS INFUSION FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT IN PEDIATRIC HIGH-RISK AND RELAPSED/REFRACTORY LEUKEMIA	18:00 - 18:00
	<i>Poster Presenter:</i> Francesco Paolo Tambaro (Italy)	
A024	COMPARISONS OF SAFETY AND EFFICACY OF ALLO-HSCT AFTER CAR T-CELL OR CHEMOTHERAPY-BASED COMPLETE	18:00 - 18:00

	REMISSION IN PEDIATRIC T-ALL <i>Poster Presenter:</i> Ruijuan Sun (China)	
A025	OUTCOMES AFTER BONE MARROW VERSUS PERIPHERAL BLOOD MATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED PROPHYLAXIS <i>Poster Presenter:</i> Joe S. Al-Ramahi (United States)	18:00 - 18:00
A026	LOWER INCIDENCE OF CHRONIC GVHD WITH ATLG AS GVHD PROPHYLAXIS IN ALL PATIENTS IN FIRST COMPLETE REMISSION UNDERGOING ALLOGENEIC SCT COMPARED TO POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Normann Steiner (Germany)	18:00 - 18:00
A027	LONGITUDINAL FOLLOW-UP ON HUMORAL AND T CELL IMMUNE RESPONSES AFTER COVID-19 VACCINATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTED PATIENTS <i>Poster Presenter:</i> Alma Wegener (Denmark)	18:00 - 18:00
A028	HAPLOIDENTICAL DONOR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION USING THIRD-PARTY CORD BLOOD COMPARED WITH MATCHED UNRELATED DONOR TRANSPLANTATION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Yajing Xu (China)	18:00 - 18:00
A029	EFFECTIVENESS OF 2ND LINE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE ERA OF CAR-T THERAPY <i>Poster Presenter:</i> Youngwoo Jeon (Korea, Republic of)	18:00 - 18:00
A030	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS: A RETROSPECTIVE MULTICENTER STUDY IN CHINA <i>Poster Presenter:</i> Erlic Jiang (China)	18:00 - 18:00
A031	SAFETY AND EFFICACY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR MUD, MMUD AND HAPLOIDENTICAL STEM CELL TRANSPLANTS IN PAEDIATRIC POPULATION <i>Poster Presenter:</i> Gloria Miguel (Spain)	18:00 - 18:00
A032	EFFICACY AND SAFETY OF THROMBOPOIETIN RECEPTOR AGONIST COMBINED WITH MSCS FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lidan Zhu (China)	18:00 - 18:00
A033	A SINGLE CENTER REAL-WORLD RETROSPECTIVE COHORT STUDY ON THE PREVENTION OF CYTOMEGALOVIRUS INFECTION WITH LETERMOVIR AFTER HLA HAPLOID HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Huanfeng Liu (China)	18:00 - 18:00
A034	BEYOND BORDERS: HSCT'S GLOBAL SITUATIONS AND INDONESIA'S PURSUIT OF HEALTH EQUITY <i>Poster Presenter:</i> Daniel Rizky (Indonesia)	18:00 - 18:00
A035	EFFECTIVENESS OF THE SIMPLIFIED COMORBIDITY INDEX COMPARED TO THE HCT-CI AS A PREDICTOR OF TRANSPLANT RELATED MORTALITY AND OVERALL SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maria Alejandra Nunez Atahualpa (Mexico)	18:00 - 18:00
A036	8 VS 12 GRAY TBI IN ALLOGENEIC SCT FOR ALL PATIENTS RESULTS IN SIMILAR SURVIVAL, BUT IMPROVED SURVIVAL FOR	18:00 - 18:00

	MRD+ PATIENTS AFTER 12 GRAY	
	<i>Poster Presenter:</i> Normann Steiner (Germany)	
A037	PROPHYLACTIC USE OF DEFIBROTIDE IN HIGH-RISK RECIPIENTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE OVER 8 YEARS	18:00 - 18:00
	<i>Poster Presenter:</i> Giulia Baresi (Italy)	
A038	POST-TRANSPLANT MAINTENANCE THERAPY WITH AZACITIDINE FOR HIGH-RISK MYELOID MALIGNANCIES: WHO BENEFITS THE MOST?	18:00 - 18:00
	<i>Poster Presenter:</i> Xin Li (China)	
A039	PHYSICIAN PERSPECTIVES ON THE BURDEN AND CLINICAL MANAGEMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN TRANSPLANT RECIPIENTS IN CENTRAL AND EASTERN EUROPE	18:00 - 18:00
	<i>Poster Presenter:</i> Radovan Vrhovac (Croatia)	
A040	THE DOSES OF POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL STEM CELL ALLOGRAFTS CAN BE REDUCED	18:00 - 18:00
	<i>Poster Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	
A041	OUTCOMES WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY RELATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Moazzam Shahzad (United States)	
A042	OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THERAPY RELATED ACUTE MYELOID LEUKEMIA: MULTICENTER REAL-LIFE EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Costanza Fraenza (Italy)	
A043	OUTCOMES OF SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC DISEASES: A SINGLE-CENTER REAL-WORLD EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Marta Castelli (Italy)	
A044	PERSPECTIVES OF GENERAL HEMATOLOGISTS ON A PROPOSED SHARED CARE MODEL FOR HSCT IN SAUDI ARABIA FOR SICKLE CELL DISEASE	18:00 - 18:00
	<i>Poster Presenter:</i> Abdulrahman Alsultan (Saudi Arabia)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
CAR-based Cellular Therapy - Preclinical		
A063	CAR T CELLS TARGETING CD28 SHOW PRECLINICAL ACTIVITY AGAINST T-ALI	18:00 - 18:00
	<i>Poster Presenter:</i> Tobias Feuchtinger (Germany)	
A064	A REVERSIBLE SWITCH FOR CAR-T CELL BY GENETIC CODE EXPANSION SYSTEM	18:00 - 18:00
	<i>Poster Presenter:</i> Yue Liu (China)	
A065	SIRT3 REGULATES CAR-T CELL DIFFERENTIATION AND EXHAUSTION STATE	18:00 - 18:00
	<i>Poster Presenter:</i> Yue Huang (China)	
A066	HAMBURG REAL-WORLD EXPERIENCE WITH AXICABTAGENE CILOLEUCEL IN AGGRESSIVE B-CELL LYMPHOMA: IN-VIVO EXPANSION CORRELATES WITH TREATMENT OUTCOME	18:00 - 18:00
	<i>Poster Presenter:</i> Francis Ayuk (Germany)	
A067	CD45-DIRECTED CAR-T CELLS WITH CD45 KNOCKOUT	18:00 - 18:00

	EFFICIENTLY KILL MYELOID LEUKEMIA AND LYMPHOMA CELLS IN-VITRO EVEN AFTER EXTENDED CULTURE	
	<i>Poster Presenter:</i> Maraike Harfmann (Germany)	
A068	COMPARISON OF CD123- AND CD33-CAR-NK CELL PREPARATIONS IN A XENOGRAFT MOUSE MODEL FOR TREATMENT OF ACUTE MYELOID LEUKEMIA	18:00 - 18:00
	<i>Poster Presenter:</i> Fenja Gierschek (Germany)	
<i>Printed Poster</i>		
18:00 - 19:00		
Hall 3 North		
Nurses Posters - Research		
NP087	HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT	18:00 - 18:00
	<i>Poster Presenter:</i> Ammar Zahreddine (Lebanon)	
NP088	PATIENT'S OWN EXPERIENCES WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION, BEING CARED FOR AT HOME OR NOT. THAT'S THE QUESTION? BUT WHAT IS THE ANSWER?	18:00 - 18:00
	<i>Poster Presenter:</i> Ann Karin Svanberg (Sweden)	
NP095	THE ROLE OF A SPECIALIST SOCIAL WORKER IN TRANSPLANT: A SERVICE AUDIT	18:00 - 18:00
	<i>Poster Presenter:</i> Rachel Davidson (United Kingdom)	
<i>Printed Poster</i>		
18:00 - 19:00		
Hall 3 North		
Stem Cell Mobilization, Collection and Engineering		
A045	THE EFFECT OF GRAFT MANIPULATION AND CRYOPRESERVATION ON DIFFERENT GRAFT COMPONENT AND ITS POTENTIAL CLINICAL APPLICATIONS	18:00 - 18:00
	<i>Poster Presenter:</i> Mohammed Kawari (Canada)	
A046	A SIMPLE PREDICTIVE ALGORITHM FOR ESTIMATION OF THE BLOOD VOLUME TO BE PROCESSED TO YIELD TARGET CELL NUMBERS FOR MANUFACTURING OF TISA-CEL® AND AXI-CEL®	18:00 - 18:00
	<i>Poster Presenter:</i> Stephanie Winter (Austria)	
A047	REAL-WORLD MOBILIZATION AND HARVEST OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING D-VTD: UK EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Jose Aspa Cilleruelo (United Kingdom)	
A048	FACTORS AFFECTING CD34+ CRUDE COLLECTION EFFICIENCY IN MOBILIZED DONORS UNDERGOING LEUKOCYTAPHERESIS	18:00 - 18:00
	<i>Poster Presenter:</i> Jesús Fernandez (Spain)	
A049	EFFICACY OF PROPHYLACTIC ANTIBIOTICS FOR THE PREVENTION OF NEUTROPENIC FEVER IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE FOR STEM CELL MOBILIZATION	18:00 - 18:00
	<i>Poster Presenter:</i> Juan Li (China)	
A050	EFFICACY OF PLERIXAFOR IN CD34⁺ STEM CELL MOBILIZATION IN HEALTHY PEDIATRIC STEM CELL DONORS	18:00 - 18:00
	<i>Poster Presenter:</i> Vimal Kumar Gunasekaran (India)	
A051	PEGFILGRASTIM FOR STEM CELL MOBILIZATION FOLLOWED BY FRESH STEM CELL INFUSION IN MULTIPLE MYELOMA	18:00 - 18:00
	<i>Poster Presenter:</i> Hegta Tainá Rodrigues Figueiroa (Brazil)	
A052	IMPROVING AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES	18:00 - 18:00

	IN PERIPHERAL T CELL LYMPHOMA : A STUDY ON CD34+ CELL EX VIVO PURGING	
	<i>Poster Presenter:</i> Youngwoo Jeon (Korea, Republic of)	
A053	A MID-APHERESIS CD34 COUNT UTILITY IN EARLY STOPPAGE OF APHERESIS IN PATIENTS/DONORS IN A PBSCT PROCEDURE - ANALYSIS OF EXPERIENCE IN TWO SOUTH INDIAN CANCER CENTRES	18:00 - 18:00
	<i>Poster Presenter:</i> Veni Prasanna Gedala (India)	
A054	PLERIXAFOR AS A MOBILIZING AGENT FOR SALVAGE HIGH-DOSE CHEMOTHERAPY IN RELAPSED/REFRACTORY TESTICULAR CANCER: AN EXPERIENCE OF 22 CASES	18:00 - 18:00
	<i>Poster Presenter:</i> Ugo De Giorgi (Italy)	
A055	ASSESSING AND REFINING PREDICTIVE MODELS OF POTENTIAL POOR MOBILIZERS	18:00 - 18:00
	<i>Poster Presenter:</i> Kai Wan (United Kingdom)	
A056	LEFT OUT IN THE COLD: STEM CELL GRAFTS ARE STILL FUNCTIONAL AFTER MORE THAN 20 YEARS IN CRYOSTORAGE	18:00 - 18:00
	<i>Poster Presenter:</i> Rebecca Axelsson Robertson (Sweden)	
A057	SAFETY AND EFFICACY OF PLERIXAFOR IN POOR MOBILIZERS: AN INTERIM ANALYSIS AND MULTICENTER PROSPECTIVE STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Jie Ji (China)	
A058	BONE MARROW HARVESTING IN ALLOGENEIC DONORS: HOW TO PREDICT SUCCESSFUL AND SATISFYING BM PRODUCT	18:00 - 18:00
	<i>Poster Presenter:</i> Tigran Torosian (Poland)	
A059	COMPARISON OF MOBILIZATION REGIMENS USED IN LYMPHOMA AND FACTORS THAT INFLUENCE PERIPHERAL BLOOD STEM CELL MOBILIZATION	18:00 - 18:00
	<i>Poster Presenter:</i> Laxma Reddy (India)	
A060	THIRTEEN-YEAR EXPERIENCE WITH PLERIXAFOR IN CHILDREN FROM A SINGLE CENTRE: TOLERABILITY, GRAFT QUALITY AND ENGRAFTMENT	18:00 - 18:00
	<i>Poster Presenter:</i> Kamélia Alexandrova (France)	
A061	AN ALTERNATIVE USE OF A COLLOIDAL SUBSTITUTE (SUCCINYLATED GELATINE) FOR QUALITY CONTROLS IN PERIPHERAL BLOOD STEM TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Claudia Del Fante (Italy)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Chronic Leukaemia and Other Myeloproliferative Disorders		
A278	IMPROVING OUTCOMES IN MDS/MPN: TREOSULFAN-BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Lorenzo Lazzari (Italy)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Nurses Posters - Adult		
NP001	GVHD PATIENT SUPPORT GROUP	18:00 - 18:00
	<i>Poster Presenter:</i> Ms. Deborah Anderson (United Kingdom)	
NP002	NURSING ROLE IN IMPLEMENTING EHEALTH FOR ALLOGENEIC	18:00 - 18:00

	STEM CELL TRANSPLANT RECIPIENTS: INITIAL FINDINGS FROM THE MYMEDULA STUDY'S RANDOMIZED CLINICAL TRIAL	
	<i>Poster Presenter:</i> Irene García-Cadenas (Spain)	
NP003	NURSE LED PERSONALISED CARE AND SUPPORT PLANNING FOR PATIENTS PREPARING FOR ALLOGENEIC BLOOD AND MARROW TRANSPLANT AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY - PATIENT CO-DESIGN	18:00 - 18:00
	<i>Poster Presenter:</i> Polly Pattenden (United Kingdom)	
NP004	TEACH-BACK METHOD IN ONCO-HEMATOLOGICAL PATIENTS' EDUCATION: A SCOPING REVIEW	18:00 - 18:00
	<i>Poster Presenter:</i> Silvia Gnechi (Italy)	
NP006	NUTRITIONAL IMPLICATIONS OF CAR-T THERAPY IN SCOTLAND	18:00 - 18:00
	<i>Poster Presenter:</i> Abigail Dean (United Kingdom)	
NP007	SETTING UP A PATIENT INITIATED FOLLOW-UP (PIFU) PROGRAMME FOR THE LONG TERM FOLLOW UP OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS- THE WESSEX BMTCT EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Jenna Sloan (United Kingdom)	
NP008	EVALUATING COGNITIVE IMPAIRMENT AND NEUROTOXICITY POST CAR T CELL THERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Eleni Gavriilaki (Greece)	
NP009	THE SAFE DELIVERY OF A 'BLOODLESS' AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA - PUTTING THE PATIENT'S WISHES AT THE FOREFRONT OF TRANSPLANT DELIVERY	18:00 - 18:00
	<i>Poster Presenter:</i> Emma Storey (United Kingdom)	
NP013	ENHANCING WARD-BASED NURSING TEACHING IN A BONE MARROW TRANSPLANT UNIT: EVALUATING THE IMPACT OF AN INDUCTION PACK FOR NEW NURSING STAFF. PILOT STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Krzysztof Dariusz Ciesielski (United Kingdom)	
NP014	A RETROSPECTIVE AUDIT OF LENGTH OF STAY AND PATIENT EXPERIENCE WITHIN A UK AMBULATORY CARE DEPARTMENT, TO DEMONSTRATE THE EFFECTIVENESS OF THIS MODEL WITHIN HSCT	18:00 - 18:00
	<i>Poster Presenter:</i> Preya Assi (United Kingdom)	
NP015	HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN OUTPATIENT SETTING: A SINGLE CENTER EXPERIENCE IN SAUDI ARABIA	18:00 - 18:00
	<i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	
NP016	"MASTERS OF SEX": INCREASING AWARENESS OF AND KNOWLEDGE ABOUT SEXUAL HEALTH OF HSCT PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Limor Mintz-Manor (Israel)	
NP017	PATIENTS' PSYCHOLOGICAL DISTRESS PRE HSCT AND CAR-T: FINDINGS FROM TWO YEARS' ROUTINE PRE-TREATMENT PSYCHOLOGICAL ASSESSMENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Ms. Surabhi Chaturvedi (United Kingdom)	
NP018	DEVELOPING AN INDUCTION PROGRAMME FOR NEWLY QUALIFIED NURSES ON A SPECIALIST HAEMATOLOGY AND TRANSPLANT UNIT	18:00 - 18:00
	<i>Poster Presenter:</i> Annie Hamilton (United Kingdom)	
NP020	IMPLEMENTATION OF A HOSPITAL- AT- HOME PROGRAM FOR AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION: SAFETY AND PATIENT-PERCEIVED SATISFACTION	18:00 - 18:00

	<i>Poster Presenter:</i> Estefanía Pérez-Lopez (Spain)	
NP022	CURRENT EXPERIENCES AND SPECIFIC PSYCHOSOCIAL SUPPORT NEEDS OF RELATED STEM CELL DONORS: A QUALITATIVE STUDY <i>Poster Presenter:</i> Fran Willemsens (Belgium)	18:00 - 18:00
NP023	THE AMBULATORY AUTOLOGOUS STEM CELL TRANSPLANT PROGRAMME FOR MULTIPLE MYELOMA; A SERVICE EVALUATION <i>Poster Presenter:</i> Ethan Brough (United Kingdom)	18:00 - 18:00
NP026	GREATIX - QUALITY IMPROVEMENT BY SHARING SUCCESS / BEST PRACTICE <i>Poster Presenter:</i> Aidan MacDonald (United Kingdom)	18:00 - 18:00
NP028	REDUCED HSCT PATIENTS' ER VISITS BY ASSIGNED 2 BEDS IN HSCT UNIT AS QUICK ER ACCESS , SINGLE CENTER IN SAUDI ARABIA <i>Poster Presenter:</i> Suha Alkhraisat (Saudi Arabia)	18:00 - 18:00
NP031	HSCT CAREGIVER ANXIETY AND DEPRESSION ASSOCIATIONS WITH QUALITY OF LIFE AND REACTION TO CARE. A LONGITUDINAL STUDY <i>Poster Presenter:</i> Arianna Rosich-Soteras (Spain)	18:00 - 18:00
NP032	NURSE LED CAR T CELL THERAPY LONG TERM EFFECTS CLINIC <i>Poster Presenter:</i> Katie Brice (United Kingdom)	18:00 - 18:00
NP033	COMMENCING LOPERAMIDE FOR DIARRHOEA PRIOR TO NEGATIVE CULTURE RESULT AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IS SAFE AND EFFECTIVE <i>Poster Presenter:</i> Amy Colada (United Kingdom)	18:00 - 18:00
NP034	"ANALYSIS OF NUTRITIONAL STATUS AND HOSPITALIZATION DURATION IN ALLOGENEIC TRANSPLANTED PATIENTS IN CROATIA: NURSING INSIGHTS OVER THE PAST 2 YEARS <i>Poster Presenter:</i> Valentina Milinković (Croatia)	18:00 - 18:00
NP035	ADHERENCE TO ORAL IMMUNOSUPPRESSORS USING THE THERAPEUTIC DRUG MONITORING: A RETROSPECTIVE STUDY <i>Poster Presenter:</i> Chiara Visintini (Italy)	18:00 - 18:00
NP041	THE FIRST CAR-T NURSING PRECEPTORSHIP PROGRAM IN THE KINGDOM OF SAUDI ARABIA <i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	18:00 - 18:00
NP049	HAS AN INCREASE IN CAR-T ACTIVITY MEANT A DELAY IN AUTOLOGOUS TRANSPLANT ADMISSIONS DUE TO CAPACITY AND ACUITY CONCERN? <i>Poster Presenter:</i> Ally Braden (United Kingdom)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Nurses Posters - Paediatric		
NP062	A NO-NONSENSE EDUCATIONAL RESOURCE FOR NO-NONSENSE PAEDIATRIC HSCT NURSES <i>Poster Presenter:</i> Andrew Gooding (United Kingdom)	18:00 - 18:00
NP063	ASSESSMENT OF PEDIATRIC EARLY WARNING SCORES IN STEM CELL TRANSPLANT PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW AND FOR PREDICTING CLINICAL DETERIORATION <i>Poster Presenter:</i> Matilde Gabrieli (Italy)	18:00 - 18:00

NP064	PAEDIATRIC SIBLING STEM CELL DONORS - ESTABLISHING A NURSE LED CLINIC <i>Poster Presenter:</i> Annette Hill (United Kingdom)	18:00 - 18:00
NP065	IMPACT OF THE NURSE-DESIGNED PROTOCOL ON CENTRAL VENOUS CATHETER-RELATED COMPLICATIONS IN PEDIATRIC HEMATO-ONCOLOGICAL PATIENTS: ONE PEDIATRIC FACILITY'S TEN-YEAR EXPERIENCE <i>Poster Presenter:</i> Stefania Braidotti (Italy)	18:00 - 18:00
NP066	REDUCING THE LENGTH OF STAY FOR PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BY PERFORMING PRE-HSCT WORKUP IN AN OUTPATIENT SETTING <i>Poster Presenter:</i> Noha Alneedy (Saudi Arabia)	18:00 - 18:00
NP067	OPTIMIZING COLLABORATION BETWEEN PATIENTS, CAREGIVERS, AND NURSES THROUGH NURSING MENTORSHIP IN PEDIATRIC HSCT <i>Poster Presenter:</i> Anouk Plug (Netherlands)	18:00 - 18:00
NP068	ASSESSING COPING STRATEGIES OF PARENTS WHOSE CHILDREN UNDERWENT HSCT <i>Poster Presenter:</i> Rosaria Pinto (India)	18:00 - 18:00
NP069	EVALUATING THE USE OF PARENTERAL NUTRITION IN PAEDIATRIC PATIENTS UNDERGOING A HAEMOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Chloe Elliott (United Kingdom)	18:00 - 18:00
NP071	DEVELOPMENT OF INDEPENDENT NURSE LED CLINIC <i>Poster Presenter:</i> Petra Brevdo (Finland)	18:00 - 18:00
NP072	WHAT ARE THE CHARACTERISTIC OF PAEDIATRIC PATIENTS WHO REQUIRE NUTRITIONAL SUPPORT DURING ALLOGENIC HSCT? <i>Poster Presenter:</i> Laura McIntyre (United Kingdom)	18:00 - 18:00
NP073	THE GOOD, THE BAD AND THE UGLY - NURSING STRATEGIES BASED ON DONOR SOURCE FOR CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSAEMIA MAJOR <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	18:00 - 18:00
NP079	ASSESSMENT BY CAREGIVERS OF THE PRE-HSCT INTERVIEW <i>Poster Presenter:</i> Juana Membrado (Spain)	18:00 - 18:00

Printed Poster
18:00 - 19:00

Hall 3 North

Haemoglobinopathy

A265	OUTCOME OF HSCT IN BETA THALASSEMIA MAJOR. EXPERIENCE FROM A LOW- AND MIDDLE-INCOME COUNTRY <i>Poster Presenter:</i> Hashim Khan (Pakistan)	18:00 - 18:00
A266	TREOSULFAN-BASED HAPLOIDENTICAL T CELL DEPLETED HSCT FOR ADOLESCENTS AND YOUNG ADULTS (AYA) WITH ADVANCED STAGE SICKLE CELL DISEASE AND THALASSEMIA <i>Poster Presenter:</i> Anja Troeger (Germany)	18:00 - 18:00
A267	IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH SEVERE SICKLE CELL DISEASE <i>Poster Presenter:</i> Nanxin Li (United States)	18:00 - 18:00
A268	COMPARISON OF THE UNRELATED TRANSPLANTATION RESULTS	18:00 - 18:00

	OF AN HLA FULLY MATCHED DONOR AND A HOMOZYGOUS MM DONOR AT ONE LOCUS IN PATIENTS WITH BETA THALASSEMIA	
	<i>Poster Presenter:</i> Koray Yalçın (Turkey)	
A269	CLINICAL OUTCOMES AND HEALTHCARE RESOURCE USE IN PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES WHO RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTS IN FRANCE	18:00 - 18:00
	<i>Poster Presenter:</i> Jessica Baldwin (United States)	
A270	SINGLE-CENTER EXPERIENCE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH SEVERE SICKLE CELL DISEASE	18:00 - 18:00
	<i>Poster Presenter:</i> Miriam P. Klahr (United States)	
A271	HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN A LOW RESOURCE COUNTRY NIGERIA. A 10 YEARS REPORT FROM A SINGLE CENTER	18:00 - 18:00
	<i>Poster Presenter:</i> Nosakahare Bazuaye (Nigeria)	
A272	IMPACT OF THE FIRST ONLINE WEBINAR OF THE WBMT NURSING GROUP IN COLLABORATION WITH THE LAGOS UNIVERSITY TEACHING HOSPITAL AND SICKLE CELL FOUNDATION OF NIGERIA	18:00 - 18:00
	<i>Poster Presenter:</i> Adetola Kassim (United States)	
<i>Printed Poster</i>		
18:00 - 19:00		
Hall 3 North		
Myeloproliferative Neoplasm		
A261	TCRALPHABETA/CD19 DEPLETED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH POST-TRANSPLANT RUXOLITINIB FOR MYELOFIBROSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Moniek de Witte (Netherlands)	
A262	MINIMAL RESIDUAL DISEASE MONITORING OF DRIVER MUTATION BY DIGITAL DROPLET PCR IS PREDICTIVE OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Maria Chiara Finazzi (Italy)	
A263	EVALUATION AND IMPLICATIONS OF PORTAL AND PULMONARY HYPERTENSION IN MYELOFIBROSIS PRIOR TO TRANSPLANT: A PRACTICE-BASED SURVEY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT	18:00 - 18:00
	<i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	
A264	IMPACT OF NUMBER OF CD34+ CELLS INFUSED ON OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Filippo Frioni (Italy)	
<i>Printed Poster</i>		
18:00 - 19:00		
Hall 3 North		
Aplastic Anaemia		
A253	EFFICACY AND SAFETY IS MAINTAINED IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA RECEIVING PEGCETACOPLAN FOR UP TO 3 YEARS	18:00 - 18:00
	<i>Poster Presenter:</i> Regina Horneff (Sweden)	
A254	MOVING TOWARD INDIVIDUAL TREATMENT GOALS WITH PEGCETACOPLAN IN PATIENTS WITH PNH AND BONE MARROW FAILURE	18:00 - 18:00

	<i>Poster Presenter:</i> Regina Horneff (Sweden)	
A255	RESULTS OF HSCT WITH TCRAB AND CD19-DEPLETION FROM MATCHED RELATED DONORS AND INFUSIONS OF CD45RA DEPLETED DONOR LYMPHOCYTES IN PEDIATRIC SEVERE APLASTIC ANEMIA <i>Poster Presenter:</i> Dmitriy Pershin (Russian Federation)	18:00 - 18:00
A256	TREATMENT OUTCOME OF HSCT IN FANCONI ANAEMIA. EXPERIENCE FROM LOW AND MIDDLE INCOME COUNTRY <i>Poster Presenter:</i> Hashim Khan (Pakistan)	18:00 - 18:00
A257	EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA PATIENTS WITH A HISTORY OF APLASTIC ANAEMIA IN PEGASUS AND PRINCE CLINICAL TRIALS <i>Poster Presenter:</i> Regina Horneff (Sweden)	18:00 - 18:00
A258	MITOCHONDRIAL METABOLISM IN FANCONI ANEMIA PATIENTS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Maura Faraci (Italy)	18:00 - 18:00
A259	ATLG HAS BETTER SAFETY THAN RATG IN THE TREATMENT OF ADULT AA WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Zhang Jianping (China)	18:00 - 18:00
A260	TREATMENT WITH DARATUMUMAB IN 4 PATIENTS WITH IMMUNE ANEMIA AFTER HSCT WITH ABO INCOMPATIBILITY OR OTHER IMMUNE-ERYTHROCYTE DISCREPANCIES <i>Poster Presenter:</i> Candela Ceballos Bolaños (Spain)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Non-infectious Late Effects, Quality of Life and Fertility		
A238	ECULIZUMAB TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	18:00 - 18:00
A239	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS OLDER THAN 70 YEARS WITH HEMATOLOGIC DISEASES: A 10-YEAR RETROSPECTIVE SINGLE CENTER ANALYSIS <i>Poster Presenter:</i> Simona Sestili (France)	18:00 - 18:00
A240	IMMUNE THROMBOCYTOPENIA FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT : RESULTS FROM A FRENCH MULTICENTRIC RETROSPECTIVE STUDY OF 35 CASES <i>Poster Presenter:</i> Antoine Gondé (France)	18:00 - 18:00
A241	AT-HOME AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT FOR ADULTS WITH HEMATOLOGICAL MALIGNANCIES. HOW FRAILTY SYNDROME IMPACTS AND EVOLVES DURING HCT PROCEDURE <i>Poster Presenter:</i> Juan Ortiz (Spain)	18:00 - 18:00
A242	POST ALLOGENIC BONE MARROW TRANSPLANT PURE RED CELL APLASIA: A NON-FATAL COMPLICATION WHERE NO INTERVENTION IS THE BEST INTERVENTION <i>Poster Presenter:</i> Isha Gambhir (India)	18:00 - 18:00
A243	FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-TC)	18:00 - 18:00

	<i>Poster Presenter:</i> Maria Queralt Salas (Spain)	
A244	LATE EFFECTS AFTER PEDIATRIC ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Mónica López Duarte (Spain)	18:00 - 18:00
A245	OUTCOMES AND RISK FACTORS FOR SURVIVAL OF LUNG TRANSPLANTATION AFTER PRIOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Dr. Juan Montoro Gómez (Spain)	18:00 - 18:00
A246	DEPRESSION IN SURVIVORS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION COMPARED WITH A MATCHED GENERAL POPULATION COMPARISON SAMPLE: THE MOSA STUDY <i>Poster Presenter:</i> Bianca Wauben (Netherlands)	18:00 - 18:00
A247	PREGNANCY OUTCOMES IN WOMEN FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT FOR HAEMATOLOGICAL CONDITIONS <i>Poster Presenter:</i> Panagiotis Kottaridis (United Kingdom)	18:00 - 18:00
A248	SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR SOLID ORGAN MALIGNANCIES AFTER ALLOGENEIC HSCT: A RETROSPECTIVE, MULTICENTRIC STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter:</i> Dr. Jan Brijs (Belgium)	18:00 - 18:00
A249	POST-TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH REDUCED RATE OF SECONDARY MALIGNANCIES POST ALLOGENEIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Dr. Nihar Desai (Canada)	18:00 - 18:00
A250	MOBILE HEALTH IN THE MANAGEMENT OF ALLOGENIC STEM CELL TRANSPLANT RECIPIENTS (MY-MEDULA STUDY): PRELIMINARY RESULTS OF THE CLINICAL TRIAL <i>Poster Presenter:</i> Sara Redondo (Spain)	18:00 - 18:00
A251	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS FROM AREAS OF CONFLICT: THE KING HUSSEIN CANCER CENTER TRANSPLANTATION PROGRAM EXPERIENCE <i>Poster Presenter:</i> Dr. Salwa Saadeh (Jordan)	18:00 - 18:00
A252	RITUXIMAB RESPONSIVE CYTOPENIA FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Joanita Kintu (United Kingdom)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Infectious Complications		
A147	BREAKTHROUGH INVASIVE FUNGAL DISEASE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: A MULTICENTER EPIDEMIOLOGICAL STUDY (CAESAR 2.0) <i>Poster Presenter:</i> Yuqian Sun (China)	18:00 - 18:00
A148	CHANGES IN THE EPIDEMIOLOGY OF INVASIVE FUNGAL DISEASES IN HSCT OVER ALMOST A QUARTER OF A CENTURY <i>Poster Presenter:</i> Marina Popova (Russian Federation)	18:00 - 18:00
A149	OUTCOMES FROM BRONCHOSCOPY AND BRONCHOALVEOLAR LAVAGE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Colin Hayes (United States)	18:00 - 18:00

A150	LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS INFECTION IS THE POTENTIAL RISK OF EBV-POSITIVE POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER HAPLOIDENTICAL STEM-CELL TRANSPLANTATION <i>Poster Presenter:</i> Xuying Pei (China)	18:00 - 18:00
A151	DIAGNOSIS OF MUCORMYCOSIS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING METAGENOMIC NEXT-GENERATION SEQUENCING: A SINGLE-CENTER CLINICAL STUDY <i>Poster Presenter:</i> Fang Xu (China)	18:00 - 18:00
A152	MARIBAVIR USE FOR REFRACTORY CMV INFECTION/DISEASE: THE RESULTS FROM THE FRENCH COMPASSIONATE PROGRAMME <i>Poster Presenter:</i> Catherine Cordonnier (France)	18:00 - 18:00
A153	COMPREHENSIVE SCREENING AND SENSITIVITY-GUIDED TREATMENT SIGNIFICANTLY REDUCES THIRTY-DAY MORTALITY OF METALLO-B-LACTAMASES PRODUCING ENTEROBACTERIALES (MBL-E) INFECTION FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM A PROSPECTIVE STUDY <i>Poster Presenter:</i> Yuqian Sun (China)	18:00 - 18:00
A154	PENTAGLOBIN® AS EARLY ADJUVANT TREATMENT FOR FEBRILE NEUTROPENIA IN HEMATOLOGICAL PATIENTS COLONIZED BY CARBAPENEM-RESISTANT ENTEROBACTERIACEAE OR PSEUDOMONAS AERUGINOSA: INTERIM ANALYSIS OF GITMO STUDY "PENTALLO" <i>Poster Presenter:</i> Daniela Clerici (Italy)	18:00 - 18:00
A155	MUCOSITIS-ASSOCIATED BLOODSTREAM INFECTIONS IN HAEMATOLOGY PATIENTS WITH FEVER DURING NEUTROPENIA <i>Poster Presenter:</i> Nick de Jonge (Netherlands)	18:00 - 18:00
A156	DESCRIPTIVE ANALYSES OF PULMONARY FUNCTION CHANGES BEFORE AND AFTER COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS. AN INFECTIOUS DISEASE WORKING PARTY STUDY <i>Poster Presenter:</i> Dr. José Luis Piñana Sanchez (Spain)	18:00 - 18:00
A157	EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE LETERMОВIR ERA <i>Poster Presenter:</i> Xiaoxia Hu (China)	18:00 - 18:00
A158	PATTERN OF SENSITIVITY OF STOOL SURVEILLANCE OVER 13 YEARS AND IMPACT OF STOOL SURVEILLANCE GUIDED SELECTION OF ANTIBIOTIC IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS <i>Poster Presenter:</i> Laxma Reddy (India)	18:00 - 18:00
A159	INVESTIGATIONAL MICROBIOME THERAPEUTIC SER-155: PRELIMINARY RESULTS FROM AN ON-GOING PHASE 1B STUDY IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) <i>Poster Presenter:</i> Swarna Pandian (United States)	18:00 - 18:00
A160	EBV REACTIVATION AND POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE ERA OF LETERMОВIR FOR CMV PROPHYLAXIS: A RETROSPECTIVE COHORT STUDY <i>Poster Presenter:</i> Sisi Zhen (China)	18:00 - 18:00
A161	CYTOMEGALOVIRUS (CMV) LOAD PREDICTS CMV DISEASE AND MORTALITY INDEPENDENT OF POSTTRANSPLANT IMMUNOSUPPRESSION AFTER HEMATOPOIETIC CELL	18:00 - 18:00

TRANSPLANTATION (HCT)*Poster Presenter:* Alicja Sadowska-Klasa (United States)

- | | | |
|------|---|---------------|
| A162 | ADENOVIRUS INFECTION IN ADULT ALLOGENEIC TRANSPLANT RECIPIENTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
<i>Poster Presenter:</i> Maria Chiara Quattrocchi (Italy) | 18:00 - 18:00 |
| A163 | NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS AMONG HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A MULTICENTER EUROPEAN CASE-CONTROL STUDY BY THE INFECTIOUS DISEASES WORKING PARTY OF EBMT
<i>Poster Presenter:</i> Maria Stamouli (Greece) | 18:00 - 18:00 |
| A164 | BACTEREMIA IN THE FIRST +100 DAYS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: MICROORGANISMS, RESISTANCE AND PROGNOSTIC IMPACT
<i>Poster Presenter:</i> Maria Huguet (Spain) | 18:00 - 18:00 |
| A165 | ISAVUCONAZOLE THERAPEUTIC DRUG MONITORING-DRIVEN TREATMENT IN A COHORT OF PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
<i>Poster Presenter:</i> Carmen Dolores De Luca (Italy) | 18:00 - 18:00 |
| A166 | THINK TO CHECK PREVIOUS SEROLOGIES WHEN CMV OR TOXOPLASMA SEROLOGIES ARE NEGATIVE AT TRANSPLANT
<i>Poster Presenter:</i> Christine Robin (France) | 18:00 - 18:00 |
| A167 | IMMUNE POPULATIONS PREDICT CONTROL OF CMV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Poster Presenter:</i> Paula Díaz-Fernández (Spain) | 18:00 - 18:00 |
| A168 | NEW ANTIMICROBIAL STEWARDSHIP PROGRAM TOOL TO REDUCE THE EMPIRICAL ANTIBACTERIAL THERAPY IN HAPLO-HSCT
<i>Poster Presenter:</i> Marina Popova (Russian Federation) | 18:00 - 18:00 |
| A169 | LETERMOVIR IS SAFE AND EFFECTIVE FOR TREATMENT AND PREVENTION OF CMV REACTIVATION IN PAEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT
<i>Poster Presenter:</i> Nathanael Lucas (United Kingdom) | 18:00 - 18:00 |
| A170 | DUAL METAGENOMICS NEXT-GENERATION SEQUENCING FOR FIRST-LINE DIAGNOSIS OF BLOODSTREAM INFECTION IN HEMATOLOGIC PATIENTS WITH FEBRILE NEUTROPENIA: A MULTICENTER PROSPECTIVE STUDY
<i>Poster Presenter:</i> Yuqian Sun (China) | 18:00 - 18:00 |
| A171 | CYTOMEGALOVIRUS-SPECIFIC T CELL IMMUNITY RECONSTITUTION AFTER LETERMOVIR WITHDRAWAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
<i>Poster Presenter:</i> Xiaoxia Hu (China) | 18:00 - 18:00 |
| A172 | CMV REACTIVATION AND ITS IMPACT ON SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN LETERMOVIR ERA - A SINGLE CENTRE STUDY
<i>Poster Presenter:</i> Lana Desnica (Croatia) | 18:00 - 18:00 |
| A173 | IMPACT OF QUANTIFERON-CMV (QNF-CMV) ON LATE ONSET CLINICALLY SIGNIFICANT CMV INFECTION (CSCMVI) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
<i>Poster Presenter:</i> Chiara Maria Dellacasa (Italy) | 18:00 - 18:00 |

A174	THERAPEUTIC DRUG MONITORING (TDM) OF PIPERACILLIN IN PATIENTS WITH NEUTROPENIC FEVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Güzin Surat (Germany)	18:00 - 18:00
A175	ESTABLISHING EBV LOAD THRESHOLDS FOR PREDICTING PERSISTING EBV-DNAEMIA AND ASSOCIATED DISEASE IN HAEMATOPOIETIC CELL TRANSPLANT RECIPIENTS <i>Poster Presenter:</i> Svenia Schmid (Switzerland)	18:00 - 18:00
A176	CLINICAL OUTCOMES OF STRONGYLOIDIASIS IN HEMATOPOIETIC CELL TRANSPLANT (HCT) RECIPIENTS <i>Poster Presenter:</i> Avneet Kaur (United States)	18:00 - 18:00
A177	MONITORING OF CMV-SPECIFIC CELL-MEDIATED IMMUNITY - PROGNOSTIC FACTORS AND CLINICAL VALUE <i>Poster Presenter:</i> Jonas Wißkirchen (Germany)	18:00 - 18:00
A178	USE OF LETERMOVIR IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS UNDER AGE OF 12: A RETROSPECTIVE MULTI-CENTRE STUDY ON BEHALF OF THE IEWP AND PDWP <i>Poster Presenter:</i> Dr. Katharina Kleinschmidt (Germany)	18:00 - 18:00
A179	CONVENTIONAL VERSUS NGS-BASED PATHOGEN DIAGNOSTICS IN FEBRILE ALLOGENEIC STEM CELL TRANSPLANT PATIENTS - A PROSPECTIVE SINGLE-CENTRE STUDY <i>Poster Presenter:</i> Sophie Weil (Germany)	18:00 - 18:00
A180	MUCORMYCOSIS IN TRANSPLANTED OR NON-TRANSPLANTED HEMATOLOGIC PATIENTS <i>Poster Presenter:</i> Jieru Wang (China)	18:00 - 18:00
A181	MULTINATIONAL STUDY ASSESSING TREATMENT PATTERNS, OUTCOMES, AND HEALTHCARE RESOURCE UTILIZATION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS INFECTION AND INTOLERANCE TO ANTI-CYTOMEGALOVIRUS THERAPIES <i>Poster Presenter:</i> María Laura Fox (United States)	18:00 - 18:00
A182	EFFICACY OF LETERMOVIR IN PREVENTING CYTOMEGALOVIRUS REACTIVATION AFTER CORD BLOOD TRANSPLANTATION <i>Poster Presenter:</i> Naoki Okada (Japan)	18:00 - 18:00
A183	SARS-COV-2 CYCLE THRESHOLD LEVELS AND COVID-19 OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION. AN INFECTIOUS DISEASE WORKING PARTY STUDY <i>Poster Presenter:</i> Dr. José Luis Piñana Sanchez (Spain)	18:00 - 18:00
A184	SINGLE-DAY TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS FOR PNEUMOCYSTIS PNEUMONIAE AND TOXOPLASMOSES INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PEDIATRIC PATIENTS <i>Poster Presenter:</i> Maria Speranza Massei (Italy)	18:00 - 18:00
A185	AN INTERIM ANALYSIS OF FOVOICIP: A MULTICENTER RANDOMIZED TRIAL OF FOSFOMYCIN VERSUS CIPROFLOXACIN FOR FEBRILE NEUTROPENIA PREVENTION IN HEMATOLOGIC PATIENTS <i>Poster Presenter:</i> Teresa Bernal (Spain)	18:00 - 18:00
A186	IMPACT OF LETERMOVIR PRIMARY AND SECONDARY PROPHYLAXIS IN A PEDIATRIC COHORT <i>Poster Presenter:</i> Marta Verna (Italy)	18:00 - 18:00
A187	EPSTEIN-BARR VIRUS REACTIVATION AND POST-TRANSPLANT	18:00 - 18:00

	LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER IMPLEMENTATION OF ANTITHYMOCYTE GLOBULIN AS GVHD PROPHYLAXIS. A SINGLE CENTER EXPERIENCE	
	<i>Poster Presenter:</i> Camilla Dao Vo (Norway)	
A188	IMPACT OF INVASIVE FUNGAL DISEASE UPDATED DEFINITIONS ON ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION OUTCOME IN ADULT PATIENTS - POST-HOC ANALYSIS OF NATION-WIDE CROSS-SECTIONAL 2012-2014	18:00 - 18:00
	<i>Poster Presenter:</i> Patrycja Mensah-Glanowska (Poland)	
A189	SURVEILLANCE BLOOD CULTURES FROM TUNNELLED CENTRAL VENOUS CATHETERS ON ADMISSION ARE OFTEN POSITIVE, GUIDE MANAGEMENT AND HELP INFORM REPORTING OF HOSPITAL ACQUIRED INFECTIONS	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Andrew Clark (United Kingdom)	
A190	ROLE OF HUMAN HERPESVIRUS 6 REACTIVATION IN T-DEplete TREG/TCON ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Valerio Viglione (Italy)	
A191	INTERLEUKIN-6 IS SIGNIFICANTLY INCREASED IN SEVERE PNEUMONIA AFTER ALLO-HSCT AND MIGHT INDUCE LUNG INJURY VIA IL-6/SIL-6R/JAK1/STAT3 PATHWAY	18:00 - 18:00
	<i>Poster Presenter:</i> Yuqian Sun (China)	
A192	ECHINOCANDIN PROPHYLAXIS IS ASSOCIATED WITH BREAKTHROUGH <i>TRICHOSPORON</i> AND <i>CANDIDA</i> INFECTIONS AND A LIMITED ROLE OF GALACTOMANNAN MONITORING AMONG ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> André Dias Américo (Brazil)	
A193	REAL WORLD EXPERIENCE OF EPSTEIN-BARR VIRUS (EBV) SCREENING FOR PERSISTENT VIRAEMIA POST HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)	18:00 - 18:00
	<i>Poster Presenter:</i> Abigail Downing (United Kingdom)	
A194	EPIDEMIOLOGY OF VIRAEMIA IN CHILDREN UNDERGOING CORD BLOOD STEM CELL TRANSPLANT (CB-SCT) WITH NON-MALIGNANT DISEASES: A RETROSPECTIVE COHORT STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Patel Zeeshan Jameel (United Kingdom)	
A195	PREVALENCE OF VZV REACTIVATION AND EFFECTIVENESS OF VACCINATION WITH RECOMBINANT ADJUVANTED ZOSTER VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL RECIPIENTS- A SINGLE-CENTER ANALYSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Ewa Karakulska-Prystupiuik (Poland)	
A196	LETERMOVIR PROPHYLAXIS REDUCED CYTOMEGALOVIRUS REACTIVATION AND RESISTANCE POST UMBILICAL CORD BLOOD TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Bingbing Yan (China)	
A197	BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS IN POSTTRANSPLANT CYCLOPHOSPHAMIDE-BASED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR IMMUNE DEFICIENCY OR DYSREGULATION	18:00 - 18:00
	<i>Poster Presenter:</i> Dimana Dimitrova (United States)	
A198	INFECTION PREVENTION MEASURES TAKEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS DURING THE COVID-19 PANDEMIC AND THEIR IMPACT ON CLINICAL OUTCOMES	18:00 - 18:00
	<i>Poster Presenter:</i> Sarah Morin (Switzerland)	
A199	EFFECT OF EARLY ADMINISTRATION OF ANTI-MRSA DRUGS ON	18:00 - 18:00

	THE COURSE OF FEBRILE NEUTROPENIA IN ALLO-SCT <i>Poster Presenter:</i> Anna Akaogi (Japan)	
A200	VISCERAL TOXOCARIAS IN THE EARLY POST-TRANSPLANT COURSE <i>Poster Presenter:</i> Iacopo Bellani (Italy)	18:00 - 18:00
A201	DE-ESCALATION ANTIBIOTIC STRATEGY IN MULTIDRUG-RESISTANCE BACTERIAL COLONIZED PATIENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. A 3-YEAR RETROSPECTIVE STUDY <i>Poster Presenter:</i> Giuseppe Sapienza (Italy)	18:00 - 18:00
A202	MARIBAVIR FOR TREATMENT OF REFRACTORY/RECURRENT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HSCT RECIPIENTS <i>Poster Presenter:</i> Marina Popova (Russian Federation)	18:00 - 18:00
A203	REAL LIFE MANAGEMENT OF ANTIBIOTIC THERAPY IN HSCT RECIPIENTS - FOCUS ON DE-ESCALATION IN PRE-ENGRAFTMENT NEUTROPENIA, THE STUDY FROM THE EBMT INFECTIOUS DISEASES WORKING PARTY (IDWP) <i>Poster Presenter:</i> Prof. Dr. Malgorzata Mikulska (Italy)	18:00 - 18:00
A204	INFECTIOUS COMPLICATIONS IN 549 BMTS DONE WITHOUT CENTRAL HEPA FILTRATION OR POSITIVE PRESSURE? <i>Poster Presenter:</i> Dr. Lawrence Faulkner (Italy)	18:00 - 18:00
A205	COVID-19 IN PATIENTS WITH HAEMATOLOGICAL DISEASES: THE ASSOCIATION OF RNAEMIA WITH CLINICAL OUTCOMES IN VACCINATED PATIENTS <i>Poster Presenter:</i> Francisco Manuel Martin Dominguez (Spain)	18:00 - 18:00
A206	COST-EFFECTIVENESS OF MARIBAVIR FOR POST-TRANSPLANT CYTOMEGALOVIRUS INFECTION THAT IS REFRACTORY TO ALTERNATIVE TREATMENTS FROM THREE HEALTHCARE SYSTEM PERSPECTIVES: ITALY, UK AND US <i>Poster Presenter:</i> Tien Bo (United States)	18:00 - 18:00
A207	INVASIVE FUNGAL INFECTIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A 4-YEAR SINGLE INSTITUTION ANALYSIS WITH FOCUS ON PROPHYLAXIS <i>Poster Presenter:</i> Marta Verna (Italy)	18:00 - 18:00
A208	ENHANCING SARS-COV-2 IMMUNITY EARLY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A THREE-DOSE RBD-TT-CONJUGATED VACCINE APPROACH <i>Poster Presenter:</i> Maryam Barkhordar (Iran)	18:00 - 18:00
A209	BLOODSTREAM INFECTIONS IN ALLOGENEIC HEMATOPOIETIC CELL RECIPIENTS: TRENDS OF INCIDENCE, SUSCEPTIBILITY AND RISK FACTORS FOR MULTIDRUG RESISTANCE <i>Poster Presenter:</i> Sara Fernandes (Brazil)	18:00 - 18:00
A210	USE OF LETERMOVIR IN PEDIATRIC POPULATION POST BONE MARROW TRANSPLANT <i>Poster Presenter:</i> Julia Marsal Ricoma (Spain)	18:00 - 18:00
	<i>Printed Poster</i> 18:00 - 19:00	Hall 3 North
	Non-infectious Early Complications	
A211	PROTECTING HLA-A AND HLA-B ANTIGENS THROUGH EPLETS ANALYSIS IN THE SETTING OF PLATELET TRANSFUSIONS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL ALLOGRAFT	18:00 - 18:00

CANDIDATES*Poster Presenter:* Nicolas Guillaume (France)

A212	CLINICAL SIGNIFICANCE OF CYTOKINE RELEASE SYNDROME FOLLOWING HLA-MISMATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MONOCENTRIC STUDY ON 250 TRANSPLANTS	18:00 - 18:00
	<i>Poster Presenter:</i> Filippo Frioni (Italy)	
A213	INVESTIGATING VASCULAR ENDOTHELIAL DYSFUNCTION BY SYNDECAN-1 FOLLOWING PEDIATRIC HSCT	18:00 - 18:00
	<i>Poster Presenter:</i> Sarah Weischendorff (Denmark)	
A214	ASSESSING THE IMPACT OF FLUID OVERLOAD ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	
A215	BEYOND PAIN MANAGEMENT: ASSESSING THE NEGATIVE IMPACT OF INTENSE OPIOID USE ON ALLOHCT SURVIVAL	18:00 - 18:00
	<i>Poster Presenter:</i> Tommy Alfaro Moya (Canada)	
A216	VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)-ASSOCIATED MORBIDITY IN CHILDREN POST HEMATOPOIETIC STEM CELL TRANSPLANTATION - A HINT FOR AN ADEQUATE PROPHYLAXIS?	18:00 - 18:00
	<i>Poster Presenter:</i> Zofia Szmit (Poland)	
A217	OUTCOME AND COMPLEMENT SYSTEM INVOLVEMENT IN PATIENTS WITH THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Jacopo Mariotti (Italy)	
A218	BONE REMODELLING ARE SIGNIFICANTLY IMPAIRED AFTER PEDIATRIC HSCT AND INFLUENCED BY DIAGNOSIS, CONDITIONING REGIMEN AND ACUTE GRAFT-VERSUS-HOST DISEASE	18:00 - 18:00
	<i>Poster Presenter:</i> Katrine Kielsen (Denmark)	
A219	IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION	18:00 - 18:00
	<i>Poster Presenter:</i> Juan Eiris (Spain)	
A220	PROINFLAMMATORY CYTOKINE RELEASE AND INFUSIONAL SIDE-EFFECTS AFTER ATG SEROTHERAPY FOR GVHD PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Rutvij Khanolkar (Canada)	
A221	ACUTE KIDNEY INJURY AND CRONIC KIDNEY DISEASE AFTER ALLOGENEIC HCT. A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	
A222	SINUSOIDAL OBSTRUCTION SYNDROME/VENO-OCCLUSIVE DISEASE: A RETROSPECTIVE STUDY OF THE SPANISH HEMATOLOGY ASSOCIATION-HEMATOPOIETIC STEM CELL TRANSPLANTATION GROUP (GETH)	18:00 - 18:00
	<i>Poster Presenter:</i> Cristina Blázquez Goñi (Spain)	
A223	SAFETY AND BENEFIT OF LIVER BIOPSY AFTER ALLOGENIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE SINGLE-CENTER STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Marie Maulini (Switzerland)	
A224	INVESTIGATION OF LABORATORY PARAMETERS BEFORE THE ONSET OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME IN	18:00 - 18:00

	CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	
	<i>Poster Presenter:</i> Bernd Gruhn (Germany)	
A225	OUTCOME OF ALLOGENEIC HCT RECIPIENTS COMPARED TO OTHER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT. A SINGLE CENTRE STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Ana Belén Bocanegra (Spain)	
A226	ADVERSE PROGNOSTIC IMPACT OF PRETRANSPLANT HEPCIDIN AND FERRITIN ON OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Michelle Pirotte (Belgium)	
A227	IMPACT OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) ON CLINICAL OUTCOMES IN ALLOGENEIC STEM CELL TRANSPLANTATION: INSIGHTS FROM A SINGLE-CENTER EXPERIENCE AT PRINCESS MARGARET CANCER CENTRE	18:00 - 18:00
	<i>Poster Presenter:</i> Mohammed Kawari (Canada)	
A228	VALIDATION OF EBMT 2023 VOD CRITERIA: IMPACT ON EARLY DIAGNOSIS AND SENSITIVITY/ESPECIFICITY OF PROBABLE VOD CATEGORY	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Mónica Cabrero (Spain)	
A229	EFFICACY AND SAFETY OF NETUPITANT/PALONOSETRON COMBINATION (NEPA) AND LOW DOSE OF DEXAMETHASONE IN PREVENTING NAUSEA AND VOMITING IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Alessandro Spina (Italy)	
A230	CYTOKINE RELEASE SYNDROME AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND ITS IMPACT ON OVERALL SURVIVAL	18:00 - 18:00
	<i>Poster Presenter:</i> Isabella Silva Pimentel Pittol (Brazil)	
A231	EXPLORING THE SAFETY PROFILE OF NORETHINDRONE IN POST-MENARCHAL STEM CELL TRANSPLANT PATIENTS: ADDRESSING VOD CONCERNS AND CAUTIONARY CONSIDERATIONS	18:00 - 18:00
	<i>Poster Presenter:</i> April Rahrig (United States)	
A232	ANALYSIS OF SAFETY OF TREOSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL IN 117 CHILDREN WITH SOLID TUMORS: SINGLE CENTER EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Kirill Kirgizov (Russian Federation)	
A233	POST-TRANSPLANT DE NOVO ANTI-HLA DONOR SPECIFIC ANTIBODIES MAY CONTRIBUTE TO POOR GRAFT FUNCTION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Xinyu Ji (China)	
A234	IMPACT OF EARLY CYCLOSPORINE INITIATION ON CYTOKINE RELEASE SYNDROME AND TRANSPLANT OUTCOMES IN PEDIATRIC T CELL REplete PERIPHERAL BLOOD HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT	18:00 - 18:00
	<i>Poster Presenter:</i> Veerendra Patil (India)	
A235	USE OF GRANULOCYTE COLONY-STIMULATING FACTORS IS FEASIBLE IN ALL DONOR SETTING WITHOUT INCREASING THE RISK OF ENGRAFTMENT SYNDROME	18:00 - 18:00
	<i>Poster Presenter:</i> Maria Luisa Giannattasio (Italy)	
A236	MIRNAS AS BIOMARKERS OF EARLY TOXICITY OF HIGH-DOSE	18:00 - 18:00

	CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	
	<i>Poster Presenter:</i> Anna Czyz (Poland)	
A237	THE UTILITY OF EXTRACORPOREAL ULTRASONOGRAPHY SCORE (HOKUS-10) IN PEDIATRIC SOS/VOD	18:00 - 18:00
	<i>Poster Presenter:</i> Atsushi Narita (Japan)	
<i>Printed Poster</i>		
	18:00 - 19:00	Hall 3 North
CAR-based Cellular Therapy - Clinical		
A069	BRIDGING THERAPY PRIOR TO TREATMENT WITH ANTI-CD19 CAR T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS - A MULTINATIONAL RETROSPECTIVE ANALYSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Tobias Feuchtinger (Germany)	
A070	SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Kexin Wang (China)	
A071	PREDICTIVE VALUE OF PRE-TREATMENT CIRCULATING TUMOR DNA GENOMIC LANDSCAPE IN PATIENTS WITH R/RMM UNDERGOING ANTI-BCMA CAR-T THERAPY: INSIGHTS FROM TUMOR CELLS AND T CELLS	18:00 - 18:00
	<i>Poster Presenter:</i> Rongrong Chen (China)	
A072	FINAL RESULTS OF PROSPECTIVE CLINICAL TRIAL EVALUATING OUTPATIENT ADMINISTRATION OF AXICABTAGENE CILOLEUCEL IN HIGH-GRADE B CELL LYMPHOMA	18:00 - 18:00
	<i>Poster Presenter:</i> Olalekan Oluwole (United States)	
A073	EUPLAGIA-1: SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE MANUFACTURED GLPG5201 ANTI-CD19 CAR-T CELLS DISPLAY EARLY PHENOTYPES IN RELAPSED/REFRACTORY CLL INCLUDING RT	18:00 - 18:00
	<i>Poster Presenter:</i> Esmée P. Hoefsmit (Netherlands)	
A074	TAILORED VERSUS WIDESPREAD ANTIFUNGAL PROPHYLAXIS IN LYMPHOMA PATIENTS TREATED WITH CD19 CAR T- CELL THERAPY: RESULTS FROM A LARGE RETROSPECTIVE COHORT	18:00 - 18:00
	<i>Poster Presenter:</i> Alejandro Luna de Abia (United States)	
A075	EFFICACY AND SAFETY IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AND 1-3 PRIOR LINES WHO RECEIVED CILTACABTAGENE AUTOLEUCEL AS STUDY TREATMENT CARTITUDE-4 TRIAL (PHASE 3)	18:00 - 18:00
	<i>Poster Presenter:</i> Jordan M. Schechter (United States)	
A076	INCIDENCES AND FACTORS ASSOCIATED WITH EARLY HEMATOTOXICITY AFTER CAR T-CELL THERAPY ASSESSED BY EHA/EBMT ICAHT CRITERIA	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Emily Liang (United States)	
A077	COMPARISON OF IMMUNOPHENOTYPIC AND FUNCTIONAL PROPERTIES OF ANTI-CD19 CAR-T CELL PRODUCTS MANUFACTURED USING CLINIMACS PRODIGY AND G-REX PLATFORMS	18:00 - 18:00
	<i>Poster Presenter:</i> Dmitriy Pershin (Russian Federation)	
A078	ALLOGENEIC HSCT AFTER CAR T-CELL THERAPY HAD DELAYED PLATELET ENGRAFTMENT, HIGHER RISK OF CYTOMEGALOVIRUS VIRUS VIREMIA AND THROMBOTIC	18:00 - 18:00

	MICROANGIOPATHY COMPARED TO CHEMOTHERAPY <i>Poster Presenter:</i> Luxin Yang (China)	
A079	AUTOMATED GRADING OF IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY <i>Poster Presenter:</i> Dr. Emily Liang (United States)	18:00 - 18:00
A080	RELEVANT STUDIES ON CYTOKINES LEVEL AND CAR-T EXPANSION ASSOCIATED TO CD7 CAR-T THERAPY <i>Poster Presenter:</i> Man Chen (China)	18:00 - 18:00
A081	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN RELAPSED REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA <i>Poster Presenter:</i> Rui Liu (China)	18:00 - 18:00
A082	SAFETY AND EFFICACY OF BENDAMUSTINE VERSUS FLUDARABINE-CYCLOPHOSPHAMIDE LYMPHODEPLETION PRIOR TO CAR-T CELL THERAPY WITH AXICABTAGENE CILOLEUCEL FOR NON-HODGKIN LYMPHOMA: A SINGLE-INSTITUTION STUDY <i>Poster Presenter:</i> Anthony Stack (United States)	18:00 - 18:00
A083	PSEUDOPROGRESSION: A FREQUENT AND CLINICALLY RELEVANT ADVERSE EVENT OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY <i>Poster Presenter:</i> Torsten Schroeder (Germany)	18:00 - 18:00
A084	CAR-T CELL TREATMENT OF LARGE B-CELL LYMPHOMA (LBCL): DO PROGRAM DURATION AND TREATMENT LINE MATTER? <i>Poster Presenter:</i> Maria-Luisa Schubert (Germany)	18:00 - 18:00
A085	GENE-EDITED UNIVERSAL CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA <i>Poster Presenter:</i> Liu Fang (China)	18:00 - 18:00
A086	REAL-WORLD EXPERIENCE OF CAR T-CELL THERAPY: A SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Susana Pereira (Portugal)	18:00 - 18:00
A087	IMPACT OF ACUTE KIDNEY INJURY IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL <i>Poster Presenter:</i> Rafael Hernani (Spain)	18:00 - 18:00
A088	CHARACTERISTICS OF CENTRAL NERVOUS SYSTEM RELAPSE AFTER CD19 CAR-T CELL THERAPY IN R/R NHL <i>Poster Presenter:</i> Mengyu Zhao (China)	18:00 - 18:00
A089	DAY7-CART COUNT ENHANCES PREDICTIVE POWER OF PET30 AND POSSIBLY ANTICIPATES CD19 LOSS IN RELAPSE AFTER CART <i>Poster Presenter:</i> Fabian Müller (Germany)	18:00 - 18:00
A090	EXCELLENT OUTCOME OF CAR-T CELL THERAPY IN CHILDREN WITH PB-ALL RELAPSING POST HSCT, WHO HAD VERY LOW MRD AT LYMPHODEPLETING CHEMOTHERAPY - POLISH CENTRES' EXPERIENCE <i>Poster Presenter:</i> Karolina Liszka (Poland)	18:00 - 18:00
A091	THE DARK SIDE OF CORTICOSTEROIDS IN CD19.CAR-T CELL THERAPY <i>Poster Presenter:</i> Marcello Roberto (Italy)	18:00 - 18:00
A092	MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFECTIVE CHARACTERISTICS AMONG DIFFERENT BCMA TARGETING CAR-T	18:00 - 18:00

	IN TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMAS	
	<i>Poster Presenter:</i> Chunrui Li (China)	
A093	IMPACT OF EARLY CAR⁻ CD4⁺ T-LYMPHOCYTES RECOVERY FOLLOWING CAR-T CELL INFUSION FOR RELAPSED OR REFRACTORY B CELL LYMPHOMAS	18:00 - 18:00
	<i>Poster Presenter:</i> Massimiliano Gambella (Italy)	
A094	ACUTE INFECTION AND BASELINE C-REACTIVE PROTEIN - KEY MARKERS OF PROGRESSION IN RELAPSED REFRACTORY DLBCL PATIENTS RECEIVING CAR-T CELL THERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Jayachandran Perumal Kalaiyarasi (United Kingdom)	
A095	THIRD-LINE CAR-T IN PATIENTS WITH EARLY RELAPSE FOLLOWING FIRST-LINE TREATMENT FOR AGGRESSIVE B-CELL LYMPHOMA: STILL A VALUABLE OPTION	18:00 - 18:00
	<i>Poster Presenter:</i> Massimiliano Gambella (Italy)	
A096	DEVELOPMENT OF DISEASE-SPECIFIC COMPOSITE END-POINTS OF TOXICITY-FREE, PROGRESSION-FREE SURVIVAL (TPFS) AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR PATIENTS WITH LARGE B-CELL LYMPHOMA AND MULTIPLE MYELOMA	18:00 - 18:00
	<i>Poster Presenter:</i> Aleksandr Lazaryan (United States)	
A097	EASIX SCORE AS A PROGNOSTIC FACTOR OF CYTOKINE RELEASE SYNDROME IN CAR-T PATIENTS - A RETROSPECTIVE ANALYSIS OF MM AND LBCL COHORTS	18:00 - 18:00
	<i>Poster Presenter:</i> Jaromir Tomasik (Poland)	
A098	HEMATOTOXICITY POST CAR-T CELL THERAPY: REAL-WORLD DATA ON RISK FACTORS AND OUTCOMES	18:00 - 18:00
	<i>Poster Presenter:</i> Zoi Bousiou (Greece)	
A099	DONOR-DERIVED CLL-1 CHIMERIC ANTIGEN RECEPTOR T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BRIDGING TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT UPDATE	18:00 - 18:00
	<i>Poster Presenter:</i> Guang-Cui He (China)	
A100	A RETROSPECTIVE REVIEW TO IDENTIFY OPTIMAL LYMPHODEPLETION PRIOR TO TISAGENLEUCIL IN PATIENTS WITH REFRACTORY OR RELAPSED LARGE B-CELL LYMPHOMA IN SCOTLAND'S NATIONAL CAR-T CENTRE	18:00 - 18:00
	<i>Poster Presenter:</i> Daire Quinn (United Kingdom)	
A101	LOCOMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - FINAL ANALYSIS AT 2-YEAR FOLLOW-UP	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Reuben Benjamin (United Kingdom)	
A102	METAGENOMIC NEXT-GENERATION SEQUENCING VISUALLY DISPLAYS A FALSE-POSITIVE DETECTION OF HIV NUCLEIC ACID RELATED TO CART TREATMENT: A CASE STUDY IN A CHILD	18:00 - 18:00
	<i>Poster Presenter:</i> M. I. Zhou (China)	
A103	IMPACT OF SERUM INTERLEUKIN 1-BETA LEVELS DURING CAR-T CELLS THERAPY ON CLINICAL OUTCOME: A SINGLE-CENTER EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Ilaria Cutini (Italy)	
A104	THE SCOTTISH EXPERIENCE WITH CAR-T CELL THERAPY: A FOCUS ON DLBCL	18:00 - 18:00
	<i>Poster Presenter:</i> David Hopkins (United Kingdom)	

A105	<p>DONOR-DERIVED LYMPHOID ANTIGEN-DIRECTED CAR-T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 17 CASES</p> <p><i>Poster Presenter:</i> Dmitriy Pershin (Russian Federation)</p>	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Multiple Myeloma		
A273	<p>REAL-WORLD OUTCOMES OF UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DEL (17P)</p> <p><i>Poster Presenter:</i> Curtis Marcoux (Canada)</p>	18:00 - 18:00
A274	<p>IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE REAL-LIFE PRIMULA STUDY</p> <p><i>Poster Presenter:</i> Immacolata Attolico (Italy)</p>	18:00 - 18:00
A275	<p>SAFETY AND EARLY EFFICACY OF TANDEM AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER DARATUMUMAB VTD INDUCTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA</p> <p><i>Poster Presenter:</i> Annalisa Natale (Italy)</p>	18:00 - 18:00
A276	<p>RESPONSE AND SURVIVAL IMPROVEMENT WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: DIFFERENT INDUCTION THERAPY IMPACT OVER THE LAST 30 YEARS</p> <p><i>Poster Presenter:</i> José Miguel Mateos Pérez (Spain)</p>	18:00 - 18:00
A277	<p>OUTCOMES OF FRAIL PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY/AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA</p> <p><i>Poster Presenter:</i> Stephanie Yohay (United States)</p>	18:00 - 18:00

Tuesday, 16. April 2024*Meetings*

07:00 - 08:45

BOISDALE

BM-PDWP - Business Meeting of the Paediatric Diseases Working Party*Chair:* Prof. Dr. Krzysztof Kalwak (Poland)*Meetings*

07:00 - 08:45

ALSH

BM-LWP - Business Meeting of the Lymphoma Working Party*Chair:* Prof. Dr. Bertram Glass (Germany)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

QM-MTE-3 - Quality Management Meet-the-Expert: Feedback from the Accreditation Committee. Challenging standards and other observations (Table 1)

QM-MTE-3

Feedback from the Accreditation Committee: Challenging standards and other observations (Table 1)

07:45 - 08:45

Speaker: Dr. Charles Crawley (United Kingdom)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-7 - Meet-the-Expert: How to improve Cellular Therapy for Myeloma and solid Tumors

MTE-7

How to improve Cellular Therapy for Myeloma and solid Tumors

07:45 - 08:45

Speaker: Prof. Dr. Maik Luu (Germany)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-6 - Meet-the-Expert: When patients with lymphoma should be considered for CAR-T in 2024

MTE-6

When patients with lymphoma should be considered for CAR-T in 2024

07:45 - 08:45

Speaker: Dr. Sridhar Chaganti (United Kingdom)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

QM-MTE-4 - Quality Management Meet-the-Expert: Feedback from the Accreditation Committee. Challenging standards and other observations (Table 2)

QM-MTE-4

Feedback from the Accreditation Committee: Challenging standards and other observations (Table 2).

07:45 - 08:45

Speaker: Dr. Bruna Gotardo (Spain)*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE - Breakfast Meet the Expert - Tuesday*Meet the Expert*

07:45 - 08:45

CASTLE Suite

MTE-5 - Meet-the-Expert: How I treat acute GVHD

MTE-5

How I treat acute GVHD

07:45 - 08:45

Speaker: Prof. Dr. Hildegard Greinix (Austria)

Data Management

08:30 - 09:20

ARGYLL Suite

DM5 - Data Management Session 5 - EBMT Registry Present & Future - interactive feedback session

DM5-1

EBMT Registry Present & Future - interactive feedback session

08:30 - 09:20

Speaker: Ms. Annelot van Amerongen (Netherlands)*Working Party Session*

09:00 - 10:15

CLYDE

ALWP - Acute Leukaemia Working Party Session | Advances in acute leukemia: an update by the ALWP*Chair:* Prof. Dr. Fabio Ciceri (Italy)

ALWP-1

Introduction

09:00 - 09:05

ALWP-2

Revisiting indications of allo-HSCT in AML

09:05 - 09:20

Speaker: Dr. Gesine Bug (Germany)

ALWP-3

Haploidentical transplantation in Acute Myeloid Leukemia

09:20 - 09:35

Speaker: Prof. Arnon Nagler (Israel)

ALWP-4

GVHD: from prophylaxis to therapy - 10 years of progress

09:35 - 09:50

Speaker: Prof. Mohamad Mohty (France)

ALWP-5

From DLI to maintenance therapy in AML

09:50 - 10:05

Speaker: Prof. Ali Bazarbachi (Lebanon)

ALWP-6

Chemo-free therapy in Ph-positive ALL

10:05 - 10:15

Speaker: Giorgia Battipaglia (Italy)*Paediatrics Day*

09:00 - 10:30

LOMOND

Paed1 - Paediatric Diseases Working Party Session*Chair:* Dr. Katharina Kleinschmidt (Germany)*Chair:* Prof. Dr. Krzysztof Kalwak (Poland)

Paed1-1

An update on F1/F2 trials in ALL

09:00 - 09:15

Speaker: Prof. Dr. Christina Peters (Austria)*Speaker:* Ms. Anita Lawitschka (Austria)

Paed1-2

Current clinical practice, results and limitations of CAR-T cell treatment in R/R pB-ALL in Europe

09:15 - 09:30

Speaker: Prof. Dr. Peter Bader (Germany)

Paed1-3

Base edited CD7 CAR-T cell therapy in relapsed T-ALL

09:30 - 09:45

Speaker: Dr. Robert Chiesa (United Kingdom)

Paed1-4

PTCY vs alfalfa depletion in haploidentical HSCT in acute leukemia

09:45 - 10:00

Speaker: Prof. Franco Locatelli (Italy)

Paed1-5

CAR-T cells for relapsed or refractory neuroblastoma - a hype or hope?

10:00 - 10:15

Speaker: Dr. Francesca Del Bufalo (Italy)

Paed1-6

Dietrich Niethammer Award (with the support of medac) - Introduction

10:15 - 10:21

Paed1-7

Dietrich Niethammer Award (with the support of medac)

10:21 - 10:29

Speaker: Dr. Francesca Del Bufalo (Italy)*Speaker:* Dr. Robert Chiesa (United Kingdom)

Educational

09:00 - 10:30

Hall 3 North

E04 - The role of new therapies in Lymphoma*Chair:* Prof. Dr. Bertram Glass (Germany)*Chair:* Dr. Kate Cwynarski (United Kingdom)

E04-1	Which patient should get an auto in the CAR-T era <i>Speaker:</i> Prof. Dr. Catherine Thieblemont (France)	09:00 - 09:25
E04-2	BiTEs vs CAR-T vs other immunotherapies <i>Speaker:</i> Dr. Gloria Iacoboni (Spain)	09:25 - 09:50
E04-3	Should any patient with lymphoma receive an allograft in 2024? <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	09:50 - 10:15
E04-4	Q&A - Discussion	10:15 - 10:30

Joint Sessions

09:00 - 10:15

Hall 3 South

JS03 - Joint Session EBMT - KSBMT | Impact of new genomic technologies in HSCT practice; patient selection, prognostication, and post-transplant monitoring*Chair:* Prof. John Snowden (United Kingdom)*Chair:* Prof. Seong Kyu Park (Korea, Republic of)

JS03-1	Introduction	09:00 - 09:05
JS03-2	EBMT: A European perspective <i>Speaker:</i> Dr. Angela Hamblin (United Kingdom)	09:05 - 09:25
JS03-3	KSBMT: An Asian perspective <i>Speaker:</i> Prof. Dr. Saeam Shin (Korea, Republic of)	09:25 - 09:45
JS03-4	Discussion and Conclusions	09:45 - 10:00

Special Session

09:00 - 10:15

Hall 2

SS4 - Joint physician-nurse session | The multi-professional MDT - Lessons from a patient story*Chair:* Dr. Fiona Dignan (United Kingdom)*Chair:* Mr. Daniel Kisielewski (Germany)*Chair:* Dr. Kathleen McHugh (United Kingdom)

SS4-1	Introduction <i>Speaker:</i> Victoria Potter (United Kingdom)	09:00 - 09:05
SS4-2	Part I - Transplant discussions	09:05 - 09:05
SS4-2.1	Patient perspective <i>Speaker:</i> Ms. Billie McPartlan (United Kingdom)	09:05 - 09:10
SS4-2.2	Physician perspective <i>Speaker:</i> Victoria Potter (United Kingdom)	09:10 - 09:15
SS4-2.3	Nurse perspective <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	09:15 - 09:20
SS4-2.4	Discussion - Q&A	09:20 - 09:25
SS4-3	Part II - GVHD, an unusual relapse, transplant #2	09:25 - 09:25
SS4-3.1	Patient perspective <i>Speaker:</i> Ms. Billie McPartlan (United Kingdom)	09:25 - 09:30
SS4-3.2	Physician perspective	09:30 - 09:35

	<i>Speaker:</i> Victoria Potter (United Kingdom)	
SS4-3.3	Nurse perspective <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	09:35 - 09:40
SS4-3.4	Discussion - Q&A	09:40 - 09:45
SS4-4	Part III - Complications and survivorship	09:45 - 09:45
SS4-4.1	Patient perspective <i>Speaker:</i> Ms. Billie McPartlan (United Kingdom)	09:45 - 09:50
SS4-4.2	Physician perspective <i>Speaker:</i> Victoria Potter (United Kingdom)	09:50 - 09:55
SS4-4.3	Nurse perspective <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	09:55 - 10:00
SS4-4.4	Discussion - Q&A	10:00 - 10:05
SS4-5	General discussion, Q&A, and closing	10:05 - 10:15

Working Party Session

09:00 - 10:20

Hall 5

CTIWP - Cellular Therapy & Immunobiology Working Party Session*Chair:* Dr. Annalisa Ruggeri (Italy)*Chair:* Prof. Dr. Jurgen Kuball (Netherlands)*Chair:* Prof. Dr. Florent Malard (France)

CTIWP-1	Presentation of the Jon J. Van Rood Award	09:00 - 09:05
CTIWP-1.1	Epitope editing enables targeted immunotherapy of acute myeloid leukaemia <i>Oral Presenter:</i> Dr. Gabriele Casirati (United States)	09:05 - 09:15
CTIWP-1.2	GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma <i>Oral Presenter:</i> Dr. Francesca Del Bufalo (Italy)	09:15 - 09:25
CTIWP-2	Consensus on DLI infusion <i>Speaker:</i> Dr. Nicole Santoro (Italy)	09:25 - 09:40
CTIWP-3	Factors influencing CART-cell manufacturing in terms of production failures and out of specification products <i>Speaker:</i> Prof. Dr. Nina Worel (Austria)	09:40 - 09:55
CTIWP-4	Gradual HLA-DPB1 mismatch score based on immunopeptidome overlap predicts alloreactivity in unrelated allogeneic stem cell transplantation <i>Speaker:</i> Mr. Joost van der Hem (Netherlands)	09:55 - 10:10
CTIWP-5	Q&A	10:10 - 10:20

Nurses Group

09:00 - 10:30

Hall 1

NG11 - Back to basics. Understanding...*Chair:* Ms. Helen Hunter (United Kingdom)*Chair:* Mr. Thomas Jezequel (France)

NG11-1	Full blood counts and approach to peri-transplant cytopenias <i>Speaker:</i> Dr. Sharon Lionel (United Kingdom)	09:00 - 09:20
NG11-2	Viral screening: what, when and why <i>Speaker:</i> Ms. Iris Agreiter (Ireland)	09:20 - 09:40

NG11-3	Bone marrow results and what do they mean <i>Speaker:</i> Dr. Jan Brijs (Belgium)	09:40 - 10:00
NG11-4	Identifying metabolic syndrome <i>Speaker:</i> Prof. Diana Greenfield (United Kingdom)	10:00 - 10:20
NG11-5	Q&A	10:20 - 10:30

Quality Management
09:00 - 10:15

Hall M1

QM1 - Quality Management 1 - Centre Session: Focus on Accreditation Process

Chair: Ms. Bernadette Odijk (Netherlands)

Chair: Ms. Anne Emmet (United Kingdom)

QM1-1	JACIE Activity & Strategy Update <i>Speaker:</i> Dr. Carla Sánchez (Spain)	09:00 - 09:15
QM1-2	Support for Centres during the Accreditation Process: E-learning Programme for Centres <i>Speaker:</i> Ms. Renza Monteleone (Italy)	09:15 - 09:30
QM1-3	Focus on Accreditation Process: "The Dutch Mountains" <i>Speaker:</i> Ms. Yvonne Westerman (Netherlands)	09:30 - 09:45
QM1-4	Interim Audits: process and evaluation <i>Speaker:</i> Mr. Bruno Di Liscia (Spain)	09:45 - 10:00
QM1-5	Q&A	10:00 - 10:15

Practise Harmonisation Day
09:00 - 10:25

FORTH

HM1 - Practise Harmonisation Day 1 | EBMT practise harmonisation projects

Chair: Prof. Ibrahim Yakoub-Agha (France)

Chair: Prof. Dr. Francesco Onida (Italy)

HM1-1	Introduction	09:00 - 09:10
HM1-2	Practice harmonization and guidelines committee of EBMT workflow process and new proposals for the second edition <i>Speaker:</i> Isabel Sánchez-Ortega (Spain) <i>Speaker:</i> Prof. Ibrahim Yakoub-Agha (France)	09:10 - 09:35
HM1-3	Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations <i>Speaker:</i> Prof. Dr. Marion Subklewe (Germany)	09:35 - 10:00
HM1-4	Management of adults and children receiving CAR T-cell therapy: best practice recommendations of the EBMT, JACIE and EHA <i>Speaker:</i> Prof. Dr. Max Topp (Germany)	10:00 - 10:25

Transplant and Search Coordinators Day
09:00 - 10:15

BOISDALE

TSCD1 - EBMT-WMDA Transplant and Search Coordinators Day 1 | Data-Analysis in donor selection

Chair: Ms. Martine Schuit (Netherlands)

TSCD1-1	HLA matching to improve transplant outcomes <i>Speaker:</i> Dr. Ann-Margaret Little (United Kingdom)	09:00 - 09:25
TSCD1-2	Trends and recommendations in donor selection <i>Speaker:</i> Dr. Irina Evseeva (United Kingdom)	09:25 - 09:50
TSCD1-3	Permissible HLA mismatches: application of HLA-EMMA	09:50 - 10:15

Speaker: Dr. Adriaan van Beek (Netherlands)

Nurses Group

09:00 - 10:30

ALSH

NG12 - Apheresis

Chair: Dr. Stefano Botti (Italy)

Chair: Ms. Sharon Robertson (United Kingdom)

NG12-1	Advances in cell collection <i>Speaker:</i> Ms. Angela Leather (United Kingdom)	09:00 - 09:20
NG12-2	Emergency therapeutic procedures <i>Speaker:</i> Ms. Elien Bienens (Belgium)	09:20 - 09:40
NG12-3	How to become an apheresis nurse <i>Speaker:</i> Ms. Andrea Suarez Prieto (Spain)	09:40 - 10:00
NG12-4	Poor mobilisers <i>Speaker:</i> Ms. Simone Van der Linden (Netherlands)	10:00 - 10:20
NG12-5	Q&A	10:20 - 10:30

Special Session

09:00 - 10:15

CARRON

SS5 - Global Committee Session | Haematopoietic, mesenchymal stem cell and CAR-T cell therapy development: a global perspective

Chair: Prof. Norbert Claude Gorin (France)

Chair: Prof. Dr. Mette Hazenberg (Netherlands)

SS5-1	Allogeneic stem cell transplantation for children affected by congenital immune diseases. Latin American perspective. <i>Speaker:</i> Prof. Dr. Gregorio Jaimovich (Argentina)	09:00 - 09:15
SS5-2	Novel cellular therapy including iPS cells driven to CAR NK therapy <i>Speaker:</i> Prof. Huang He (China)	09:15 - 09:30
SS5-3	Current status and new developments in MSC <i>Speaker:</i> Prof. Dr. Rafael Duarte (Spain)	09:30 - 09:45
SS5-4	Stem cell transplantation for autoimmune diseases in the Singapore General Hospital <i>Speaker:</i> Prof. William Hwang (Singapore)	09:45 - 10:00
SS5-5	Roundtable and questions	10:00 - 10:15

Pharmacists Day

09:00 - 10:30

GALA

Pharm5 - Pharmacists Training session

Chair: Mr. Nick Duncan (United Kingdom)

ePoster

09:00 - 18:00

ePoster area

ePoster Viewing

Data Management

09:30 - 10:20

ARGYLL Suite

DM6 - Data Management Session 6 - Extended Dataset

DM6-1	Extended Dataset <i>Speaker:</i> Ms. Alina Kuliesh (Netherlands)	09:30 - 10:20
-------	--	---------------

Breaks

10:30 - 11:00

CLYDE

Coffee Break, ePoster Viewing, Visit Exhibition*Industry Theatre*

10:30 - 10:55

IT

IT4 - A new therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM) | Pfizer*Chair:* Emma Searle (United Kingdom)*Plenary Session*

11:00 - 12:30

CLYDE

P03 - Cellular therapies of the future*Chair:* Dr. Annalisa Ruggeri (Italy)*Chair:* Prof. Dr. Christian Chabannon (France)

P03-1	Future design of CAR T <i>Speaker:</i> Prof. Dr. Maik Luu (Germany)	11:00 - 11:25
P03-2	CRISPR/Cas9 & Base edited allogeneic CAR T cells for ALL <i>Speaker:</i> Prof. Dr. Waseem Qasim (United Kingdom)	11:25 - 11:50
P03-3	Cellular therapy in solid malignancies <i>Speaker:</i> Dr. Pavlina Spiliopoulou (United Kingdom)	11:50 - 12:15
P03-4	Q&A - Discussion	12:15 - 12:30

Paediatrics Day

11:00 - 12:15

LOMOND

Paed2 - Inborn Errors Working Party Session*Chair:* Prof. Benedicte Neven (France)

Paed2-1	Retroviral and lentiviral vectors based Gene therapy in PIDs; were do we stand? <i>Speaker:</i> Prof. Sung-Yun Pai (United States)	11:00 - 11:20
Paed2-2	New strategies of gene therapy in PIDs <i>Speaker:</i> Dr. Thomas Fox (United Kingdom)	11:20 - 11:40
Paed2-3	Gene therapy in metabolic diseases <i>Speaker:</i> Rob Wynn (United Kingdom)	11:40 - 12:00
Paed2-4	Discussion	12:00 - 12:15

Special Session

11:00 - 12:15

Hall 3 North

SS6 - Survival, Equity, Access*Chair:* Ms. Henny Braund (United Kingdom)*Chair:* Dr. Robert Danby (United Kingdom)

SS6-1	The first 50 years of Anthony Nolan <i>Speaker:</i> Prof. Charlie Craddock (United Kingdom)	11:00 - 11:20
SS6-2	Where are we now with VUD registries and HLA typing strategies <i>Speaker:</i> Dr. Neema Mayor (United Kingdom)	11:20 - 11:40
SS6-3	Where are we going now? Novel donor selection strategies <i>Speaker:</i> Prof. Bronwen Shaw (United States)	11:40 - 12:00
SS6-4	Q&A - Discussion	12:00 - 12:15

Joint Sessions

11:00 - 12:30

Hall 3 South

JS04 - Joint Session EBMT - ISCT | How EU Can Better Approach Regulations on ATMPs and SoHO?*Chair:* Prof. Dr. Fermín Sánchez Guijo (Spain)*Chair:* Prof. Dr. Anna Sureda (Spain)

JS04-1	How the revision of EU pharmaceutical legislation will boost innovation in the field of ATMPs <i>Speaker:</i> Ms. Paschalia Koufokotsiou (Belgium)	11:00 - 11:20
JS04-2	European regulatory challenges and opportunities for the development of ATMPs: can we envision successful public-private collaborations? <i>Speaker:</i> Dr. Miguel Forte (Belgium)	11:20 - 11:40
JS04-3	How Can EBMT and partnering Societies Contribute to this landscape? <i>Speaker:</i> Prof. Dr. Nina Worel (Austria)	11:40 - 12:00
JS04-4	The new SoHO regulation: what will it mean for you in 2027? <i>Speaker:</i> Dr. Stefaan Van Der Spiegel (Belgium)	12:00 - 12:20
JS04-5	Q&A	12:20 - 12:30

Working Party Session

11:00 - 12:15

Hall 2

LWP - Lymphoma Working Party Session*Chair:* Prof. Dr. Bertram Glass (Germany)

LWP-1	Report of LWP activities + Introduction Jian Jian Luan award <i>Speaker:</i> Prof. Dr. Bertram Glass (Germany)	11:00 - 11:10
LWP-2	A PROPENSITY SCORE-MATCHED ANALYSIS ON OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL FROM ZUMA-2 AND ALLOGENEIC STEM CELL TRANSPLANTATION FROM EBMT DATABASE IN RELAPSED/REFRACTORY POST-BTKI MANTLE CELL LYMPHOMA <i>Oral Presenter:</i> Nora Liebers (Germany)	11:10 - 11:25
LWP-3	PTCL and AITL <i>Speaker:</i> Prof. Dr. Norbert Schmitz (Germany)	11:25 - 11:41
LWP-4	EATL <i>Speaker:</i> Prof. Dr. Olivier Hermine (France)	11:41 - 11:57

Workshop

11:00 - 12:30

Hall 5

W04 - Chronic GVHD*Chair:* Prof. Dr. Thomas Luft (Germany)*Chair:* Dr. Monia Marchetti (Italy)

W04-1	Personalising cGVHD therapy <i>Speaker:</i> Dr. Francesca Bonifazi (Italy)	11:00 - 11:25
W04-2	Lung GVHD - pathophysiology and management <i>Speaker:</i> Dr. Saskia Bos (United Kingdom)	11:25 - 11:50
W04-3	Practical assessment and patient related outcomes in GVHD <i>Speaker:</i> Dr. Maria Teresa Lupo Stanghellini (Italy)	11:50 - 12:15
W04-4	Q&A - Discussion	12:15 - 12:30

Nurses Group

11:00 - 12:30

Hall 1

NG13 - Advanced and cellular therapies*Chair:* Mr. Daniel Kisielewski (Germany)*Chair:* Ms. Bethany Colton (United Kingdom)

NG13-1	Acute toxicities of advanced and cellular therapy <i>Speaker:</i> Mr. Matthias Naegele (Switzerland)	11:00 - 11:20
NG13-2	Training curriculum <i>Speaker:</i> Ms. Ruth Clout (United Kingdom)	11:20 - 11:40
NG13-3	Ambulatory CAR-T <i>Speaker:</i> Ms. Maia Collins (United Kingdom)	11:40 - 12:00
NG13-4	Nurse-led long-term follow-up of CAR T cell therapy in patient <i>Speaker:</i> Ms. Mirjam Oudshoorn (Netherlands)	12:00 - 12:20
NG13-5	Q&A	12:20 - 12:30

Quality Management

11:00 - 12:15

Hall M1

QM2 - Quality Management 2 - Inspector Session: Updates for Inspectors*Chair:* Mr. Eugenia Trigos (Spain)*Chair:* Mr. Olivier Urbain (Belgium)

QM2-1	Inspector training: one year on <i>Speaker:</i> Mr. Eugenia Trigos (Spain) <i>Speaker:</i> Dr. Laura Lombardi (Italy)	11:00 - 11:15
QM2-2	Update on Inspector Committee Activity <i>Speaker:</i> Ms. Dania Arabi (Saudi Arabia)	11:15 - 11:30
QM2-3	The role of a Team Leader <i>Speaker:</i> Dr. Charles Crawley (United Kingdom)	11:30 - 11:45
QM2-4	How to compile a 'good' inspection report? <i>Speaker:</i> Dr. Richard Olaussen (Norway)	11:45 - 12:00
QM2-5	Q&A	12:00 - 12:15

Practise Harmonisation Day

11:00 - 12:15

FORTH

HM2 - Practise Harmonisation Day 2 | CMWP harmonisation workshops*Chair:* Prof. Ibrahim Yakoub-Agha (France)*Chair:* Dr. Lisa Pleyer (Austria)

HM2-1	Allogeneic HCT for Mast cell disorders <i>Speaker:</i> Dr. Donal McLornan (United Kingdom)	11:00 - 11:25
HM2-2	Allogeneic HCT for CMML: recommendations from the EBMT practice harmonization and guidelines committee <i>Speaker:</i> Prof. Dr. Francesco Onida (Italy)	11:25 - 11:50
HM2-3	Q&A	11:50 - 12:05

Transplant and Search Coordinators Day

11:00 - 12:15

BOISDALE

TSCD2 - EBMT-WMDA Transplant and Search Coordinators Day 2 | Search Cases*Chair:* Dr. Ann-Margaret Little (United Kingdom)

TSCD2-1	Case 1	11:00 - 11:25
---------	---------------	---------------

	<i>Speaker:</i> Rob Wynn (United Kingdom)	
TSCD2-2	Case 2 <i>Speaker:</i> Dr. Diarmaid O'Donghaile (Ireland)	11:25 - 11:50
TSCD2-3	Case 3 <i>Speaker:</i> Prof. Adriana Balduzzi (Italy)	11:50 - 12:15
<i>Nurses Group</i>		
11:00 - 12:30		
ALSH		
NG14 - Paediatric Session		
<i>Chair:</i> Ms. Ida Bremer-Ophorst (Netherlands)		
<i>Chair:</i> Ms. Maria Finch (United Kingdom)		
NG14-1	Oncofertility care in paediatric patients and survivors <i>Speaker:</i> Ms. Irene Ijgosse (Netherlands)	11:00 - 11:30
NG14-2	"I have a greater thirst for life" - The importance of capturing positive experiences when assessing quality of life of young people with cancer <i>Speaker:</i> Prof. Dr. Anne-Sophie Darlington (United Kingdom)	11:30 - 12:00
NG14-3	The treatment journey of a teenager <i>Speaker:</i> Ms. A. Tapley (United Kingdom)	12:00 - 12:30
<i>Working Party Session</i>		
11:00 - 12:20		
CARRON		
ADWP - Autoimmune Diseases Working Party Session		
<i>Chair:</i> Dr. Tobias Alexander (Germany)		
<i>Chair:</i> Prof. Maria Carolina de Oliveira (Brazil)		
ADWP-0	Introduction <i>Speaker:</i> Dr. Raffaella Greco (Italy)	11:00 - 11:05
ADWP-1	CAR-T cells and novel biologics for myositis <i>Speaker:</i> Prof. Dr. Joerg Henes (Germany)	11:05 - 11:25
ADWP-2	HSCT for SSc: connective tissue remodelling and cardiopulmonary fitness <i>Speaker:</i> Prof. Maria Carolina de Oliveira (Brazil)	11:25 - 11:45
ADWP-3	HSCT in MS and prognostic biomarkers <i>Speaker:</i> Prof. Matilde Inglese (Italy)	11:45 - 12:05
ADWP-4	Viral reactivations (CMV & EBV) after autologous HSCT for ADs <i>Speaker:</i> Dr. Tobias Alexander (Germany)	12:05 - 12:20
<i>Nurses Group</i>		
11:00 - 12:30		
GALA		
NG15 - Skills Lab 1 Research Workshop - Crafting effective research tools: survey creation and interview guide development		
<i>Chair:</i> Dr. Isabel Salcedo-Diego (Spain)		
<i>Chair:</i> Dr. Lynn Leppla (Germany)		
NG15-1	How to create a survey <i>Speaker:</i> Dr. Jarl Mooyart (Netherlands)	11:00 - 11:45
NG15-2	How to develop an interview guide <i>Speaker:</i> Ms. Annika Kisch (Sweden)	11:45 - 12:30

<i>Data Management</i>		
11:00 - 11:50		ARGYLL Suite
DM7 - Data Management Session 7 - Exports and OMOP in the new EBMT Registry		
DM7-1	OMOP	11:00 - 11:50
	<i>Speaker:</i> Mr. Ignacio García (Netherlands)	
 <i>Data Management</i>		
12:00 - 12:50		ARGYLL Suite
DM8 - Data Management Session 8 - Data Quality		
DM8-1	Data Quality	12:00 - 12:50
	<i>Speaker:</i> Ms. Alina Kuliesh (Netherlands)	
 <i>Breaks</i>		
12:30 - 13:00		CLYDE
Lunch Break, ePoster Viewing, Visit Exhibition		
 <i>Meetings</i>		
12:45 - 14:00		Hall M1
BM-ALWP - Business Meeting of the Acute Leukaemia Working Party		
<i>Chair:</i> Prof. Dr. Fabio Ciceri (Italy)		
 <i>Meetings</i>		
12:45 - 14:00		FORTH
BM-CTIWP - Business Meeting of the Cellular Therapy & Immunobiology Working Party		
<i>Chair:</i> Dr. Annalisa Ruggeri (Italy)		
 <i>Meetings</i>		
12:45 - 14:00		BOISDALE
BM-IEWP - Business Meeting of the Inborn Errors Working Party		
<i>Chair:</i> Prof. Benedicte Neven (France)		
 <i>Meetings</i>		
12:45 - 14:00		ALSH
BM-HWP - Business Meeting of the Haemoglobinopathies Working Party		
<i>Chair:</i> Dr. Emanuele Angelucci (Italy)		
 <i>Industry Symposium</i>		
13:00 - 14:00		Hall 1
IS32 - 30 Years of ECP - Patient-centered therapy using Therakos ECP technology, then, now and in the future		
<i>Chair:</i> Dr. Michelle Kenyon (United Kingdom)		
IS32-1	Introduction	13:00 - 13:05
	<i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	
IS32-2	A holistic view of the GvHD patient journey	13:05 - 13:25
	<i>Speaker:</i> Dr. Francesca Kinsella (United Kingdom)	
IS32-3	A nurse's (operator's) perspective on the Therakos ECP treatment	13:25 - 13:45
	<i>Speaker:</i> Laura Dalling (United Kingdom)	
IS32-4	Q&A session - All speakers	13:45 - 14:00

<i>Statistics</i>		
13:00 - 14:00		CARRON
STATS2 - Statistical Workshop		
<i>Chair:</i> Dr. Liesbeth de Wreede (Netherlands)		
STATS2-1	Time-dependent effects: when do they matter?	13:00 - 14:00
	<i>Speaker:</i> Mr. Edouard Bonneville (Netherlands)	
	<i>Speaker:</i> Dr. Simona Iacobelli (Italy)	
	<i>Speaker:</i> Dr. Esteban Arrieta Bolaños (Germany)	
<i>Industry Meet the Expert</i>		
13:00 - 14:00		CASTLE Suite
S-MTE - Meet the Expert		
<i>Industry Meet the Expert</i>		
13:00 - 14:00		CASTLE Suite
S-MTE-4 - Collaborative Excellence: Bridging Haematology and Data Sciences for superior Stem Cell Collections Terumo		
<i>Chair:</i> Jesús Fernandez (Spain)		
<i>Industry Theatre</i>		
13:10 - 13:45		IT
IT5 - Treosulfan and haploidentical SCT - A "perfect match"? medac		
IT5-1	Is Treosulfan already Standard of Care in children?	13:10 - 13:10
	<i>Speaker:</i> Selim Corbacioglu (Germany)	
IT5-2	Treosulfan in adult haploSCT: the way to go	13:10 - 13:10
	<i>Speaker:</i> Muhammad Saif (United Kingdom)	
<i>Breaks</i>		
14:00 - 14:30		CLYDE
Break, ePoster Viewing, Visit Exhibition		
<i>Plenary Session</i>		
14:30 - 16:00		CLYDE
P04 - GVHD - State of the Art		
<i>Chair:</i> Victoria Potter (United Kingdom)		
<i>Chair:</i> Prof. Dr. Jean El-Cheikh (Lebanon)		
P04-1	Tales from the crypt: New approaches to GI GVHD	14:30 - 14:55
	<i>Speaker:</i> Prof. James Ferrara (United States)	
P04-2	GVHD prophylaxis in 2024 and beyond	14:55 - 15:20
	<i>Speaker:</i> Prof. Ronjon Chakraverty (United Kingdom)	
P04-3	Biology driven treatment approaches for acute GVHD	15:20 - 15:45
	<i>Speaker:</i> Prof. Robert Zeiser (Germany)	
P04-4	Q&A - Discussion	15:45 - 16:00
<i>Paediatrics Day</i>		
14:30 - 15:45		LOMOND
Paed3 - Paediatric Diseases Oral Session		
<i>Chair:</i> Prof. Adriana Balduzzi (Italy)		
<i>Chair:</i> Prof. Dr. Brenda Gibson (United Kingdom)		
Paed3-01	MODEL-BASED DOSING OF ANTI-THYMOCYTE GLOBULIN IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPROVES SURVIVAL CHANCES: UPDATED	14:30 - 14:39

	RESULTS FROM THE PHASE II PARACHUTE-TRIAL COMBINED WITH REAL-WORLD DATA	
	<i>Oral Presenter:</i> Dr. Rick Admiraal (Netherlands)	
Paed3-02	IMPACT OF MINIMAL RESIDUAL DISEASE AT HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITHIN THE FORUM TRIAL	14:39 - 14:48
	<i>Oral Presenter:</i> Prof. Adriana Balduzzi (Italy)	
Paed3-03	ACUTE GVHD IN PATIENTS ENROLLED IN THE PROSPECTIVE, INTERNATIONAL FORUM TRIAL: CLINICAL RESULTS	14:48 - 14:57
	<i>Oral Presenter:</i> Pietro Merli (Italy)	
Paed3-04	HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE <18MONTHS: RESULTS FROM THE HR-NBL1/SIOPEN TRIAL	14:57 - 15:06
	<i>Oral Presenter:</i> Ruth Ladenstein (Austria)	
Paed3-05	SECOND HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION (HCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) IN CHILDREN WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES RELAPSED OR GRAFT FAILED	15:06 - 15:15
	<i>Oral Presenter:</i> Davide Leardini (Italy)	
Paed3-06	LONG-TERM RESULTS OF RANDOMISED PHASE 2 TRIAL TO COMPARE TREOSULFAN WITH BUSULFAN BASED CONDITIONING IN CHILDREN WITH NON-MALIGNANT DISEASES	15:15 - 15:24
	<i>Oral Presenter:</i> Rita Beier (Germany)	
Paed3-07	HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TEENAGE AND YOUNG ADULT PATIENTS WITH ACUTE LEUKAEMIA IN THE UK AND IRELAND: COMPARISONS WITH CHILDREN AND ADULTS	15:24 - 15:33
	<i>Oral Presenter:</i> Graham McIlroy (United Kingdom)	
Paed3-08	HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN AND ADOLESCENTS WITH HEMATOLOGIC MALIGNANCIES: A RETROSPECTIVE MULTICENTRIC STUDY FROM THE SFGM-TC AND THE SFCE	15:33 - 15:42
	<i>Oral Presenter:</i> Cléo Hautefeuille (France)	
<i>Educational</i>		
14:30 - 16:00		Hall 3 North
E05 - Accessing optimal treatment for Myeloma		
<i>Chair:</i> Prof. Dr. Monica Engelhardt (Germany)		
<i>Chair:</i> Dr. Charlotte Pawlyn (United Kingdom)		
E05-1	Is there still a role for Autograft in MM	14:30 - 14:55
	<i>Speaker:</i> Prof. Gordon Cook (United Kingdom)	
E05-2	Going for cure! The role of CAR-T	14:55 - 15:20
	<i>Speaker:</i> Dr. Sergio Giralt (United States)	
E05-3	Issues of Equity and Access: ethnicity and access to clinical trials	15:20 - 15:45
	<i>Speaker:</i> Dr. Rakesh Popat (United Kingdom)	
E05-4	Q&A - Discussion	15:45 - 16:00
<i>Oral Session</i>		
14:30 - 15:45		Hall 3 South
OS05 - Oral Session 5 Optimising donor Choice		
<i>Chair:</i> Dr. Pramila Krishnamurthy (United Kingdom)		
<i>Chair:</i> Dr. Anne Parker (United Kingdom)		

OS5-01	IMPACT OF HAPLOIDENTICAL OR MISMATCHED UNRELATED DONOR AGE (<35 VS >35 YEARS) ON TRANSPLANTATION WITH PTCY OUTCOMES: ON BEHALF OF THE ALWP OF THE EBMT <i>Oral Presenter:</i> Prof. Arnon Nagler (Israel)	14:30 - 14:39
OS5-02	SALVAGE HAPLOIDENTICAL TRANSPLANTATION FROM A DIFFERENT HAPLOIDENTICAL DONOR USING FLU/CY REGIMEN FOR GRAFT FAILURE AFTER FIRST HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION: AN UPDATED FOLLOW-UP <i>Oral Presenter:</i> Yuqian Sun (China)	14:39 - 14:48
OS5-03	MATCHED RELATED VERSUS MATCHED UNRELATED VERSUS HAPLOIDENTICAL DONORS IN FLT3-ITD+ AML PATIENTS IN CR1: A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY	14:48 - 14:57
OS5-04	SUPERIOR DISEASE CONTROL WITH YOUNGER MATCHED UNRELATED DONOR VS OLDER-AGED MATCHED SIBLING DONOR IN RECIPIENTS ≥50-YEARS WITH ALL, AML, OR MDS USING CNI-BASED GVHD PROPHYLAXIS <i>Oral Presenter:</i> Karthik Nath (United States)	14:57 - 15:06
OS5-05	ALTERNATIVE DONORS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN ADOLESCENT AND YOUNG ADULTS: A REPORT FROM THE SFGM-TC <i>Oral Presenter:</i> Aude-Marie Fourmont (France)	15:06 - 15:15
OS5-06	COMPARING THE OUTCOMES OF USING NON-FIRST-DEGREE RELATED DONORS TO FIRST-DEGREE RELATED DONORS IN HAPLOIDENTICAL HSCT FOR HEMATOLOGICAL MALIGNANCIES: A CASE-CONTROL ANALYSIS <i>Oral Presenter:</i> Fang Xu (China)	15:15 - 15:24
OS5-07	COMPARATIVE STUDY FOR HAPLO, MSD AND MUD ALLO-HCTS FOR CBF AML PATIENTS IN CR2: A STUDY FROM THE GLOBAL COMMITTEE AND ALWP OF THE EBMT <i>Oral Presenter:</i> Yishan Ye (China)	15:24 - 15:33
OS5-08	OLD MATCHED SIBLING DONOR VERSUS YOUNG HAPLOIDENTICAL DONOR FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TRANSPLANTED IN FIRST REMISSION <i>Oral Presenter:</i> Xavier Poiré (Belgium)	15:33 - 15:42

Workshop

14:30 - 16:00

Hall 2

W05 - CAR T technologies*Chair:* Prof. Dr. Stephanie Nguyen (France)*Chair:* Prof. Dr. Roman Hajek (Czech Republic)

W05-1	Emerging CAR technologies: Universal approaches including NK <i>Speaker:</i> Claire Roddie (United Kingdom)	14:30 - 14:55
W05-2	Monitoring vector integration sites in vivo for clonal tracking and safety assessment <i>Speaker:</i> Dr. Eugenio Montini (Italy)	14:55 - 15:20
W05-3	Novel CART technologies: iPSC CAR T cells <i>Speaker:</i> Dr. Maria Themeli (Netherlands)	15:20 - 15:45
W05-4	Q&A - Discussion	15:45 - 16:00

Workshop

14:30 - 16:00

Hall 5

W06 - Monitoring techniques applied to HSCT and Cellular Therapy*Chair:* Prof. Dr. Felicitas Thol (Germany)*Chair:* Dr. Susana Rives (Spain)

W06-1	MRD monitoring in AML: implications for HSCT <i>Speaker:</i> Prof. Sylvie Freeman (United Kingdom)	14:30 - 14:55
W06-2	MRD and treatment decision making in paediatric ALL <i>Speaker:</i> Dr. Valerie de Haas (Netherlands)	14:55 - 15:20
W06-3	Integrating genomics and MRD in transplant decision making <i>Speaker:</i> Dr. Jurjen Versluis (Netherlands)	15:20 - 15:45
W06-4	Q&A - Discussion	15:45 - 16:00

Nurses Group

14:30 - 16:00

Hall 1

NG16 - Infections*Chair:* Ms. Claudia Boglione (Italy)*Chair:* Ms. Aileen Nield (United Kingdom)

NG16-1	Catheters in hematology patients and catheter-related infections <i>Speaker:</i> Ms. Christel Janssens (Belgium)	14:30 - 14:50
NG16-2	Fungal infections and resistance <i>Speaker:</i> Dr. Alberto Mussetti (Spain)	14:50 - 15:10
NG16-3	New drugs and approaches for viral complications <i>Speaker:</i> Dr. Chloé Antier (France)	15:10 - 15:30
NG16-4	Toxoplasma <i>Speaker:</i> Mr. Thomas Jezequel (France)	15:30 - 15:50
NG16-5	Q&A	15:50 - 16:00

Quality Management

14:30 - 15:45

Hall M1

QM3 - Quality Management 3 - JACIE Anniversary Session*Chair:* Dr. Lynn Manson (United Kingdom)

QM3-1	FACT-JACIE Standards 1st-9th: Evolution of Quality Standards <i>Speaker:</i> Prof. Dr. Phyllis Warkentin (United States)	14:30 - 14:45
QM3-2	Interim Update: 9th Edition of FACT-JACIE Standards <i>Speaker:</i> Dr. Lynn Manson (United Kingdom)	14:45 - 15:00
QM3-3	Case for Standalone IEC accreditation <i>Speaker:</i> Ms. Jade Mulligan (United Kingdom)	15:00 - 15:15
QM3-4	Best Quality Management Abstract Award Presentation MONITORING ALLOGENEIC TRANSPLANT CENTERS PERFORMANCE USING THE CUSUM METHOD <i>Oral Presenter:</i> Florence Mesnil (France)	15:15 - 15:30
QM3-5	Q&A	15:30 - 15:45

Practise Harmonisation Day

14:30 - 15:45

FORTH

HM3 - Practise Harmonisation Day 3 | IDWP harmonisation workshop*Chair:* Prof. Dr. Per Ljungman (Sweden)

HM3-1	Harmonizing infection definitions <i>Speaker:</i> Dr. José Luis Piñana Sanchez (Spain)	14:30 - 14:45
HM3-2	Defining Bloodstream Infections in Patients Following Hematopoietic Cell Transplantation <i>Speaker:</i> Prof. Dina Averbuch (Israel)	14:45 - 15:00
HM3-3	Q&A	15:00 - 15:15
<i>Transplant and Search Coordinators Day</i>		
14:30 - 15:45		BOISDALE
TSCD3 - EBMT-WMDA Transplant and Search Coordinators Day 3 Optimising Registry Operations		
<i>Chair:</i> Dr. Deborah Buk (Germany)		
TSCD3-1	Comparison of HLA typing: buccal vs blood samples <i>Speaker:</i> Dr. Neema Mayor (United Kingdom)	14:30 - 14:55
TSCD3-2	Reduced time to transplant: selecting extensively typed cord blood units <i>Speaker:</i> Dr. Nerea Castillo (Spain)	14:55 - 15:20
TSCD3-3	Donor engagement: understanding and improving communication with generation Z. How can we strengthen their commitment? <i>Speaker:</i> Ms. Nicole Silverstolpe (Sweden)	15:20 - 15:45
<i>Nurses Group</i>		
14:30 - 16:00		ALSH
NG17 - Keeping patients safe		
<i>Chair:</i> Ms. Sara Main (United Kingdom)		
<i>Chair:</i> Ms. Ariadna Domenech (Spain)		
NG17-1	Falls prevention strategies <i>Speaker:</i> Ms. Kay Biljohn (United Kingdom)	14:30 - 14:50
NG17-2	Medication errors/management <i>Speaker:</i> Ms. Sarah Deuss (Belgium)	14:50 - 15:10
NG17-3	Communication challenges and how to overcome them <i>Speaker:</i> Ms. Hilda Mekelenkamp (Netherlands)	15:10 - 15:30
NG17-4	Workforce investment with the focus on training investments <i>Speaker:</i> Ms. Simona Calza (Italy)	15:30 - 15:50
NG17-5	Q&A	15:50 - 16:00
<i>General</i>		
14:30 - 15:45		CARRON
GS3 - EBMT General Assembly		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
GS3-1	President's Report <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	14:30 - 14:55
GS3-2	Secretary's Report <i>Speaker:</i> Prof. John Snowden (United Kingdom)	14:55 - 15:05
GS3-3	Treasurer's Financial Report <i>Speaker:</i> Prof. Dr. Mette Hazenberg (Netherlands)	15:05 - 15:15
GS3-4	Election Results 2024 <i>Speaker:</i> Prof. John Snowden (United Kingdom)	15:15 - 15:20

GS3-5	Outgoing Board members <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	15:20 - 15:25
GS3-6	Q&A	15:25 - 15:30
<i>Nurses Group</i> 14:30 - 16:00		GALA
NG18 - Skills lab 2 Apheresis		
<i>Chair:</i> Ms. Natalia Lorente (Spain)		
<i>Chair:</i> Ms. Angela Leather (United Kingdom)		
NG18-1	Introduction and apheresis survey results	14:30 - 14:45
NG18-2	Common challenges of apheresis	14:45 - 15:20
NG18-3	Audit, quality and research	15:20 - 15:35
NG18-4	How to grow an Apheresis nurse - addressing workforce challenges through education	15:35 - 15:55
NG18-5	Closing remarks	15:55 - 16:00
<i>Data Management</i> 14:30 - 16:00		ARGYLL Suite
DMT3 - Hands-On EBMT Registry Training Session 3		
DMT3-1	Data Entry	14:30 - 14:30
DMT3-2	Filtering	14:30 - 14:30
DMT3-3	Common Requests	14:30 - 14:30
<i>Breaks</i> 16:00 - 16:30		CLYDE
Coffee Break, ePoster Viewing, Visit Exhibition		
<i>Workshop</i> 16:30 - 18:00		CLYDE
W07 - Challenges in AML		
<i>Chair:</i> Dr. Keith Wilson (United Kingdom)		
<i>Chair:</i> Victoria Potter (United Kingdom)		
W07-1	Transplanting with residual/refractory disease <i>Speaker:</i> Prof. Dr. Johannes Schetelig (Germany)	16:30 - 16:55
W07-2	Drug maintenance strategies post allogeneic stem cell transplant <i>Speaker:</i> Prof. Mark Levis (United States)	16:55 - 17:20
W07-3	Immunotherapy in AML <i>Speaker:</i> Prof. Dr. Marion Subklewe (Germany)	17:20 - 17:45
W07-4	Q&A - Discussion	17:45 - 18:00
<i>Paediatrics Day</i> 16:30 - 17:45		LOMOND
Paed4 - Inborn Errors Oral Session		
<i>Chair:</i> Prof. Benedicte Neven (France)		
<i>Chair:</i> Prof. Dr. Michael Albert (Germany)		
Paed4-01	PRE-TRANSPLANT IMMUNE DYSREGULATION PREDICTS FOR	16:30 - 16:39

	POOR OUTCOME FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADOLESCENTS AND ADULTS WITH INBORN ERRORS OF IMMUNITY (IEI) <i>Oral Presenter:</i> Dr. Thomas Fox (United Kingdom)	
Paed4-02	OUTCOME OF PATIENTS WITH SIGNAL-TRANSDUCER AND ACTIVATOR OF OF TRANSCRIPTION 1 MUTATIONS (STAT1) GAIN-OF-FUNCTION VARIANTS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION - AN IEWP/PIDTC STUDY <i>Oral Presenter:</i> Emilie Pauline Buddingh (Netherlands)	16:39 - 16:48
Paed4-03	HAPLOIDENTICAL STEM-CELL TRANSPLANTATION FOR CHRONIC GRANULOMATOUS DISEASE, AN EBMT-IEWP RETROSPECTIVE STUDY <i>Oral Presenter:</i> Quentin Riller (France)	16:48 - 16:57
Paed4-04	HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CTLA-4 INSUFFICIENCY: AN EBMT INBORN ERRORS WORKING PARTY STUDY <i>Oral Presenter:</i> Christo Tsilifis (United Kingdom)	16:57 - 17:06
Paed4-05	HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PTCY IN VIVO DEPLETED T-CELL FOR NON-SCID INBORN ERRORS OF IMMUNITY: A MONOCENTRIC CENTER EXPERIENCE <i>Oral Presenter:</i> Jean-Sebastien Diana (France)	17:06 - 17:15
Paed4-06	VENO-OCCLUSIVE DISEASE AND EARLY CARDIAC EVENTS IN CHILDREN RECEIVING ALLOGENIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Oral Presenter:</i> Alice Corsia (France)	17:15 - 17:24
Paed4-07	HAEMATOPOIETIC STEM CELL GENE THERAPY FOR HURLER SYNDROME: CLINICAL SKELETAL OUTCOME DATA AND STUDY OF THE SKELETAL CROSS-CORRECTION MECHANISMS <i>Oral Presenter:</i> Maria Ester Bernardo (Italy)	17:24 - 17:33
Paed4-08	A PRETRANSPLANT INFLAMMATORY SIGNATURE IS ASSOCIATED WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND MORTALITY IN PEDIATRIC PATIENTS <i>Oral Presenter:</i> Anne B. Verbeek (Netherlands)	17:33 - 17:42
<i>Educational</i> 16:30 - 18:00		Hall 3 North
E06 - Management of infectious disease		
<i>Chair:</i> Dr. Anne Parker (United Kingdom) <i>Chair:</i> Dr. Rafael de la Camara (Spain)		
E06-1	Emerging treatments and prophylaxis for viral infection <i>Speaker:</i> Prof. Dr. Rafael Duarte (Spain)	16:30 - 16:55
E06-2	Vaccination following HSCT and CAR-T: state-of-the-art and future considerations <i>Speaker:</i> Prof. Thushan de Silva (United Kingdom)	16:55 - 17:20
E06-3	Emerging antifungal resistant pathogens <i>Speaker:</i> Prof. Dr. Malgorzata Mikulska (Italy)	17:20 - 17:45
E06-4	Q&A - Discussion	17:45 - 18:00

Oral Session

16:30 - 17:45

Hall 3 South

OS06 - Oral Session 6 | Factors influencing outcomes in CAR-T therapy

Chair: Dr. Sridhar Chaganti (United Kingdom)

Chair: Dr. Emma Nicholson (United Kingdom)

- | | | |
|--------|---|---------------|
| OS6-01 | SINGLE CENTRE LONG-TERM OUTCOMES OF RELAPSED/REFRACTORY PAEDIATRIC B-ALL AFTER GENOME-EDITED 'UNIVERSAL' CAR19 T CELL THERAPY
<i>Oral Presenter:</i> Daniela Guardo (United Kingdom) | 16:30 - 16:39 |
| OS6-02 | ELEVATED MYELOID-DERIVED SUPPRESSOR CELL (MDSC) LEVELS RESULT IN REDUCED CAR-T CELL EXPANSION AND IMPAIRED EFFICACY
<i>Oral Presenter:</i> Eugenio Galli (Italy) | 16:39 - 16:48 |
| OS6-03 | DONOR-DERIVED CAR-T CELLS FOR THE TREATMENT OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
<i>Oral Presenter:</i> Fang Zhou (China) | 16:48 - 16:57 |
| OS6-04 | ITACITINIB FOR THE PREVENTION OF IMMUNE EFFECTOR CELL THERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME: RESULTS FROM THE PHASE 2 INCB 39110-211 PLACEBO-CONTROLLED RANDOMIZED COHORT
<i>Oral Presenter:</i> Richard Maziarz (United States) | 16:57 - 17:06 |
| OS6-05 | DONOR-DERIVED CAR-T CELLS ARE SAFELY AND EFFECTIVELY CO-INFUSED WITH THE ALLOGENIC GRAFT, DEPLETED OF AB T CELLS IN CHILDREN WITH ADVANCED B-CELL NEOPLASM
<i>Oral Presenter:</i> Alexey Maschan (Russian Federation) | 17:06 - 17:15 |
| OS6-06 | SITE-SPECIFIC RESPONSES AND EXTRANODAL INVOLVEMENT IMPLICATIONS IN LARGE B-CELL LYMPHOMAS TREATED WITH CD19-CART THERAPY
<i>Oral Presenter:</i> Alejandro Luna de Abia (United States) | 17:15 - 17:24 |
| OS6-07 | POST-TRANSPLANT RELAPSE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN THE ERA OF CAR-T CELL THERAPY. A MULTICENTER ANALYSIS OF GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC) PEDIATRIC COMMITTEE
<i>Oral Presenter:</i> Marta Gonzalez Vicent (Spain) | 17:24 - 17:33 |
| OS6-08 | MACROPHAGE ACTIVATION SYNDROME IN CAR-T: AN ANALYSIS OF DIAGNOSTIC CRITERIA
<i>Oral Presenter:</i> Mafalda Urbano (Portugal) | 17:33 - 17:42 |

Oral Session

16:30 - 17:45

Hall 2

OS07 - Oral Session 7 | Minimising GVHD risk

Chair: Ms. Marie Czech (Germany)

Chair: Dr. Harpreet Kaur (United Kingdom)

- | | | |
|--------|---|---------------|
| OS7-01 | LIPOCALIN-2 REDUCES ACUTE GRAFT-VERSUS-HOST DISEASE SEVERITY IN MICE
<i>Oral Presenter:</i> Ms. Marie Czech (Germany) | 16:30 - 16:39 |
| OS7-02 | GITMO PROSPECTIVE STUDY IN 266 CGVHD PATIENTS, RECEIVING BEST AVAILABLE TREATMENT; VALIDATION OF A SOFTWARE FOR CGVHD SCORING AND RESPONSE EVALUATION ACCORDING TO NIH 2014
<i>Oral Presenter:</i> Attilio Olivieri (Italy) | 16:39 - 16:48 |
| OS7-03 | VASOACTIVE INTESTINAL POLYPEPTIDE SYNTHESIS BY THE GUT ENTERIC NEURAL PLEXUS PROMOTES A DIVERSE MICROBIOME | 16:48 - 16:57 |

	AND CONFERS RESISTANCE TO GRAFT VERSUS HOST DISEASE	
	<i>Oral Presenter:</i> Edmund K. Waller (United States)	
OS7-04	PTCY PLUS ATG COMPARED TO PTCY ALONE IN HAPLOIDENTICAL TRANSPLANTATION WITH PBSGS: A RETROSPECTIVE STUDY ON BEHALF OF THE CTIWP OF THE EBMT	16:57 - 17:06
	<i>Oral Presenter:</i> Antoine Capes (France)	
OS7-05	TARGETING PI3K^{DELTA} FUNCTION FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE	17:06 - 17:15
	<i>Oral Presenter:</i> Qingxiao Song (China)	
OS7-06	GALECTIN-9 RELEASED BY CHEMOTHERAPY-DAMAGED INTESTINAL EPITHELIUM ATTRACTS AND STIMULATES ACTIVATION OF ALLO T CELLS	17:15 - 17:24
	<i>Oral Presenter:</i> Suze Anne Jansen (Netherlands)	
OS7-07	CLINICAL EXPERIENCE IN THE USE OF MESENCHYMAL STROMAL CELLS IN PEDIATRIC GRAFT-VERSUS-HOST DISEASE: ON BEHALF OF THE SPANISH GROUP OF STEM CELL TRANSPLANTATION (GETH)	17:24 - 17:33
	<i>Speaker:</i> Julia Marsal Ricoma (Spain)	
OS7-08	DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)	17:33 - 17:42
	<i>Oral Presenter:</i> Javier Delgado Serrano (Spain)	
<i>Workshop</i>		
	16:30 - 18:00	Hall 5
W08 - EBMT debates		
<i>Chair:</i> Dr. Grant McQuaker (United Kingdom)		
<i>Chair:</i> Prof. Charlie Craddock (United Kingdom)		
W08-1	2nd allo v DLI in relapse post-HSCT (pro second HSCT)	16:30 - 16:45
	<i>Speaker:</i> Dr. Marie Robin (France)	
W08-2	2nd allo v DLI in relapse post-HSCT (pro DLI)	16:45 - 17:00
	<i>Speaker:</i> Prof. Dr. Christoph Scheid (Germany)	
W08-3	2nd auto in MM utility (pro)	17:00 - 17:15
	<i>Speaker:</i> Prof. Graham Jackson (United Kingdom)	
W08-4	2nd auto in MM utility (against)	17:15 - 17:30
	<i>Speaker:</i> Dr. Charlotte Pawlyn (United Kingdom)	
W08-5	Discussion & vote	17:30 - 18:00
<i>Nurses Group</i>		
	16:30 - 18:00	Hall 1
NG19 - Current ethical considerations		
<i>Chair:</i> Ms. Deborah Anderson (United Kingdom)		
<i>Chair:</i> Ms. Kelly Hennessy (United Kingdom)		
NG19-1	Germline predisposition traits	16:30 - 16:55
	<i>Speaker:</i> Dr. Carmelo Gurnari (United States)	
NG19-2	Designer donors	16:55 - 17:20
	<i>Speaker:</i> Prof. Dr. Kathelijn Keymolen (Belgium)	
NG19-3	Introducing advance care planning	17:20 - 17:45
	<i>Speaker:</i> Mr. Andres Moya Davila (United Kingdom)	
NG19-4	Discussion	17:45 - 18:00

Quality Management

16:30 - 17:45

Hall M1

QM4 - Quality Management 4 - Addressing Common Deficiencies*Chair:* Ms. Lea Brandt Kristensen (Denmark)*Chair:* Ms. Renza Monteleone (Italy)

QM4-1	IEC Standards <i>Speaker:</i> Dr. Cristina Castilla-Llorente (France)	16:30 - 16:45
QM4-2	Addressing the Audit Standards <i>Speaker:</i> Ms. Helena Munro (United Kingdom)	16:45 - 17:00
QM4-3	ISBT128 Labelling <i>Speaker:</i> Dr. Olga López (Spain)	17:00 - 17:15
QM4-4	Quality Management in Apheresis Units <i>Speaker:</i> Prof. Dr. Ann de Becker (Belgium)	17:15 - 17:30
QM4-5	Q&A	17:30 - 17:45

Practise Harmonisation Day

16:30 - 17:45

FORTH

HM4 - Practise Harmonisation Day 4 | CTIWP, TCWP and ADWP harmonisation workshops*Chair:* Prof. Dominique Farge (France)*Chair:* Prof. Basil Sharrack (United Kingdom)

HM4-1	Donor lymphocyte infusion: recommendations on behalf of the Practice Guidelines and Harmonization Committee and the Cellular Therapy and Immunobiology Working Party of the EBMT <i>Speaker:</i> Dr. Nicole Santoro (Italy)	16:30 - 17:00
HM4-2	Autoimmune diseases undergoing innovative cell therapies <i>Speaker:</i> Dr. Raffaella Greco (Italy)	17:00 - 17:33
HM4-3	Q&A	17:33 - 17:45

Transplant and Search Coordinators Day

16:30 - 17:45

BOISDALE

TSCD4 - EBMT-WMDA Transplant and Search Coordinators Day 4 | EBMT-WMDA partners for 30 years*Chair:* Lydia Foeken (Netherlands)

TSCD4-1	Partners in donor care - sharing patient outcome data <i>Speaker:</i> Dr. Deborah Buk (Germany)	16:30 - 16:55
TSCD4-2	Cellular Therapy: current landscape and future directions for WMDA <i>Speaker:</i> Ms. Salmah Ahmed (United Kingdom)	16:55 - 17:20
TSCD4-3	EBMT and WMDA: past and future collaboration <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	17:20 - 17:45

Nurses Group

16:30 - 18:00

ALSH

NG20 - Research abstracts finalists*Chair:* Dr. Sabine Valenta (Switzerland)*Chair:* Dr. Isabel Salcedo-Diego (Spain)

NG20-01	COST-EFFECTIVENESS EVALUATION OF AN EHEALTH-FACILITATED INTEGRATED CARE MODEL FOR ALLOGENEIC STEM CELL TRANSPLANTATION- THE GERMAN SMILE HYBRID EFFECTIVENESS IMPLEMENTATION TRIAL <i>Oral Presenter:</i> Dr. Lynn Leppla (Germany)	16:30 - 16:45
---------	---	---------------

NG20-02	PATIENTS' PERSPECTIVES ON THE IMPLEMENTATION OF AN EHEALTH FACILITATED INTEGRATED CARE MODEL FOR ALLOGENEIC STEM CELL TRANSPLANTATION - FINDINGS FROM THE SMILE PROJECT BELGIUM <i>Oral Presenter:</i> Kristina Arnahoutova (Belgium)	16:45 - 17:00
NG20-03	FEASIBILITY OF A DEVELOPED PERSON-CENTRED CARE MODEL TARGETING NEEDS OF PATIENTS IN THE CONTEXT OF ALLO-HSCT <i>Oral Presenter:</i> Dr. Jeanette Winterling (Sweden)	17:00 - 17:15
NG20-04	PATIENTS' PERSPECTIVES ON PSYCHOSOCIAL SUPPORT IN ALLOGENEIC STEM CELL TRANSPLANTATION WITH A RELATED DONOR <i>Oral Presenter:</i> Lotte Kinds (Belgium)	17:15 - 17:30
NG20-05	EVALUATING THE IMPACT OF ONLINE SPECIALIZED TRAINING ON THE KNOWLEDGE AND ATTITUDE OF NURSES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LOW-RESOURCE SETTINGS: A CROSS-SECTIONAL STUDY <i>Oral Presenter:</i> Blessing Aziken-John (Nigeria)	17:30 - 17:45
<i>Oral Session</i> 16:30 - 17:45		CARRON
OS08 - Oral Session 8 Cellular Therapy for autoimmune and inflammatory Diseases		
<i>Chair:</i> Dr. Alice Mariottini (Italy)		
<i>Chair:</i> Dr. Majid Kazmi (United Kingdom)		
OS8-01	CLINICAL OUTCOMES OF HIGH DOSE IMMUNOSUPPRESSIVE THERAPY (HDIT) WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS PATIENTS: LONG-TERM SINGLE CENTER EXPERIENCE <i>Oral Presenter:</i> Denis Fedorenko (Russian Federation)	16:30 - 16:39
OS8-02	ENGINEERED AIR-TREG CELLS AS A NOVEL THERAPY CONCEPT FOR INFLAMMATION-DRIVEN DISEASES <i>Oral Presenter:</i> Sebastian Bittner (Germany)	16:39 - 16:48
OS8-03	GAMMA DELTA T CELLS RECONSTITUTION IN LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - HOMEOSTATIC STEADY-STATE? <i>Oral Presenter:</i> Faisal Alagrafi (Sweden)	16:48 - 16:57
OS8-04	AUTOLOGOUS HSCT IN MULTIPLE SCLEROSIS: THE UK EXPERIENCE 2002-2023 (ON BEHALF OF THE BSBMT CTC GROUP) <i>Oral Presenter:</i> Dr. Majid Kazmi (United Kingdom)	16:57 - 17:06
OS8-05	AUTOLOGOUS HSCT FOR MULTIPLE SCLEROSIS SHOULD BE DONE EARLY IN THE COURSE OF THE DISEASE <i>Oral Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	17:06 - 17:06
OS8-06	BEAM/ATG OR CYCLOPHOSPHAMIDE/ATG AS CONDITIONING REGIMEN IN AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS: A RETROSPECTIVE ANALYSIS OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY <i>Oral Presenter:</i> Prof. John Snowden (United Kingdom)	17:06 - 17:15
OS8-07	FULLY HUMAN CD19-TARGETED CAR T CELLS IN A CASE OF REFRACTORY ANTI-ACHR ANTIBODY POSITIVE MYASTHENIA GRAVIS <i>Oral Presenter:</i> Dimitrios Mouggiakakos (Germany)	17:15 - 17:24
OS8-08	AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS - A 25-YEAR	17:24 - 17:33

MONOCENTRIC EXPERIENCE*Oral Presenter:* Dr. Alice Mariottini (Italy)*Nurses Group*

16:30 - 18:00

GALA

NG21 - Skills Lab 3 | Query Flash Talks*Chair:* Mr. John Murray (United Kingdom)*Chair:* Ms. Sandrine Bremathas (United Kingdom)

NG21-01	THE STRAIGHT AND MARROW PODCAST - EVERYTHING YOU ALWAYS WANTED TO KNOW ABOUT ALLOGENEIC BONE MARROW TRANSPLANTS	16:30 - 16:38
	<i>Oral Presenter:</i> Yvonne Panek-Hudson (Australia)	
NG21-02	ENTERAL NUTRITION CAN REDUCE WEIGHT LOSS AND MAY AFFECT LENGTH OF STAY IN MYELOABLATIVE STEM CELL TRANSPLANT: AN INDICATION FOR A PROACTIVE ENTERAL NUTRITION PATHWAY	16:38 - 16:46
	<i>Oral Presenter:</i> Abibat Gbadamosi (United Kingdom)	
NG21-03	POSTGRADUATE SPECIALIZATION PROGRAM IN HEMATOPOIETIC STEM CELL TRANSPLANT AND CELLULAR THERAPY NURSING: ANALYSIS OF THE FIRST THREE EDITIONS	16:46 - 16:54
	<i>Oral Presenter:</i> Ms. Julia Ruiz Pato (Spain)	
NG21-04	IDENTIFYING BURDEN OF DRUG ALLERGY AND DEVELOPING A PATIENT PATHWAY FOR DE-LABELLING DRUG ALLERGY IN CHILDREN AND ADOLESCENTS PRIOR TO TRANSPLANT	16:54 - 17:02
	<i>Oral Presenter:</i> Karen Nicholson (United Kingdom)	
NG-21-05	TWENTY YEAR FOLLOW UP OF QUALITY OF LIFE IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY - FROM INFANCY TO ADULTHOOD	17:02 - 17:10
	<i>Oral Presenter:</i> Revathi Raj (India)	
NG21-06	ASSESSMENT OF BURDEN AMONG PRIMARY CAREGIVER OF POST HEMATOPOIETIC STEM CELL TRANSPLANT AND OTHER CELLULAR THERAPIES PATIENTS	17:10 - 17:18
	<i>Oral Presenter:</i> Lalita Bhoir (India)	
NG21-07	PROVISION OF ARTIFICIAL NUTRITION IN BEAM AUTOLOGOUS STEM CELL TRANSPLANT PATIENTS	17:18 - 17:26
	<i>Oral Presenter:</i> Maeve O'Shea (United Kingdom)	
NG21-08	ROLL OUT OF ULTRASOUND GUIDED PERIPHERAL VEIN CANNULATION TRAINING ACROSS SEVEN NHSBT-THERAPEUTIC APHERESIS SERVICES UNITS IN ENGLAND	17:26 - 17:34
	<i>Oral Presenter:</i> Daniel Putensen (United Kingdom)	
NG21-09	Discussion	17:34 - 18:00

Printed Poster

18:00 - 19:00

Hall 3 North

Poster Session in Hall 3*Printed Poster*

18:00 - 19:00

Hall 3 North

Solid Tumours

B278

HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION IN ADULT PRIMARY MEDIASTINAL GERM CELL TUMORS. A RETROSPECTIVE STUDY OF THE EBMT,

18:00 - 18:00

CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY*Poster Presenter:* Simona Secondino (Italy)*Printed Poster*

18:00 - 19:00

Hall 3 North

Nurses Posters - Research

- NP087 **HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANT** 18:00 - 18:00
Poster Presenter: Ammar Zahreddine (Lebanon)
- NP088 **PATIENT'S OWN EXPERIENCES WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION, BEING CARED FOR AT HOME OR NOT. THAT'S THE QUESTION? BUT WHAT IS THE ANSWER?** 18:00 - 18:00
Poster Presenter: Ann Karin Svanberg (Sweden)
- NP095 **THE ROLE OF A SPECIALIST SOCIAL WORKER IN TRANSPLANT: A SERVICE AUDIT** 18:00 - 18:00
Poster Presenter: Rachel Davidson (United Kingdom)

Printed Poster

18:00 - 19:00

Hall 3 North

Nurses Posters - Paediatric

- NP062 **A NO-NONSENSE EDUCATIONAL RESOURCE FOR NO-NONSENSE PAEDIATRIC HSCT NURSES** 18:00 - 18:00
Poster Presenter: Andrew Gooding (United Kingdom)
- NP063 **ASSESSMENT OF PEDIATRIC EARLY WARNING SCORES IN STEM CELL TRANSPLANT PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW AND FOR PREDICTING CLINICAL DETERIORATION** 18:00 - 18:00
Poster Presenter: Matilde Gabrieli (Italy)
- NP064 **PAEDIATRIC SIBLING STEM CELL DONORS - ESTABLISHING A NURSE LED CLINIC** 18:00 - 18:00
Poster Presenter: Annette Hill (United Kingdom)
- NP065 **IMPACT OF THE NURSE-DESIGNED PROTOCOL ON CENTRAL VENOUS CATHETER-RELATED COMPLICATIONS IN PEDIATRIC HEMATO-ONCOLOGICAL PATIENTS: ONE PEDIATRIC FACILITY'S TEN-YEAR EXPERIENCE** 18:00 - 18:00
Poster Presenter: Stefania Braidotti (Italy)
- NP066 **REDUCING THE LENGTH OF STAY FOR PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS BY PERFORMING PRE-HSCT WORKUP IN AN OUTPATIENT SETTING** 18:00 - 18:00
Poster Presenter: Noha Alneedy (Saudi Arabia)
- NP067 **OPTIMIZING COLLABORATION BETWEEN PATIENTS, CAREGIVERS, AND NURSES THROUGH NURSING MENTORSHIP IN PEDIATRIC HSCT** 18:00 - 18:00
Poster Presenter: Anouk Plug (Netherlands)
- NP068 **ASSESSING COPING STRATEGIES OF PARENTS WHOSE CHILDREN UNDERWENT HSCT** 18:00 - 18:00
Poster Presenter: Rosaria Pinto (India)
- NP069 **EVALUATING THE USE OF PARENTERAL NUTRITION IN PAEDIATRIC PATIENTS UNDERGOING A HAEMOPOIETIC STEM CELL TRANSPLANT** 18:00 - 18:00
Poster Presenter: Chloe Elliott (United Kingdom)
- NP071 **DEVELOPMENT OF INDEPENDENT NURSE LED CLINIC** 18:00 - 18:00
Poster Presenter: Petra Brevdo (Finland)

NP072	WHAT ARE THE CHARACTERISTIC OF PAEDIATRIC PATIENTS WHO REQUIRE NUTRITIONAL SUPPORT DURING ALLOGENIC HSCT? <i>Poster Presenter:</i> Laura McIntyre (United Kingdom)	18:00 - 18:00
NP073	THE GOOD, THE BAD AND THE UGLY - NURSING STRATEGIES BASED ON DONOR SOURCE FOR CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSAEMIA MAJOR <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	18:00 - 18:00
NP079	ASSESSMENT BY CAREGIVERS OF THE PRE-HSCT INTERVIEW <i>Poster Presenter:</i> Juana Membrado (Spain)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		Hall 3 North
Nurses Posters - Adult		
NP001	GVHD PATIENT SUPPORT GROUP <i>Poster Presenter:</i> Ms. Deborah Anderson (United Kingdom)	18:00 - 18:00
NP002	NURSING ROLE IN IMPLEMENTING EHEALTH FOR ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: INITIAL FINDINGS FROM THE MYMEDULA STUDY'S RANDOMIZED CLINICAL TRIAL <i>Poster Presenter:</i> Irene García-Cadenas (Spain)	18:00 - 18:00
NP003	NURSE LED PERSONALISED CARE AND SUPPORT PLANNING FOR PATIENTS PREPARING FOR ALLOGENEIC BLOOD AND MARROW TRANSPLANT AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY - PATIENT CO-DESIGN <i>Poster Presenter:</i> Polly Pattenden (United Kingdom)	18:00 - 18:00
NP004	TEACH-BACK METHOD IN ONCO-HEMATOLOGICAL PATIENTS' EDUCATION: A SCOPING REVIEW <i>Poster Presenter:</i> Silvia Gneccchi (Italy)	18:00 - 18:00
NP006	NUTRITIONAL IMPLICATIONS OF CAR-T THERAPY IN SCOTLAND <i>Poster Presenter:</i> Abigail Dean (United Kingdom)	18:00 - 18:00
NP007	SETTING UP A PATIENT INITIATED FOLLOW-UP (PIFU) PROGRAMME FOR THE LONG TERM FOLLOW UP OF ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS- THE WESSEX BMTCT EXPERIENCE <i>Poster Presenter:</i> Jenna Sloan (United Kingdom)	18:00 - 18:00
NP008	EVALUATING COGNITIVE IMPAIRMENT AND NEUROTOXICITY POST CAR T CELL THERAPY <i>Poster Presenter:</i> Eleni Gavriilaki (Greece)	18:00 - 18:00
NP009	THE SAFE DELIVERY OF A 'BLOODLESS' AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA - PUTTING THE PATIENT'S WISHES AT THE FOREFRONT OF TRANSPLANT DELIVERY <i>Poster Presenter:</i> Emma Storey (United Kingdom)	18:00 - 18:00
NP013	ENHANCING WARD-BASED NURSING TEACHING IN A BONE MARROW TRANSPLANT UNIT: EVALUATING THE IMPACT OF AN INDUCTION PACK FOR NEW NURSING STAFF. PILOT STUDY <i>Poster Presenter:</i> Krzysztof Dariusz Ciesielski (United Kingdom)	18:00 - 18:00
NP014	A RETROSPECTIVE AUDIT OF LENGTH OF STAY AND PATIENT EXPERIENCE WITHIN A UK AMBULATORY CARE DEPARTMENT, TO DEMONSTRATE THE EFFECTIVENESS OF THIS MODEL WITHIN HSCT <i>Poster Presenter:</i> Preya Assi (United Kingdom)	18:00 - 18:00

NP015	HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN OUTPATIENT SETTING: A SINGLE CENTER EXPERIENCE IN SAUDI ARABIA <i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	18:00 - 18:00
NP016	"MASTERS OF SEX": INCREASING AWARENESS OF AND KNOWLEDGE ABOUT SEXUAL HEALTH OF HSCT PATIENTS <i>Poster Presenter:</i> Limor Mintz-Manor (Israel)	18:00 - 18:00
NP017	PATIENTS' PSYCHOLOGICAL DISTRESS PRE HSCT AND CAR-T: FINDINGS FROM TWO YEARS' ROUTINE PRE-TREATMENT PSYCHOLOGICAL ASSESSMENTS <i>Poster Presenter:</i> Ms. Surabhi Chaturvedi (United Kingdom)	18:00 - 18:00
NP018	DEVELOPING AN INDUCTION PROGRAMME FOR NEWLY QUALIFIED NURSES ON A SPECIALIST HAEMATOLOGY AND TRANSPLANT UNIT <i>Poster Presenter:</i> Annie Hamilton (United Kingdom)	18:00 - 18:00
NP020	IMPLEMENTATION OF A HOSPITAL- AT- HOME PROGRAM FOR AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION: SAFETY AND PATIENT-PERCEIVED SATISFACTION <i>Poster Presenter:</i> Estefanía Pérez-Lopez (Spain)	18:00 - 18:00
NP022	CURRENT EXPERIENCES AND SPECIFIC PSYCHOSOCIAL SUPPORT NEEDS OF RELATED STEM CELL DONORS: A QUALITATIVE STUDY <i>Poster Presenter:</i> Fran Willemsens (Belgium)	18:00 - 18:00
NP023	THE AMBULATORY AUTOLOGOUS STEM CELL TRANSPLANT PROGRAMME FOR MULTIPLE MYELOMA; A SERVICE EVALUATION <i>Poster Presenter:</i> Ethan Brough (United Kingdom)	18:00 - 18:00
NP026	GREATIX - QUALITY IMPROVEMENT BY SHARING SUCCESS / BEST PRACTICE <i>Poster Presenter:</i> Aidan MacDonald (United Kingdom)	18:00 - 18:00
NP028	REDUCED HSCT PATIENTS' ER VISITS BY ASSIGNED 2 BEDS IN HSCT UNIT AS QUICK ER ACCESS , SINGLE CENTER IN SAUDI ARABIA <i>Poster Presenter:</i> Suha Alkhraisat (Saudi Arabia)	18:00 - 18:00
NP031	HSCT CAREGIVER ANXIETY AND DEPRESSION ASSOCIATIONS WITH QUALITY OF LIFE AND REACTION TO CARE. A LONGITUDINAL STUDY <i>Poster Presenter:</i> Arianna Rosich-Soteras (Spain)	18:00 - 18:00
NP032	NURSE LED CAR T CELL THERAPY LONG TERM EFFECTS CLINIC <i>Poster Presenter:</i> Katie Brice (United Kingdom)	18:00 - 18:00
NP033	COMMENCING LOPERAMIDE FOR DIARRHOEA PRIOR TO NEGATIVE CULTURE RESULT AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IS SAFE AND EFFECTIVE <i>Poster Presenter:</i> Amy Colada (United Kingdom)	18:00 - 18:00
NP034	"ANALYSIS OF NUTRITIONAL STATUS AND HOSPITALIZATION DURATION IN ALLOGENEIC TRANSPLANTED PATIENTS IN CROATIA: NURSING INSIGHTS OVER THE PAST 2 YEARS <i>Poster Presenter:</i> Valentina Milinković (Croatia)	18:00 - 18:00
NP035	ADHERENCE TO ORAL IMMUNOSUPPRESSORS USING THE THERAPEUTIC DRUG MONITORING: A RETROSPECTIVE STUDY <i>Poster Presenter:</i> Chiara Visintini (Italy)	18:00 - 18:00

NP041	THE FIRST CAR-T NURSING PRECEPTORSHIP PROGRAM IN THE KINGDOM OF SAUDI ARABIA <i>Poster Presenter:</i> Inaam Shehab Eddine (Saudi Arabia)	18:00 - 18:00
NP049	HAS AN INCREASE IN CAR-T ACTIVITY MEANT A DELAY IN AUTOLOGOUS TRANSPLANT ADMISSIONS DUE TO CAPACITY AND ACUITY CONCERN? <i>Poster Presenter:</i> Ally Braden (United Kingdom)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		Hall 3 North
Myelodysplastic Syndromes		
B275	WT1 GENE MUTATIONS IMPACT POST-TRANSPLANT RELAPSE IN MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS 2 PATIENTS <i>Poster Presenter:</i> Wewen Guo (China)	18:00 - 18:00
B276	OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - A SINGLE-CENTER RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Marketa Stastna Markova (Czech Republic)	18:00 - 18:00
B277	CHALLENGES AND REALITIES OF HEMATOPOIETIC CELL TRANSPLANTATION OF MYELODYSPLASTIC SYNDROMES PATIENTS IN LATIN AMERICA: A SURVEY <i>Poster Presenter:</i> Fernando Barroso Duarte (Brazil)	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		Hall 3 North
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution		
B126	PRE-EMPTIVE DONOR LYMPHOCYTE INFUSION AS OPTIMAL TREATMENT FOR RELAPSED ACUTE MYELOID LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:A FRENCH-ITALIAN EXPERIENCE WITH 103 PATIENTS <i>Poster Presenter:</i> Michele Malagola (Italy)	18:00 - 18:00
B127	HLA-DR+ REGULATORY T CELLS ARE ASSOCIATED WITH THE ONSET AND SEVERITY OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Kinga Hosszu (United States)	18:00 - 18:00
B128	MAINTENANCE THERAPY WITH OLAPARIB AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TP53 MUTATED HEMATOLOGIC MALIGNANCIES <i>Poster Presenter:</i> Zhihui Li (China)	18:00 - 18:00
B129	PERSISTENCE OF MINOR HISTOCOMPATIBILITY ANTIGEN- AND VIRUS-SPECIFIC T CELLS IN LEUKEMIC REMISSION AFTER HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Lisa Marie Schulz (Germany)	18:00 - 18:00
B130	SERIAL LINEAGE CHIMERISM ANALYSIS IMPROVES EARLY DIAGNOSIS OF GRAFT FAILURE AFTER ALLOGENEIC HAPLOIDENTICAL HSCT <i>Poster Presenter:</i> Rebeca Bailén Alomoro (Spain)	18:00 - 18:00
B131	PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION <i>Poster Presenter:</i> Yue-Wen Wang (China)	18:00 - 18:00

B132	CYTOKINE PROFILES ASSOCIATED WITH GRAFT VERSUS HOST DISEASE AND RECENT THYMIC EMIGRANT T CELL RECONSTITUTION AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Devin McAvoy (United States)	18:00 - 18:00
B133	FAVOURABLE IMPACT OF POST-TRANSPLANT MINIMAL DISEASE NEGATIVITY ASSESSED BY FLOW CYTOMETRY ON SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES <i>Poster Presenter:</i> Radwan Massoud (Germany)	18:00 - 18:00
B134	FLOW-CYTOMETRIC AND TRANSCRIPTIONAL CHARACTERIZATION OF RECENT THYMIC EMIGRANTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) <i>Poster Presenter:</i> Marco Maria Sindoni (Italy)	18:00 - 18:00
B135	LOW PERCENTAGES OF EARLY B-CELL PRECURSORS IN THE BONE MARROW MAY PREDICT THE DEVELOPMENT OF CGVHD FOLLOWING PEDIATRIC HSCT <i>Poster Presenter:</i> Elisa Christine Peen (Denmark)	18:00 - 18:00
B136	MEASURABLE RESIDUAL DISEASE (MRD) AND T-CELL CHIMERISM ARE PROGNOSTIC BIOMARKERS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS UNDERGOING ALLOGENEIC STEM CELLS TRANSPLANTATION (ASCT) <i>Poster Presenter:</i> Elisa Meddi (Italy)	18:00 - 18:00
B137	NK CELLS CHIMERISM STATUS IS A POTENTIAL EARLY PREDICTOR OF RELAPSE AFTER ALLO-HSCT IN ACUTE LEUKEMIA <i>Poster Presenter:</i> Xing Chen (China)	18:00 - 18:00
B138	THE NUMBER OF CENTRAL MEMORY CD8+ T CELLS INFUSED AND THEIR EARLY RECOVERY AFTER ALLOGENEIC HSCT WAS ASSOCIATED WITH A DECREASED RISK OF DISEASE RELAPSE <i>Poster Presenter:</i> Valle Gómez García de Soria (Spain)	18:00 - 18:00
B139	CONTRASTING GENE EXPRESSION PROFILES AND SIGNALING PATHWAYS BETWEEN CIRCULATING DONOR-AND HOST-DERIVED MONOCYTES DURING TOLERANCE IN MIXED CHIMERISM FOLLOWING UNRELATED DONOR CADAVERIC BMT AND LUNG TRANSPLANT <i>Poster Presenter:</i> Paul Szabolcs (United States)	18:00 - 18:00
B140	MEASURABLE RESIDUAL DISEASE AND CHIMERISM ANALYSIS INTERPLAY: IMPACT IN PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Rebeca Bailén Alomoro (Spain)	18:00 - 18:00
B141	THE INFLUENCE OF GRAFT IMMUNE COMPOSITION ON IMMUNE RECOVERY AND TRANSPLANT OUTCOME: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Stefania Leone (Italy)	18:00 - 18:00
B142	RELAPSE MONITORING BY NPM1-PCR AND ITS PROGNOSTIC VALUE BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Oliver Kriege (Germany)	18:00 - 18:00
B143	GUIDING POST-TRANSPLANT RELAPSE TREATMENT IN MYELOID MALIGNANCIES WITH QPCR MONITORING OF CHIMERISM DYNAMIC FROM PERIPHERAL WHOLE BLOOD - SINGLE CENTRE EXPERIENCE <i>Poster Presenter:</i> Polona Novak (Slovenia)	18:00 - 18:00

B144	SNP-BASED NEXT-GENERATION SEQUENCING (NGS) ALLOWS A RELIABLE QUANTIFICATION OF CHIMERISM AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION IN COMPARISON WITH SHORT-TANDEM REPEATS (STR) <i>Poster Presenter: Estefanía Pérez-Lopez (Spain)</i>	18:00 - 18:00
B145	THE COMBINATION OF DISEASE BIOLOGY WITH PRE-HSCT MRD STATUS COULD BETTER STRATIFY RELAPSE RISK AFTER HSCT AMONG ADULT AML PATIENTS IN FIRST COMPLETE REMISSION <i>Poster Presenter: Marcello Roberto (Italy)</i>	18:00 - 18:00
<i>Printed Poster</i> 18:00 - 19:00		Hall 3 North
Conditioning Regimens		
B087	ATG-TARGETED DOSING STRATEGY REDUCED CMV/EBV REACTIVATION AND IMPROVED SURVIVAL WITHOUT INCREASING GVHD AFTER URD-PBSCT : A SINGLE-CENTER, PROSPECTIVE ,SINGLE-ARM, CLINICAL TRIAL <i>Poster Presenter: Sheng Chen (China)</i>	18:00 - 18:00
B088	COMPARISON OF TWO REDUCED-INTENSITY CONDITIONING REGIMENS: BALTIMORE WITH CLOFARABINE VERSUS THIOTEPA-BUSULFAN-FLUDARABINE IN ADULTS RECEIVING HAPLOIDENTICAL TRANSPLANTATION FOR MYELOID MALIGNANCIES: A RETROSPECTIVE STUDY OF THE SFGM-TC <i>Poster Presenter: Prof. Patrice Chevallier (France)</i>	18:00 - 18:00
B089	IMPACT OF FLUDARABINE DOSE ON OUTCOME AFTER ALLO-HCT WITH REDUCED INTENSITY CONDITIONING FOR OLDER PATIENTS WITH AML: A STUDY FROM THE ALWP OF THE EBMT <i>Poster Presenter: Guillaume Dachy (Belgium)</i>	18:00 - 18:00
B090	TOXICITY COMPARISON OF TWO REDUCED INTENSITY CONDITIONING (RIC) TRANSPLANT REGIMENS FOR ADULT ALL IN CR1/2: RESULTS FROM THE RANDOMISED PHASE 2 MULTICENTRE ALL-RIC TRIAL <i>Poster Presenter: Dr. Anna Castleton (United Kingdom)</i>	18:00 - 18:00
B091	CXCR4 DIRECTED ENDORADIO THERAPY WITH [¹⁷⁷Lu] PENTIXATHER ADDED TO TBI IS FEASIBLE AND SPARES THE HEMATOPOIETIC NICHE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter: Krischan Braitsch (Germany)</i>	18:00 - 18:00
B092	EVALUATION OF THE TRANSPLANT CONDITIONING INTENSITY (TCI) SCORE FOR SECOND ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT2) - A STUDY OF THE ALWP OF THE EBMT <i>Poster Presenter: Giuliano Filippini Velázquez (Germany)</i>	18:00 - 18:00
B093	VENETOCLAX COMBINED WITH FLUDARABINE AND MELPHALAN CONDITIONING REGIMEN IN PATIENTS &GT; 50 YEARS WITH MYELOID MALIGNANCIES: INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, PHASE II TRIAL <i>Poster Presenter: Panpan Zhu (China)</i>	18:00 - 18:00
B094	FLUDARABINE/TREOSULFAN VS. FLUDARABINE/TBI CONDITIONING FOR ALLOSCT FOR AML AND MDS: COMPARABLE SURVIVAL RATES BUT DIVERGENT IMMUNE RECONSTITUTION <i>Poster Presenter: Matthias Stelljes (Germany)</i>	18:00 - 18:00
B095	CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): INTERMEDIATE-DOSE TBI DOES THE JOB	18:00 - 18:00

	<i>Poster Presenter:</i> Prof. Dr. Thomas Luft (Germany)	
B096	5-YEAR TRANSPLANT SUCCESS AFTER TREOSULFAN CONDITIONING <i>Poster Presenter:</i> Rohtesh S. Mehta (United States)	18:00 - 18:00
B097	EFFICACY ANALYSIS OF HAPLOIDENTICAL TRANSPLANTATION USING BUSULFAN/CYCLOPHOSPHAMIDE AND MELPHALAN AS CONDITIONING REGIMEN FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Zhijie Wei (China)	18:00 - 18:00
B098	POST-TRANSPLANT CYCLOPHOSPHAMIDE RESULTS IN LOW INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN UNRELATED OR MATCHED-SIBLING DONOR STEM CELL TRANSPLANTATION WITHOUT COMPROMISING IMMUNE RECONSTITUTION AND GRAFT-VERSUS-LEUKEMIA EFFECT <i>Poster Presenter:</i> Ioannis Tsonis (Greece)	18:00 - 18:00
B099	CONDITIONING INTENSITY IN STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT <i>Poster Presenter:</i> Dr. Jaime Sanz (Spain)	18:00 - 18:00
B100	EVALUATION OF A BALTIMORE MODIFIED NON-TBI CONDITIONING BEFORE ALLOGENEIC TRANSPLANT FROM HAPLOIDENTICAL OR MISMATCHED UNRELATED DONORS, RESULTS FROM A MONOCENTRIC RETROSPECTIVE STUDY <i>Poster Presenter:</i> Victoria Volpari (France)	18:00 - 18:00
B101	EXPLORING THE IMPACT OF CONDITIONING REGIMEN INTENSITY ON ALLOGENEIC STEM CELL TRANSPLANT OUTCOMES: INSIGHTS FROM A SINGLE-CENTER STUDY <i>Poster Presenter:</i> Vera Radici (Italy)	18:00 - 18:00
B102	IMPACT OF PRETRANSPLANT MRD IN PATIENTS ALLOGRAFTED FOR AML AFTER TREOSULFAN-BASED CONDITIONING <i>Poster Presenter:</i> Jacob Pyka (Germany)	18:00 - 18:00
B103	FLUDARABINE TREOSULFAN REDUCED-INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN FRAIL/OLDER AML PATIENTS: PRELIMINARY RESULTS OF A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Raynier Devillier (France)	18:00 - 18:00
B104	PHARMACOKINETIC ANALYSIS OF TARGETED DOSING OF ANTITHYMOCYTE GLOBULIN IN ADULTS: A PROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Jishan Du (China)	18:00 - 18:00
B105	THE COMBINATION OF FLUDARABINE, BUSULFAN AND ANTI-T LYMPHOCYTE GLOBULIN IS WELL TOLERATED AND OFFERS EFFECTIVE REDUCED INTENSITY CONDITIONING THERAPY FOR PATIENTS WITH MYELOID DISEASE <i>Poster Presenter:</i> Chris Armstrong (Ireland)	18:00 - 18:00
B106	COMPARING PTCY AND GIAC IN HAPLOIDENTICAL SETTINGS: UPDATED ANALYSIS FROM A NATIONWIDE TRANSPLANTATION REGISTRY <i>Poster Presenter:</i> Yi-Wei Lee (Taiwan)	18:00 - 18:00
B107	THE RESULTS OF ALLOGENEIC HSCT AFTER TREOSULFAN-BASED CONDITIONING REGIMEN IN CHILDREN WITH AML: MULTICENTER RETROSPECTIVE STUDY OF THE	18:00 - 18:00

	POLISH PEDIATRIC STUDY GROUP FOR HSCT <i>Poster Presenter:</i> Agnieszka Sobkowiak-Sobierajska (Poland)	
B108	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN AML PATIENTS AFTER CONDITIONING WITH FLUDARABINE/TOTAL BODY IRRADIATION(2GY) WITH OR WITHOUT ANTI-THYMOCYTE GLOBULINE OR POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Poster Presenter:</i> Thomas Heinicke (Germany)	18:00 - 18:00
B109	CONFIRMING BETTER OUTCOMES WITH TBI-BASED MYELOABLATIVE CONDITIONING FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION EVEN IN SECOND COMPLETE REMISSION <i>Poster Presenter:</i> Mario Delia (Italy)	18:00 - 18:00
B110	POST TRANSPLANT CYCLOPHOSPHAMIDE PLUS ABATACEPT LEADS TO DECREASED DAY +30 CHIMERISM LEVELS <i>Poster Presenter:</i> Peter Abdelmessieh (United States)	18:00 - 18:00
B111	HEMATOPOIETIC STEM CELL TRANSPLANT WITH REGULATORY AND CONVENTIONAL T CELL ADOPTIVE IMMUNOTHERAPY IN TP53-MUTATED/DELETED AML <i>Poster Presenter:</i> Antonio Pierini (Italy)	18:00 - 18:00
B112	LOMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN (LEAM) PROTOCOL AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH LYMPHOMAS: A SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Željko Prka (Croatia)	18:00 - 18:00
B113	SAFETY AND EFFICACY OF BUSULFAN 9.6 BASED RIC (AUGMENTED RIC) IN OLDER PATIENTS WITH AML WHO ARE NOT SUITABLE FOR MAC <i>Poster Presenter:</i> Kalina Abrol (Canada)	18:00 - 18:00
B114	TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE IMPROVES THE OUTCOME OF PATIENTS WITH POOR-RISK ACUTE LEUKEMIA <i>Poster Presenter:</i> Anthony Stein (United States)	18:00 - 18:00
B115	TREOSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE: A RETROSPECTIVE ANALYSIS <i>Poster Presenter:</i> Aura Arola (Finland)	18:00 - 18:00
B116	CONDITIONING WITH I.V. BUSULFAN, ONCE VERSUS FOUR TIMES DAILY IN ADULTS: IMPACT ON PHARMACOKINETICS, ORGAN TOXICITIES AND SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Prof. Jakob Passweg (Switzerland)	18:00 - 18:00
B117	NON MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING IN ELDERLY PATIENTS WITH PTCY. A MULTICENTRE RETROSPECTIVE COHORT ANALYSIS FROM GATMO-TC <i>Poster Presenter:</i> Mariano Berro (Argentina)	18:00 - 18:00
B118	IMPACT OF TRANSPLANT CONDITIONING INTENSITY ON BOTH ACUTE AND CHRONIC GVHD IN HAPLO-PTCY TRANSPLANT: TWO GITMO CENTRES' EXPERIENCE <i>Poster Presenter:</i> Dr. Maria Teresa Lupo Stanghellini (Italy)	18:00 - 18:00
B119	CHANGES IN PROGNOSTIC VARIABLES FOR ALLOGENEIC	18:00 - 18:00

	TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING IN ELDERLY PATIENTS OVER TIME	
	<i>Poster Presenter:</i> Prof. Seong Kyu Park (Korea, Republic of)	
B120	COMPARISON OF FLUDARABINE-MELPHALAN AND FLUDARABINE-TREOSULFAN AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Maria Liga (Greece)	
B121	PHARMACOKINETIC-TARGETING AND DOSE-ADJUSTMENT OF I.V. BUSULFAN FOR MYELOABLATIVE CONDITIONING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Rutvij Khanolkar (Canada)	
B122	OUTCOMES OF PATIENTS WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA IN CR1 UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION THROUGH A FIXED TRANSPLANTATION POLICY INCLUDING A CHEMOTHERAPY-BASED CONDITIONING	18:00 - 18:00
	<i>Poster Presenter:</i> Raffaella Ceretti (Italy)	
B123	DESENSITISATION TREATMENT FOR HLA-DONOR SPECIFIC ANTIBODIES IN EX-VIVO T CELL DEPLETED HAPLOIDENTICAL ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT - A MULTI-CENTRE RETROSPECTIVE STUDY IN SINGAPORE	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. William Hwang (Singapore)	
B124	PROMISING OUTCOMES IN HAPLOIDENTICAL TRANSPLANTATION USING ABATACEPT IN COMBINATION WITH POST TRANSPLANT CYCLOPHOSPHAMIDE IN TREOSULFAN BASED CONDITIONING REGIMEN	18:00 - 18:00
	<i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	
B125	A NOVEL REDUCED TOXICITY CONDITIONING REGIMEN FOR OLDER MYELODYSPLASTIC NEOPLASMS PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A PROSPECTIVE COHORT STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Wen-Jing Yu (China)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Lymphoma and Chronic Lymphocytic Leukaemia		
B264	THE IMPACT OF ORAL AND GUT MICROBIOTA WITH CONSIDERATION OF CLINICAL AND IMMUNOLOGICAL FACTORS ON MUCOSITIS OUTCOMES: AN ASIAN HAEMATOPOIETIC STEM CELL TRANSPLANT POPULATION	18:00 - 18:00
	<i>Poster Presenter:</i> Shu Ping Wong (Malaysia)	
B265	FACTORS AFFECTING OUTCOME OF SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA RELAPSING OR PROGRESSING AFTER A FRONT-LINE PET-ADAPTED THERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. Alessandro Rambaldi (Italy)	
B266	REDUCED RELAPSE INCIDENCE AFTER CHECK-POINT INHIBITORS RELATIVE TO BRENTUXIMAB VEDOTIN AS SALVAGE THERAPY BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA: A RETROSPECTIVE ANALYSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Jacopo Mariotti (Italy)	
B267	LOW NON-RELAPSE MORTALITY ASSOCIATED WITH ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION AFTER CAR-T	18:00 - 18:00

	FAILURE IN PATIENTS AFFECTED BY LARGE B CELL LYMPHOMA	
	<i>Poster Presenter:</i> Jacopo Mariotti (Italy)	
B268	TREOSULFAN-BASED CONDITIONING AND SIROLIMUS-PTCY GVHD PROPHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR AGGRESSIVE B-CELL NHL	18:00 - 18:00
	<i>Poster Presenter:</i> Lorenzo Lazzari (Italy)	
B269	OUTCOME OF HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA AT A SINGLE INSTITUTION OVER 20 YEARS	18:00 - 18:00
	<i>Poster Presenter:</i> Joanna Romejko-Jarosińska (Poland)	
B270	IMPROVING RESULTS OF ALLO-HCT FOR PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA. A SINGLE CENTER EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Andrzej Frankiewicz (Poland)	
B271	THE SINGLE-CELL LANDSCAPE EXPLORING ABNORMAL T CELL STATES AND DEVELOPMENTAL TRAJECTORIES IN HETEROGENEOUS NON-HODGKIN LYMPHOMA	18:00 - 18:00
	<i>Poster Presenter:</i> Yuqing Wang (China)	
B272	BEYOND TRANSPLANTATION: BRENTUXIMAB'S IMPACT ON LONG-TERM OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN ROMANIAN TRANSPLANT CENTERS	18:00 - 18:00
	<i>Poster Presenter:</i> Alina Daniela Tanase (Romania)	
B273	A NOVEL PROGNOSTIC NOMOGRAM BASED ON IMAGING AND MOLECULAR PARAMETERS FOR NEWLY DIAGNOSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Dezhi Huang (China)	
B274	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)	18:00 - 18:00
	<i>Poster Presenter:</i> Małgorzata Sobczyk-Kruszelnicka (Poland)	
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Immunodeficiency Diseases and Macrophages		
B254	OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MONOGENIC INFLAMMATORY BOWEL DISEASE	18:00 - 18:00
	<i>Poster Presenter:</i> Xiaowen Zhai (China)	
B255	CLINICAL CHARACTERISATION AND OUTCOME OF 125 CASES WITH GRISCELLI SYNDROME	18:00 - 18:00
	<i>Poster Presenter:</i> Maaïke Kusters (United Kingdom)	
B256	OUTCOMES FOR ALLOGENEIC SCT FOR PATIENTS WITH INBORN ERRORS OF IMMUNITY UTILIZING REDUCED INTENSITY CONDITIONING REGIMEN WITH TARGETED BUSULFAN	18:00 - 18:00
	<i>Poster Presenter:</i> Sonali Chaudhury (United States)	
B257	OUTCOME OF THE PATIENTS DIAGNOSED WITH SEVERE COMBINED IMMUNODEFICIENCY THROUGH NEWBORN SCREENING IN CATALONIA (2017-2023)	18:00 - 18:00
	<i>Poster Presenter:</i> Maria Isabel Benitez Carabante (Spain)	
B258	HSCT AS A CURATIVE TREATMENT OPTION IN PATIENTS WITH A PRIMARY IMMUNODEFICIENCY DUE TO IL2RB-DEFECT: DESCRIPTION OF A SMALL COHORT	18:00 - 18:00

	<i>Poster Presenter:</i> Ommo E. Mauss (Germany)	
B259	WHICH ALTERNATIVE TO CHOOSE? - A COMPARATIVE STUDY BETWEEN MATCHED UNRELATED AND HAPLOIDENTICAL DONOR TRANSPLANTS IN CHILDREN WITH INBORN ERRORS OF IMMUNITY IN LOW-MIDDLE-INCOME COUNTRIES <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	18:00 - 18:00
B260	MUD-HSCT IN A RARE COMBINED IMMUNODEFICIENCY WITH ARPC1B DEFICIENCY-CASE REPORT <i>Poster Presenter:</i> Devyani Surange (India)	18:00 - 18:00
B261	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN TWO PEDIATRIC PATIENTS WITH CENTRAL NERVOUS SYSTEM-RESTRICTED FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS <i>Poster Presenter:</i> Dimana Dimitrova (United States)	18:00 - 18:00
B262	SIL2-RA AND ST2 LEVELS BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION ARE ASSOCIATED WITH MORTALITY IN HLH PATIENTS <i>Poster Presenter:</i> Anne B. Verbeek (Netherlands)	18:00 - 18:00
B263	HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN FOR PRIMARY IMMUNE DEFICIENCIES: THE EXPERIENCE OF SINGLE CENTER <i>Poster Presenter:</i> Ali Antmen (Turkey)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Paediatric Issues		
B146	PLASMA REG3A AND CITRULLINE LEVELS PREDICT GASTROINTESTINAL AGVHD BEFORE CLINICAL ONSET IN PEDIATRIC HSCT <i>Poster Presenter:</i> Sarah Weischendorff (Denmark)	18:00 - 18:00
B147	THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Alexey Maschan (Russian Federation)	18:00 - 18:00
B148	OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR HURLER SYNDROME AFTER IMPLEMENTATION NEWBORN SCREENING IN US AND EUROPE <i>Poster Presenter:</i> Jaap Jan Boelens (United States)	18:00 - 18:00
B149	ADDITION OF DINUTUXIMAB-BETA ON DAY -1 TO IMPROVE GRAFT-VERSUS-NEUROBLASTOMA EFFECTS OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN RELAPSED HIGH-RISK NEUROBLASTOMA <i>Poster Presenter:</i> Christina Lämmle (Germany)	18:00 - 18:00
B150	HHV-6 INFECTION MAY IMPAIR IMMUNE RECONSTITUTION FOLLOWING PEDIATRIC HAPLO-HSCT <i>Poster Presenter:</i> Katrine Kielsen (Denmark)	18:00 - 18:00
B151	FINAL HEIGHT AND IMPACT OF GROWTH HORMONE TREATMENT IN CHILDREN RECEIVING TBI-BASED CONDITIONING REGIMEN BEFORE HSCT FOR ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Jean-Hugues Dalle (France)	18:00 - 18:00
B152	ENGRAFTMENT SYNDROME AND ACUTE GVHD AFTER HAPLOIDENTICAL POST-TRANSPLANT CYCLOPHOSPHAMIDE: A PAEDIATRIC MULTICENTRIC EXPERIENCE	18:00 - 18:00

	<i>Poster Presenter:</i> Maura Faraci (Italy)	
B153	PULMONARY COMPLICATIONS IN CHILDREN FOLLOWING HAEMATOPOIETIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Hannah Walker (Australia)	18:00 - 18:00
B154	EXCELLENT SURVIVAL USING T-REPLETE UMBILICAL CORD BLOOD TRANSPLANT IN HIGH RISK PAEDIATRIC MYELOID LEUKAEMIA, INCLUDING IN REFRACTORY DISEASE <i>Poster Presenter:</i> Kate Davies (United Kingdom)	18:00 - 18:00
B155	TCRAB+/CD19+-DEPLETION IN HEMATOPOIETIC STEM CELLS TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONORS IN CHILDREN WITH HIGH-RISK ACUTE MYELOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Larisa Shelikhova (Russian Federation)	18:00 - 18:00
B156	IMPLEMENTATION OF CYP3A5 GENOTYPING TO INDIVIDUALISE TACROLIMUS DOSE IN PAEDIATRIC PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Iván López Torija (Spain)	18:00 - 18:00
B157	EPIDEMIOLOGY OF GUT COLONIZATION AND INFECTION BY CARBAPENEM-RESISTANT GRAM-NEGATIVE BACILLI (CR-GNB) IN PEDIATRIC HEMATO-ONCOLOGICAL AND TRANSPLANTED PATIENTS <i>Poster Presenter:</i> Prof. Adriana Balduzzi (Italy)	18:00 - 18:00
B158	ALPHA/BETA-DEPLETION AND EARLY TIMING OF SEROTHERAPY PROVIDES RELIABLE ENGRAFTMENT AND LOW TRANSPLANT RELATED MORBIDITY IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MUCOPOLYSACCHARIDOSIS <i>Poster Presenter:</i> Annika Ewert (Germany)	18:00 - 18:00
B159	CARDIORESPIRATORY FITNESS, PHYSICAL PERFORMANCE, AND METABOLIC SYNDROME IN ADULT SURVIVORS OF PAEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Anne Nissen (Denmark)	18:00 - 18:00
B160	HEMATOPOIETIC TRANSPLANTATION WITH CD45RA⁺ DEPLETION AND ADOPTIVE THERAPY WITH CD45RO⁺ T-LYMPHOCYTES AND NK CELLS IN PEDIATRIC PATIENTS DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT DISEASES <i>Poster Presenter:</i> Mercedes Gasior Kabat (Spain)	18:00 - 18:00
B161	PSYCHOLOGICAL IMPACT OF HEMATOPOIETIC STEM CELL DONATION ON PEDIATRIC SIBLING DONORS <i>Poster Presenter:</i> Sara Mostafa Makkeyah (Egypt)	18:00 - 18:00
B162	AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIGH-RISK NEUROBLASTOMA: A LONG-TERM FOLLOW-UP <i>Poster Presenter:</i> Isabelina Ferreira (Portugal)	18:00 - 18:00
B163	OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH DIAMOND-BLACKFAN ANEMIA - REPORT OF THE POLISH PEDIATRIC STUDY GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Anna Pieczonka (Poland)	18:00 - 18:00
B164	OUTCOMES OF ALLO-HSCT FROM MISMATCHED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN WITH NON- MALIGNANT DISEASES <i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	18:00 - 18:00
B165	CARDIOVASCULAR RISK FACTORS AND SUBCLINICAL ORGAN	18:00 - 18:00

	DAMAGE ARE COMMON AND INCREASING OVER TIME IN CHILDREN AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	
	<i>Poster Presenter:</i> Damaris Werner (Germany)	
B166	POSITIVE PRE-TRANSPLANT RESPIRATORY VIRAL PCR IS ASSOCIATED WITH INCREASED DAY 100 TRANSPLANT-RELATED MORTALITY IN PEDIATRIC HSCT RECIPIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Jane Trainor (United States)	
B167	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME	18:00 - 18:00
	<i>Poster Presenter:</i> Tatyana Bykova (Russian Federation)	
B168	INCIDENCE AND CHARACTERISTICS OF EPILEPSY AFTER ACUTE CENTRAL NERVOUS SYSTEM COMPLICATIONS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Davide Leardini (Italy)	
B169	COMPARISONS OF PROGNOSIS OF ALLO-HSCT AFTER CAR-T CELL THERAPY OR CHEMOTHERAPY IN PAEDIATRIC PATIENTS OF REFRACTORY/RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA : A MULTICENTER STUDY CCCG-ALL-2015	18:00 - 18:00
	<i>Poster Presenter:</i> Bohan Li (China)	
B170	TCR-AB DEPLETED HAPLOIDENTICAL TRANSPLANT WITH CD 45 RA- DEPLETED MEMORY T CELL ADD-BACK IN PAEDIATRIC NON-MALIGNANT DISEASES IN A SINGLE PAEDIATRIC CENTER: 10-YEAR RESULTS	18:00 - 18:00
	<i>Poster Presenter:</i> Tan Ah Moy (Singapore)	
B171	AIEOP EXPERT BOARD RECOMMENDATIONS FOR MANAGEMENT OF POST-HCT HEMORRHAGIC CYSTITIS IN PEDIATRIC SETTING	18:00 - 18:00
	<i>Poster Presenter:</i> Gianluca Dell'Orso (Italy)	
B172	RISK FACTORS IN HIGH RISK NEUROBLASTOMA PATIENTS OVER 5 YEARS: RESULTS FROM THE HR-NBL1/SIOPEN TRIAL	18:00 - 18:00
	<i>Poster Presenter:</i> Ruth Ladenstein (Austria)	
B173	EXCELLENT SURVIVAL AND LONG TERM OUTCOMES IN INFANTS RECEIVING TOTAL BODY IRRADIATION FOR CONDITIONING PRIOR TO ALLOGENEIC TRANSPLANT	18:00 - 18:00
	<i>Poster Presenter:</i> Sonali Chaudhury (United States)	
B174	BCG-VACCINE COMPLICATIONS IN CHILDREN WITH INFANT ACUTE LYMPHOBLASTIC LEUKEMIA	18:00 - 18:00
	<i>Poster Presenter:</i> Alexandra Laberko (Russian Federation)	
B175	WORKFORCE CONSENSUS RECOMMENDATIONS FOR PAEDIATRIC HSCT CENTRES ON BEHALF OF THE PAEDIATRIC SUB-COMMITTEE OF THE BRITISH SOCIETY OF BLOOD, BONE MARROW TRANSPLANTATION CELLULAR THERAPY (BSBMTCT)	18:00 - 18:00
	<i>Poster Presenter:</i> Reem Elfeky (United Kingdom)	
B176	HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH A CONTROLLED NUMBER OF CD3+ CELLS AND POST-TRANSPLANT CYCLOPHOSPHAMIDE: EXPERIENCE FROM A SINGLE PEDIATRIC CENTER	18:00 - 18:00
	<i>Poster Presenter:</i> Giulia Albrici (Italy)	
B177	PLASMA AMINO ACIDS AND FECAL CALPROTECTIN USAGE FOR THE PREDICTION OF INTESTINAL INJURY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN	18:00 - 18:00
	<i>Poster Presenter:</i> Igne Kairiene (Lithuania)	

Printed Poster

18:00 - 19:00

Hall 3 North

Stem Cell Donor

- B002 **DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSAS) IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MISMATCHED DONORS, ON BEHALF OF GITMO AND AIBT** 18:00 - 18:00
Poster Presenter: Anna Paola Iori (Italy)
- B003 **DETERMINING THE PREDICTIVE IMPACT OF DONOR PARITY ON THE OUTCOMES OF HUMAN LEUKOCYTE ANTIGEN MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTS: A RETROSPECTIVE, SINGLE-CENTER STUDY** 18:00 - 18:00
Poster Presenter: Maryam Barkhordar (Iran)
- B004 **POST-TRANSPLANTATION CYCLOPHOSPHAMIDE IMPROVES GRAFT-VERSUS-HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL IN HLA-DPB1 MISMATCHED UNRELATED DONOR ALLOGENEIC TRANSPLANT** 18:00 - 18:00
Poster Presenter: Yung-Tsi Bolon (United States)
- B005 **THE RESCUE TRANSPLANTATION STRATEGY FOR GRAFT FAILURE: DONOR SELECTION AND GVHD PROPHYLAXIS IN THE CURRENT ERA** 18:00 - 18:00
Poster Presenter: Mizuki Watanabe (Japan)
- B006 **UNRELATED DONOR SELECTION FOR STEM CELL TRANSPLANT USING POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT** 18:00 - 18:00
Poster Presenter: Dr. Jaime Sanz (Spain)
- B007 **PATIENT HLA GENOTYPE AND REGISTRY DIVERSITY STRONGLY INFLUENCE DONOR SEARCH DURATION AND SUCCESS** 18:00 - 18:00
Poster Presenter: Stefanie V. Dorner (Germany)
- B008 **FEASIBILITY AND SAFETY OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PERIPHERAL BLOOD STEM CELL MOBILIZATION AND COLLECTION BY APHERESIS IN RELATED DONORS AGED 65 AND OVER** 18:00 - 18:00
Poster Presenter: Kahina Amokrane (France)
- B009 **HAPLOIDENTICAL VERSUS MISMATCHED UNRELATED ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES: AN ANALYSIS ON 1413 PATIENTS FROM THE GERMAN REGISTRY** 18:00 - 18:00
Poster Presenter: Andrea Gantner (Germany)
- B010 **THE POST-PANDEMIC HAEMATOPOIETIC STEM CELL (HSC) GRAFT CRYOPRESERVATION TRENDS AND THEIR EFFECTS ON UNRELATED DONOR REGISTRIES: THE UK EXPERIENCE** 18:00 - 18:00
Poster Presenter: Dr. Robert Danby (United Kingdom)
- B011 **ALLOGENIC STEM CELL TRANSPLANTATION AND PERI TRANSPLANT STRATEGIES IN PATIENTS WITH MISMATCH DONORS - A SINGLE CENTER EXPERIENCE IN 151 PATIENTS** 18:00 - 18:00
Poster Presenter: Benno Biermann (Germany)
- B012 **SURVIVAL PROGNOSTIC FACTORS AFTER A SECOND ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION** 18:00 - 18:00
Poster Presenter: Ms. Tatiana Fernández-Barge (Spain)
- B013 **QUALITY OF ENGRAFTMENT AND INCIDENCE OF ACUTE GVHD GRADE II - IV POST PERIPHERAL HAEMOPOIETIC CELLS CRYOPRESERVATION IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION FROM HLA IDENTICAL DONORS** 18:00 - 18:00

	<i>Poster Presenter:</i> Anna Maria Raiola (Italy)	
B014	WHAT WORKS AND WHAT DOES NOT? - THE IMPACT OF DONOR CHARACTERISTICS IN T REPLETE HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST -TRANSPLANT CYCLOPHOSPHAMIDE IN CHILDREN <i>Poster Presenter:</i> Anuraag Reddy Nalla (India)	18:00 - 18:00
B015	OUTCOMES OF OLDER ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE BASED PROPHYLAXIS <i>Poster Presenter:</i> Victoria Murillo Cortés (Spain)	18:00 - 18:00
B016	RECIPIENT-DONOR HLA-B LEADER MISMATCHING IMPACT ON THE HAPLOIDENTICAL TRANSPLANTATION OUTCOMES FOR PEDIATRIC ACUTE LEUKEMIA PATIENTS <i>Poster Presenter:</i> Tahereh Rostami (Iran)	18:00 - 18:00
B017	COMPARING THE CLINICAL OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED-SIBLING DONORS AND ALTERNATIVE DONORS IN PATIENTS WITH SEVERE THALASSEMIA : SYSTEMATIC REVIEW AND META-ANALYSIS <i>Poster Presenter:</i> Sirichai Srichairatanakool (Thailand)	18:00 - 18:00
B018	IMPACT OF DONOR BLOOD GROUP AND CMV MATCH ON ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER LONG TERM FOLLOW UP STUDY <i>Poster Presenter:</i> Muhammad Saif (United Kingdom)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Autoimmune Diseases		
B235	THYMIC SIZE LONGITUDINAL CHANGES ON CHEST HIGH-RESOLUTION COMPUTED TOMOGRAPHY AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS <i>Poster Presenter:</i> Gregory Pugnet (France)	18:00 - 18:00
B236	LONG TERM PERSISTENCE OF T MEMORY STEM CELLS FOLLOWING AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS <i>Poster Presenter:</i> Prof. John Moore (Australia)	18:00 - 18:00
B237	EFFECTS OF HIGH DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS FROM PATIENT'S PERSPECTIVE: LONG-TERM QUALITY OF LIFE OUTCOMES <i>Poster Presenter:</i> Denis Fedorenko (Russian Federation)	18:00 - 18:00
B238	THE MATHEC-SFGM-TC REGISTRY FOR CELL THERAPY IN AUTOIMMUNE DISEASES: A DEDICATED TOOL FOR REAL-WORLD DATA COLLECTION <i>Poster Presenter:</i> Prof. Dominique Farge (France)	18:00 - 18:00
B239	ATG AND OTHER SEROTHERAPY IN CONDITIONING REGIMENS FOR ASCT IN AUTOIMMUNE DISEASES: A SURVEY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP) <i>Poster Presenter:</i> Rosamaria Nitti (Italy)	18:00 - 18:00
B240	ADOPTING A STANDARD OF CARE: AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SCLERODERMA <i>Poster Presenter:</i> Ernesto Ayala (United States)	18:00 - 18:00
B241	FLUDARABINE AND CYCLOPHOSPHAMIDE AS A SAFE AND	18:00 - 18:00

	EFFECTIVE LYMPHOABLATIVE CONDITIONING REGIMEN FOR MULTIPLE SCLEROSIS (MS)	
	<i>Poster Presenter:</i> Denis Fedorenko (Russian Federation)	
B242	IMMUNE RESET AND GRAFT COMPOSITION IN AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS: EARLY RECOVERY OF NATURAL KILLER CELLS MAY BE IMPORTANT IN EFFECTING DURABLE RESPONSES	18:00 - 18:00
	<i>Poster Presenter:</i> Latoya Reid (Jamaica)	
B243	REDUCED PRO-INFLAMMATORY INTERLEUKINS IL-6 AND IL-8 SECRETED BY SKIN FIBROBLASTS IN SYSTEMIC SCLEROSIS PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Gunter Assmann (Germany)	
B244	THE QUALITY OF LIFE OF PERSONS WITH MULTIPLE SCLEROSIS IMPROVES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Guillermo José Ruiz-Delgado (Mexico)	
	<i>Printed Poster</i>	
	18:00 - 19:00	Hall 3 North
Acute Leukaemia		
B178	AUTOLOGOUS VERSUS HAPLOIDENTICAL DONOR STEM CELL TRANSPLANTATION FOR FAVORABLE-AND INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA IN FIRST REMISSION AND UNDETECTABLE MINIMAL RESIDUAL DISEASE: A MULTI-CENTER, PROSPECTIVE STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Jia Chen (China)	
B179	OUTCOME OF ALLOGRAFTED ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH THE PEDIATRIC-INSPIRED, MRD-ORIENTED GIMEMA LAL 1913 PROTOCOL IN THE REAL-LIFE: A CAMPUS ALL STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Gianluca Cavallaro (Italy)	
B180	INTENSIVE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL CAN OVERCOME THE POOR PROGNOSIS OF T(6;9)/DEK-NUP214 AML	18:00 - 18:00
	<i>Poster Presenter:</i> Hai He (China)	
B181	FREQUENCY AND IMPACT OF SOMATIC MUTATIONS ON OUTCOMES OF ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. Ali Bazarbachi (Lebanon)	
B182	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: A STUDY FROM THE SOCIÉTÉ FRANCOPHONE DE GREFFE DE MOELLE ET THÉRAPIE CELLULAIRE (SFGM-TC)	18:00 - 18:00
	<i>Poster Presenter:</i> Yves Chalandon (Switzerland)	
B183	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A SURVEY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. Sebastian Giebel (Poland)	
B184	OUTCOME OF PATIENTS WITH IDH-MUTATED AML FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Thomas Schroeder (Germany)	

B185	<p>UMBILICAL CORD BLOOD TRANSPLANT COMBINING CAR-T CELL THERAPY IS HIGHLY EFFECTIVE AND RELATIVELY SAFE FOR CHILDHOOD RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</p> <p><i>Poster Presenter:</i> Liu Fang (China)</p>	18:00 - 18:00
B186	<p>CD22-TARGETED IMMUNOTHERAPY FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-ALL WHO PREVIOUSLY EXPOSED TO CD19-TARGETED IMMUNOTHERAPY</p> <p><i>Poster Presenter:</i> He Huang (China)</p>	18:00 - 18:00
B187	<p>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RESCUES THE DISMAL OUTCOMES OF INTERMEDIATE-RISK AML PATIENTS WITH <i>DNMT3A</i>^{MUT}<i>NPM1</i>^{MUT}<i>FLT3-ITD</i>^{MUT}: A MULTICENTER STUDY</p> <p><i>Poster Presenter:</i> Wenxuan Huo (China)</p>	18:00 - 18:00
B188	<p>COMPARISON OF THE PROGNOSTIC IMPACT BETWEEN ELN2022 AND ELN2017 RISK CLASSIFICATION IN ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH AML</p> <p><i>Poster Presenter:</i> Yanmin Zhao (China)</p>	18:00 - 18:00
B189	<p>EFFICACY AND SAFETY OF THE THIRD-GENERATION TKI OLVEREMBATINIB IN ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA WITH RELAPSED DISEASE OR PERSISTENT MRD BRIDGING TO ALLO-HSCT</p> <p><i>Poster Presenter:</i> XiaoYu Zhang (China)</p>	18:00 - 18:00
B190	<p>INTRACELLULAR CYTOKINE ASSAYS IN COMBINATION WITH DEGRANULATION ASSAY CONTRIBUTE SIGNIFICANTLY TO DETECT AND QUANTIFY LEUKEMIA SPECIFIC IMMUNE CELLS IN AML PATIENTS' BLOOD OR CULTURE SETTINGS</p> <p><i>Poster Presenter:</i> Helga Schmetzer (Germany)</p>	18:00 - 18:00
B191	<p>TOTAL MARROW AND LYMPHOID IRRADIATION IN COMBINATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GRAFT VERSUS HOST DISEASE PROPHYLAXIS CONFERS FAVORABLE GVHD-FREE/RELAPSE-FREE SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA</p> <p><i>Poster Presenter:</i> Anthony Stein (United States)</p>	18:00 - 18:00
B192	<p>INCREASED MESENCHYMAL STROMAL CELLS SENESCENCE AND HIGH CXCL14 LEVELS IN BONE MARROW ARE LINKED WITH THE OCCURRENCE OF GVHD AFTER HEMATOPOIETIC STEM CELLS TRANSPLANTATION</p> <p><i>Poster Presenter:</i> Alexandra Guelton (France)</p>	18:00 - 18:00
B193	<p>CORRELATION OF THE OVERALL SURVIVAL IN MIXED-PHENOTYPE ACUTE LEUKAEMIA AND ACUTE LYMPHOBLASTIC LYMPHOMA WITH THE REFINED DISEASE RISK INDEX APPLIED IN AN UPPER-MIDDLE INCOME COUNTRY</p> <p><i>Poster Presenter:</i> Naty López-Córdova (Peru)</p>	18:00 - 18:00
B194	<p>ASSOCIATION BETWEEN GUT MICROBIOTA AND LEUKEMIA: A BIDIRECTIONAL MULTIVARIABLE MENDELIAN RANDOMIZATION STUDY</p> <p><i>Poster Presenter:</i> DaHua Lan (China)</p>	18:00 - 18:00
B195	<p>SIGNIFICANT IMPROVEMENT OF SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA OVER TWO DECADES - A SINGLE CENTER RETROSPECTIVE ANALYSIS</p> <p><i>Poster Presenter:</i> Paula Kessler (Germany)</p>	18:00 - 18:00
B196	<p>OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOLLOWING BLINATUMOMAB IN CHILDREN</p>	18:00 - 18:00

	AND YOUNG ADULTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	
	<i>Poster Presenter:</i> Dr. Mattia Algeri (Italy)	
B197	THE ROLE OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CONSOLIDATION OF MINIMAL RESIDUAL DISEASE-NEGATIVE REMISSION IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS AFTER PHARMACOLOGIC IMMUNOTHERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	
B198	AZACITIDINE AND VENETOCLAX WITH OR WITHOUT DLI IN RELAPSED MYELOID MALIGNANCIES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE MULTICENTER STUDY OF THE SFGM-TC	18:00 - 18:00
	<i>Poster Presenter:</i> Turot Mélanie (France)	
B199	FLAG-IDA/VENETOCLAX IS ASSOCIATED WITH HIGHER REMISSION RATES AND IMPROVED POST-TRANSPLANT SURVIVAL COMPARED TO VENETOCLAX/AZACITIDINE IN RELAPSED/REFRACTORY AML PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Radwan Massoud (Germany)	
B200	COMPARISON OF OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND EX-VIVO TCRAB+CD19 DOUBLE-NEGATIVE SELECTED GRAFT IN ACUTE MYELOID LEUKEMIA	18:00 - 18:00
	<i>Poster Presenter:</i> László Gopcsa (Hungary)	
B201	EFFICACY AND SAFETY ANALYSIS OF PROPHYLACTIC BRENTUXIMAB VEDOTIN ADMINISTRATION AFTER PEDIATRIC ACUTE LEUKEMIA HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Zhu Huili (China)	
B202	OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA IN YOUNG ADULTS COMPARED WITH CHILDREN, ADOLESCENTS AND ELDERLY PATIENTS IN GERMANY	18:00 - 18:00
	<i>Poster Presenter:</i> Jochen J. Frietsch (Germany)	
B203	PHASE I/II STUDY OF CYCLOPHOSPHAMIDE AND BENDAMUSTINE AS POST-TRANSPLANTATION GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN REFRACTORY MYELOID NEOPLASMS	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	
B204	REAL-WORLD OUTCOME OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT STANDARD INDUCTION CHEMOTHERAPY	18:00 - 18:00
	<i>Poster Presenter:</i> Francesca Biavasco (Germany)	
B205	DURING CB TRANSPLANT IN MRD-POSITIVE AML, RELAPSE IS USUALLY EARLY, IS REDUCED BY ACUTE GVHD AND IS INFLUENCED BY CICLOSPORIN EXPOSURE: A MULTICENTER NATIONAL EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Srividhya Senthil (United Kingdom)	
B206	IMPACT OF RESPONSE TO THE FIRST INDUCTION COURSE IN AML PATIENTS ON ALLOHSCT OUTCOMES WITH PTCY	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	
B207	POST-TRANSPLANT TYROSINE KINASE INHIBITOR MAINTENANCE IN PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA DELIVERS BENEFIT TOWARD IMPROVED OVERALL,	18:00 - 18:00

	RELAPSE-FREE, GVHD/RELAPSE-FREE SURVIVAL AND DECREASED NON-RELAPSE MORTALITY WITHOUT REDUCED RELAPSE	
	<i>Poster Presenter:</i> Eshrak Al-Shaibani (Canada)	
B208	IMPACT OF DONOR AND STEM-CELL SOURCE IN ADULTS WITH HIGH-RISK PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA TRANSPLANTED IN FIRST COMPLETE REMISSION: A STUDY FROM GRAALL AND SFGM-TC	18:00 - 18:00
	<i>Poster Presenter:</i> Nathalie Dhédin (France)	
B209	HOW DISEASE STATUS IMPACTS ON LONG-TERM SURVIVAL AFTER ALLOGENEIC TRANSPLANT IN ACUTE MYELOID LEUKEMIA: ANALYSIS ON 456 PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Maria Teresa Lupo Stanghellini (Italy)	
B210	TLS::ERG FUSION GENE PREDICTS A POOR PROGNOSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A SINGLE CENTER STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Gele Tong (China)	
B211	HIGH TOLERABILITY OF PROLONGED AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML LACKING A TARGETABLE MUTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Cuong An Do (Switzerland)	
B212	OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA FLT3 IN THE ERA OF FLT3 INHIBITORS - STUDY OF THE POLISH ADULT LEUKAEMIA GROUP (PALG)	18:00 - 18:00
	<i>Poster Presenter:</i> Barbara Nasilowska-Adamska (Poland)	
B213	CLINICAL CHARACTERISTICS AND PROGNOSIS OF ADULT T CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH ACTIVATING RAS MUTATIONS	18:00 - 18:00
	<i>Poster Presenter:</i> Mimi Xu (China)	
B214	VENETOCLAX-BASED SALVAGE: A LESS TOXIC AND EFFECTIVE THERAPY TO BRIDGE TO TRANSPLANT IN RELAPSE/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA(ALL) IN LOW AND MIDDLE-INCOME COUNTRIES(LMIC)	18:00 - 18:00
	<i>Poster Presenter:</i> Sujay Rainchwar (India)	
B215	PREVENTION AND TREATMENT OF ACUTE MYELOID LEUKEMIA RELAPSE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANT: A NATIONAL SURVEY BY GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO)	18:00 - 18:00
	<i>Poster Presenter:</i> Giorgia Battipaglia (Italy)	
B216	TRENDS IN THE USE OF HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT	18:00 - 18:00
	<i>Poster Presenter:</i> Prof. Sebastian Giebel (Poland)	
B217	ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIA - A SINGLE CENTER 25-YEARS EXPERIENCE	18:00 - 18:00
	<i>Poster Presenter:</i> Veronika Válková (Czech Republic)	
B218	STRUCTURAL ANALYSIS OF LEUKEMIA-ASSOCIATED PROTEIN PTPN21 REVEALS A DOMINANT-NEGATIVE EFFECT OF THE FERM DOMAIN ON ITS PHOSPHATASE ACTIVITY	18:00 - 18:00
	<i>Poster Presenter:</i> Zijun Qian (China)	

B219	EARLY DETECTION OF RELAPSE AND PROMPT TREATMENT WITH DLI FACILITATED BY PROPHYLACTIC LYMPHOCYTE STORAGE PERI-TRANSPLANT RESULTS IN EFFECTIVE DISEASE CONTROL IN ACUTE LEUKAEMIA AND MDS <i>Poster Presenter:</i> Daire Quinn (United Kingdom)	18:00 - 18:00
B220	THIOTEPA, BUSULFAN, AND FLUDARABINE CONDITIONING REGIMEN IN T-CELL REplete HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOR ADULTS WITH ACUTE MYELOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSION <i>Poster Presenter:</i> Ahmad Ibrahim (Lebanon)	18:00 - 18:00
B221	REDUCED INTENSITY CHEMOTHERAPY WITH TYROSINE KINASE INHIBITOR FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION WAS EFFECTIVE IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA <i>Poster Presenter:</i> Dong Won Baek (Korea, Republic of)	18:00 - 18:00
B222	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS EVALUATED BY FLOW CYTOMETRY ASSOCIATES WITH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES <i>Poster Presenter:</i> Liangyi Liu (China)	18:00 - 18:00
B223	IMPACT OF CO-MUTATIONS ON THE TRANSPLANT OUTCOMES IN AML PATIENTS WITH DNMT3A MUTATION <i>Poster Presenter:</i> Xavier Cheng-Hong Tsai (Taiwan)	18:00 - 18:00
B224	ADAT1-MEDIATED TRNA 37 A-TO-I EDITING PROMOTES LEUKAEMOGENESIS VIA CONTROLLING TRANSLATIONAL EFFICIENCY OF HOXA13 DURING MYELOID DIFFERENTIATION <i>Poster Presenter:</i> Lin Xia (China)	18:00 - 18:00
B225	SALVAGE TREATMENTS HAVE EXTREMELY POOR OUTCOMES FOR PATIENTS WITH RELAPSED T-ACUTE LYMPHOBLASTIC LEUKAEMIA POST TRANSPLANT <i>Poster Presenter:</i> Dr. Alexandros Rampotas (United Kingdom)	18:00 - 18:00
B226	FEASIBILITY OF ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PREVIOUSLY TREATED WITH CPX-351: REPORT FROM A SINGLE CENTER <i>Poster Presenter:</i> Sabrina Giammarco (Italy)	18:00 - 18:00
B227	VENETOCLAX PLUS LOW-DOSE AZACITIDINE IS EFFECTIVE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH INTERMEDIATE/HIGH-RISK ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Caixia Wang (China)	18:00 - 18:00
B228	COMPARISON OF VENETOCLAX-BASED NON-ANTHRACYCLINE INDUCTION THERAPY VERSUS 3 + 7 FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS <i>Poster Presenter:</i> Tran-Der Tan (Taiwan)	18:00 - 18:00
B229	MYELOFIBROSIS GRADE II-III IS AN INDEPENDENT RISK FACTOR FOR RELAPSE OF ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Erlic Jiang (China)	18:00 - 18:00
B230	INCIDENCE AND MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKAEMIA RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LIMITED RESOURCE COUNTRIES	18:00 - 18:00

	<i>Poster Presenter:</i> Nour Ben Abdeljelil (Tunisia)	
B231	IMPACT OF BODY MASS INDEX ON OUTCOME IN ADULT PATIENTS WITH ACUTE MYELOID AND ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Silvia Cingelova (Slovakia)	18:00 - 18:00
B233	VENETOCLAX COMBINED WITH HMAS-BASED THERAPY AS PRE-EMPTIVE TREATMENT FOR ACUTE MYELOID LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Mimi Xu (China)	18:00 - 18:00
B234	VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA <i>Poster Presenter:</i> Qingxiao Song (China)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Non-haematopoietic Stem Cells and Regenerative Medicine		
B001	REDUCED PRESENCE OF MESENCHYMAL STEM CELLS IN BONE MARROW ASPIRATES OF FEMALE PATIENTS PERSISTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter:</i> Judith Schaffrath (Germany)	18:00 - 18:00
<i>Printed Poster</i>		
18:00 - 19:00		Hall 3 North
Inborn Errors, Granulocyte and Osteoclast Disorders		
B245	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INBORN ERRORS OF IMMUNITY (IEI): GAP BETWEEN NEED AND REALITY IN A LIMITED RESOURCE SETTING—A FIVE-YEAR SINGLE-CENTER EXPERIENCE <i>Poster Presenter:</i> Stalin Ramprakash (India)	18:00 - 18:00
B246	AN INNOVATIVE PLATFORM APPROACH FOR THE DEVELOPMENT OF EX-VIVO HEMATOPOIETIC STEM AND PROGENITOR CELL-GENE THERAPY FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH SKELETAL INVOLVEMENT <i>Poster Presenter:</i> Maria Ester Bernardo (Italy)	18:00 - 18:00
B247	HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CURRENT PERSPECTIVE IS SAFE FOR MUCOPOLYSACCHARIDOSIS TYPE VI PATIENTS <i>Poster Presenter:</i> Koray Yalçın (Turkey)	18:00 - 18:00
B248	HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED AND MISMATCHED DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND ANTITHYMOCYTE GLOBULIN IN CHILDREN WITH PRIMARY IMMUNODEFICIENCIES <i>Poster Presenter:</i> Alexandra Laberko (Russian Federation)	18:00 - 18:00
B249	CONDITIONING FOR SECOND HSCTS FROM THE SAME DONOR AFTER MYELOID AUTOLOGOUS RECONSTITUTION IN PATIENTS WITH IEI AND THALASSEMIA: IMMUNOSUPPRESSION IS NOT ALWAYS REQUIRED <i>Poster Presenter:</i> Manfred Hoenig (Germany)	18:00 - 18:00
B250	DESIGN OF A RANDOMIZED PHASE 3 CLINICAL TRIAL (HURCULES) INVESTIGATING THE SAFETY AND EFFICACY OF OTL-203 IN MPS-IH VERSUS ALLOGENEIC HAEMATOPOIETIC	18:00 - 18:00

STEM CELL TRANSPLANTATION*Poster Presenter:* Maria Ester Bernardo (Italy)

B251 **SINGLE CENTER OBSERVATION ON CLINICAL PRESENTATION, TRANSPLANTATION AND OUTCOME OF SEVEN PATIENTS WITH ZAP-70 DEFICIENCY** 18:00 - 18:00

Poster Presenter: Felix Immanuel Maier (Germany)

B252 **POLYMORPHISM OR RISK ALLELE? PRF1 A91V IN TRANS WITH A "SEVERE" PRF1 MUTATION** 18:00 - 18:00

Poster Presenter: Oliver Wegehaupt (Germany)

B253 **IMMUNE-MEDIATED CYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH INHERITED METABOLIC DISORDERS** 18:00 - 18:00

Poster Presenter: Hirotoshi Sakaguchi (Japan)*Printed Poster*

18:00 - 19:00

Hall 3 North

Graft-versus-host Disease - Preclinical and Animal Models

B019 **DR3 AND GITR AGONISTS BOOST ENDOGENOUS TREG POOL TO PREVENT ACUTE GVHD** 18:00 - 18:00

Poster Presenter: Juan Fernando Gamboa Vargas (Germany)

B020 **ROLE OF BCL2 IN GRAFT VERSUS HOST DISEASE** 18:00 - 18:00

Poster Presenter: Jose A. Perez-Simon (Spain)

B021 **DIMETHYL FUMARATE INHIBITS TFH DIFFERENTIATION AND CGVHD VIA NRF2** 18:00 - 18:00

Poster Presenter: Huanle Gong (China)

B022 **SPECIFIC INHIBITION OF PATHOLOGICAL ANGIOGENESIS TO DECREASE ACUTE GVHD** 18:00 - 18:00

Poster Presenter: Dr. Katarina Riesner (Germany)

B023 **ENDOTHELIAL-TO-MESENCHYMAL TRANSITION IN CHRONIC GVHD** 18:00 - 18:00

Poster Presenter: Dr. Katarina Riesner (Germany)

B024 **RAPID ADAPTATION OF DONOR REGULATORY T CELLS (TREG) TO RECIPIENT TISSUES FOR THE CONTROL OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)** 18:00 - 18:00

Poster Presenter: Franziska Pielmeier (Germany)

B025 **INHIBITION OF MYELOPEROXIDASE AMELIORATES MURINE ACUTE GRAFT-VERSUS-HOST DISEASE** 18:00 - 18:00

Poster Presenter: Michelle Klesse (Germany)

B026 **DEFECTIVE HIF-1A EXPRESSION IN BONE MARROW ENDOTHELIAL PROGENITOR CELLS MAY PROMOTE ACUTE GRAFT-VERSUS-HOST-DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION** 18:00 - 18:00

Poster Presenter: Wen-Kai Zhang (China)

B027 **IFN-GAMMA INDUCES ACUTE GRAFT-VERSUS-HOST DISEASE BY PROMOTING HMGB1-MEDIATED NUCLEAR-TO-CYTOPLASM TRANSLOCATION AND AUTOPHAGIC DEGRADATION OF P53** 18:00 - 18:00

Poster Presenter: Yajing Xu (China)

B028 **DEFINING THE TRANSCRIPTOMIC LANDSCAPE OF ACUTE SKIN GVHD AT SINGLE CELL RESOLUTION** 18:00 - 18:00

Poster Presenter: Callum Wright (United Kingdom)

B029 **IMPROVING THE THERAPEUTIC EFFECT OF HUMAN UMBILICAL** 18:00 - 18:00

	CORD MESENCHYMAL STEM CELLS ON ACUTE GRAFT-VERSUS-HOST DISEASE BY CRISPLD2-OVEREXPRESSION	
	<i>Poster Presenter:</i> Qingxiao Song (China)	
B030	TRNA METHYLTRANSFERASE DNMT2 MODULATES GVHD PROCESS VIA TRNA M⁵C MODIFICATION	18:00 - 18:00
	<i>Poster Presenter:</i> Shijie Yang (China)	
B031	RUXOLITINIB USE DURING DONOR STEM CELL MOBILIZATION RESULTS IN RECIPIENTS IMMUNOMODULATION POST BONE MARROW TRANSPLANT IN MURINE MODEL AND MIGHT REDUCE GRAFT VERSUS HOST DISEASE	18:00 - 18:00
	<i>Poster Presenter:</i> Vamsi Kota (United States)	
B032	AMPK COORDINATES GLYCOLYTIC COMPENSATION IN GVHD-CAUSING T CELLS	18:00 - 18:00
	<i>Poster Presenter:</i> Archana Ramgopal (United States)	
B033	ROS DEFICIENCY OF RECEIPT DERIVED MDSCS EXACERBATES ALLO-REACTIVE T CELLS RESPONSES DURING HYPERACUTE GVHD	18:00 - 18:00
	<i>Poster Presenter:</i> Erlic Jiang (China)	
<i>Printed Poster</i>		
	18:00 - 19:00	Hall 3 North
Graft-versus-host Disease - Clinical		
B034	EFFECTOR SITE IMMUNE DYNAMICS IN REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE: A ROCKSTAR TRIAL COMPANION STUDY AFTER BELUMOSUDIL TREATMENT	18:00 - 18:00
	<i>Poster Presenter:</i> Jacqueline Mays (United States)	
B035	CAST REGIMEN FOR GVHD PROPHYLAXIS YIELDS LOWER RELAPSE RATE AND IMPROVED DISEASE-FREE SURVIVAL: A CIBMTR PROPENSITY SCORE MATCHED CASE-CONTROL ANALYSIS	18:00 - 18:00
	<i>Poster Presenter:</i> Stephen Spellman (United States)	
B036	SEQUENTIAL INTRAVENOUS UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (MSCS) FOR SALVAGE TREATMENT OF STEROID-REFRACTORY ACUTE GVHD (RS-AGVHD): A PHASE IB/II STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Yanmin Zhao (China)	
B037	GRAFT VERSUS HOST DISEASE PROPHYLAXIS WITH TACROLIMUS, SIROLIMUS AND MMF IN PATIENTS UNDERGOING ALLOGENIC TRANSPLANT WITH REDUCED INTENSITY CONDITIONING	18:00 - 18:00
	<i>Poster Presenter:</i> Lucía López Corral (Spain)	
B038	NOVEL GVHD PROPHYLAXIS WITH POST-TRANSPLANT INTERMEDIATE DOSE CYTOXAN AND ABATACEPT - LOW RATES OF ACUTE GVHD AND TRANSPLANT-RELATED TOXICITY	18:00 - 18:00
	<i>Poster Presenter:</i> Yuliya Shestovska (United States)	
B039	REDUCING PTCY DOSE IN PATIENTS RECEIVING CAST FOR GVHD PREVENTION RESULTS IN ACCELERATED ENGRAFTMENT AT THE COST OF HIGHER INCIDENCE OF GVHD	18:00 - 18:00
	<i>Poster Presenter:</i> J. Andres Suarez-Londono (United States)	
B040	RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Virginia Escamilla Gómez (Spain)	

B041	PHASE 1 TRIAL INVESTIGATING THE SAFETY AND TOLERABILITY OF LEFLUNOMIDE IN PATIENTS WITH STEROID-DEPENDENT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT) <i>Poster Presenter: Amandeep Salhotra (United States)</i>	18:00 - 18:00
B042	COMPARISON OF EFFICACY AND TOLERABILITY OF RUXOLITINIB ALONE OR RUXOLITINIB WITH EXTRACORPOREAL PHOTOPHERESIS OR EXTRACORPOREAL PHOTOPHERESIS MONOTHERAPY FOR STEROID REFRACTORY AGVHD: A GITMO RETROSPECTIVE STUDY <i>Poster Presenter: Marta Lisa Battista (Italy)</i>	18:00 - 18:00
B043	MINI-DOSE METHOTREXATE COMBINED WITH METHYLPREDNISOLONE FOR INITIAL TREATMENT OF MILD ACUTE GVHD: A MULTI-CENTER, RANDOMIZED TRIAL <i>Poster Presenter: Yu Wang (China)</i>	18:00 - 18:00
B044	IMPROVED LONG-TERM OUTCOME OF RUXOLITINIB PLUS ECP VS RUXOLITINIB ALONE IN STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (SR-AGVHD) <i>Poster Presenter: Prof. Dr. Nicolaus Kröger (Germany)</i>	18:00 - 18:00
B045	ANTITHYMOCYTE GLOBULIN (ATG) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN MULTICENTER STUDY: EVALUATING OUTCOMES ACCORDING TO CYTOGENETIC RISK <i>Poster Presenter: Mihee Kim (Korea, Republic of)</i>	18:00 - 18:00
B046	COMPARISON BETWEEN POSTTRANSPLANT CYCLOPHOSPHAMIDE AND ATG BASED REGIMENS AS GVHD PROPYLAXIS IN ONE-ANTIGEN MISMATCH UNRELATED DONOR TRANSPLANTATION <i>Poster Presenter: Marta Lisa Battista (Italy)</i>	18:00 - 18:00
B047	PROSPECTIVE EVALUATION OF PLASMA INFLAMMATORY PROTEINS FOR PREDICTION OF SEVER GRAFT-VERSUS-HOST DISEASE AFTER TRANSPLANT	18:00 - 18:00
B048	LYMPHOPENIA BUT NOT ABSOLUTE LYMPHOCYTE COUNT BEFORE ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) ADMINISTRATION IMPACTS TRANSPLANT OUTCOMES IN MATCHED UNRELATED PERIPHERAL BLOOD STEM CELL ALLOGENEIC STEM CELL TRANSPLANTATION <i>Poster Presenter: Radwan Massoud (Germany)</i>	18:00 - 18:00
B049	A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL TO EXPLORE THE ROLE OF MESENCHYMAL STEM CELLS IN PREVENTING GRAFT VERSUS HOST DISEASE <i>Poster Presenter: Han Yao (China)</i>	18:00 - 18:00
B050	RUXOLITINIB AS SECOND-LINE TREATMENT FOR BOS AFTER HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter: Feng Chen (China)</i>	18:00 - 18:00
B051	POST-TRANSPLANTATION CYCLOPHOSPHAMIDE WITH OR WITHOUT PROPHYLACTIC DONOR LYMPHOCYTE INFUSION AFTER HLA-MATCHED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MDS/AMI <i>Poster Presenter: Mr. Joost van der Hem (Netherlands)</i>	18:00 - 18:00
B052	IMPROVED GRFS WHEN ATG/ATLG IS USED IN ALLO-PBSCT FROM MATCHED SIBLING DONORS - AN EBMT REGISTRY STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY <i>Poster Presenter: Dr. Agnieszka Piekarska (Poland)</i>	18:00 - 18:00
B053	NAVIGATING GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN	18:00 - 18:00

	MATCHED SIBLING DONOR ALLOGENEIC TRANSPLANTS: A COMPARATIVE ANALYSIS OF POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS DIVERSE REGIMENS - INSIGHTS FROM A SINGLE-CENTER EXPERIENCE	
	<i>Poster Presenter:</i> Dennis Kim (Canada)	
B054	POST TRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN PATIENTS RECEIVING HLA MISMATCHED (7/8) UNRELATED DONOR FOR MYELOID MALIGNANCIES: RESULTS OF THE GITMO PROSPECTIVE PHYLOS TRIAL	18:00 - 18:00
	<i>Poster Presenter:</i> Anna Maria Raiola (Italy)	
B055	EXTRACORPOREAL PHOTOPHERESIS AS SALVAGE TREATMENT IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD: A MULTICENTER, RETROSPECTIVE STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Dr. Mattia Algeri (Italy)	
B056	BELUMOSUDIL PHASE 1 DOSE-ESCALATION STUDY IN HEALTHY VOLUNTEERS AND PHASE 2 STUDY IN PATIENTS WITH CGVHD WHO FAILED ≥ 1 LINE OF SYSTEMIC THERAPY IN CHINA	18:00 - 18:00
	<i>Poster Presenter:</i> Ying Wang (China)	
B057	IMPACT OF RESPIRATORY FUNCTION TESTS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Francisco Manuel Martin Dominguez (Spain)	
B058	MANAGEMENT OF CORTICOSTEROIDS IN PATIENTS RECEIVING RUXOLITINIB TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A POST HOC ANALYSIS FROM THE RANDOMIZED PHASE 3 REACH3 STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Valkal Bhatt (United States)	
B059	A PROGNOSTIC MODEL FOR NON-RELAPSE MORTALITY RISK BASED ON MACHINE LEARNING IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION	18:00 - 18:00
	<i>Poster Presenter:</i> Xiawei Zhang (China)	
B060	A HIGH FREQUENCY OF TYPE 3 DENDRITIC CELLS IN CD1C+DC ON DAY +28 AFTER HSCT COULD BE AN EFFECTIVE INDICATOR OF SEVERE GVHD IN PEDIATRIC PATIENTS	18:00 - 18:00
	<i>Poster Presenter:</i> Xin Liu (China)	
B061	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH UNRELATED CORD BLOOD ENHANCES SURVIVAL AND REDUCES THE INCIDENCE OF AGVHD FOR PEDIATRIC ACUTE MYELOID LEUKEMIA	18:00 - 18:00
	<i>Poster Presenter:</i> Zhijie Wei (China)	
B062	RUXOLITINIB AND ANTI-TNF-ALPHA THERAPY SUBSTANTIALLY IMPROVE SURVIVAL IN PEDIATRIC PATIENTS WITH SEVERE STEROID REFRACTORY GVHD	18:00 - 18:00
	<i>Poster Presenter:</i> Ingo Müller (Germany)	
B063	IMMUNOPHENOTYPE OF EXTRACELLULAR VESICLES AS A BIOMARKER OF CHRONIC GRAFT-VERSUS-HOST-DISEASE: A PILOT STUDY	18:00 - 18:00
	<i>Poster Presenter:</i> Luisa Giaccone (Italy)	
B064	T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION WITH ALEMTUZUMAB IS A VIABLE ALTERNATIVE TO POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME	18:00 - 18:00
	<i>Poster Presenter:</i> Alexandra Rojek (United States)	
B065	EXTENDED ABATACEPT USE WITH SEROTHERAPY TO REDUCE	18:00 - 18:00

	ACUTE GVHD INCIDENCE IN PEDIATRIC PATIENTS TRANSPLANTED FROM HLA-MISMATCHED UNRELATED DONORS <i>Poster Presenter:</i> Pietro Merli (Italy)	
B066	ENDOTHELIAL DYSFUNCTION AND RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A PRELIMINARY ANALYSIS OF A SINGLE CENTRE STUDY <i>Poster Presenter:</i> Giulia Losi (Italy)	18:00 - 18:00
B067	EXTENDED ABATACEPT DOSING MAY REDUCE RATES OF CHRONIC GRAFT VS HOST DISEASE IN PEDIATRIC PATIENTS UNDERGOING BONE MARROW TRANSPLANT FOR UNDERLYING HEMATOLOGICAL DISEASES <i>Poster Presenter:</i> Michael Grimley (United States)	18:00 - 18:00
B068	COMPARISON OF THE EFFICACY OF MYCOPHENOLATE MOFETIL AFTER ORAL OR INTRAVENOUS ADMINISTRATION IN THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE	18:00 - 18:00
B069	NEAR ELIMINATION OF GVHD WITH AN ABBREVIATED CALCINEURIN AND M-TOR INHIBITOR-FREE GVHD PREVENTION REGIMEN <i>Poster Presenter:</i> Samer Al-Homsi (United States)	18:00 - 18:00
B070	EFFICACY AND SAFETY OF REDUCED-DOSES OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PERIPHERAL BLOOD STEM CELL TRANSPLANTATION OUTSIDE THE HAPLOIDENTICAL SETTING <i>Poster Presenter:</i> Sara Redondo (Spain)	18:00 - 18:00
B071	A LOW TRAJECTORY OF PLATELETS IN THE EARLY STAGES AFTER TRANSPLANTATION IS LINKED TO THE DEVELOPMENT OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) <i>Poster Presenter:</i> Erlic Jiang (China)	18:00 - 18:00
B072	ADDITION OF TOCILIZUMAB TO STANDARD GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM MOTHER DONORS: A NESTED CASE-CONTROL STUDY <i>Poster Presenter:</i> Lizhen Liu (China)	18:00 - 18:00
B073	GVHD PROPHYLAXIS WITH THREE VERSUS FIVE DRUGS COMBINATION IN AML PATIENTS UNDERGOING ALLOGENEIC TRANSPLANT FROM HLA MISMATCHED UNRELATED OR HAPLOIDENTICAL RELATED DONOR <i>Poster Presenter:</i> Alessandra Picardi (Italy)	18:00 - 18:00
B074	CYTOKINE SECRETION DURING REDUCED INTENSITY CONDITIONING HAEMATOPOIETIC STEM CELL TRANSPLANT FOR MYELOID DISEASE, AN OPPORTUNITY FOR OUTCOME PREDICTION <i>Poster Presenter:</i> Chris Armstrong (Ireland)	18:00 - 18:00
B075	INTERFERON GAMMA ACTIVITY IN IMPAIRED HAEMATOPOIETIC STEM CELL (HSC) PROLIFERATION AND GRAFT-VERSUS-HOST DISEASE <i>Poster Presenter:</i> Régis Peffault de Latour (France)	18:00 - 18:00
B076	DELETIONS OF COMPLEMENT FACTOR H-RELATED GENES CFHR-1 AND CFHR-3 AND ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Poster Presenter:</i> Dr. Lars Klinge Gjørde (Denmark)	18:00 - 18:00
B077	EXTERNAL VALIDATION OF SAINT LOUIS SCORE TO PREDICT ACUTE GRAFT-VERSUS-HOST DISEASE SEVERITY	18:00 - 18:00

	<i>Poster Presenter:</i> Alessandro Criscimanna (Italy)	
B078	EVALUATION OF RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING REGIMENS <i>Poster Presenter:</i> Kristina Maas-Bauer (Germany)	18:00 - 18:00
B079	THE MACROPHAGE ACTIVATION MARKER SCD163 AND ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HSCT <i>Poster Presenter:</i> Maja Munk Kristoffersen (Denmark)	18:00 - 18:00
B080	ETIOLOGY OF DIARRHEA IN PATIENTS UNDERGOING COLONOSCOPIC BIOPSIES POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR SUSPECTED ACUTE GUT GRAFT VERSUS HOST DISEASE <i>Poster Presenter:</i> Niket Mantri (India)	18:00 - 18:00
B081	ABATACEPT ADDED TO POST TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXYS IN ALLOGENEIC HEMATOPOYETIC STEM CELL TRANSPLANTATION: ONE SINGLE CENTER EXPERIENCE <i>Poster Presenter:</i> Paula Fernández- Caldas González (Spain)	18:00 - 18:00
B082	SAFETY AND EFFICACY OF THE ROCK2-INHIBITOR BELUMOSUDIL IN CGVHD TREATMENT - A RETROSPECTIVE, MULTICENTER REAL-WORLD DATA ANALYSIS <i>Poster Presenter:</i> Silke Heidenreich (Germany)	18:00 - 18:00
B083	EFFICACY AND SAFETY OF IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A SYSTEMATIC REVIEW <i>Poster Presenter:</i> Daniel Rizky (Indonesia)	18:00 - 18:00
B084	WHEN SHOULD RUXOLITINIB BE CEASED? A SINGLE CENTRE, RETROSPECTIVE, REAL-WORLD ANALYSIS OF RUXOLITINIB IN GRAFT VS HOST DISEASE POST ALLOGENEIC STEM CELL TRANSPLANT <i>Poster Presenter:</i> Harshita Rajasekariah (Australia)	18:00 - 18:00
B085	CLINICAL RESPONSE AND IMMUNOLOGICAL RECOVERY IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) TREATED WITH THE ASSOCIATION OF EXTRACORPOREAL PHOTOPHERESIS (ECP) AND RUXOLITINIB <i>Poster Presenter:</i> Eleonora Toffoletti (Italy)	18:00 - 18:00
B086	GVHD PROPHYLAXIS WITH POST-TRANSPLANT HIGH DOSE CYTOXAN OVERCOMING THE BARRIER OF ALLOGENEIC HCT IN FUNCTIONAL HIGH-RISK PATIENTS <i>Poster Presenter:</i> Yuliya Shestovska (United States)	18:00 - 18:00

Wednesday, 17. April 2024*Meet the Expert*

07:30 - 08:30

CASTLE Suite

MTE-9 - Meet-the-Expert: Autoimmune disease; who to consider for cellular therapy/autograftMTE-9 **Autoimmune disease; who to consider for cellular therapy/autograft**

07:30 - 08:30

Speaker: Prof. John Snowden (United Kingdom)*Meet the Expert*

07:30 - 08:30

CASTLE Suite

MTE-8 - Meet-the-Expert: How I transplant patients with PIDMTE-8 **How I transplant patients with PID**

07:30 - 08:30

Speaker: Prof. Mary Slatter (United Kingdom)*Meet the Expert*

07:30 - 08:30

CASTLE Suite

QM-MTE-5 - Quality Management Meet-the-Expert: JACIE Inspectors updateQM-MTE-5 **JACIE Inspectors update**

07:30 - 08:30

Speaker: Ms. Tuula Rintala (United Kingdom)*Meet the Expert*

07:30 - 08:30

CASTLE Suite

MTE - Breakfast Meet the Expert - Wednesday*Meet the Expert*

07:30 - 08:30

CASTLE Suite

MTE-11 - Meet-the-Expert: Strategies to reduce the risk of disease relapse in patients transplanted for AMLMTE-11 **Strategies to reduce the risk of disease relapse in patients transplanted for AML**

07:30 - 08:30

Speaker: Prof. Charlie Craddock (United Kingdom)*Meet the Expert*

07:30 - 08:30

CASTLE Suite

MTE-10 - Meet-the-Expert: Myelofibrosis: Who and how to transplantMTE-10 **Myelofibrosis: Who and how to transplant**

07:30 - 08:30

Speaker: Prof. Dr. Nicolaus Kröger (Germany)*Educational*

08:30 - 10:00

CLYDE

E07 - GVHD - Improving outcomes*Chair:* Marie Thérèse Rubio (France)*Chair:* Prof. Olaf Penack (Germany)E07-1 **The influence of graft source and composition on GVHD**

08:30 - 08:55

Speaker: Dr. Mattia Algeri (Italy)E07-2 **Steroid refractory acute GVHD; current management**

08:55 - 09:20

Speaker: Prof. Dr. Zinaida Peric (Croatia)E07-3 **Patient unmet needs in GVHD management & care**

09:20 - 09:45

	<i>Speaker:</i> Prof. Dr. Helene Schoemans (Belgium)	
E07-4	Q&A - Discussion	09:45 - 10:00
<i>Oral Session</i> 08:30 - 09:45		LOMOND
OS09 - Oral Session 9 Donor Factors Impacting transplant outcomes		
<i>Chair:</i> Dr. Wendy Ingram (United Kingdom)		
<i>Chair:</i> Dr. David Irvine (United Kingdom)		
OS9-01	EVALUATING THE IMPACT OF ABO COMPATIBILITY ON ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES A CONTEMPORARY AND COMPREHENSIVE STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY <i>Oral Presenter:</i> Dr. Mustafa Güven (Turkey)	08:30 - 08:39
OS9-02	VLA-4 AGONIST PROMOTE ENGRAFTMENT AND CELL IMMUNE RECONSTITUTION OF ALLOGENEIC HEMATOPOIETIC STEM CELLS <i>Oral Presenter:</i> Qiaomei He (China)	08:39 - 08:48
OS9-03	IMPACT OF GVHD PROPHYLAXIS ON THE OUTCOMES OF 8/10 HLA-MISMATCHED UNRELATED DONOR ALLOGRAFT: AN ANALYSIS ON BEHALF OF THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT <i>Oral Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	08:48 - 08:57
OS9-04	COMPARISON OF EARLY IMMUNE RECONSTITUTION AFTER HAPLOIDENTICAL HSCT IN CHILDREN WITH ACUTE LEUKEMIA: PBSC WITH TCRAB+/CD19+ DEPLETION VERSUS BM WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE <i>Oral Presenter:</i> Alexandra Laberko (Russian Federation)	08:57 - 09:06
OS9-05	HOW RISKY IS A SECOND ALLOGENEIC STEM CELL TRANSPLANTATION? AN EBMT REGISTRY ANALYSIS BY THE TRANSPLANT COMPLICATIONS WORKING PARTY <i>Oral Presenter:</i> Dr. Katarina Riesner (Germany)	09:06 - 09:15
OS9-06	HOW DOES CRYOPRESERVATION IMPACT ALLOGENIC BONE MARROW AND MOBILIZED STEM CELL GRAFT CLINICAL OUTCOME? FROM HEMATOPOIETIC STEM CELL QUALITY CONTROL TO OVERALL SURVIVAL <i>Oral Presenter:</i> Clotilde Aussel (France)	09:15 - 09:24
OS9-07	DONOR AGE AND CMV STATUS ARE ASSOCIATED WITH T-CELL IMMUNOPHENOTYPE IN G-CSF MOBILIZED GRAFTS: AN INITIAL ANALYSIS FROM THE DKMS AND NMDP GRAFT COMPOSITION STUDY <i>Oral Presenter:</i> Kate Markey (United States)	09:24 - 09:33
OS9-08	YOUNG MATCHED UNRELATED DONORS SHOULD BE PRIORITIZED OVER OLDER-AGED MATCHED SIBLING DONORS AND YOUNG HAPLOIDENTICAL DONORS IN ALLOGENEIC TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN RECIPIENTS ≥50-YEARS <i>Oral Presenter:</i> Karthik Nath (United States)	09:33 - 09:42
<i>Educational</i> 08:30 - 10:00		Hall 3 North
E08 - Improving transplant outcomes		
<i>Chair:</i> Prof. Benedicte Neven (France)		
<i>Chair:</i> Prof. Dr. Krzysztof Kalwak (Poland)		
E08-1	Hematopoietic Stem Cell expansion: current indications and future prospects	08:30 - 08:55

	<i>Speaker:</i> Prof. Dr. Guy Sauvageau (Canada)	
E08-2	Novel approaches to conditioning therapy <i>Speaker:</i> Prof. Persis Amrolia (United Kingdom)	08:55 - 09:20
E08-3	Pioneering transplant programmes in the developing world <i>Speaker:</i> Dr. Lawrence Faulkner (Italy)	09:20 - 09:45
E08-4	Q&A - Discussion	09:45 - 10:00
 <i>Joint Sessions</i>		
08:30 - 10:00		Hall 3 South
JS05 - Joint Session EBMT / CIBMTR / ASTCT / APBMT / LABMT - Exploring the Contributions of Laboratory, Translational, and Big Data Science in HCT/CAR T within Our Organizations and Meetings		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
<i>Chair:</i> Prof. Bronwen Shaw (United States)		
<i>Chair:</i> Prof. Dr. Alok Srivastava (India)		
<i>Chair:</i> Dr. Cristobal Frutos (Paraguay)		
<i>Chair:</i> Prof. Miguel Ángel Perales (United States)		
JS05-1	Where are we coming from? <i>Speaker:</i> Prof. Bronwen Shaw (United States) <i>Speaker:</i> Prof. Dr. Alok Srivastava (India) <i>Speaker:</i> Dr. Cristobal Frutos (Paraguay) <i>Speaker:</i> Prof. Miguel Ángel Perales (United States) <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	08:30 - 09:05
JS05-2	Panel Discussion - all with: <i>Panelist:</i> Prof. Yoshiyuki Takahashi (Japan) <i>Panelist:</i> Prof. Dr. Gregorio Jaimovich (Argentina) <i>Panelist:</i> Prof. Dr. Mette Hazenberg (Netherlands)	09:05 - 10:00
 <i>Workshop</i>		
08:30 - 10:00		Hall 2
W09 - MPN		
<i>Chair:</i> Dr. Donal McLornan (United Kingdom)		
<i>Chair:</i> Dr. Christina Rautenberg (Germany)		
W09-1	Allo-HCT in adult patients with CMML <i>Speaker:</i> Prof. Ibrahim Yakoub-Agha (France)	08:30 - 08:55
W09-2	MF - Who and how <i>Speaker:</i> Dr. Nico Gagelmann (Germany)	08:55 - 09:20
W09-3	Complex case 1 <i>Speaker:</i> Dr. Nerses Ghahramanyan (Armenia)	09:20 - 09:28
W09-4	Complex case 2 <i>Speaker:</i> Ms. Johanna Richter (Germany)	09:28 - 09:36
W09-5	Complex case 3 <i>Speaker:</i> Dr. Mustafa Güven (Turkey)	09:36 - 09:44
W09-6	Q&A - Discussion	09:44 - 10:00
 <i>Oral Session</i>		
08:30 - 09:45		Hall 5
OS10 - Oral Session 10 Cellular Therapy for lymphoproliferative disorders		
<i>Chair:</i> Dr. Kate Cwynarski (United Kingdom)		
<i>Chair:</i> Paul G. Richardson (United States)		
OS10-01	RATES OF RESPONSE TO SALVAGE TREATMENT AFTER POST-CAR-T PROGRESSION/RELAPSE IN LARGE B-CELL LYMPHOMA	08:30 - 08:39

	PATIENTS - A DATA METAANALYSIS	
	<i>Oral Presenter:</i> Jaromir Tomasik (Poland)	
OS10-02	PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1-3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B)	08:39 - 08:48
	<i>Oral Presenter:</i> Tessa Kerre (United States)	
OS10-03	PATIENT-REPORTED OUTCOMES CARTITUDE-4 STUDY (PHASE 3) OF CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA AFTER 1-3 LINES OF THERAPY	08:48 - 08:57
	<i>Oral Presenter:</i> Roberto Mina (Italy)	
OS10-04	BASELINE SBCMA PLASMA LEVEL HAS NO IMPACT ON THE EFFICACY OF EQUICABTAGENE AUTOLEUCEL, A BCMA-CAR T CELL THERAPY IN PATIENTS WITH RRMM: SUBANALYSIS OF FUMANBA-1 TRIAL	08:57 - 09:06
	<i>Oral Presenter:</i> Lu-Gui Qiu (China)	
OS10-05	OUTCOMES IN AFRICAN-AMERICAN (AA) AND WHITE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING RVD-ALONE VS RVD+ASCT IN DETERMINATION: EFFICACY, SAFETY, AND SECOND PRIMARY MALIGNANCIES (SPMS)	09:06 - 09:15
	<i>Oral Presenter:</i> Paul G. Richardson (United States)	
OS10-06	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES AND SÉZARY SYNDROME: A RETROSPECTIVE ANALYSIS INCLUDING 63 CONSECUTIVE PATIENTS WITH LONG-TERM MEDIAN FOLLOW-UP	09:15 - 09:24
	<i>Oral Presenter:</i> Prof. Dr. Francesco Onida (Italy)	
OS10-07	ALLOGENEIC TRANSPLANTATION AFTER IMMUNOTHERAPY OR DRUG-CONJUGATED ANTIBODY FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: A COMPARISON WITH A HISTORICAL COHORT	09:24 - 09:33
	<i>Oral Presenter:</i> Jacopo Mariotti (Italy)	
OS10-08	COMPARISON OF THIOTEPA-BASED CONDITIONING REGIMENS FOR OLDER ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA RECEIVING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION	09:33 - 09:42
	<i>Oral Presenter:</i> Othman Salim Akhtar (United States)	

Nurses Group

08:30 - 10:00

Hall 1

NG22 - Disease update - Malignant diseases*Chair:* Ms. Catriona Taylor (United Kingdom)*Chair:* Ms. Cristina Baiana (Belgium)

NG22-1	Multiple myeloma	08:30 - 08:50
	<i>Speaker:</i> Ms. Maaïke de Ruijter (Netherlands)	
NG22-2	Acute myeloid leukemia	08:50 - 09:10
	<i>Speaker:</i> Ms. Cara Manson (United Kingdom)	
NG22-3	Acute lymphoblastic leukemia	09:10 - 09:30
	<i>Speaker:</i> Dr. Deborah Yallop (United Kingdom)	
NG22-4	Non-hodgkin lymphoma	09:30 - 09:50
	<i>Speaker:</i> Ms. Jenni Davies (United Kingdom)	
NG22-5	Q&A	09:50 - 10:00

GoCART Coalition

08:30 - 09:45

Hall M1

GCC1 - GoCART Coalition session 1 | GoCART Scientific Excellence Research Studies*Chair:* Ms. Natacha Bolaños (Spain)*Chair:* Prof. Dr. Martin Dreyling (Germany)

GCC1-1	Update on the GoCART Coalition activities and the Scientific Excellence Work Package <i>Speaker:</i> Prof. Dr. Jurgen Kuball (Netherlands)	08:30 - 08:45
GCC1-2	Impact of preceding therapy of CAR T-cells in B-ALL and impact of consolidative HCT following complete remission post CART <i>Speaker:</i> Dr. Valentín Ortiz-Maldonado (Spain)	08:45 - 09:00
GCC1-3	Autoimmune and auto inflammatory complications after CAR T-cell therapy <i>Speaker:</i> Dr. Matteo Doglio (Italy)	09:00 - 09:15
GCC1-4	Efficacy and toxicity of CAR T-cell therapy in patients with primary and secondary CNS lymphoma <i>Speaker:</i> Dr. Anna Ossami Saidy (Germany)	09:15 - 09:30
GCC1-5	CAR-T cells activities in Japan <i>Speaker:</i> Prof. Dr. Yoshiko Atsuta (Japan)	09:30 - 09:45

How do I... ?

08:30 - 09:45

BOISDALE

HDI5 - How do I transplant a patient with advanced systemic mastocytosis in the TKI era? | Supported through an unrestricted educational grant by Blueprint Medicines*Chair:* Dr. Pramila Krishnamurthy (United Kingdom)*Chair:* Dr. Maria Pagoni (Greece)

HDI5-1	Introduction - setting the scene <i>Speaker:</i> Dr. Pramila Krishnamurthy (United Kingdom)	08:30 - 08:35
HDI5-2	Diagnosis and management of SM including SM-AHM <i>Speaker:</i> Prof. Dr. Andreas Reiter (Germany)	08:35 - 09:05
HDI5-3	Transplantation of patients with SM <i>Speaker:</i> Dr. Deborah Christen (Germany)	09:05 - 09:25
HDI5-4	Discussion	09:25 - 09:45

Nurses Group

08:30 - 10:00

ALSH

NG23 - Donors*Chair:* Ms. Colette Currie (United Kingdom)*Chair:* Ms. Annika Kisch (Sweden)

NG23-1	Donor selection - Right donor, right patient <i>Speaker:</i> Ms. Daphna Hutt (Israel)	08:30 - 08:50
NG23-2	The experience of children and adolescents who donated stem cells to their ill sibling <i>Speaker:</i> Ms. Carina Rinaldo (Sweden)	08:50 - 09:10
NG23-3	Taking care of donors <i>Speaker:</i> Ms. Maria Finch (United Kingdom)	09:10 - 09:30
NG23-4	Donating Stem Cells to a stranger: My experience <i>Speaker:</i> Mr. Will Briant (United Kingdom)	09:30 - 09:50
NG23-5	Q&A	09:50 - 10:00

Lab Scientists Day

08:30 - 09:45

CARRON

LS1 - Lab Scientists Day 1 | Cellular Therapy Product Processing and Quality Assessment*Chair:* Ms. Gillian McGaffin (United Kingdom)

LS1-1	Cryopreservation of HPC, donor lymphocytes and CAR-T cells <i>Speaker:</i> Dr. Mike Watts (United Kingdom)	08:30 - 08:50
LS1-2	Inborn errors of immunity and depletion protocols <i>Speaker:</i> Ms. Kay Carruthers (United Kingdom)	08:50 - 09:10
LS1-3	Assessing the impact of the Covid-19 pandemic on cellular therapy products and processes <i>Speaker:</i> Dr. John Girdlestone (United Kingdom)	09:10 - 09:30
LS1-4	Q&A - Discussion	09:30 - 09:45

Special Session

08:30 - 09:45

GALA

SS8 - EBMT Benchmarking session*Chair:* Prof. John Snowden (United Kingdom)*Chair:* Isabel Sánchez-Ortega (Spain)

SS8-1	Benchmarking of Survival Outcomes in Hematopoietic Stem Cell Transplantation: An update from CIBMTR <i>Speaker:</i> Prof. Doug Rizzo (United States)	08:30 - 08:55
SS8-2	Tribute to Riccardo Saccardi: update of the EBMT Benchmarking project <i>Speaker:</i> Prof. John Snowden (United Kingdom)	08:55 - 09:05
SS8-3	Statistical aspects of EBMT benchmarking: past, present, future <i>Speaker:</i> Prof. Dr. Hein Putter (Netherlands)	09:05 - 09:20
SS8-4	Impact of benchmarking on health services planning <i>Speaker:</i> Dr. Fiona Dignan (United Kingdom)	09:20 - 09:45

ePoster

08:30 - 14:30

ePoster area

ePoster Viewing*Breaks*

10:00 - 10:30

CLYDE

Coffee Break, ePoster Viewing, Visit Exhibition*Joint Sessions*

10:30 - 11:45

CLYDE

JS06 - Joint Session - EBMT/BSH/BSBMTCT | Covid*Chair:* Josh Wright (United Kingdom)*Chair:* Prof. John Snowden (United Kingdom)

JS06-1	Covid and vaccination related thrombosis <i>Speaker:</i> Prof. Dr. Marie Scully (United Kingdom)	10:30 - 10:55
JS06-2	Lessons for the world from the Covid-19 pandemic <i>Speaker:</i> Prof. Eduardo Olavarria (United Kingdom)	10:55 - 11:20
JS06-3	The EBMT role during the pandemic <i>Speaker:</i> Prof. Dr. Per Ljungman (Sweden)	11:20 - 11:45

Educational

10:30 - 11:45

LOMOND

E09 - Transplant in non-malignant disease*Chair:* Dr. Deborah Richardson (United Kingdom)*Chair:* Prof. John Moore (Australia)

E09-1	Auto transplant for multiple sclerosis <i>Speaker:</i> Prof. Dr. Paolo Muraro (United Kingdom)	10:30 - 10:50
E09-2	Allogeneic HSCT for adults with Immunodeficiency <i>Speaker:</i> Prof. Emma Morris (United Kingdom)	10:50 - 11:10
E09-3	Challenges in HSCT for AA/PNH: approaching the older patient <i>Speaker:</i> Prof. Antonio Risitano (Italy)	11:10 - 11:30
E09-4	Q&A - Discussion	11:30 - 11:45

Oral Session

10:30 - 11:45

Hall 3 North

OS12 - Oral Session 12 | Optimising conditioning*Chair:* Dr. Erin Hurst (United Kingdom)*Chair:* Dr. Anna Castleton (United Kingdom)

OS12-01	A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO ADDRESS THE IMPACT OF TARGETED FLUDARABINE ON THE INCIDENCE OF VIRAL COMPLICATIONS AFTER TCRALPHABETA/CD19 DEPLETED ALLO-HCT <i>Oral Presenter:</i> Moniek de Witte (Netherlands)	10:30 - 10:39
OS12-02	OPTIMIZING BUSULFAN DOSING IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ROLE OF BODY COMPOSITION, THERAPEUTIC DRUG MONITORING AND PHARMACOGENETICS <i>Oral Presenter:</i> Khalil Ben Hassine (Switzerland)	10:39 - 10:48
OS12-03	TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) WITH FLUDARABINE-MELPHALAN AS CONDITIONING FOR MATCHED-DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) IN PATIENTS WITH HIGH-RISK ACUTE LEUKEMIAS OR MDS <i>Oral Presenter:</i> Monzr Al Malki (United States)	10:48 - 10:57
OS12-04	MOCRAVIMOD FAVOURABLY AFFECTS OVERALL SURVIVAL IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Udo Holtick (Switzerland)	10:57 - 11:06
OS12-05	TREOSULFAN VERSUS BUSULFAN-BASED CONDITIONING REGIMENS FOR FIRST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN CHILDREN WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: A RETROSPECTIVE PDWP/EBMT STUDY <i>Oral Presenter:</i> Hemalatha G. Rangarajan (United States)	11:06 - 11:15
OS12-06	FLUDARABINE PLUS TREOSULFAN OR TBI AS A CONDITIONING THERAPY BEFORE ALLOGENEIC HSCT IN ACUTE LYMPHOBLASTIC LEUKEMIA. A MATCHED-PAIR ANALYSIS FROM THE ALWP OF THE EBMT <i>Oral Presenter:</i> Ryszard Swoboda (Poland)	11:15 - 11:24
OS12-07	PHASE II STUDY OF PHARMACOKINETIC MODEL-BASED ATG DOSING TO IMPROVE SURVIVAL THROUGH ENHANCED IMMUNE RECONSTITUTION IN PATIENTS UNDERGOING EX VIVO CD34-SELECTED ALLOGENEIC HCT (PRAISE-IR) <i>Oral Presenter:</i> Michael Scordo (United States)	11:24 - 11:33

OS12-08	TREOSULFAN- VERSUS BUSULFAN-BASED CONDITIONING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME: A SINGLE-CENTRE RETROSPECTIVE PROPENSITY SCORE-MATCHED COHORT STUDY <i>Oral Presenter:</i> Tommy Alfaro Moya (Canada)	11:33 - 11:42
<i>Educational</i>		
10:30 - 11:45		Hall 3 South
E10 - Challenges in MDS		
<i>Chair:</i> Prof. Dr. Claudia Haferlach (Germany)		
<i>Chair:</i> Prof. Dr. Valeria Santini (Italy)		
E10-1	Risk stratifying MDS in the era of IPSS-M <i>Speaker:</i> Prof. Mario Cazzola (Italy)	10:30 - 10:50
E10-2	Optimising transplant outcomes for high risk disease <i>Speaker:</i> Dr. Pramila Krishnamurthy (United Kingdom)	10:50 - 11:10
E10-3	VEXAS syndrome: diagnosis and management <i>Speaker:</i> Dr. Carmelo Gurnari (United States)	11:10 - 11:30
E10-4	Q&A - Discussion	11:30 - 11:45
<i>Workshop</i>		
10:30 - 11:45		Hall 2
W10 - Cellular therapy in other disease		
<i>Chair:</i> Dr. Matteo Doglio (Italy)		
<i>Chair:</i> Dr. Tobias Alexander (Germany)		
W10-1	CAR-T in autoimmune disease <i>Speaker:</i> Dr. Raffaella Greco (Italy)	10:30 - 10:53
W10-2	A phase 1 trial to treat melanoma with TCR-engineered T cells: current standing and future perspectives <i>Speaker:</i> Prof. Dr. Reno Debets (Netherlands)	10:53 - 11:13
W10-3	Optimising CAR-T for solid tumors <i>Speaker:</i> Dr. Monica Casucci (Italy)	11:13 - 11:33
W10-4	Q&A - Discussion	11:33 - 11:45
<i>Oral Session</i>		
10:30 - 11:45		Hall 5
OS13 - Oral Session 13 GVHD		
<i>Chair:</i> Dr. Francesca Kinsella (United Kingdom)		
<i>Chair:</i> Dr. Charles Crawley (United Kingdom)		
OS13-01	BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ≥2 PRIOR LINES OF SYSTEMIC THERAPY: 3-YEAR FOLLOW-UP OF THE ROCKSTAR STUDY <i>Oral Presenter:</i> Dr. Corey Cutler (United States)	10:30 - 10:39
OS13-02	PTCY, TAC/ CSA, MMF VS ATG, TAC / CSA, MTX GVHD PROPHYLAXIS POST SIBLING AND UNRELATED TRANSPLANTATIONS FOR AML: FROM THE ALWP OF THE EBMT <i>Oral Presenter:</i> Prof. Arnon Nagler (Israel)	10:39 - 10:48
OS13-03	THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY <i>Oral Presenter:</i> Alexandros Spyridonidis (Greece)	10:48 - 10:57

OS13-04	RANDOMIZED MULTICENTER TRIAL OF CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE AND RUXOLITINIB IN UNRELATED AND HAPLOIDENTICAL TRANSPLANTATIONS: A FINAL ANALYSIS OF THE PRIMARY ENDPOINT <i>Oral Presenter:</i> Dr. Ivan Moiseev (Russian Federation)	10:57 - 11:06
OS13-05	POST-TRANSPLANT CYCLOPHOSPHAMIDE, ABATACEPT, AND VEDOLIZUMAB TO PREVENT GVHD AFTER HSCT FROM HAPLOIDENTICAL DONORS IN CHILDREN WITH ACUTE LEUKEMIA: RESULTS OF A PROSPECTIVE TRIAL <i>Oral Presenter:</i> Alexandra Laberko (Russian Federation)	11:06 - 11:15
OS13-06	AXATILIMAB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSES IN FIBROSIS-DOMINANT ORGANS IN AGAVE-201 <i>Oral Presenter:</i> Jose A. Perez-Simon (Spain)	11:15 - 11:24
OS13-07	POOLED FECAL ALLOGENEIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE : RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE <i>Oral Presenter:</i> Prof. Dr. Florent Malard (France)	11:24 - 11:33
OS13-08	RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY IN PEDIATRIC POPULATION <i>Oral Presenter:</i> Virginia Escamilla Gómez (Spain)	11:33 - 11:42

Nurses Group
10:30 - 11:30

Hall 1

NG24 - Oral Session Adult II

Chair: Ms. Maaike de Ruijter (Netherlands)

Chair: Ms. Emma Chalmers (United Kingdom)

NG24-01	KNOWLEDGE AND PERCEPTIONS ON STEM CELL DONATION AMONG ITALIAN POPULATION: A GITMO NG STUDY <i>Oral Presenter:</i> Dr. Stefano Botti (Italy)	10:30 - 10:45
NG24-02	THE PERCEPTION OF PATIENTS WITH ACUTE GVHD ABOUT ORAL MEDICATION ADHERENCE: A QUALITATIVE STUDY <i>Oral Presenter:</i> Chiara Visintini (Italy)	10:45 - 11:00
NG24-03	DEVELOPMENT OF A CARE PATHWAY FOR ADULT PATIENTS WITH SICKLE CELL DISEASE UNDERGOING AN ALLOGENEIC STEM CELL TRANSPLANTATION: A QUALITATIVE STUDY <i>Oral Presenter:</i> Elisabeth. Maria Suijk (Netherlands)	11:00 - 11:15
NG24-04	SYMPTOMS OF CHRONIC GRAFT-VERSUS-HOST DISEASE FROM PATIENTS POINT OF VIEW <i>Oral Presenter:</i> Lucija Jurišić (Croatia)	11:15 - 11:30

GoCART Coalition
10:30 - 11:45

Hall M1

GCC2 - GoCART Coalition session 2 | National CART networks

Chair: Dr. Julio Delgado (Spain)

Chair: Prof. Dr. Christian Chabannon (France)

GCC2-1	The Spanish academic Network of advanced Therapies: TERA V <i>Speaker:</i> Prof. Dr. José Maria Moraleda-Jiménez (Spain)	10:30 - 10:42
GCC2-2	The Italian network: the Italian Life Science Hub on ATMP (LSH-AT) <i>Speaker:</i> Prof. Franco Locatelli (Italy)	10:42 - 10:54

GCC2-3	The DUTCH ATMP network: DARE-NL <i>Speaker:</i> Prof. Dr. Harry Dolstra (Netherlands)	10:54 - 11:06
GCC2-4	SWECARNET: The Swedish CAR T cell network <i>Speaker:</i> Prof. Dr. Stephan Mielke (Sweden)	11:06 - 11:18
GCC2-5	Home brewed CARTs made in Germany <i>Speaker:</i> Prof. Dr. Michael Schmitt (Germany)	11:18 - 11:30
GCC2-6	Q&A - Discussion	11:30 - 11:45

Special Session

10:30 - 11:45

FORTH

SS7 - Evidence generation for optimal patient outcomes in 21st century*Chair:* Dr. Myriam Labopin (France)*Chair:* Prof. Mhairi Copland Copland (United Kingdom)

SS7-1	Real world evidence to aid decision making <i>Speaker:</i> Ms. Meena Venkatachalam (United Kingdom)	10:30 - 10:50
SS7-2	Generating practice informing transplant data. The role of Registries. <i>Speaker:</i> Prof. Mohamad Mohty (France)	10:50 - 11:10
SS7-3	Optimizing the conduct of multi-center prospective transplant trials <i>Speaker:</i> Dr. Steven Devine (United States)	11:10 - 11:30
SS7-4	Q&A - Discussion	11:30 - 11:45

Oral Session

10:30 - 11:45

BOISDALE

OS11 - Oral Session 11 | Gene and novel cell therapy*Chair:* Dr. Anne Charlotte Adriane Mudde (United Kingdom)*Chair:* Dr. Ben Carpenter (United Kingdom)

OS11-01	INTERIM ANALYSIS ON NEUROLOGICAL OUTCOMES IN HURLER SYNDROME PATIENTS TREATED WITH EX-VIVO HAEMATOPOIETIC STEM CELL GENE THERAPY <i>Oral Presenter:</i> Giulia Consiglieri (Italy)	10:30 - 10:39
OS11-02	ANALYSIS OF PRE-TRANSPLANTATION CMV-SPECIFIC HUMORAL IMMUNITY AS A PREDICTOR OF CMV REACTIVATION AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT) USING VIRSCAN SEROLOGIC PROFILING AND PENTAMERIC COMPLEX-SPECIFIC NEUTRALIZATION <i>Oral Presenter:</i> Dannel Zamora (United States)	10:39 - 10:48
OS11-03	LENTIVIRAL HAEMATOPOIETIC STEM CELL GENE THERAPY (ATIDARSAGENE AUTOTEMCEL) FOR LATE JUVENILE METACHROMATIC LEUKODYSTROPHY (MLD)	10:48 - 10:57
OS11-04	REKLAIM, A NOVEL PHASE IB CLINICAL TRIAL OF FBX-101 (AAVRH10.GALC) INTRAVENOUSLY ADMINISTERED AFTER UCBT FOR THE TREATMENT OF INFANTILE AND LATE INFANTILE KRABBE DISEASE <i>Oral Presenter:</i> Maria Escolar (United States)	10:57 - 11:06
OS11-05	MULTIVALENT-SPECIFIC T CELLS AS LIVING DRUGS FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS POST ALTERNATIVE-DONOR HEMATOPOIETIC CELL TRANSPLANTATION <i>Oral Presenter:</i> Ioannis Kyriakou (Greece)	11:06 - 11:15

OS11-06	LONG-TERM AND REAL-WORLD SAFETY AND EFFICACY OF RETROVIRAL GENE THERAPY FOR ADENOSINE DEAMINASE DEFICIENCY <i>Oral Presenter:</i> Maddalena Migliavacca (Italy)	11:15 - 11:24
OS11-07	CMV SPECIFIC T-CELL ACTIVITY DETERMINES THE RISK OF CLINICALLY SIGNIFICANT CMV REACTIVATION FOLLOWING LETERMОВIR PROPHYLAXIS AFTER ALLO-HSCT <i>Oral Presenter:</i> Timothé Duplessix (Germany)	11:24 - 11:33
OS11-08	DEVELOPING A UNIVERSAL HAEMATOPOIETIC STEM CELL GENE EDITING THERAPY FOR XIAP DEFICIENCY <i>Oral Presenter:</i> Dr. Anne Charlotte Adriane Mudde (United Kingdom)	11:33 - 11:42

Nurses Group

10:30 - 11:45

ALSH

NG25 - Eating well and eating right before, during and after transplant*Chair:* Ms. Kader Caliskan (Turkey)*Chair:* Ms. Polona Klanscek (Slovenia)

NG25-1	Nutritional pre-habilitation <i>Speaker:</i> Ms. Christel Kupperts (Belgium)	10:30 - 10:50
NG25-2	Nutritional assessment and care during transplant <i>Speaker:</i> Ms. Katie Ahern (Ireland)	10:50 - 11:10
NG25-3	Looking after the microbiome post transplant <i>Speaker:</i> Prof. Dr. Esther Martinez (Spain)	11:10 - 11:30
NG25-4	Discussion	11:30 - 11:45

Lab Scientists Day

10:30 - 11:45

CARRON

LS2 - Lab Scientists Day 2 | Chimeric Antigen Receptor Cell Manufacturing*Chair:* Dr. Adeel Saleem (Netherlands)

LS2-1	Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML <i>Speaker:</i> Prof. Dr. Marion Subklewe (Germany)	10:30 - 10:50
LS2-2	Comparison of point-of-care produced CAR T-cells with commercial CAR T-cells from the laboratory perspective <i>Speaker:</i> Dr. Carlijn Voermans (Netherlands)	10:50 - 11:10
LS2-3	Scalable manufacturing of CAR T cells for cancer immunotherapy <i>Speaker:</i> Prof. Dr. Ulrike Koehl (Germany)	11:10 - 11:30
LS2-4	Q&A - Discussion	11:30 - 11:45

Oral Session

10:30 - 11:45

GALA

OS14 - Oral Session 14 | Improving patient centred care*Chair:* Dr. Kathleen McHugh (United Kingdom)*Chair:* Ms. Dawn Hart (United Kingdom)

OS14-01	PATIENT'S PERCEPTION ON E-HEALTH-BASED AFTERCARE FOLLOWING CELLULAR THERAPIES - A MULTICENTER ANALYSIS <i>Oral Presenter:</i> Friederike Schmitz (Germany)	10:30 - 10:39
OS14-02	PHYSICIAN VERSUS PATIENT PERCEPTION OF DISEASE, SYMPTOMATIC BURDEN AND PREFERENCE FOR TREATMENT ADMINISTRATION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): RESULTS FROM A REAL-WORLD	10:39 - 10:48

STUDY*Oral Presenter:* Maria-Magdalena Balp (Switzerland)

OS14-03	THE INFORMATIONAL NEEDS OF POST HAEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS IN ENGLAND: A QUALITATIVE EXPLORATION	10:48 - 10:57
	<i>Oral Presenter:</i> Blossom Bell (United Kingdom)	
OS14-04	PHARMACEUTICAL INTERVENTIONS WITHIN A BMT/ CART PREHABILITATION SERVICE - ONE YEAR OUTCOME DATA	10:57 - 11:06
	<i>Oral Presenter:</i> Ms. Siobhan Smith (United Kingdom)	
OS14-05	HEALTH PROFESSIONALS' PERSPECTIVES TOWARDS THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA AMONG HAEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN THE UK: A NATIONAL SURVEY STUDY	11:06 - 11:15
	<i>Oral Presenter:</i> Dr. Gemma Pugh (United Kingdom)	
OS14-06	PATIENT PERSPECTIVES TOWARDS QUALITY-OF-LIFE DATA COLLECTION FOLLOWING HAEMATOPOIETIC CELL TRANSPLANT: A QUALITATIVE INTERVIEW STUDY CO-DESIGNED WITH PATIENT INPUT	11:15 - 11:24
	<i>Oral Presenter:</i> Dr. Gemma Pugh (United Kingdom)	
OS14-07	FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH-CT)	11:24 - 11:33
	<i>Oral Presenter:</i> Maria Queralt Salas (Spain)	
OS14-08	PATIENT-CENTERED VALUE BASED HEALTHCARE FOLLOW-UP PROGRAM FOR PATIENTS AFTER PEDIATRIC STEM CELL TRANSPLANTATION: IMPLEMENTATION OF PATIENTS REPORTED OUTCOME AND EXPECTATIONS IN CLINICAL PRACTICE	11:33 - 11:42
	<i>Oral Presenter:</i> Trude M. Minnee-Guijt (Netherlands)	

Breaks

11:45 - 12:30

CLYDE

Lunch Break, ePoster Viewing, Visit Exhibition*Educational*

12:30 - 13:45

CLYDE

E12 - Optimising alternative donor source outcomes*Chair:* Prof. Bronwen Shaw (United States)*Chair:* Prof. Sebastian Giebel (Poland)

E12-1	Optimising outcomes in Cord transplant	12:30 - 12:55
	<i>Speaker:</i> Prof. Vanderson Rocha (Brazil)	
E12-2	Optimising outcomes in Haploidentical transplant	12:55 - 13:20
	<i>Speaker:</i> Dr. Jaime Sanz (Spain)	
E12-3	Discussion: Cord vs Haplo	13:20 - 13:45

Special Session

12:30 - 13:45

LOMOND

SS9 - The impact of AI on the future of Transplant and Cell Therapy*Chair:* Dr. Thomas Coats (United Kingdom)*Chair:* Prof. Eduardo Olavarria (United Kingdom)

SS9-1	Data-driven approaches to the severity grading of acute GVHD	12:30 - 12:50
	<i>Speaker:</i> Dr. Amin Turki (Germany)	

SS9-2	Impact on drug development and clinic trials: the future of synthetic data <i>Speaker:</i> Prof. Dr. Matteo Della Porta (Italy)	12:50 - 13:10
SS9-3	Multimodal data integration for precision Cellular Therapy <i>Speaker:</i> Dr. Roni Shouval (United States)	13:10 - 13:30
SS9-4	Q&A - Discussion	13:30 - 13:45
<i>Oral Session</i>		
12:30 - 13:45		Hall 3 North
OS15 - Oral Session 15 Predicting and managing complications of stem cell transplant		
<i>Chair:</i> Dr. Junya Kanda (Japan)		
<i>Chair:</i> Dr. Varun Mehra (United Kingdom)		
OS15-01	DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT <i>Oral Presenter:</i> Dr. Nico Gagelmann (Germany)	12:30 - 12:39
OS15-02	DONOR-DERIVED IMMUNE RECONSTITUTION PROFILE OF AGGRESSIVE NEUROMYELITIS OPTICA IN LONG-TERM DISEASE REMISSION AFTER ALLOGENEIC TRANSPLANTATION <i>Oral Presenter:</i> Giorgio Orofino (Italy)	12:39 - 12:48
OS15-03	EASIX SCORE AS A PREDICTIVE TOOL FOR SINUSOIDAL OBSTRUCTION SYNDROME IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Edoardo Muratore (Italy)	12:48 - 12:57
OS15-04	APPLICATION OF RECENTLY PROPOSED EBMT/ASTCT/CIBMTR/APCMT CONSENSUS RISK STRATIFICATION FOR TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) IN CHILDREN <i>Oral Presenter:</i> Michelle Schoettler (United States)	12:57 - 13:06
OS15-05	SALVAGE THERAPY WITH NINTEDANIB AND LOW-DOSE RUXOLITINIB LEADS TO SIGNIFICANT IMPROVEMENT IN PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME WHO FAILED CALCINEURIN AND GLUCOCORTICOIDS AFTER ALLOGENEIC TRANSPLANTATION <i>Oral Presenter:</i> Ya Luo (China)	13:06 - 13:15
OS15-06	SUBSEQUENT NEOPLASMS AFTER UMBILICAL CORD BLOOD TRANSPLANTATION IN THE JAPANESE AND EUROPEAN POPULATIONS <i>Oral Presenter:</i> Dr. Junya Kanda (Japan)	13:15 - 13:24
OS15-07	OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION (VOD/SOS) FOLLOWING POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY): RESULTS FROM THE DEFIFRANCE REGISTRY <i>Oral Presenter:</i> Prof. Mohamad Mohty (France)	13:24 - 13:33
OS15-08	EARLY POST-TRANSPLANTATION HEMOPHAGOCYTOSIS (PTHPS) IS ASSOCIATED WITH HIGH MORTALITY AFTER HAPLOIDENTICAL HCT: DECIPHERING THE RISK FACTORS AND PATHOGENESIS <i>Oral Presenter:</i> Dr. Sarita Rani Jaiswal (India)	13:33 - 13:42

Educational

12:30 - 13:45

Hall 3 South

E11 - Haemoglobinopathy*Chair:* Prof. Dr. Evangelia Yannaki (Greece)*Chair:* Dr. Valeria Pinto (Italy)

E11-1	Sibling transplant for adults with SCD: long term follow-up and secondary malignancy <i>Speaker:</i> Dr. Matthew Hsieh (United States)	12:30 - 12:50
E11-2	Haploidentical HSCT for haemoglobinopathies <i>Speaker:</i> Prof. Josu de la Fuente (United Kingdom)	12:50 - 13:10
E11-3	Gene editing and gene addition therapy for haemoglobinopathies <i>Speaker:</i> Prof. Franco Locatelli (Italy)	13:10 - 13:30
E11-4	Q&A - Discussion	13:30 - 13:45

Oral Session

12:30 - 13:45

Hall 2

OS16 - Oral Session 16 | CAR-T outcomes in ALL*Chair:* Dr. Beki James (United Kingdom)*Chair:* Dr. Eleni Tholouli (United Kingdom)

OS16-01	IN VIVO TRANSFER OF CD4⁺ T CELLS RESHAPES CD8⁺ T CELL DIFFERENTIATION TRAJECTORY IN HUMANS <i>Oral Presenter:</i> Andrew McIntyre (United Kingdom)	12:30 - 12:39
OS16-02	RECIRCULATING REGULATORY T CELLS MEDIATE THYMIC REGENERATION <i>Oral Presenter:</i> Andri Leo Lemarquis (United States)	12:39 - 12:48
OS16-03	IN VIVO LOWER CD4/CD8 CARCIK-CD19 CELL RATIO IS ASSOCIATED WITH EARLY TREATMENT RESPONSE IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA <i>Oral Presenter:</i> Benedetta Rambaldi (Italy)	12:48 - 12:57
OS16-04	SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE-MANUFACTURED CD19 CAR T-CELL THERAPY (GLPG5101) IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL): RESULTS FROM THE PHASE 1 ATALANTA-1 TRIAL <i>Oral Presenter:</i> Yves Beguin (Netherlands)	12:57 - 13:06
OS16-05	SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE-MANUFACTURED CD19 CAR T-CELL THERAPY (GLPG5201) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1 EUPLAGIA-1 STUDY <i>Oral Presenter:</i> Dr. Valentín Ortiz-Maldonado (Spain)	13:06 - 13:15
OS16-06	A MACROPHAGES-BASED IMMUNOTHERAPY OF SOLID TUMORS MICROENVIRONMENT: PRELIMINARY RESULTS OF THE TEM-GBM_01 STUDY <i>Oral Presenter:</i> Francesca Farina (Italy)	13:15 - 13:24
OS16-07	TRANSCRIPTIONAL REWIRING OF NK CELL FEATURES IMPRINTED BY DIFFERENT MODALITIES OF POST-TRANSPLANTATION LEUKEMIA RELAPSE <i>Oral Presenter:</i> Giorgio Orofino (Italy)	13:24 - 13:33
OS16-08	DISTURBED MITOCHONDRIAL DYNAMICS REINFORCE CAR-T CELL EXHAUSTION <i>Oral Presenter:</i> Mi Shao (China)	13:33 - 13:42

Oral Session

12:30 - 13:45

Hall 5

OS17 - Oral Session 17 | Acute Leukaemia allograft outcomes

Chair: Dr. Gesine Bug (Germany)

Chair: Dr. Gillian Horne (United Kingdom)

OS17-01	THE DISEASE RISK STRATIFICATION SYSTEM (DRSS): VALIDATION AND REFINEMENT IN A CONTEMPORARY ACUTE LEUKEMIA COHORT - AN ALWP EBMT STUDY <i>Oral Presenter:</i> Dr. Roni Shouval (United States)	12:30 - 12:39
OS17-02	¹³¹I-APAMISTAMAB-LED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT DEMONSTRATES SURVIVAL BENEFIT AND OVERCOMES HIGH-RISK TP53 MUTATIONS IN PATIENTS WITH R/R AML <i>Oral Presenter:</i> Dr. Hannah Choe, MD (United States)	12:39 - 12:48
OS17-03	20-YEAR STEADY INCREASE IN POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA: A REPORT FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY <i>Oral Presenter:</i> Prof. Ali Bazarbachi (Lebanon)	12:48 - 12:57
OS17-04	20-YEAR STEADY INCREASE IN POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES FOR PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. A STUDY FROM THE EBMT ACUTE LEUKEMIA WORKING PARTY <i>Oral Presenter:</i> Prof. Ali Bazarbachi (Lebanon)	12:57 - 13:06
OS17-05	PROGNOSTIC FACTORS IMPACTING POST-TRANSPLANT OUTCOMES IN ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A REGISTRY-BASED STUDY BY THE EBMT ACUTE LEUKEMIA WORKING PARTY <i>Oral Presenter:</i> Prof. Dr. Jean El-Cheikh (Lebanon)	13:06 - 13:15
OS17-06	PRE-HCT NEXT-GENERATION SEQUENCING (NGS-MRD) AND OUTCOMES OF PEDIATRIC, ADOLESCENT, AND YOUNG ADULT B-ALL PATIENTS UNDERGOING ALLOGENEIC HCT: UPDATE FROM THE OBSERVATIONAL ARM OF PTCTC ONC1701 <i>Oral Presenter:</i> Troy Quigg (United States)	13:15 - 13:24
OS17-07	REAL-WORLD EXPERIENCE WITH CPX-351 FOR PATIENTS WITH AML - LONG-TERM FOLLOW-UP WITH FOCUS ON YOUNGER PATIENTS (<60 YEARS OLD) AND ALLOGENEIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Dr. Christina Rautenberg (Germany)	13:24 - 13:33
OS17-08	IMPAIRED CD45RO-CCR7+ NAÏVE CD8+T CELLS IN AML ARE ASSOCIATED WITH LOWER OVERALL SURVIVAL <i>Oral Presenter:</i> Yongping Zhang (China)	13:33 - 13:42

Nurses Group

12:30 - 14:00

Hall 1

NG26 - Survivorship & NG Closing Session

Chair: Dr. Michelle Kenyon (United Kingdom)

NG26-1	Implementation of the new the EBMT-ASTCT late effects guidelines <i>Speaker:</i> Dr. Rachel Phelan (United States)	12:30 - 12:50
NG26-2	Long-term psychological care <i>Speaker:</i> Dr. Kathleen McHugh (United Kingdom)	12:50 - 13:10
NG26-3	Patient experience: a survivorship story <i>Speaker:</i> Dr. Nicola Hodge (United Kingdom)	13:10 - 13:30

NG26-4	Best of the best <i>Speaker:</i> Dr. Michelle Kenyon (United Kingdom)	13:30 - 13:40
NG26-5	Highlights of physicians sessions <i>Speaker:</i> Prof. Alejandro Madrigal (United Kingdom)	13:40 - 13:55
NG26-6	Presentation of Annual Meeting 2025 <i>Speaker:</i> Ms. Claudia Boglione (Italy)	13:55 - 14:00

GoCART Coalition

12:30 - 13:45

Hall M1

GCC3 - GoCART Coalition session 3 | CART initiatives*Chair:* Prof. Dr. Jurgen Kuball (Netherlands)*Chair:* Prof. Dr. José Maria Moraleda-Jiménez (Spain)

GCC3-1	The new EBMT registry and CART and how to update the data we collect <i>Speaker:</i> Ms. Annemiek Markslag (Netherlands)	12:30 - 12:45
GCC3-2	Harmonizing education - The Dutch experience <i>Speaker:</i> Dr. Emma de Pater (Netherlands)	12:45 - 13:00
GCC3-3	T2EVOLVE - Standards, Harmonization and Education in the CAR T cell field <i>Speaker:</i> Prof. Dr. Maik Luu (Germany)	13:00 - 13:15
GCC3-4	Development of a Harmonised European Parameter Set and Core Data Structure for the Evaluation of CAR T-Cell Therapies (CART-CD), a GoCART Coalition and T2Evolve joint Initiative <i>Speaker:</i> Prof. Bjoern Chapuy (Germany)	13:15 - 13:30
GCC3-5	Q&A - Discussion	13:30 - 13:45

Joint Sessions

12:30 - 13:45

BOISDALE

JS07 - Joint Session EBMT - HARMONY Alliance | Harnessing Data-innovation for better outcomes*Chair:* Prof. Dr. Anna Sureda (Spain)*Chair:* Prof. Dr. Valeria Santini (Italy)

JS07-1	EBMT's view on sharing data and data-driven research to offer new opportunities for bone marrow transplant professionals <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	12:30 - 12:40
JS07-2	Data-innovation in MDS: Converting data into insights <i>Speaker:</i> Prof. Dr. Valeria Santini (Italy)	12:40 - 12:55
JS07-3	Data-innovation in MDS: Transplant vs. non-transplant strategies in MDS: a joint EBMT-HARMONY study <i>Speaker:</i> Dr. Carmelo Gurnari (United States)	12:55 - 13:05
JS07-4	Data-innovation in AML - The HARMONY AML risk of relapse tool to guide alloHSCt decision-making <i>Speaker:</i> Prof. Dr. Lars Bullinger (Germany)	13:05 - 13:15
JS07-5	Round table discussion including interaction with the session participants about sharing data and joint research opportunities in MDS and AML <i>Panelist:</i> Dr. Donal McLornan (United Kingdom) <i>Panelist:</i> Prof. Dr. Fabio Ciceri (Italy) <i>Panelist:</i> Prof. Dr. Anna Sureda (Spain) <i>Panelist:</i> Prof. Dr. Valeria Santini (Italy) <i>Panelist:</i> Dr. Carmelo Gurnari (United States) <i>Panelist:</i> Prof. Dr. Lars Bullinger (Germany)	13:15 - 13:45

Oral Session

12:30 - 13:45

ALSH

OS18 - Oral Session 18 | Transplant in MDS and Aplastic anaemia

Chair: Dr. Margaret MacMillan (United States)

Chair: Dr. Camilla Frieri (Italy)

- | | | |
|---------|--|---------------|
| OS18-01 | ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED FEATURES AS PER THE INTERNATIONAL CONSENSUS CLASSIFICATION (ICC) 2022: FROM THE ALWP OF THE EBMT
<i>Oral Presenter:</i> Prof. Arnon Nagler (Israel) | 12:30 - 12:39 |
| OS18-02 | PREDICTING TRANSPLANTATION-, TRANSFUSION- AND TREATMENT-FREE SURVIVAL AFTER IMMUNE SUPPRESSIVE TREATMENT FOR ADULTS WITH ACQUIRED APLASTIC ANEMIA
<i>Oral Presenter:</i> Cjm Halkes (Netherlands) | 12:39 - 12:48 |
| OS18-03 | TCRALPHA/BETA DEPLETED MOBILIZED PBSCS WITHOUT CALCINEURIN INHIBITORS IN PATIENTS WITH FANCONI ANEMIA
<i>Oral Presenter:</i> Dr. Margaret MacMillan (United States) | 12:48 - 12:57 |
| OS18-04 | ADDITION OF RUXOLITINIB TO STANDARD GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
<i>Oral Presenter:</i> XiaoYu Zhang (China) | 12:57 - 13:06 |
| OS18-05 | UNRELATED DONOR TRANSPLANTATION IN APLASTIC ANEMIA WITH A QUADRUPLE GVHD PROPHYLAXIS
<i>Oral Presenter:</i> Sabrina Giammarco (Italy) | 13:06 - 13:15 |
| OS18-06 | UPFRONT MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE IDIOPATHIC APLASTIC ANEMIA AND REFRACTORY CYTOPENIA OF CHILDHOOD IN PEDIATRIC PATIENTS. SPANISH EXPERIENCE
<i>Oral Presenter:</i> Maria Luz Uria Oficialdegui (Spain) | 13:15 - 13:24 |
| OS18-07 | POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) COMPARED TO ATG IN PATIENTS WITH MDS ALLOGRAFTED WITH UNRELATED DONOR: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
<i>Oral Presenter:</i> Yves Chalandon (Switzerland) | 13:24 - 13:33 |
| OS18-08 | IMPACT OF MYELODYSPLASIA-RELATED GENE MUTATIONS ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION WITH POST-TRANSPLANT SORAFENIB MAINTENANCE IN <i>FLT3-ITD</i> AML PATIENTS: A MULTI-CENTER, RETROSPECTIVE COHORT STUDY
<i>Oral Presenter:</i> Yanmin Zhao (China) | 13:33 - 13:42 |

Oral Session

12:30 - 13:45

CARRON

OS19 - Oral Session 19 | Transplantation for inborn errors of metabolism and immune-deficiencies

Chair: Dr. Subarna Chakravorty (United Kingdom)

Chair: Dr. Valeria Calbi (Italy)

- | | | |
|---------|--|---------------|
| OS19-01 | ASSOCIATION OF BUSULFAN EXPOSURE WITH SURVIVAL AND TOXICITY AFTER HCT FOR PRIMARY IMMUNE DEFICIENCY IN CHILDREN AND YOUNG ADULTS; A MULTI-CENTER, RETROSPECTIVE COHORT ANALYSIS
<i>Oral Presenter:</i> Tim (T.) Bognàr (Netherlands) | 12:30 - 12:39 |
| OS19-02 | NON-NEUROLOGICAL, NON-SKELETAL OUTCOMES AFTER HAEMATOPOIETIC STEM AND PROGENITOR CELL-GENE THERAPY IN HURLER PATIENTS: RETROSPECTIVE COMPARISON WITH ALLOGENEIC HAEMATOPOIETIC STEM CELL | 12:39 - 12:48 |

TRANSPLANTATION*Oral Presenter:* Francesca Tucci (Italy)

OS19-03	HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR C1Q DEFICIENCY <i>Oral Presenter:</i> Helena Buso (Italy)	12:48 - 12:57
OS19-04	FACTORS INFLUENCING IMMUNE RECOVERY (IR) AFTER HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN 114 PATIENTS WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) <i>Oral Presenter:</i> Andrea Meinhardt (United Kingdom)	12:57 - 13:06
OS19-05	OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH GATA2 DEFICIENCY <i>Oral Presenter:</i> Alejandra Escobar Vasco (United States)	13:06 - 13:15
OS19-06	OUTCOMES OF SECOND CONDITIONED TRANSPLANT AFTER AN UNCONDITIONED STEM CELL INFUSION IN INFANTS AND CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) <i>Oral Presenter:</i> Zohreh Nademi (United Kingdom)	13:15 - 13:24
OS19-07	HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR STAT3 DOMINANT-NEGATIVE HYPER-IGE SYNDROME: INTERNATIONAL STUDY <i>Oral Presenter:</i> Christo Tsilifis (United Kingdom)	13:24 - 13:33
OS19-08	VALIDATION OF COMORBIDITY INDEX FOR PATIENTS WITH INBORN ERRORS OF IMMUNITY UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION <i>Oral Presenter:</i> Alexandra Laberko (Russian Federation)	13:33 - 13:42

Oral Session
12:30 - 13:45

GALA

OS20 - Oral Session 20 | Myeloproliferative Outcomes and transplant*Chair:* Dr. Deborah Richardson (United Kingdom)*Chair:* Prof. Dr. Andreas Reiter (Germany)

OS20-01	TARGETED-AUC VS FIXED-DOSE BUSULFAN AS PART OF REDUCED INTENSITY CONDITIONING PRIOR TO ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS PATIENTS <i>Oral Presenter:</i> Dr. Claudia Langebrake (Germany)	12:30 - 12:39
OS20-02	ASSOCIATION BETWEEN STEM CELL SOURCE, CD34+ CELL DOSE AND OUTCOMES AFTER HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS: AN ANALYSIS FROM THE CMWP OF THE EMBT <i>Oral Presenter:</i> Tomasz Czerw (Poland)	12:39 - 12:48
OS20-03	OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY <i>Oral Presenter:</i> Ms. Tatiana Fernández-Barge (Spain)	12:48 - 12:57
OS20-04	CLINICAL OUTCOMES OF PATIENTS WITH BLAST PHASE CHRONIC MYELOID LEUKEMIA AND UTILITY OF ALLOGENEIC STEM CELL TRANSPLANTATION IN IMPROVING LONG-TERM SURVIVAL <i>Oral Presenter:</i> Benjamin McCormick (United States)	12:57 - 13:06
OS20-05	IMPACT OF ATG/ATLG ON OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH MYELOFIBROSIS: A PROPENSITY SCORE MATCHED ANALYSIS	13:06 - 13:15

	<i>Oral Presenter:</i> Kristin Rathje (Germany)	
OS20-06	SEQUENTIAL CONDITIONING DOES NOT IMPROVE OUTCOMES OF ALLOGENEIC STEMCELL TRANSPLANTATION IN CMML PATIENTS <i>Oral Presenter:</i> Radwan Massoud (Germany)	13:15 - 13:24
OS20-07	MUTATION CLEARANCE AFTER AND DISEASE BURDEN BEFORE TRANSPLANTATION PREDICT RELAPSE IN PATIENTS WITH MYELOFIBROSIS <i>Oral Presenter:</i> Dr. Nico Gagelmann (Germany)	13:24 - 13:33
OS20-08	SPLENIC IRRADIATION PRIOR TO HEMATOPOIETIC CELL TRANSPLANTATION REDUCES RISK OF RELAPSE IN MYELOFIBROSIS <i>Oral Presenter:</i> Dr. Nico Gagelmann (Germany)	13:33 - 13:42
<i>General</i>		
14:00 - 14:30		LOMOND
GS4 - Closing Session		
<i>Chair:</i> Prof. Dr. Anna Sureda (Spain)		
<i>Chair:</i> Dr. Grant McQuaker (United Kingdom)		
<i>Chair:</i> Prof. Charlie Craddock (United Kingdom)		
GS4-1	Presentation of the Springer Nature Poster Awards <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	14:00 - 14:05
GS4-2	Best Young Abstracts <i>Speaker:</i> Prof. Dr. Mette Hazenberg (Netherlands)	14:05 - 14:10
GS4-3	Congress Presidents closing remarks <i>Speaker:</i> Dr. Grant McQuaker (United Kingdom) <i>Speaker:</i> Prof. Charlie Craddock (United Kingdom)	14:10 - 14:15
GS4-4	Presentation of the 51st Annual Meeting of the EBMT <i>Speaker:</i> Prof. Dr. Fabio Ciceri (Italy)	14:15 - 14:25
GS4-5	EBMT President closing remarks <i>Speaker:</i> Prof. Dr. Anna Sureda (Spain)	14:25 - 14:30